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Rheumatoid arthritis (RA) is a chronic autoimmune disorder characterised by joint 
inflammation and bone destruction. The presence of autoantibodies, years before the 
clinical onset of disease, and the efficacy of rituximab, a B-cell depleting therapy, highlight 
a pathogenic role for B cells in the initiation and development of RA. Different groups have 
recently identified a novel subset of B cells named age-associated B cells (ABCs). Studies 
in murine autoimmune models and patients suffering from autoimmune diseases described 
these cells as CD19high CD21- CD11c+. Moreover, a subset of synovial fluid B cells with 
a similar phenotype, also expressing FcRL4, has been demonstrated to contribute to RA 
pathogenesis. I aimed to fully characterise, phenotypically, transcriptionally and 
functionally, peripheral blood ABCs in patients suffering from early RA. 
I have shown that although my study did not show significant differences in the frequency 
of peripheral blood ABCs between RA patients and other disease and healthy controls, the 
percentage of cells with an ABC phenotype in the synovial fluid is very high in patients 
suffering from inflammatory arthritides. I characterised these cells phenotypically and 
confirmed that they have high expression of activation and co-stimulatory molecules, in 
addition to expressing high levels of T-bet and the members of the FcRL family (i.e. 
FcRL2-5). Moreover, these cells are actively proliferating and a high proportion of them 
have a class-switched memory B cells phenotype expressing IgG. Interestingly, the 
transcriptome analysis showed that the ABCs are a subset of B cells, distinct from naïve, 
CD5+ and memory B cell subsets, with a unique transcriptome profile. ABCs had a high 
expression of chemokine receptors, such as CXCR3, as well as adhesion molecules, such 
as integrins and CD97, supporting a role for the migration of these cells into inflammatory 
sites. In addition, ABCs also had high expression of apoptotic markers, such as caspases 
and Fas. Finally, the functional characterisation of ABCs showed that these cells are 
capable of secreting IgM and IgG after stimulation. However, due to low cell numbers and 
high cell death, very low quantities of secreted cytokines were detected; making it very 
difficult to determine if these cells could contribute to inflammation. 
Overall, I confirmed that the ABC subset is an activated memory-like B cell subset which 
could potentially migrate into inflammatory sites and promote disease pathogenesis. 
However, exactly how these cells contribute to RA pathogenesis is still unknown and 
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1.1 Rheumatoid Arthritis   
1.1.1 Rheumatoid Arthritis Pathogenesis 
Rheumatoid arthritis (RA) is a chronic autoimmune disorder characterised by joint 
inflammation and bone destruction. RA was regarded as an autoimmune disease resulting 
from immune dysregulation after the discovery of a genetic association with the Human 
Leukocyte Antigen (HLA) class II molecules and other innate and adaptive immune system 
molecules, presence of autoantibodies, and the development of a murine model for RA 
using immunisation with type II collagen, a candidate autoantigen in RA (McInnes and 
Schett, 2011). RA has a prevalence of around 1% in the UK population, affecting adults of 
working age (Humphreys et al., 2013). Moreover, RA is associated with high morbidity 
and mortality, which shortens the patient’s lifespan and increases the risk of work-related 
disability and impaired quality of life (Innala et al., 2016). Interestingly, RA has a higher 
prevalence in females compared to males, with a ratio of 3 females per 1 male being 
affected (Kvien et al., 2006). The risk factors for the development of RA include both 
genetic and environmental, with the strongest associations being seen with female sex, a 
family history of RA, the presence of certain HLA class II alleles and exposure to tobacco 
smoke (Deane et al., 2017). Evidence suggest that the risk factors have an effect before the 
clinical onset of the disease presents, due to the presence of autoantibodies and other 
biomarkers many years before symptoms appear (Deane and El-Gabalawy, 2014).  
RA is a heterogeneous disease both in terms of clinical presentation and pathogenesis. RA 
patients can be divided into two major subgroups based on the presence or absence of 
autoantibodies against citrullinated proteins, called anti-citrullinated protein antibodies 
(ACPAs), and autoantibodies specific for the Fc part of immunoglobulin G, known as 
rheumatoid factor (RF). The presence of ACPA and/or RF defines the form of RA known 
as seropositive RA that constitutes approximately two-thirds of all the disease cases 
(Malmstrom et al., 2017).  Interestingly, ACPA is specific for RA, but RF is not and can 
be found in other arthritides. The seropositive form of RA causes typically more bone and 
joint destruction and the patients respond better to B cell depletion therapy using the anti-
CD20 antibody, Rituximab (Chatzidionysiou et al., 2011). 
At diagnosis patients present classically with a symmetrical polyarthritis of the small joints 
of the hands and feet. The inflammation of the joints, or synovitis, occurs when a wide 
range of immune cells, such as T cells, B cells, macrophages and neutrophils, infiltrate the 
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synovial compartment (McInnes and Schett, 2011). All these cells contribute to RA 
pathogenesis by producing proinflammatory mediators, such as TNF-α, IFN-γ and IL-6. 
These pro-inflammatory mediators in turn create a positive feedback loop and further 
activate adaptive and innate immune pathways. These mediators also activate other resident 
cells, such as synovial fibroblasts, chondrocytes and osteoclasts, which promote tissue 
damage and remodelling, culminating in cartilage and bone destruction. All in all, this 
persistent inflammation drives the chronic phase in the pathogenesis of RA (Figure 1.1). 
The current approach used to treat RA firstly involves global immune suppression using 
conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs), such as 
methotrexate. If the patient does not respond to this treatment the next phase is the 
introduction of a newer therapy called biologics that cause more specific 
immunomodulation. The first biologic developed was Infliximab, a monoclonal antibody 
directed against TNF (Elliott et al., 1994). The following years saw an explosion of other 
biologic therapies, of interest in this thesis is Rituximab, an anti-CD20 antibody, which can 
be used to deplete B cells. Biologic therapies are generally more effective than DMARDs 
and have significantly improved the outcome of patients suffering from RA (Cheung and 
McInnes, 2017). Unfortunately, these treatments do not work on all patients, as only two 
thirds of patients respond to therapy. Consequently, there is an unmet need for new 
therapies in RA and therefore, exploring novel targets of pathogenic cellular subsets will 





Figure 1. 1. Representative diagram of a healthy joint and a rheumatoid arthritis 
joint. A. Schematic of a healthy joint with the thin synovial membrane which produces 
lubricating synovial fluid. B. Schematic of a rheumatoid arthritis joint. In RA, the synovial 
membrane is invaded by inflammatory cells as T and B cells. Moreover, the synoviocytes 
proliferate and the membrane becomes hyperplastic destroying the cartilage and the bone. 
Image obtained from Strand et al., 2007.
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1.1.2 Early Rheumatoid Arthritis 
Understanding the triggering event of RA continues to be challenging and identifying the 
possible triggers has proved remarkably difficult. A model for the longitudinal disease 
course of RA proposed by Malmstrӧm et al. and review by Smolen et al. divides the disease 
development in four phases (Malmstrom et al., 2017; Smolen et al., 2018). Phase 1 
represents triggering of the disease by an environmental stimulus plus the genetic risk at 
mucosal surfaces. Phase 2, maturation, occurs when the autoimmune response gradually 
matures, epitopes start spreading and autoantibody titres (ACPAs and RF) increase. This 
phase happens in regional lymph nodes and other secondary lymphoid organs. In Phase 3, 
the targeting, leukocytes are recruited into the joints and there is production of pro-
inflammatory mediators, which further activate cells and cause joint swelling. Moreover, 
ACPAs and RF autoantibodies also contribute to this inflammation. In phase 4, a second 
hit in the joints produced by a microtrauma or an infection could lead to synovial vascular 
activation, leading to additional recruitment of more pro-inflammatory cells into the joints. 
This leads to cartilage destruction, bone loss and joint damage. This phase 4 corresponds 
with the development of the classical symptomatology of RA caused by chronic 
inflammation of the joint (Figure 1.2).  
Different studies have demonstrated that treating patients at an early stage (phase 3), in the 
so-called window of opportunity, has better long-term outcomes in terms of patient 
morbidity and disease control (Smolen et al., 2016; Stoffer et al., 2016). This is translated 
in the clinic by the rapid initiation and escalation of DMARDs in the early stages after 
diagnosis. The aim of this approach is to achieve rapid and sustained low disease activity 
as soon as a patient has been diagnosed (Lard et al., 2001).  
In the clinic, the 2010 ACR/European League Against Rheumatism (EULAR) 
classification criteria was designed in part to make earlier diagnosis of RA feasible (Aletaha 
et al., 2010). However, from a research context, identifying the pathological processes that 
occur in early disease would provide new therapeutic targets and strategies with long term 
benefits. Moreover, studying the immune dysregulation in RA patients treated with 
DMARDs and glucocorticoids can limit our understanding of the disease process as these 
treatments can mask the immunological processes that are taking place.  
There is a great deal of interest in, and an advantage to studying the early onset of RA. It is 
thought that in RA a break of tolerance to self-antigens leads to the development of 
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autoimmunity. However, the point when this breach happens is still unknown and may vary 
between individuals (Deane and Holers, 2019). In recent years studies have shown that 
autoantibodies can be detected in the blood of individuals at risk years before the onset of 
the disease (Deane and El-Gabalawy, 2014). Moreover, there is emerging evidence that 
initiation and propagation of RA autoimmunity could occur at mucosal sites (Catrina et al., 
2014).  
In summary, studying early diagnosed patients before the start of therapy (i.e. drug naïve) 
will bring insights into the early pathogenesis of RA, which will help identify RA suffers 
and enable early, tailored treatment initiation, which will in turn improve their response to 





Figure 1. 2. Mechanisms involved in initiation and progression of rheumatoid 
arthritis. A.  Phase 1 represents triggering of the disease -by an environmental stimuli plus 
the genetic risk at mucosal surfaces such as the lungs, the gum or the gut. B. Phase 2, 
maturation, occurs when the autoimmune response gradually matures, epitopes start 
spreading and autoantibody titres (ACPAs and RF) increase. This phase is thought to 
happen in regional lymph nodes and other secondary lymphoid organs. C. In Phase 3, the 
targeting, the recruitment of leukocyte into the joints together with ACPAs and RF 
autoantibodies cause joint swelling. A wide range of recruited cells, as well as resident cells 
produce pro-inflammatory mediators which further promote inflammation. D. A second hit 
in the joints produced by a microtrauma or an infection could lead to synovial vascular 
activation, leading to additional recruitment of more pro-inflammatory cells into the joints. 
This leads to cartilage destruction, bone loss and joint damage. This phase 4 would 
correspond with the development of the classical symptomatology of RA caused by chronic 
inflammation of the joint. Adapted from Smolen et al., 2018. 
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1.2 Immune system overview 
The function of the immune system is to protect us from organisms that can cause disease. 
We are constantly in contact with organisms via inhalation, skin contact or ingestion and 
whether these organisms cause disease or not depends on their pathogenicity and also on 
the integrity of our immune system (Parkin and Cohen, 2001). The immune system is 
composed of lymphoid organs, cells and cytokines, which together protects the body from 
pathogens. The immune response is divided into two arms: an innate response, 
characterised by a rapid reaction, which provides immediate host defence, and an adaptive 
response, which takes more time to develop but it is characterised by an antigen specific 
response (Figure 1.3). A key function of the immune system is the recognition of self and 
non-self. This feature is essential to prevent damage to the body and when it fails an 
autoimmune, self-reactive response can develop resulting in destruction of organs (Kumar 
et al., 2017).  
1.2.1 Innate immunity 
Innate immunity is the first line of host defence against pathogens. Its importance in 
survival is demonstrated by the highly conserved innate response mechanisms across 
species (Yatim and Lakkis, 2015). The innate immune system is composed of physical 
barriers, such as mucosal surfaces, the complement system and innate immune cells. This 
group of cells consists of neutrophils, eosinophils, basophils, dendritic cells (DCs), 
monocytes/macrophages, innate lymphoid cells (ILCs), mast cells and natural killer cells 
(Janeway and Medzhitov, 2008).  
Although pathogens are very diverse, they all express conserved molecular structures not 
present in the eukaryotic organisms. Because related species of microbes have similar 
structures, this allows for the recognition of infectious non-self organisms by the immune 
system. These structures include components of microbial membranes, cell walls, proteins 
and DNA, and are called pathogen-associated molecular patterns (PAMPs) (Dempsey et 
al., 2003). These common structures are recognised by highly conserved receptors named 
pattern recognition receptors (PRRs). The best known of these PRRs are Toll-like receptors 
(TLRs), which detect the presence of pathogens and induce activation of inflammatory 
innate immune responses (Medzhitov, 2001).  
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The innate immune system is the first line of defence, it is a rapid response, but its lack of 
specificity can lead to tissue damage. Therefore, a more specific response, the adaptive 
immune response, is also needed.  
1.2.2 Adaptive immunity 
Adaptive immunity provides a more specific response to pathogens. This response involves 
antigen-presenting cells (APCs) directing T and indirectly, B lymphocytes (cells) to 
facilitate pathogen-specific effector pathways and generate immunologic memory. 
Lymphocytes are derived from progenitor cells in the bone marrow. T cells then develop 
and mature in the thymus and B cells do the same in the bone marrow. As part of this 
development/maturation process gene rearrangement of the antigen-recognition receptors, 
the T cell receptor (TCR) in T cells and the B cell receptor (BCR) in B cells, leads to the 
generation of unique antigen-specific receptors for T cells and B cells, with each individual 
T cell and B cell expressing receptors for a single specificity that recognises a single 
cognate antigen (Bonilla and Oettgen, 2010). Once a developed T cell or B cell enters the 
periphery, as a naïve cell, they can be activated in lymphoid organs, resulting in initiation 
of an adaptive immune response. In addition, some of these activated antigen-specific cells 
will became long-lived memory cells, which upon a second encounter with the same 
pathogen, will activate and produce a more rapid and robust protective response.  
The cells of the innate and adaptive immune system interact and work together to fight 
pathogens. Briefly, DCs, as professional antigen-presenting cells, present antigens in the 
form of peptides (processed forms of protein) to both to CD8+ and CD4+ cells via major 
histocompatibility complex (MHC) class I and class II molecules, respectively. The T cell 
recognises the presented antigen via their TCR, but only if the TCR is specific for that 
particular peptide. This interaction of MHC molecule-peptide complexes with the TCR is 
the first step in T cell activation and is known as signal 1(Williams and Bevan, 2007). But 
signal 1, antigen presentation, is not the only signal required for full T cell activation. DCs 
also provide co-stimulatory signals and cytokines (den Haan et al., 2014). The second 
signal (signal 2) is provided through co-stimulatory molecules, for example CD80 and 
CD86, expressed by DCs, which bind to CD28 on the T cell. Finally, a third signal (signal 
3) is transmitted through the release of cytokines. The cytokines milieu where the T cell 
activation happens will drive T helper (Th) cells towards one of several different 
differentiation pathways and will therefore result in different effector functions (Bonilla 
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and Oettgen, 2010). These three signals are required for the T cell to reach its expansion 
potential and fully activate (Curtsinger and Mescher, 2010).  
B cells are activated in a different manner to T cells. In brief, mature, naïve B cells can 
recognise antigens through their BCR, which, at this stage, includes both IgM and IgD 
isotypes (den Haan et al., 2014). B cells can be activated in two ways, depending on the 
type of antigen: T-dependent (TD) antigens, requiring T cell help, and T-independent (TI) 
antigens, which do not require T cell help. For TD antigens in order for B cells to fully 
activate, in addition to antigen recognition via their BCR, B cells also need help from T 
cells, particularly T follicular helper (Tfh) cells found in germinal centres. Recognition of 
antigen via the BCR, together with co-stimulatory signals and cytokines produced by T 
cells, leads to B cell activation, resulting in B cell proliferation, antibody affinity maturation 
and  immunoglobulin (Ig) class switch recombination (MacLennan, 1994). For TI antigens, 
B cells respond to the antigen independently of T cell help through BCR and other PRR 
receptor signalling or throughout chronic BCR stimulation by a specific antigen (Weller et 
al., 2001). Activation of B cells via the TD route leads to the generation of antigen-specific 
memory B cells, which results in a recall response that occurs more rapidly and consists of 
high affinity antibodies of the IgG, IgA or IgE isotypes (Ahmed and Gray, 1996). However, 
activation of B cells via the TI route induces very poor and short-lived memory responses, 
mainly producing antibodies of the IgM isotype. 
B cell maturation and differentiation as well as their role in the pathogenesis of RA are 





Figure 1. 3. The immune response consists of two arms: an innate response and an adaptive response. A. The innate response is the first line 
of host defence against pathogens. It is composed of epithelial barriers, the complement system and a group of innate cell populations. Their 
function is to detect the presence of pathogens and induce activation of inflammatory immune responses. B. The adaptive response provides a 
more specific response to antigens. This response involves B cells recognising a specific antigen and with T cell help differentiating into antibody 
secreting cells. Moreover, dendritic cells present antigens to T cells, which will expand and become effector T cells. This response facilitates 
pathogen-specific effector pathways and generates immunologic memory. Image obtained from Kumar et al., 2017.
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1.2.3 Immune system dysfunction in RA 
As explained before, RA has been regarded as an autoimmune disease resulting from 
immune dysregulation since the discovery of a genetic association between allelic HLA 
class II variants and the presence of autoantibodies. However, our understanding of how 
the immune response contributes to RA disease pathogenesis is constantly evolving as more 
research is conducted in the area. The immune dysregulation present in RA affects both 
types of immune response, innate and adaptive, as well as stromal cells, such as fibroblast 
and osteoclasts (Firestein and McInnes, 2017). In terms of the dysregulation of the innate 
response, macrophages present in the inflamed joints have been shown to secrete pro-
inflammatory cytokines, such as IL-1 and TNF-α and enzymes, such as metalloproteinases, 
which contribute to joint damage (Kinne et al., 2000). In addition, macrophages have high 
expression of HLA molecules which allows them to act as antigen presenting cells and 
therefore perpetuate the dysregulated adaptive response via the activation of T cells and B 
cells. 
Regarding the adaptive response, over recent years T cells have been acknowledged as one 
of the main pathological cell subsets in RA (Cope, 2008). The most convincing evidence 
that T cells play a role in RA pathogenesis is their high levels of infiltration in synovial 
biopsies (Duke et al., 1982). Moreover, genome wide association studies (GWAS) 
confirmed the association of HLA-DRB1 and other non-HLA regions such as protein 
tyrosine phosphatase-22 (PTPN22) and cytotoxic T-lymphocyte-associated antigen 4 
(CTLA-4) to the genetic risk of RA (Plenge et al., 2005). Additionally, inhibition of T cell 
co-stimulation by abatacept, a soluble antibody fusion protein of the CTLA-4 extracellular 
domain, which binds the co-stimulatory molecules CD80 and CD86 with higher affinity 
than CD28, improved the symptoms of RA (Kremer et al., 2003). However, describing a 
specific pathogenic T cell subset has been proven very difficult. RA was historically 
considered a Th1 disease due to IFN-γ expression in murine RA models (McInnes and 
Schett, 2007). Nevertheless, more recent studies using murine models suggested a Th17 
population may be a potent effector T cell subset in RA and other autoimmune diseases. 
IL-17 is present in the synovial fluid and the cytokine environment of the synovial fluid 
could potentially support Th17 differentiation. Th2 cytokines have also been suggested to 
play a role in early RA pathogenesis (Raza et al., 2005). Moreover, dysregulation of 
regulatory T cells (Tregs), a subset of T cells that dampens immune response, has also been 
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hypothesised to have reduced functional abilities in RA patients, which would make them 
less efficient at supressing inflammatory responses (Cooles et al., 2013).  
The presence of autoantibodies in RA patients, years before the onset of the disease 
confirms a role for B cells in RA disease initiation and progression (Conigliaro et al., 2016). 
The presence of ACPA autoantibodies has been associated with a progressive and 
destructive disease outcome, showing erosion lesions earlier and at a greater frequency in 
ACPA+ patients (Burska et al., 2014). Moreover, RF autoantibodies recognise IgG Fc 
fragments, crosslinking them and creating immune complexes. This immune complexes 
can then trigger complement activation, which initiates innate immune responses and 
inflammation (Brown et al., 1982). B cells can further contribute to disease pathogenesis 
through their production of cytokines, and via their ability to present antigens and activate 
T cells. Moreover, B cells have also been shown to be increased in the inflamed synovial 
compartment in RA (Page and Miossec, 2004). The contribution of B cells to RA 
pathogenesis is further discussed in section 1.3.3. 
As mentioned previously, there is growing evidence that autoimmunity may initiate at 
mucosal surfaces, such the lungs, the oral mucosa and the gastrointestinal tract. The exact 
mechanisms for this initiation are not fully understood. However, it is thought that local 
tissue stress leads to the post-translational modification of peptides, such as citrullination, 
which in turn drives subsequent antibody formation (Yap et al., 2018). Nevertheless, how 
the disease emerges in the joints is still unknown. Some groups hypothesise that a second 
“hit” in the joints produced by a microtrauma or an infection could lead to synovial vascular 
activation. Innate cells in the synovia, like mast cells, may then release vasoactive 
mediators and increase antibody access to the joint. Autoantibodies in the joint may 
therefore activate the complement cascade and release chemoattractants. This would lead 
to the activation of other resident cells, the recruitment of new innate and adaptive immune 
cells, and the promotion of stromal cell activation (Tan and Smolen, 2016). The recruitment 
of immune cells could in turn drive the production of more pro-inflammatory cytokines and 
chemokines self-perpetuating a positive feedback loop and eventually producing chronic 
inflammation (Firestein and McInnes, 2017). 
In summary, for years, CD4+ T cells have been thought to orchestrate the immune cascade 
in RA, as evidenced by the efficacy of blocking T cell co-stimulation for reducing RA 
activity (Kremer et al., 2003). Activated CD4+ T cells, as well as producing pro-
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inflammatory mediators, provide help for autoreactive B cells to differentiate into 
autoantibody-producing plasma cells. These factors, together with cytokines secreted by 
macrophages and fibroblast stimulated by activated CD4+ T cells, are crucial to perpetuate 
and maintain the chronic inflammation in the joints.  
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1.3 B cells 
The first discovery of a subset of cells, now known as B cells, came in 1890 with the 
discovery of circulating antitoxins in immunity to diphtheria and tetanus by Emil von 
Behring and Shibasaburo Kitasato. Later, Paul Ehrlich proposed that an immune cell 
carrying many different antibody receptors would bind an antigen and release receptors 
which would specifically bind that antigen (Cooper, 2015). The elucidation and purification 
of the antibodies led to rapid discoveries and to the recognition of B cells as a separate 
lymphocyte lineage. 
1.3.1 Naïve and memory B cells 
B cells develop from stem cells in the bone marrow and go through several maturation and 
activation stages in peripheral lymph nodes and spleen, until, as plasma cells, they can 
return to the bone marrow (Hardy and Hayakawa, 2001). B cells can be divided into two 
main subtypes: naïve and memory B cells. 
Immature B cells in the bone marrow undergo recombination of the V, D and J segments 
to produce an IgD or IgM BCR expressed on the cell surface. If this immature B cell 
succeeds in producing a functional BCR, it differentiates into a mature, naïve B cell. Mature 
naïve B cells are found in peripheral blood and lymphoid organs (Figure 1.4). They are 
characterised by the expression of IgD and IgM but lack switched-class IgG and the 
activation marker CD27 (LeBien and Tedder, 2008). Each mature naïve B cell expresses a 
unique BCR, which leads to a wide repertoire of naïve B cells capable of recognising a 
huge range of antigens. Many naïve B cells that leave the bone marrow contain autoreactive 





Figure 1. 4. B cell maturation and differentiation in secondary lymphoid organs. A. 
Summary of the development of human B cells. Immature B cells leave the bone marrow 
and enter a lymphoid follicle where they mature and express IgM and IgD. Mature naïve B 
cells expressing mainly IgD enter circulation looking for an antigen to bind. Antigen-
activated B cells will proliferate and differentiate with some of these going on to secrete 
IgM, whereas others undergo somatic hypermutation to improve antigen affinity. If affinity 
binding is improved the cell will undergo class switching and some will become IgG-
secreting plasma cells, whereas others will become circulating memory B cells preparing 
for future infections. B. B cells enter the lymphoid organ and migrate to the primary follicle. 
Stimulated antigen-specific B cells will interact with antigen-specific T helper cells at the 
interface between T and B zone. There B cells are stimulated and proliferate forming a 
primary focus. Some B cells will migrate to medullary cords and secrete antibody whereas 
other will migrate to the follicle and form a germinal centre where rapid proliferation, 
somatic mutation, selection and isotype switching will occur. Images obtained from 
Janeway et al., 2008.
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Mature B cells can be activated through the BCR following crosslinking with soluble or 
particulate antigens. The antigens recognise by the BCR are usually soluble antigens, 
however, B cells can also acquire and present antigens which are part of the surface of 
follicular dendritic cells (FDCs) and resident macrophages in the lymph node (Suzuki et 
al., 2009), as well as from apoptotic immune cells (Ciechomska et al., 2011). Importantly, 
they can internalise and process these antigens to present them to T cells in the context of 
MHCII. Following this interaction, B cells will receive stimulatory signals from the T cells 
such as CD40L/CD40 crosslinking and cytokines and a TD immune response is initiated. 
Mature naïve B cells are activated by the antigen through the BCR and at the border of the 
T cell and the B cell zone encounter antigen-specific T cells (Jacob and Kelsoe, 1992) 
(Figure 1.4). This interaction leads to further activation and proliferation of the B cells; 
some of the cells will become IgM short-lived plasma cells, whereas other will migrate into 
the B cell zone. Here, a germinal centre will develop: the B cells undergo proliferation and 
somatic hypermutation (SHM), which introduces mutations in the BCR variable region 
genes leading to generation of a diverse range of clones. Many of the mutations will 
produce a BCR with lower affinity and the B cells will be deleted via apoptosis (Rajewsky, 
1996). However, if the new BCR has improved affinity for its cognate antigen, the B cell 
will be positively selected. They will be selected for specificity and affinity through 
competition for native antigen captured on the surface of FDCs. The B cells with high 
affinity BCR will internalise and process the captured antigen and present it to antigen-
specific Tfh cells, allowing them to receive a second survival signal. The selected B cells 
can return to the dark zone of the germinal centre for further cycles of hypermutation and 
selection to optimise affinity. Furthermore, the B cells with high affinity BCR will undergo 
class-switch recombination in order to allow for the production of other immunoglobulin 
isotypes with the capacity of being secreted and distinct effector functions. This cell will 
undergo proliferation and depending on the transcription factor profile, some cells will 
differentiate into long-lived plasma cells with high antibody production, which will migrate 
to the bone marrow (Shapiro-Shelef and Calame, 2005). Other cells will differentiate into 
memory B cells, which will circulate as resting cells until they are reactivated by 
recognition of their cognate antigen. Although plasma cell differentiation transcription 
factors are well known the program that drives memory B cell differentiation is poorly 
understood (Seifert and Kuppers, 2016).  
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The circulating memory B cell pool, upon reactivation by their cognate antigen, can 
differentiate into plasma cells and help increase antibody titres during reinfection. In 
addition, memory B cells can re-enter germinal centres and undergo further affinity 
maturation rounds to readapt to the pathogen (Yoshida et al., 2010). 
The functions of antibodies are well known; antibodies can bind pathogens to target them 
for killing. Antibodies can also activate the complement system through the classical 
pathway and or can target pathogens to be phagocytosed by macrophages (Forthal, 2014). 
However, memory B cells can perform other functions apart from antibody production, for 
example they are capable of presenting antigens to T cells, as well as having multiple effects 
via the secretion of cytokines (LeBien and Tedder, 2008). A part from presenting antigens 
to T cells, B cells can influence T cell differentiation via expression of co-stimulatory 
molecules as well as via the production of cytokines which will regulate T cell fate (Gray 
et al., 2007a). B cell activation can develop without T cell help, leading to a TI immune 
response. The resulting plasma cells will produce antibodies, commonly of an IgM isotype, 
of low affinity and usually they do not give rise to long-lived memory B cells (Defrance et 
al., 2011). These TI responses generally depend on further B cell activation through TLRs 
or enhanced crosslinking through repetitive epitopes for example on carbohydrate antigens.  
1.3.2 CD5+ B cells 
CD5 expression on B cells was first described in mice (Berland and Wortis, 2002). In mice, 
three populations of B cells have been characterised, B1 B cells, B2 B cells and marginal 
zone (MZ) B cells. B1 B cells play an important role in innate immunity in opposition to 
B2 B cells which are involved in adaptive responses (Duan and Morel, 2006). MZ B cells 
are found in the spleen and have characteristics of both B1 and B2 B cells (Martin et al., 
2001). B1 B cells in mice have expression of CD5 and spontaneously produce low affinity 
IgM antibodies, reactive to self-antigens (Hayakawa et al., 1984). However, only a subset 
of B1 B cells expresses CD5, called B1a. The rest of B1 cells are negative for CD5 and are 
called B1b B cells. In humans, CD5 expression has also been observed in a B cell 
population. CD5 expression in humans marks a naïve B cell population and nearly all the 
B cells in neonates have expression of CD5. However, this expression decreases in 
peripheral blood with age, resulting in around 10-20% of B cells in blood in healthy adult 
individuals which are positive for CD5 (Carsetti et al., 2004). Like in mice, human CD5+ 
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B cells secrete polyreactive natural antibodies recognising self-antigens (Prieto and 
Felippe, 2017).  
Due to their ability to spontaneously produce autoantibodies, CD5+ B cells have been 
suggested to be implicated in autoimmune diseases. Some studies have found the CD5+ B 
cell subset is expanded in autoimmune diseases, such as RA or primary Sjogren’s syndrome 
(Berland and Wortis, 2002). However, their role in autoimmune diseases remains disputed. 
Some studies suggest CD5+ B cells protect against autoimmunity by producing the 
regulatory cytokine IL-10 (Dalloul, 2009). Other studies suggest CD5+ B cells contribute 
to autoimmune pathogenesis by producing polyreactive IgM antibodies that have low 
affinity and broad specificities (Duan and Morel, 2006). Treatment of RA patients with 
alemtuzumab, an anti-CD52 antibody that causes lymphocyte depletion, induced DMARD-
free clinical remission on 6 of 25 patients (Lorenzi et al., 2008). Our group followed a 
cohort of alemtuzumab treated patients 12 and 20 years after treatment and showed that 
alemtuzumab causes long-term alterations in lymphocyte subsets, with a reduction of CD4+ 
and CD8+ memory T cells and a decline in total CD19+ B cells as well as the CD5+ B cell 
subset and transitional regulatory B cells (CD9+ CD24high CD38high) (Anderson et al., 
2012; Cooles et al., 2016). From the B cell data, the CD5+ B cells results were interesting 
and were therefore chosen as a B cell subset to further characterise. 
1.3.3 B cells in RA 
As mentioned before, autoantibodies are a hallmark of RA. This suggests an important role 
for B cells in the initiation and the progression of RA. The most frequent autoantibodies 
are RF and ACPAs, but the specific autoantigen for these antibodies has not been well 
defined (Conigliaro et al., 2016). Moreover, these antibodies are present in individuals at 
risk, years before the onset of the disease. Recently, other autoantibodies have been 
associated with RA, such as anti-carbamylated protein antibodies (anti-CarP) (Brink et al., 
2015). 
Many naïve B cells containing autoreactive BCRs arise regularly (Grimaldi et al., 2005). 
In healthy individuals, most of the autoreactive B cells are removed through central or 
peripheral tolerance checkpoints. These checkpoints prevent B cells recognising self-
antigens or not functioning correctly to proliferate and differentiate. However, in RA, both 
mechanisms are defective, a defective central tolerance checkpoint in the bone marrow 
leads to an increase percentage of polyreactive early B cell precursors (Wardemann et al., 
20 
 
2003). The later peripheral tolerance checkpoint in RA has also been shown to be defective, 
which results in the accumulation of large numbers of self-reactive B cells in the mature 
naïve B cell compartment. This failure in removing autoreactive B cells may favour the 
development of autoimmunity (Bugatti et al., 2014). Therefore, a defect in B cell 
development might explain the presence of autoantibodies years before the disease onset 
(Yurasov and Nussenzweig, 2007).  
The interaction between B cells and T cells is the basis for the theory that in some 
autoimmune diseases, an amplification cycle, triggered by a certain factor, allows persistent 
inflammation and immunopathology. In RA, RF producing B cells provide one example of 
how autoreactive B cells might become self-perpetuating in this disease. RF is a soluble 
antibody specific for the Fc region of IgG, which can polymerise with the complement 
protein C3d. This complex can then bind to the complement receptor CR2, also known as 
CD21, on B cells, which can then provide a positive-feedback signal to the cell. Moreover, 
the BCR specific for RF can endocytose foreign antigens and consequently stimulate T 
cells that will then help activate the B cell by cytokines release (Leadbetter et al., 2002; 
Edwards and Cambridge, 2006). In the case of the ACPA antibodies, it is clear that T cells 
may be needed for B cell stimulation and production of autoantibodies as they are mainly, 
but not exclusively, IgG, so they require T cell-dependent class switching (Alivernini et al., 
2019). This is not as clear in the case of RF, since these autoantibodies are often IgM, but 
can also be IgG and IgA. 
Furthermore, a pathogenic role for B cells is confirmed by the efficacy of rituximab, an 
anti-CD20 antibody depleting therapy, in RA. Plasma cells are not targeted by anti-CD20 
antibodies, as they do not express CD20, and autoantibody levels are altered to varying 
degrees after treatment. These data suggest that the role of B cells in the pathogenesis of 
RA is not just linked to autoantibody production (McInnes and Schett, 2011). B cells can 
further contribute to disease pathogenesis due to their antigen presentation ability, leading 
to T cell activation, as well as production of cytokines (Figure 1.5). B cells can effectively 
present antigens to stimulate T cells and support optimal development of memory CD4+ T 
cells. RF+ B cells can uptake antigen immune complexes through their RF-specific receptor 
and process and present the peptides from the antigen, inducing T cell activation 
(Leadbetter et al., 2002).  
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In addition to antigen presentation, B cells can stimulate pathogenic immune responses 
through cytokine secretion (Figure 1.5). These cytokines, such as IL-6, IL-17 and TGF-β, 
can target T cells, and are known to have an effect on Th cell differentiation (Wong et al., 
2006). Furthermore, there is growing evidence that B cells in RA can contribute to the local 
synthesis of cytokines acting on other pathogenic cell types, including immune and non-
immune. There have been reports showing that synovial B cells have high expression of 
RANKL and TNF-α, which can act on osteoclasts promoting osteoclastogenesis (Yeo et 
al., 2015). Moreover, lymphocyte aggregates have been detected in the synovium of 
patients with early arthritis (van de Sande et al., 2011). 
In addition, regulatory B cells (Bregs) have been proven important in autoimmunity. Bregs, 
which have suppressive abilities that dampen an immune response, have been reported to 
be decreased in the blood of RA patients compared to healthy controls (Ma et al., 2014) 
(Figure 1.5). Moreover, injection of apoptotic cells into a collagen-induced arthritis (CIA) 
model prevented the development of CIA. Elucidation of the cellular mechanisms revealed 
that apoptotic cells have a direct effect on B cells, inducing production of IL-10, which in 
turn leads to the differentiation of an IL-10 producing regulatory T cell subset (Gray et al., 
2007b). 
Interestingly, growing evidence show that B cells activated via T-independent responses 
could play an important role in autoimmunity. Collaboration between T and B cells creates 
a positive loop that amplifies and perpetuates the activation of autoreactive responses 
(Shlomchik et al., 2001). Nevertheless, it has been published that activation of autoreactive 
B cells which produced autoantibodies did not require T cell help (Herlands et al., 2008), 
indicating that B cell activation is an initial step in systemic autoimmunity, which would 
be followed by consecutive activation of autoreactive T cells by these B cells. Moreover, 
TLR7 and TLR9 activation of the autoreactive B cells is a critical requirement for the 
activation of these cells with or without T cell help. Additionally, because somatic 
hypermutation can lead to the formation of autoreactive B cells, mechanisms of control are 
important in GC (Shokat and Goodnow, 1995). However, in the presence of chronic antigen 
stimulation and innate pathways activation, B cells can escape these mechanisms to control 
autoreactive B cells activating in the GC and the cells can undergo class switch outside 
GCs (William et al., 2002). This leading role of autoreactive B cells initiating autoimmune 
responses would explain the efficacy of B cell depletion therapies in autoimmune diseases 




Figure 1. 5. Potential B cell functional roles which may contribute to rheumatoid 
arthritis pathogenesis. 1. Antigen specific B and T cell interactions leads to the activation 
and differentiation of plasma cells, which are responsible for the production of 
autoantibodies. 2. Additionally, activated B cells provide help to T cells and induce 
differentiation of effector T cells which produce pro-inflammatory cytokines. 3. B cells can 
secrete pro-inflammatory cytokines, such as interleukin IL-1, IL-6, TNF-α and IL-17A. 4. 
Pro-inflammatory cytokines and RANKL produced by activated B cells, as well as T cells, 
macrophages, and synovial fibroblasts, promote the differentiation and activation of 
osteoclasts, leading to bone destruction. 5. However, B cells can also be immunoregulatory 
through the production of IL-10. Adapted from Bugatti et al., 2014.
23 
 
1.4 ABC-like cells 
Several groups have recently identified a novel subset of B cells named age-associated B 
cells (ABCs). These cells could potentially be involved in RA pathogenesis due to their 
potential ability to produce autoantibodies, cytokines and present antigens. Studies to 
characterise this subset have been performed in murine models, as well as a handful of 
human studies using healthy individuals and patients with autoimmune diseases. Table 1.1 
and 1.2, at the end of this section, summarise the different studies and shows the different 
characteristics of the ABC-like cells described by the different groups. 
1.4.1 Murine ABCs 
Rubtsov et al., described a population of murine B cells that express the integrins, CD11b 
and CD11c, but lack the complement receptor type 2, CD21(Rubtsov et al., 2011). It was 
found that these cells are increased in the spleen of aged female mice compared to young 
females or males of any age. Because this subpopulation appears in high frequency in aged 
mice, they were named ABCs. Characterisation of these cells revealed that they are slightly 
larger in size than follicular B cells (FO B cells). Moreover, these cells were positive for 
CD5 and expressed high levels of the co-stimulatory molecules, CD80 and CD86, as well 
as MHC-class II, suggesting they have an activated phenotype. This subset was increased 
in mice prone to autoimmune disease (NZB/WF1 and Mer-/- mice, which develop a lupus-
like disease) when compared to age-matched healthy mice (C57BL/6 mice). Hao et al., also 
described a similar B cell subset that lacked expression of CD21 in healthy old female mice 
(Hao et al., 2011). However, this subset lacked expression of CD5 and did not have an 
activated phenotype, as levels of MHC class II and CD86 were comparable with FO B cells. 
They described the subset as an exhausted B cell population but called them ABCs as they 
emerge with age. 
Murine ABCs, when stimulated by a TLR7 agonist, produce IgM similar to other B cell 
subsets, but also produce higher amounts of IgG (Rubtsov et al., 2013; Rubtsova et al., 
2017). These IgG antibodies recognise chromatin, demonstrating that ABCs may be a 
source of autoantibodies, and the higher frequency of ABCs in autoimmune-susceptible 
mice may directly affect the onset of autoimmunity. Interestingly, simultaneous stimulation 
with TLR and BCR ligation produce a strong response, resulting in extensive division and 
high numbers of responding cells (Hao et al., 2011). Moreover, chronic stimulation of B 
cells via TLR7 was sufficient to induce accumulation of ABCs, resulting in autoantibody 
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production (Rubtsov et al., 2011). Other studies using mice showed that accumulation of 
CD11c+T-bet+ ABCs induced dysregulation in T follicular helper differentiation through 
their potent antigen-presenting function which lead to a compromised formation of antigen-
specific GC B cell responses and antibody maturation (Zhang et al., 2019b). These findings 
provide a link between ABCs and autoantibody production. 
Gene expression analysis and flow cytometry showed overexpression of CD11c, in addition 
to transcripts of Ig heavy chain and CD138 (Syndecan-1), supporting their role as a unique 
antibody-secreting population that may be a plasma cell precursor (Rubtsov et al., 2011). 
Curiously, ABCs expressed genes are also found in helper and cytotoxic T cells such as T-
bet, perforin and granzyme A. Therefore, T-bet was described as a specific transcription 
factor for ABCs and other papers that characterised this subset used T-bet as an indicator 
of a B cell subset with an ABC-like phenotype. Rubstova et al., went on to demonstrate 
that T-bet expression in B cells is critical for the development of pathology and the rapid 
mortality in systemic lupus erythematosus (SLE) mice (Rubtsova et al., 2017). Moreover, 
they found that in the absence of T-bet expression, ABCs frequencies and numbers were 
reduced and that there was a significant reduction of anti-chromatin IgG2a levels. 
Despite the growing appreciation for the importance of T-bet in B cells, the signals that 
result in B cell expression of T-bet are not well understood. Studies using knockout mice 
show that IL-21 and IFN-γ together with TLR engagement promotes T-bet expression in B 
cells (Naradikian et al., 2016b). Moreover, IL-21 alone also induced CD11c expression. 
Conversely, IL-4 antagonised the induction of T-bet. Other studies in knockout mice 
demonstrated a role of interferon-regulatory factors (IRFs), IRF5 in the absence of SWEF 
proteins in the generation of ABC-like cells. SWAP-70 and DEF6 are the only two 
members of a Rho-family GTPase proteins, which regulate interferon-regulatory factors 
(IRFs). In the absence of SWEF proteins, there was a dysregulated activity of IRF5 in 
response to stimulation with IL-21 and this led to an enhanced generation of ABC-like cells 
in these mice (Manni et al., 2018).  
Other studies in T-bet+ B cells showed that T-bet expression was required for the formation 
of long-lived antibody-secreting cells (Stone et al., 2019). This study showed that T-bet 
facilitates differentiation of IFN-γ activated inflammatory effector B cells into antibody 




1.4.2 Human ABCs 
In autoimmune patients suffering from SLE and autoimmune cytopenia, a population of B 
cells, which are CD19high CD21- and that share features with murine ABCs, has been 
identified (Warnatz et al., 2002; Wehr et al., 2004). One of the main differences between 
murine ABCs and this human CD21low B cell subset is that only a proportion of 
autoimmune patients have high frequencies of this CD21low B cell subset in their 
peripheral blood. Rubtsov et al., investigated human ABCs, defined as CD19high CD21-
CD11c+ B cells, in the peripheral blood of RA, Systemic sclerosis (SSc) and SLE patients, 
and found high frequencies of this subset in a proportion of patients with RA and SSc 
(Rubtsov et al., 2011). The expanded ABC population was observed at a higher frequency 
in women over 60 years old suffering from RA compared to younger women and men of 
any age. Another study, which compared healthy controls and patients with RA and defined 
ABC-like cells as CD21lowCD86+, found that the RA patients had higher frequencies than 
the healthy controls (Shimabukuro-Vornhagen et al., 2017). 
CD21low B cells have been described in different diseases ranging from infections to 
autoimmunity (Isaak et al., 2006; Charles et al., 2011; Ma et al., 2019). The common 
feature in all these diseases is chronic immune stimulation. CD21, also known as 
complement receptor type 2, binds to complement fragments bound to antigens. On B cells, 
CD21 forms a complex with CD19 and CD81 and functions as a co-receptor for the BCR 
(Cherukuri et al., 2001). Therefore, through its complement binding ability, CD21 can 
enhance B cell responses to an antigen, and via the CD21/CD19/CD81 complex can 
modulate the strength of the BCR signal. Activation of B cells can lead to a reduction in 
expression of CD21 (Masilamani et al., 2003), suggesting that the CD21low B cell subset 
may be maintained in situations in which low-level chronic antigen stimulation is present, 
such as in chronic inflammatory conditions (Winslow et al., 2017). 
With regard to the phenotype of these CD21low B cells there are some discrepancies in the 
reported expression of several surface molecules, such as CD27. This discrepancy could be 
due to the presence of more than one subset within the CD21low population. Focusing on 
RA, two CD21low B cell subsets have been found to be expanded in peripheral blood: one 
expresses CD27, while the other lacks expression of this receptor (Thorarinsdottir et al., 
2015). Rubtsov et al., found that the CD27+ subset also express CD11c and CD5, in 
addition to activation markers, such as CD80 and CD86, and were considered to be memory 
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B cells as they were class-switched (Rubtsov et al., 2011). The CD27- cells, characterised 
by Isnardi et al., also express CD11c but displayed unmutated IgM (Isnardi et al., 2010). 
Moreover, this particular CD27-CD21low B cell subset responded poorly to BCR 
stimulation and displayed autoreactive traits and were therefore, described as anergic naïve 
B cells.  
The CD21low B cell subset described by the three different groups had high expression of 
the co-stimulatory molecules CD80 and CD86, as well as the MHC class II molecule, HLA-
DR (Isnardi et al., 2010; Rubtsov et al., 2011; Shimabukuro-Vornhagen et al., 2017). These 
CD21-CD11c+ B cells were also positive for T-bet. Rubtsova et al., demonstrated that T-
bet expression in B cells is critical for B cell activation and generation of germinal centre 
B cells (Rubtsova et al., 2017). In addition, B cell expression of T-bet was also required 
for effective T cell activation, possibly due to T-bet expressing ABCs being potent antigen 
presenting cells. This highlights two possible roles of ABCs in autoimmune pathogenesis, 
autoantibody production and antigen-presentation to T cells. Figure 1.6 shows a model for 




Figure 1. 6. Origin, fate and function of T-bet+ B cells. Microbial pathogens and apoptotic debris can trigger signalling of innate receptors 
recognising nucleic acids. These signals in conjunction with a Th1 cytokine milieu composed of IL-21 and IFN-γ (and absence of IL-4, which is 
inhibitory) can induce expression of T-bet in B cells. There is evidence suggesting that there is a requirement for cognate help and germinal centre-
dependent formation of T-bet+ B cells. However, these cells can also develop extrafollicularly under certain circumstances. T-bet expression drives 
class switching to IgG1 isotype antibodies. T-bet+ memory B cells are persistent, most likely due to self-renewal, and can be progenitors of plasma 
cells or differentiate into other effector cell lineages upon re-challenge. Because of their persistence and roles in antibody secretion and other B 
cell functions, T-bet+ B cells are key players in protective humoral immunity, as well as in pathogenic processes. Adapted from Knox et al., 2019. 
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Recent studies have investigated the origin of these cells. Similar to murine studies, in 
patients with SLE, IL-21 was able to induce CD11c+T-bet+ B cells and promote the 
differentiation of these cells into autoreactive antibody-secreting plasma cells (Wang et al., 
2018). This study highlights a role for IL-21 in the generation of cells with an ABCs-like 
phenotype. This is further supported by studies in mice which show that IL-21 and IFN-γ 
together with TLR engagement promotes T-bet expression in B cells (Naradikian et al., 
2016b).   
Other studies have also investigated expression of antibodies by ABCs to determine if these 
cells have undergone class switching, in addition to determining their replicative ability. 
The subset described by Shimabukuro-Vornhagen et al., as CD21lowCD86+ B cells 
contained a large proportion of proliferating cells, assessed by the expression of Ki67, and 
a high degree of class-switched cells which were IgM and IgD negative (Shimabukuro-
Vornhagen et al., 2017). In line with these results, Rubtsov et al., found that ABCs were 
negative for IgD and IgM, but positive for IgG (Rubtsov et al., 2011). However, Isnardi et 
al., found that CD21low B cells from RA patients preferentially expressed IgM and/or IgD, 
whereas CD21low B cells from healthy donors were class-switched B cells (Isnardi et al., 
2010). This further supports the idea that the CD21low B cell subset described by some 
groups is a heterogeneous, mixed B cell population. 
Transcriptome analysis was also performed to assess gene expression in ABCs and 
CD21low B cells. Shimabukuro-Vornhagen et al., reported that CD21lowCD86+ B cells 
had high gene expression of chemokine receptors and adhesion molecules involved in 
extravasation and recruitment to sites of inflammation, such as CD11a, CCR3, CCR5, 
CCR10 and CXCR2 (Shimabukuro-Vornhagen et al., 2017). In addition, their gene 
expression for lymph node homing receptors was low. On the contrary, transcriptome 
analysis by Isnardi et al., found that CD21low B cells downregulate genes encoding 
survival and activation proteins, as well as cytokine and chemokine receptors that stimulate 
B cell proliferation. In contrast, this subset up-regulated inhibitory receptors to supress B 
cell activation and proliferation (Isnardi et al., 2010). 
Isnardi et al., characterised CD21low B cells as lacking the ability to become activated, 
proliferate or secrete antibodies upon BCR triggering (Isnardi et al., 2010). This subset was 
referred to as anergic and their irresponsive state was suggested to result from chronic BCR 
exposure to self-antigens. This result is consistent with Shimabukuro-Vornhagen et al., 
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who found that CD21lowCD86+ B cells have impaired BCR-induced signalling 
(Shimabukuro-Vornhagen et al., 2017). The results from Shimabukuro-Vornhagen et al., 
agree with the suggestion that, if this B cell subset is already in an activated state, they will 
be less responsive to BCR stimulation. Although Isnardi et al., found that the CD21low B 
cells are prone to die by apoptosis, and stimulation by their BCR, or via CD40 or TLR9 
ligation, does not rescue them from cell death (Isnardi et al., 2010), other groups have 
shown that murine ABC-like cells do respond to TLR engagement; TLR7 and TLR9 
stimulation was sufficient to induce proliferation and antibody production (Hao et al., 2011; 
Rubtsov et al., 2011). These reported differences with regard to response to stimuli could 
be explained by the fact that the CD21low B cell subset investigated by Isnardi et al., is a 
different subset to other ABC-like B cells or ABCs, as their CD21low B cells are described 
as being anergic, and only one marker, CD21, in addition to CD19, is used to identify the 
population. Additionally, these differences could be due to species variation as the Hao et 
al., and Rubtsov et al., studies were done using mouse cells.  
There is some debate on whether these ABCs and CD21low B cells are naïve B cells, 
memory B cells or plasma cells. As explained before, there could be two subsets of 
CD21low CD11c+ B cells. The CD21low B cell subset described by Isnardi et al., are naïve 
B cells because they are not class-switched B cells (Isnardi et al., 2010). Nevertheless, the 
CD21lowCD86+ B cell subset characterised by Shimaburuko-Vornhagen et al., could be 
in a translational state between germinal centre B cells and early plasmablasts based on 
their phenotypic and functional characterisation (Shimabukuro-Vornhagen et al., 2017). 
As ABCs and CD21low B cells are increased in inflammatory diseases, such as RA, they 
could be involved in the pathophysiology of this disease and would therefore, be a 
promising target for the development of new therapies for the treatment of autoimmune 
diseases. As explained before, Rituximab is effective in some patients with RA 
(Tavakolpour et al., 2019), but development of more specific therapies could be more 
efficient and be effective in a larger number of patients. Nevertheless, new markers for 
these newly discovered ABCs and CD21low B cell subsets are still needed in order to 
develop therapies against novel targets. 
Sadly, our knowledge of these cells is obscured by the fact that the cells are defined in 
different ways by different investigators, in addition to the fact that the ABC population is 
heterogeneous in surface marker expression, and presumably, function (Phalke and 
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Marrack, 2018). For this reason, more studies on the phenotype, gene expression and 
function of these subsets of B cells will help characterise these cells and elucidate their role 
in health and disease. 
1.4.3 FcRL4+ B cells 
An interesting new subset of the synovial fluid B cells has recently investigated by my co-
supervisor, Professor Dagmar Scheel-Toellner. This subset express FcRL4 and produce the 
cytokines Receptor Activator of Nuclear factor Kappa-B Ligand (RANKL) and TNF-α, 
which stimulates the differentiation and activation of osteoclasts (Yeo et al., 2011). This 
FcRL4+ B cell subset shows some similarities with the ABCs described in peripheral blood. 
These cells express low levels of CD21 and were positive for CD11c. Moreover, other 
studies in mice have shown that CD21low B cells display altered ataxia telangiectasia-
mutated (ATM) function, leading to increased RANKL production and bone erosion, as 
well as a rise in circulating CD21low B cells (Mensah et al., 2019). The FcLR4+ synovial 
B cells are considered class-switched memory B cells because they express CD27, IgG and 
IgA but do not express IgD and CD38. Moreover, this FcRL4+ subset shows elevated 
expression of adhesion molecules and the chemokines receptors CCR1 and CCR5, in 
addition to high expression of co-stimulatory molecules, CD80 and CD86. Interestingly, 
FcRL4 has been shown to attenuate BCR signalling but augment B cell activation through 
TLR9 signalling (Sohn et al., 2011). Ligands for TLR9, like bacterial DNA containing CpG 
motifs, have been found in the synovial fluid of patients with RA (Zhao et al., 2018). It is 
feasible that FcRL4 expression on the B cells in RA patients, may enhance immune 
activation through TLR9, or via other receptors known to be potently activated by disease-
relevant ligands, such as immune complexes containing citrullinated proteins. FcRL4+ B 
cells express more IgA, a mucosal immunity-associated Ig, than FcRL4- B cells, which is 
interesting as currently there is growing evidence supporting the hypothesis that RA 
pathogenesis could start with mucosal inflammation in the gum, the gut and the lungs 
(Catrina et al., 2014). Additional studies are needed to determine if these FcRL4+IgA+ B 
cells are generated due to an IgA immune response in the mucosa and later they migrate to 
the joints. Moreover, since the ABCs and CD21low B cell subsets described in this review 
share several surface markers with the FcRL4+ B cells in synovia, it may be possible that 
the ABCs are the blood precursors of these FcRL4+ B cells found in RA joints (Amara et 
al., 2017). Further work is needed to investigate the relationship of ABCs and ABC-like 
cells with the novel joint FcRL4+ B cell population.
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Rubtsov et al., 2011 
Rubtsova et al., 2017 
CD19 high  
CD11c+ 
CD21- 
High: CD5, CD80, CD86 and HLA-DR 





Hao et al., 2011 
CD19+ 
CD21- 
Normal CD86 and HLA-DR  
Negative: CD5 
TLR9 and 
TLRs + BCR 
IgM and low IgD 
Human 
Rubtsov et al., 2011 
CD19 high  
CD11c+ 
CD21- 
High: CD5, CD80, CD86, CD20 and CD27 
Negative: CD23- and CD38low 
- IgG 
Wang et al., 2018 
CD19 high 
CD11c high  
T-bet+ 
High: CD32, CD95, CD20 and FcRL5 
Negative: CD5, CD21, CD23 and CD138 
Low: CD27, CD38 and CD40 
Respond to coculture 
with anti-CD3-










High: CD80, HLA-DR and HLA-ABC 
Positive: CD27 and Ki67 
Low: CD40 
Chronic CD40L 
No response to BCR 
IgG 
Isnardi et al., 2010 
CD19+ 
CD21- 
High: CD5, CD80, MHC class II  and CD20 
Positive: T-Bet 




A bit by TLR9 
IgM and/or IgD 
RA 
synovia 
Yeo et al., 2015 
Amara et al., 2017 
CD19high  
FcRL4+ 
High: CD80, CD86 and CD11c  
Positive: CD27+ and FcRL5+ 





Table 1. 1. ABC-like cell characteristics described by different groups. ABC-like cells have been characterised in mice, human and RA synovia. 
Summary of the markers used to describe ABC-like cells by each group, as well as information on their response to stimulation and their 
immunoglobulin expression profile is shown.  
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  Main markers Activation status B cell type Increased in Function 
Mouse 
Rubtsov et al., 
2011 
Rubtsova et al., 
2017 
CD19 high  
CD11c+ 
CD21- 
Activated B cells 
Plasmablast (precursors 
of plasma cells) 






Hao et al., 2011 
CD19+ 
CD21- 




Rubtsov et al., 
2011 
CD19 high  
CD11c+ 
CD21- 
Activated B cells - RA and SSc 
Possibly antigen  
presenting cells 
Autoantibody secretion 
Wang et al., 2018 
CD19 high 
CD11c high  
T-bet+ 
Activated B cells 
Memory B cells, rapidly 
differentiate into plasma 
cells 
SLE Autoantibody secretion 
Shimabukuro-





Activated B cells 
Translation state: between 
germinal centre and early 
plasmablasts 




Isnardi et al., 2010 
CD19+ 
CD21- 
Anergic B cells Naïve B cells RA and CVID - 
RA 
synovia 
Yeo et al., 2015 
Amara et al., 2017 
CD19high  
FcRL4+ 
Activated B cells Switched memory B cells Synovial fluid in RA 
Possibly potent antigen 
presenting cells 
 
Table 1. 2. ABC-like cell characteristics described by different groups. ABC-like cells have been characterised in mice, human and RA synovia. 
Summary of the activation status, as well as the classification of the ABC-like cells by each group. Information on the disease in which these cells 
were described as well as they postulated function is shown. 
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1.5 Fc Receptor Like (FcRLs) family  
Fc receptor-like (FcRL) molecules were identified around 15 years ago. In 2006, a uniform 
nomenclature was established to designate the FcRL family, as prior to this the members 
of this family were given different names when they were first discovered by several groups 
(Maltais et al., 2006; Li et al., 2014a). A summary of the information for each FcRL family 
member can be found in Table 1.3, at the end of this section. 
FcRL1 to FcRL5 are located in what is called the human FcRL1-5 gene cluster. It spans 
approximate a 300 kb region of the chromosome 1q21-22 and it encodes type I 
transmembrane glycoproteins with 3-9 extracellular Ig-like domains and cytoplasmic tails 
with immunoreceptor tyrosine-based-activating (ITAM), -switch (ITSM) and/or -
inhibitory (ITIM) motifs (Figure 1.7) (Mechetina et al., 2002). FcRL6 codes for a 
transmembrane receptor with similar features, but it is located at a separate locus. Finally, 
two additional relatives were discovered; FcRLA and FcRLB, which lack transmembrane 
segments and are intracellular proteins. All the FcRLs members, except for FcRL6, are 
preferentially expressed by B cells (Ehrhardt et al., 2007).  
 
Figure 1. 7. Protein structure of the human FcRL family molecules. In the extracellular 
space, immunoglobulin domains are shown as circles. These are colour-coded to indicate 
their phylogenetic relationships. FcRL cytoplasmic tails possess consensus sequences for 
immunoreceptor tyrosine-based activating motifs (ITAM) in red, immunoreceptor 
tyrosine-based inhibitory motifs (ITIM) in green and immunoreceptor tyrosine-based 





The cellular distribution of FcRL1-5 varies between each member of the family. However, 
in general, their expression increases with B cell differentiation and peaks in circulating 
cells and those localised to secondary lymphoid tissues (Davis et al., 2001). FcRL1 emerges 
at the pre-B cell stage and increases with B cell maturation, with higher expression in naïve 
and memory subpopulations. FcRL2 and FcRL3 both peak on memory B cells in the 
periphery and mark a circulation innate-like MZ B cell equivalent (Polson et al., 2006). 
However, FcRL3 is also expressed outside the B cell lineage by subpopulations of cytotoxic 
NK cells and CD8+ T cells, as well as a dysfunctional population of CD4+ regulatory T 
cells (Swainson et al., 2010). FcRL4 is expressed in a subpopulation of tissue-based 
memory B cells located in mucosa-associated lymphoid tissues (MALT) and its expression 
in circulating B cells is scarce (Falini et al., 2003). Additionally, FcRL4 is expressed by a 
B cell subset found in the synovial fluid of patients suffering from RA (Yeo et al., 2015). 
Lastly, FcRL5 has a broader distribution that reaches the highest surface density on 
terminally differentiated plasma cells derived from the bone marrow (Polson et al., 2006). 
Unfortunately, the ligands for most of the FcRLs family members are still unknown. Only 
the ligands for FcRL4 and FcRL5, and recently for FcRL3, have been described. Previous 
reports suggested that FcRLs might be Fc receptors as for their high homology to FcγRI 
(Hatzivassiliou et al., 2001). Wilson et al. showed that FcRL4 and FcRL5, but not the other 
FcRLs, can bind heat-aggregated IgA and IgG, respectively (Wilson et al., 2012). 
Transfected cells with the different FcRL family members where incubated with heat-
aggregated IgA, IgG and IgM and binding of the immunoglobulins to FcRLs expressing 
cells was assessed by flow cytometry. No binding of human IgM to any of the FcRL family 
members was observed, however FcRL4 showed binding to IgA and FcRL5 to IgG. The 
FcRL5 findings were confirmed by Franco et al. demonstrating that FcRL5 binds IgG not 
through the Fc receptor fragment but via other mechanisms (Franco et al., 2013). 
Additionally, the FcRL4 findings were confirm by my co-supervisor in Birmingham, 
Professor Dagmar Scheel-Toellner (unpublished). Recently, the ligand for FcRL3 has been 
postulated to be secreted IgA (Agarwal et al., 2020). Nevertheless, the IgA found to bind 
FcRL3 was not heat-aggregated but was secretory IgA from human colostrum. Secretory 
IgA binding to FcRL3 was assessed by surface plasmon resonance and further confirmed 
by flow cytometry on transfected cell lines and primary B cells and Treg cells.  
The role of these receptors in both innate and adaptive immunity is still under investigation. 
The cytoplasmic properties of FcRLs are complex. Most FcRLs cytoplasmic tail possess 
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both ITAM-like and ITIM elements. The possession of these intracellular sequences 
indicates that most of these molecules may be capable of exerting a dual-modulation, i.e. 
they may activate or inhibit responses (Ehrhardt et al., 2007). FcRL1 is the only FcRL 
family member with two ITAM-like sequences and appears to act as a co-activation 
receptor. Its ligation by receptor-specific monoclonal antibodies and crosslinking with the 
BCR enhances calcium flux augmenting B cell activation and proliferation (Leu et al., 
2005). 
Regarding the other FcRLs, several groups have carried out work exploring the 
contributions of the FcRL2-5 cytoplasmic tyrosine-based motifs on BCR-mediated 
activation (Haga et al., 2007; Kochi et al., 2009; Jackson et al., 2010). Their engagement 
alone does not appear to impact basal B cell function. Nevertheless, crosslinking the FcRL 
and the BCR induces phosphorylation of intracellular tyrosine residues of the BCR and 
promotes docking of the SHP-1 and/or SHP-2 SH-2 domain-containing phosphatases at 
consensus ITIMs (Figure 1.8). The outcome of these repressive signals is, therefore, an 
attenuation of antigen receptor-mediated calcium mobilisation and MAPK activation that 
results in apoptosis.  
Nonetheless, recent work has begun to explore the effects of human FcRLs on innate-driven 
responses. Different studies on FcRL3 and FcRL4 provided evidence that these proteins 
promote TLR-mediated signalling. Exposure of FcRL4 expressing B cells to the TLR9 
agonist CpG prompted co-localisation of these receptors in endosomes and the upregulation 
of CD23, an indicator of TLR activation (Sohn et al., 2011). FcRL3 studies show that 
engagement of FcRL3 with specific monoclonal antibodies enhanced TLR9 triggered blood 
B cell proliferation, survival, and induction of CD25, CD86 and HLA-DR activation 
markers (Li et al., 2013). FcRL3 had inverse effects on antibody production and blocked 
the differentiation of antibody-secreting cells. Flow cytometry analysis revealed that 
FcRL3 enhances CpG-mediated NF-kB p65 and MAPK pERK and p38 activation (Figure 
1.8).  
In T cells, Agarwal et al., showed that stimulation of Tregs with FcRL3 ligand, secreted 
IgA, impaired Treg-mediated inhibition of responder cell proliferation, concluding that 
secreted IgA through its binding to FcRL3, inhibits Treg cell suppressive function (Agarwal 
et al., 2020). Moreover, FcRL3 stimulation promoted the transition of Treg cells towards a 
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Th17-like phenotype, which in inflammatory environments with secretion of IgA, might 
contribute to pathogen and tumour clearance.  
 
Figure 1. 8. FcRL3 regulation of adaptive and innate signalling pathways. Co-ligation 
of FcRL3 with the BCR facilitates the recruitment of SHP-1 and SHP-2 that inhibit Syk 
and PLCγ2 phosphorylation on the BCR and suppresses downstream calcium signalling 
and induces apoptosis. Nevertheless, after exposure to CpG, a TLR9 agonist, FcRL3 
expressing B cells activate the NF-κB and MAPK/pERK pathways that drive proliferation. 
Phosphorylated ERK additionally induces expression of the BLIMP1 plasma cell 
commitment factor which stimulates B cell differentiation and antibody production. In 
addition, simultaneous crosslinking of FcRL3 in TLR9-activated B cells significantly 
elevates NF-κB and pERK to promote proliferation and survival. However, this augmented 
pERK activation in TLR9 and FcRL3 co-stimulated B cells represses BLIMP1 induction 
and therefore abolishes plasma cell differentiation and antibody production.  Image 
obtained from Li et al., 2014.
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In addition, expression of FcRLs and their involvement with immune-mediated disorders 
has also been investigated. Multiple groups have detected expression and dysregulation of 
FcRLs in various lymphoproliferative disorders. FcRL2 was upregulated in the mutated-
indolent subtype of leukaemia and emerged as an aggression biomarker (Li et al., 2008). 
Several FcRLs have also drawn interest because of their upregulation in lymphocyte 
populations in individuals with infectious diseases. For example, in patients afflicted with 
chronic viral diseases, such as HIV and hepatitis C, there is appearance of an FcRL4+ 
population of B cells (Moir et al., 2008).  
Regarding tolerance and autoimmunity, disease risk associations for single nucleotide 
polymorphisms (SNP) located in regions of the FcRL genes have arisen in a variety of 
disorders. The principal variant (rs7528684) was located in a potential NF-κB consensus 
binding motif within the FcRL3 promoter region (Kochi et al., 2005). The C susceptibility 
allele of this SNP (169T → C) generated a more orthodox NF-κB binding sequence, with 
higher promoter activity via p50, p65 and c-Rel binding and exerted a dose-dependent 
regulatory effect on FcRL3 transcript and protein expression. These results suggesting that 
the FcRL3 polymorphism may be a risk factor for RA were confirmed by our group (Clark 
et al., 2020). Clark et al. identified both a methylation and an expression quantitative trait 
locus (mQTL and eQTL, respectively) in the FcRL3 region on B cells and T cells from 
patients with RA. However, there have been conflicting results as many studies found no 
link for FcRL3 with autoimmune disease susceptibility (Eyre et al., 2006). These 
discrepancies may reflect differences in racial and ethnic backgrounds. 
In summary, expression of FcRLs and their link to both innate and adaptive immune 
responses, for example the preferential expression of FcRL2 and FcRL3 by innate-like MZ 
B cells and their capacity to promote T-cell independent responses, is an interesting new 
avenue to explore with regard to autoimmune diseases. As several FcRLs appear to serve 
as facilitators of innate stimulation, and as TLR stimulation of ABCs, or ABC-like B cells, 
seems to be important for not only generation of these cells, but also plays a role in their 
function, determining the role of FcRLs on cell function is another interesting area for 
investigation. Finally, the significance of FcRLs as pathologic, diagnostic, prognostic and 
therapeutic agents is showing great promise in a large number of lymphoid malignancies 




 FcRL1 FcRL2 FcRL3 FcRL4 FcRL5 FcRL6 FcRLA FcRLB 
Cytoplasmic tail 2 ITAMs 
1 ITAM and 2 
ITIMs 
1 ITAM and 1 
ITIM 
2 ITIMs and 1 
ITSM 












Distribution Pan B cell 
Memory B cells  
(circulating MZ) 
B cells, T cells 








cells and NK 
cells 
Germinal 
centre B cells 
Germinal 
centre B cells 





or intact IgG 







Table 1. 3. Summary table of the FcRL family members’ characteristics. Each FcRL family member is shown in a different colour. Information 
about their cytoplasmic tail motifs, the cellular location, the distribution and their ligands is shown in each row. 
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1.6 Hypothesis, aims and objectives 
I hypothesised that ABCs represent a differentiated, activated and pathogenic B cell 
population in RA. These cells are capable of migrating to sites of inflammation and 
perpetuate inflammation and disease pathogenesis via the secretion of autoantibodies and 
pro-inflammatory mediators.  
The aims of my study were to: 
1. Determine the frequency of ABCs in peripheral blood and synovial fluid in early 
and established RA patients compared to disease controls and age-matched healthy 
controls.  
2. Phenotypically characterise peripheral blood ABCs.  
3. Determine the transcriptomic profile of ABCs from early RA patients compared to 
disease controls and age-matched healthy controls.   
4. Investigate the function of ABCs.  
5. Conduct a preliminary study to elucidate the role of FcRL3 expression on B cell 
function.  
The specific objectives were to: 
1. Compare ABCs frequency in peripheral blood in different inflammatory arthritides 
as well as healthy controls using flow cytometry.  
2. Compare expression of different markers (co-stimulatory, activation, transcription 
factors, immunoglobulin, etc.) between ABCs and other B cell subsets using flow 
cytometry.  
3. Determine the transcriptomic profile of ABCs and other B cell subsets from early 
RA patients compared to disease controls and healthy controls using NanoString 
Technology.  
4. Investigate the function of ABCs by assessing their secretion of immunoglobulins 
and their cytokine production profile after culture and stimulation. 
5. Explore the potential role for FcRL3 on B cell function using a stably transduced B 






Chapter 2. Materials and methods 
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2.1 Patient recruitment   
2.1.1 Ethics 
Ethical approval for the recruitment of patients was provided by North East – Newcastle & 
North Tyneside 2 Research Ethics Committee, for the project entitled Prognostic and 
therapeutic biomarkers in an observational inception cohort: the Northeast Early Arthritis 
Cohort: REC reference 12/NE/0251. In addition, ethics for healthy volunteers were 
provided by two ethically approved projects: 1. For the project entitled The role of 
inflammation in human immunity, ethical approval was provided by the County of Durham 
and Tees Valley Research Ethics Committee, REC reference 12/NE/0121; and 2. For the 
project titled Understanding Mechanisms of Immune Mediated Disease, ethical approval 
was obtained from The Animal Welfare and Ethical Review Body (AWERB), Newcastle 
University, project ID Number: ID 633. 
2.1.2 Early Arthritis Clinic 
Patients were recruited from the Newcastle Early Arthritis Clinic (NEAC), in the 
Musculoskeletal Unit at the Freeman Hospital, Newcastle-upon-Tyne. Patients referred to 
the NEAC from their primary healthcare provider have suspected inflammatory arthritis 
and are seen within 14 weeks of symptoms onset. At visit 1 (week 1) patients are reviewed 
by the nurse specialist, their disease activity is assessed, an ultrasound examination is 
performed and routine blood test is collected for clinical tests to assess inflammation and 
rheumatology markers. Disease activity is measured by the DAS28, DAS stands for 
“Disease Activity Score” and 28 refers to the 28 joints examined in this assessment. This 
score is calculated by the number of tender joints, the number of swollen joints, the patient’s 
assessment on their global health using the visual analogue scale and with the inflammatory 
markers CRP or ESR. At visit 2, a week later, a consultant rheumatologist examines the 
patient and considering the patient’s clinical history, the examination and the above 
investigations, a diagnosis is made.  
Patients diagnosed with RA following the 2010 ACR/EULAR classification criteria were, 
where possible, recruited. Other disease controls were also recruited, which included 
patients diagnosed with psoriatic arthritis, ACPA+ arthralgia, undifferentiated, crystal and 
reactive arthritis. All these patients were naïve to disease modifying anti-rheumatic drugs 
(DMARDs) and biological therapies.  
43 
 
For all these patients, where possible, RF and CCP antibody titres, ESR and CRP values, 
DAS28 score (only for RA patients), smoking status, age and sex were recorded.  
2.1.3 Established RA patients 
Patients with a diagnosis of RA and a disease duration of more than 12 months were also 
recruited. These patients were recruited from the rheumatology clinics/day unit services at 
the Musculoskeletal Unit at the Freeman Hospital, Newcastle-upon-Tyne. All the patients 
recruited were treated only with DMARDs, methotrexate (MTX), hydroxychloroquine 
(HCQ) and sulfasalazine (SSZ), but not with biological therapies. Any patient that had 
received any oral, intramuscular or intra-articular glucocorticoid steroids in the last 3 
months were excluded. For all the patients an attempt was made to record the anti-
rheumatic treatments, the RF and CCP antibody titres, ESR and CRP values, DAS28 score, 
smoking status, age and sex. 
2.1.4 Healthy controls 
An effort was made to recruit healthy volunteers that would match in age and sex the 
patients. Volunteers over 50 years old were recruited mainly from staff at Newcastle 
University. In addition, through Voice Global, a group led by Newcastle University whose 
members support a range of research activity, age-matched healthy volunteers were also 
recruited. All the volunteers had no personal history of autoimmunity or other 
musculoskeletal conditions. 
2.2 Primary cellular techniques 
2.2.1 Cell isolation 
Peripheral blood mononuclear cells (PBMCs) isolation 
Blood was collected into BD EDTA Vacutainer® tubes (BD Biosciences, CA, USA) and 
diluted 1:1 with room temperature (RT) Hanks Balanced Salt Solution (HBSS, Lonza, 
Switzerland) containing 2mM EDTA (Fisher Scientific, NH, USA). 20ml of the diluted 
blood was layered slowly onto 15ml of Lymphoprep (Axis-Shield Diagnostics Ltd, UK) 
and was then centrifuged at 895g for 30 minutes at RT. PBMCs were recovered from the 
surface of the density centrifugation medium (Figure 2.1). PBMCs from up 2 tubes were 
pooled together and topped up to 50ml with cold HBSS containing 1% Foetal Calf Serum 
(FCS, Labtech, UK). The resultant cell suspension was centrifuged at 600g for 8 minutes 
at 4°C. The supernatant was aspirated and the cells were topped up to 50ml with cold HBSS 
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containing 1% FCS and centrifuged again at 250g for 8 minutes at 4°C to remove platelets.  
Cells from the different tubes were pooled together and strained through a 70µm nylon 
filter to remove any debris/clumps. Cells were then counted using a Burker counting 
chamber with Trypan Blue (Sigma-Aldrich, MO, USA) exclusion and were used for 
subsequent downstream assays. 
CD3+ T cell depletion of PBMCs 
For the functional work, CD3+ T cells were depleted from the PBMCs in order to reduce 
the flow cytometry sorting time needed for the isolation of the different B cell subsets. 
CD3+ T cells were depleted by positive selection using a CD3 MicroBead Kit (Miltenyi 
Biotech, Germany). Depletion was performed as per manufacturer’s instructions. For the 
magnetic separation LS columns from Miltenyi Biotech were used. Because depletion was 
performed to exclude the T cells, the flow through was used for flow cytometry sorting, 
and therefore, purity of the CD3+ T cell population was not assessed.  
Synovial fluid mononuclear cells (SFMCs) isolation 
Synovial fluid (SF) was collected into a universal tube and diluted 1:1 with RT HBSS 
containing 2mM EDTA. Hyaluronidase (Sigma-Aldrich, MO, USA) was added to the SF 
at a concentration of 10 U/ml and heparin (Wockhardt, UK) at 1 IU/ml. The SF was then 
incubated in a water bath at 37°C for 40 minutes. 20ml of the treated SF was layered slowly 
Figure 2. 1. Scheme of separation of PBMCs using the density centrifugation medium 
Lymphoprep. 20ml of blood were diluted 1:1 with HBSS and slowly layered onto 15ml 
of Lymphoprep. The tubes were centrifuged at 895g for 30 minutes at room temperature. 
PBMCs were recovered from the surface of the density centrifugation medium and washed 
for downstream applications. Created with Biorender.com.  
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onto 15ml of Lymphoprep and this was then centrifuged at 895g for 30 minutes at RT. Cells 
in the interface were harvested and topped up to 50ml with cold HBSS containing 1% FCS. 
The cell suspension was centrifuged at 600g for 8 minutes at 4°C. The supernatant was 
aspirated and the cells were topped up to 50ml with cold HBSS containing 1% FCS and 
centrifuged again at 250g for 8 minutes at 4°C. Cells were then counted using a Burker 
counting chamber with Trypan Blue exclusion and were used for subsequent downstream 
assays. 
2.2.2 Cell culture 
Sorted B cell activation 
Sorted B cells were cultured in RPMI 1640 medium (Sigma-Aldrich, MO, USA) containing 
10% (v/v) FCS and supplemented with 2 mM L-glutamine, 100 U/ml penicillin and 100 
µg/ml streptomycin (all Sigma-Aldrich, MO, USA). B cells were cultured at a density of 
20,000 cells per well in 96-well round-bottom plates in a final volume of 200µl of culture 
medium. At initiation of culture, B cells were stimulated with a combination of the TLR7 
ligand, Imiquimod (1μg/ml, InvivoGen, CA, USA), TLR9 agonists, ODN 2216 – CpG A 
and ODN 2006 – CpG B (both 1μg/ml, InvivoGen, CA, USA), Poke Weed Mitogen (PWM, 
5μg/ml, Sigma-Aldrich, MO, USA), anti-CD40 antibody (10μg/ml, clone HB14, mouse 
IgG1, Biolegend, CA, USA), human IL-21 (0.05μg/ml, Miltenyi Biotech, Germany), 
human IL-4 (0.05μg/ml, Immunotools, Germany) and IFN-gamma (0.02μg/ml, Peprotech, 
UK). B cells were cultured for 5 days at 37°C with 5% CO2 prior to analysis by flow 
cytometry. Supernatants were frozen at -80°C prior to further analysis by MSD or ELISA.  
Whole blood activation 
Blood was collected into BD Heparin Vacutainer® tubes. Heparinised blood was required 
rather than EDTA-treated blood because EDTA chelates Ca2+ which is necessary for the 
activation of the cells. Heparin does not chelate Ca2+ and is therefore the preferred anti-
coagulant for whole blood functional assays. In a 24-well plate, 500µl of blood were diluted 
1:1 with RT RPMI 1640 medium. Two different stimulation cocktails were added to the 
corresponding wells: 1. PWM (5μg/ml), the TLR7 ligand, Imiquimod (1μg/ml) and TLR9 
agonists ODN 2216 – CpG A and ODN 2006 – CpG B (both 1μg/ml); 2. TLR7 and TLR9 
ligands as described above, but PWM was substituted by anti-IgM/IgG antibody (10μg/ml, 
polyclonal, goat IgG, eBioscience, CA, USA). Blood was stimulated for 24 and 48 hours 
at 37°C with 5% CO2. After the incubation time, cells were analysed by flow cytometry for 
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the expression of activation markers (see Table 2.1) following the whole blood staining 
protocol (see section 2.5.1) adjusting the volumes of antibodies used to higher amounts of 
blood used.   
2.2.3 Cell freezing and thawing 
Cell freezing 
Cells were pelleted at 400g for 8 minutes at 4°C and resuspended in FCS with a maximum 
concentration of 20 x 106 cells in 500µl. FCS containing 20% dimethyl sulfoxide (DMSO; 
Sigma-Aldrich, MO, USA) was added drop wise in equal volume, resulting in a final 
concentration of 10% DMSO. This suspension was added to cryovials (1ml per vial) and 
the cryovials were placed in a CoolCell® (BioCision, CA, USA), which was then stored at 
-80°C overnight to facilitate controlled freezing at a rate of -1°C/minute. The frozen 
cryovials of cells were then moved to liquid nitrogen for long term storage. 
Cell thawing 
Frozen cryovials were warmed to 37°C for 5 minutes in a standard water bath submerging 
the lower half of the vial only. Cells were mixed and transferred drop wise to a universal 
container containing warmed (37°C) thawing medium (HBSS supplemented with 10% 
FCS) to a final volume of 25 ml. Suspensions were centrifuged at 400g for 8 minutes at RT 
and the pellet was resuspended in warm thawing medium and centrifuged as stated above. 
Cells were then counted with a Burker counting chamber using Trypan Blue exclusion and 
were then used for subsequent downstream assays.  
2.2.4 Cytospins 
Sorted cells were pelleted and resuspended in 50µl of FCS. Slides were placed in the 
cytospin cartridges along with a carbon filter facing the centre of the cytospin. Cells were 
transferred to each cytospin well and centrifuged at 350 rpm for 8 minutes (Shandon 
Cytospin 4, ThermoFisher Scientific, MA, USA). The slides were left to dry overnight.  
The next day, they were placed in a jar containing cold methanol for 30 seconds to fix the 
slide. Giemsa staining was performed using the Hematek 3000 machine (Siemens 
Healthineers, Germany) and the Wright-Giemsa Stain Pack (Siemens Healthineers, 




2.3 Cytokine and antibody measurement   
2.3.1 Enzyme-linked immunosorbent assays (ELISAs) 
Enzyme-linked immunosorbent assays, ELISAs, was used to quantify secreted IgG from 
the supernatants of the stimulated B cell subsets. IgG was detected using the Human IgG 
total ELISA Ready-SET-Go!™ Kit (eBioscience, CA, USA). IgG quantification was done 
as per manufacturer’s instructions following the kit’s two day protocol: The plate was 
coated overnight and the blocking and incubation with the sample and the secondary 
antibody were all done on the second day.  
Because the B cells used in the cell culture activation assays were from seropositive patients 
(RF and CCP antibody positives), and as RF is a heterophilic antibody, i.e. binds 
immunoglobulins, there was a potential interference of RF with the accuracy of the ELISA 
results. Supernatants from stimulated memory B cells and ABCs were sent to the Newcastle 
laboratories (Newcastle Hospitals NHS Trust) for the detection of RF. The lower end of 
detection was 10 IU/ml for the RF antibody. CCP antibodies were also measured out of 
interest, with its lower end of detection being 0.5 U/ml. However, no autoantibodies either 
for RF and CCP were detected, for that reason, the ELISAs were run as per manufacturer’s 
protocol and no further action regarding heterophilic antibodies was taken.  
2.3.2 MSD plates 
Meso Scale Discovery (MSD, Meso Scale Discovery, Maryland, USA) biomarker assays 
provide a rapid and convenient method for measuring the levels of targets within a single, 
small-volume sample. MSD multiplex plate allows for the detection of up to 10 targets in 
a single volume. This is achieved as the well surface is composed of a carbon electrode 
onto which each different capture antibody is coated in one of the ten spots (Figure 2.2). 
Like in a sandwich immunoassay, the sample to be analysed is loaded and the analyte binds 
to the capture antibody. Then a detection antibody, labelled with SULFO-TAGTM, an 
electrochemiluminescent compound, binds the analyte and emits light when a voltage is 
applied to the electrodes on the plate surface. The light intensity is measured by the analyser 
and allows quantification of each analyte.  
Using the MSD multiplexing technology, 9 cytokines were measured from culture 
supernatants of the sorted B cell subsets, as well as from the FcRL3 transfected Ramos B 
cells and controls after stimulation. The chosen assay was a U-PLEX Custom Biomarker 
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(human) plate with the following cytokines: GM-CSF, IL-2, IL-6, IL-10, IL-12p70, IL-23 
and TNF-alpha.  
The Isotyping Panel 1 (Human/NHP) Kit also from MSD was used to measure 
immunoglobulin isotype in the supernatants of sorted B cell subsets and transfected Ramos 
B cells as per manufacturer’s instructions. 
 
 
Figure 2. 2. MSD multiplex assay. MSD multiplex plate surface is composed of a carbon 
electrode onto which each capture antibody is coated in one of the ten spots. Like in a 
sandwich immunoassay, the analyte binds to the capture antibody. Then a detection 
antibody, labelled with SULFO-TAGTM, an electrochemiluminescent compound, bind the 
analyte and emits light when a voltage is applied to the electrodes on the plate surface. The 
light intensity is measured by the analyser and allows quantification of each analyte. Image 
taken from the MSD Multispot manual 
(https://www.mesoscale.com/~/media/files/product%20inserts/human%20proinflam%209
-plex%20us.pdf). 
2.4 Flow Cytometry  
2.4.1 Cell surface protein expression in whole blood 
Blood was collected into BD EDTA Vacutainer® tubes. Reverse pipetting was used to 
transfer 200μl of blood into a 2ml microcentrifuge tube. Each antibody (see Tables 2.1 – 
2.4 for fluorophore labelled antibody panels used) at a pre-titrated dilution was added to 
the blood and the tubes were then incubated in a water bath at 37°C for 30 minutes. After 
this time, red blood cells (RBC) were immediately lysed by adding 10 volumes of pre-
warmed 1x BD FACS Lysing solution (BD Biosciences, CA, USA) and the tubes were 
incubated at 37°C for 12 minutes. Tubes were then centrifuged at 600g for 8 minutes at RT 
and the supernatant was decanted. The cell pellet was washed with FACS buffer 
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(Dulbecco’s Phosphate Buffered Saline (D-PBS) containing 0.5% BSA, 1mM EDTA and 
0.01% Sodium azide) and centrifuged at 600g for 8 minutes at RT. The supernatant was 
decanted and the cell pellet was resuspended in 300μl of FACS buffer and transferred to a 
FACS tube (BD Biosciences, CA, USA) to be acquired on a BD LSR Fortessa X20™ 
(Becton Dickinson, NJ, USA). 
For the intracellular staining panel (Table 2.2) cells were first surface stained as outlined 




Fluorophore Clone Dilution factor Company 
CD3 PE-CF594 UCHT1 1:200 BD Biosciences, CA, USA 
CD33 PE-CF594 WM53 1:33 BD Biosciences, CA, USA 
CD19 BUV395 SJ25C1 1:100 BD Biosciences, CA, USA 
CD20 BV510 2H7 1:200 Biolegend, CA, USA 
CD11c APC S-HCL-3 1:200 BD Biosciences, CA, USA 
CD21 PE BU32 1:200 Biolegend, CA, USA 
CD5 PE-Cy7 UCHT2 1:100 eBioscience, CA, USA 
CD27 BV650 O323 1:200 Biolegend, CA, USA 
IgD AF700 IA6-2 1:100 Biolegend, CA, USA 
CD80 BB515 L307.4 1:100 BD Biosciences, CA, USA 
CD86 BV711 IT2.2 1:200 Biolegend, CA, USA 
CD69 APC-Vio770 FN-50 1:50 Miltenyi Biotech, Germany 
HLA-DR PerCP L203 1:50 RnD Systems, MN, USA 
CD40 BV421 5C3 1:50 Biolegend, CA, USA 










Fluorophore Clone Dilution factor Company 
CD3 PE-CF594 UCHT1 1:200 BD Biosciences, CA, USA 
CD33 PE-CF594 WM53 1:33 BD Biosciences, CA, USA 
CD19 BUV395 SJ25C1 1:100 BD Biosciences, CA, USA 
CD20 BV510 2H7 1:200 Biolegend, CA, USA 
CD11c APC S-HCL-3 1:200 BD Biosciences, CA, USA 
CD21 PE BU32 1:200 Biolegend, CA, USA 
CD5 PE-Cy7 UCHT2 1:100 eBioscience, CA, USA 
CD27 FITC M-T271 1:100 BD Biosciences, CA, USA 
IgD AF700 IA6-2 1:100 Biolegend, CA, USA 
T-bet BV421 O4-46 1:10 BD Biosciences, CA, USA 
Ki67 BV711 Ki-67 1:10 Biolegend, CA, USA 




Fluorophore Clone Dilution factor Company 
CD3 PE-CF594 UCHT1 1:200 BD Biosciences, CA, USA 
CD33 PE-CF594 WM53 1:33 BD Biosciences, CA, USA 
CD19 BUV395 SJ25C1 1:100 BD Biosciences, CA, USA 
CD20 BV510 2H7 1:200 Biolegend, CA, USA 
CD11c BV421 B-LY6 1:50 BD Biosciences, CA, USA 
CD21 PE-Cy7 BU32 1:100 Biolegend, CA, USA 
CD5 APC-Cy7 L17F12 1:200 Biolegend, CA, USA 
CD27 BV650 O323 1:200 Biolegend, CA, USA 
IgD AF700 IA6-2 1:100 Biolegend, CA, USA 
FcRL3 BB515 H5 1:200 BD Biosciences, CA, USA 
FcRL4 PE 413D12 1:100 Biolegend, CA, USA 
FcRL5 APC 509f6 1:50 Biolegend, CA, USA 








Fluorophore Clone Dilution factor Company 
CD3 PE-CF594 UCHT1 1:200 BD Biosciences, CA, USA 
CD33 PE-CF594 WM53 1:33 BD Biosciences, CA, USA 
CD19 BUV395 SJ25C1 1:100 BD Biosciences, CA, USA 
CD20 BV510 2H7 1:200 Biolegend, CA, USA 
CD11c BV421 B-LY6 1:50 BD Biosciences, CA, USA 
CD21 PE-Cy7 BU32 1:100 Biolegend, CA, USA 
CD5 APC-Cy7 L17F12 1:200 Biolegend, CA, USA 
CD27 BV650 O323 1:200 Biolegend, CA, USA 
IgD AF700 IA6-2 1:100 Biolegend, CA, USA 
FcRL2 PE REA474 1:20 Miltenyi Biotech, Germany 
FcRL1 APC REA440 1:100 Miltenyi Biotech, Germany 
FcRL2 PE B24 1:100 Gift from Prof Nagata, Japan 




Fluorophore Clone Dilution factor Company 
CXCR3 AF488 1C6 1:50 BD Biosciences, CA, USA 
CXCR4 APC REA649 1:100 Miltenyi Biotech, Germany 
CXCR5 BV510 J252D4 1:100 Biolegend, CA, USA 
CD95/FAS PE REA738 1:100 Miltenyi Biotech, Germany 
CD97 FITC VIM3b 1:100 Biolegend, CA, USA 
Granzyme B PE-CF594 GB11 1:10 BD Biosciences, CA, USA  
Perforin PE-Cy7 B-D48 1:10 Biolegend, CA, USA 
Table 2. 5. Fluorophore labelled antibodies used for the validation of the NanoString 
markers. 
2.4.2 Intracellular protein expression  
To assess intracellular expression of Ki67 and T-bet, whole blood was first stained for 
surface antibodies (as described in 2.5.1 above). The surface stained cells were resuspended 
in 200μl FACS buffer and transferred to a 96-well v-bottom plate (CoStar, DC, USA). Cells 
were then permeabilised in 300μl of 1x Perm buffer (eBioscience, CA USA) for 30 minutes 
at 4°C in the dark. To reduce background staining, the cells were blocked with 2% mouse 
serum (Sigma-Aldrich, MO, USA) in 50μl volume for 15 minutes at 4°C in the dark before 
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adding Ki67 and T-bet antibodies at the pre-titrated dilution (Table 2.2). Cells were 
incubated for 30 minutes at 4°C in the dark. After this time, the cells were washed, 
resuspended in 300μl of FACS buffer and transferred to a FACS tube (BD Biosciences, 
CA, USA) to be acquired on a BD LSR Fortessa X20™. 
2.4.3 Cell surface protein expression in PBMCs 
1 x 106 cells were transferred to a 96-well v-bottom plate and centrifuged at 400g for 3 
minutes. To reduce background staining, cells were resuspended in 50μl of FACS buffer 
containing 2% mouse serum and incubated for 15 minutes at 4°C in the dark. Wells were 
then topped up with FACS buffer and centrifuged at 400g for 3 minutes. Cells were 
resuspended in 50μl of FACS buffer mastermix containing each antibody (see Table 2.6 
for the fluorophore labelled antibodies used). The cells were incubated at 4°C for 30 
minutes in the dark. After this time, the plate was centrifuged at 400g for 3 minutes, blotted 
and resuspended in 100μl of PBS (Sigma-Aldrich, MO, USA) containing 1μl of Zombie 
Aqua (Biolegend, CA, USA) to stain dead cells. Cells were incubated at 4°C for 15 minutes 
in the dark, then washed twice with FACS buffer, resuspended in a final volume of 300μl 
of FACS buffer and fixed in 1% formaldehyde (TAAB laboratories, UK) before acquisition 
on a BD LSR Fortessa X20™. 
Surface 
marker 
Fluorophore Clone Dilution factor Company 
CD3 PE-CF594 UCHT1 1:50 BD Biosciences, CA, USA 
CD33 PE-CF594 WM53 1:50 BD Biosciences, CA, USA 
CD19 BUV395 SJ25C1 1:100 BD Biosciences, CA, USA 
CD11c BV421 B-LY6 1:20 BD Biosciences, CA, USA 
CD21 PE-Cy7 BU32 1:50 Biolegend, CA, USA 
CD5 APC-Cy7 L17F12 1:100 Biolegend, CA, USA 
CD27 BV650 O323 1:10 Biolegend, CA, USA 
IgD AF700 IA6-2 1:50 Biolegend, CA, USA 
IgM BB515 G20-127 1:20 BD Biosciences, CA, USA 
IgG BV786 G18-145 1:50 BD Biosciences, CA, USA 
IgA PE IS11-8E10 1:50 Miltenyi Biotech, Germany 




2.4.4 Flow cytometry analysis  
All the flow cytometry data was analysed using the software FlowJo Version 10 (Treestar 
Inc, OR, USA). For the phenotypic characterisation and the determination of the frequency 
of ABCs, the gating strategy shown in Figure 3.1 in Chapter 3 was used to create the gates 
for each of the four populations of B cells of interest. First, doublets and autofluorescent 
cells were excluded. Lymphocytes were gated using SSC-A vs FSC-A, and from the 
lymphocyte gate, the B cells were gated. A dump channel was used to exclude other cell 
types, CD3 for T cells, CD16 and CD14 for all monocytes, CD56 for NK cells and most 
importantly CD33 for dendritic cells. Exclusion of dendritic cells is very important as these 
cells are positive for CD11c and may contaminate the ABC population, therefore I used an 
antibody to exclude CD33+ cells. From the B cell gate, ABCs were gated as CD11c+ 
CD21-, from the remaining CD19+ cells, CD5+ cells were gated as CD5+ CD19+. From 
the CD5- fraction, naïve B cells (IgD+ CD27-) and memory B cells (IgD- CD27+) were 
gated. 
Expression of each of the phenotypic markers in each of the subsets was determined by 
creating a quadrant gate in the lymphocytes gate of the marker against CD19 and copying 
that gate into the subsets to assess the number of positive cells for that marker in each subset 
(Figure 4.1 in Chapter 4).  
In some cases, the expression of a particular antigen was clear bimodal, resulting in clear 
positives and negatives meaning gates could be easily determined. However, for most 
phenotypic markers, gates were set on fluorescence minus one (FMO) controls, and in a 
few cases the gates were set based in an unstained population of cells. The use of unstained 
cells informs us about the background fluorescence and the autofluorescence properties of 
the sample and gates can be set to delineate the negative population. An FMO control 
includes all of the antibody conjugates present in the test sample except one. The use of an 
FMO control helps to identify the positive population when the expression of that marker 
is low. This method allows the assessment of the spread of fluorescence as another 
fluorophore from another channel may leak into the channel of interest causing a false 
positive staining. 
2.4.5 Flow cytometry cell sorting 
Previously isolated PBMCs or the CD3-depleted PBMC fraction were resuspended in cold 
FACS buffer to a final concentration of 20 x 106 cells/ml and 1ml of this cell suspension 
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was added to a microcentrifuge tube. The cells were centrifuged at 400g for 8 minutes at 
4°C. The cell pellet was resuspended in the fluorophore labelled antibody mix (see Table 
2.7) which also contained 4μg/ml of human IgG (Gift from Professor Sophie Hambleton, 
Newcastle University, UK) in a total volume of 50μl FACS buffer. The cells were incubated 
for 30 minutes at 4°C in the dark. After this incubation time, cells were washed with PBS 
and centrifuged at 400g for 8 minutes at 4°C. Cell pellets were resuspended in 100μl of 
PBS containing 2μl of Zombie UV (Biolegend, CA, USA) to stain for dead cells. Cells 
were incubated at 4°C for 15 minutes in the dark and then washed twice with FACS buffer. 
Cells from each microcentrifuge tube were transferred to a FACS tube and the volume was 
made up to 2ml with FACS buffer, resulting in a cell density of 10 x 106 cells/ml. 
Right before sorting, the cells were transferred into a new FACS tube and strained through 
a 30μm cell strained (CellTrics - Sysmex, IL, USA). This was performed immediately prior 
to sorting to avoid small cell clumps blocking the sorter’s nozzle. The BD FACSARIA II 
(Becton Dickinson, NJ, USA) with a 70μm nozzle was used to sort the four immune cell 
subsets. The gating strategy is shown in Figure 5.1 in Chapter 5 and the fluorophore labelled 
antibodies used are shown in Table 2.7. 
Surface 
marker 
Fluorophore Clone Dilution factor Company 
CD3 PE-CF594 UCHT1 1:12.5 BD Biosciences, CA, USA 
CD33 PE-CF594 WM53 1:12.5 BD Biosciences, CA, USA 
CD19 BUV395 SJ25C1 1:10 BD Biosciences, CA, USA 
CD20 BV510 2H7 1:12.5 Biolegend, CA, USA 
CD11c APC S-HCL-3 1:10 BD Biosciences, CA, USA 
CD21 PE BU32 1:16.5 Biolegend, CA, USA 
CD5 PE-Cy7 UCHT2 1:12.5 eBioscience, CA, USA 
CD27 FITC M-T271 1:12.5 BD Biosciences, CA, USA 
IgD AF700 IA6-2 1:16.5 Biolegend, CA, USA 





2.5 NanoString Technologies  
The NanoString Technologies uses the nCounter® gene expression platform to capture and 
count individual mRNA transcripts (Geiss et al., 2008). Briefly, the assay consists of a 
multiplexed probe library with two sequence-specific probes for each gene of interest, 
which has been previously tested and optimised by NanoString. The first probe is a capture 
probe of around 50 nucleotides plus a short common sequence coupled to an affinity tag 
such as biotin (Figure 2.3.A). The second probe, the reporter probe also consists of 50 
nucleotides and is coupled to a specific colour barcode per each target gene, providing the 
detection signal. Both probes hybridise with the target of interest in a solution phase (Figure 
2.3.B). Excess probes are removed by affinity purification and the remaining target- probe 
complexes are bound the nCounter cartridge surface, aligned and immobilised using 
electrophoresis (Figure 2.3.C). Finally, the cartridge is placed in a digital analyser for image 
acquisition and data processing (Figure 2.3.D). The level of expression is measured by 
counting the number of codes for each mRNA. 
The main advantages of the nCounter® system are the ability of measuring total mRNA 
transcripts without requiring amplification, meaning no gene-specific biases are 
introduced. Moreover, unlike in microarrays, hybridisation of the probe and the target 
happens in solution, allowing for a higher sensitivity, especially of lower expressed genes. 
Additionally, nCounter® technology is ideal for small samples with limited amounts of 





2.5.1 Methodology and genes analysed 
The transcriptome of the flow cytometry sorted B cell subsets were analysed using the 
NanoString nCounter Human immunology V2 Panel (NanoString Technologies Inc, WA, 
USA). For the full list of genes assessed see Appendix A.1. An additional 20 custom genes 
were added to the plate, in order to expand B cell relevant markers, identify DNA/RNA 
intracellular sensing pathways and identify retrotransposon activity (Table 2. 8, sequences 
included in Appendix A.2). 
  
Figure 2. 3. NanoString nCounter technology. A. NanoString probes. Each gene of 
interest (target) is detected using a capture probe and a target probe, which will bind the 
mRNA of the gene and make the target-probe complex. B. Probe and target gene 
hybridisation. Probes hybridise with the target in a solution phase. C. Target-probe 
complex is immobilised in the cartridge. Target-probe complex binds the cartridge via the 
capture probe and is then immobilised by electrophoresis in the cartridge. D. Barcode count. 
The cartridge is then placed in a digital analyser which counts each reporter barcode and 
gives, therefore gene counts.  
Adapted from https://www.nanostring.com/scientific-content/technology-
overview/ncounter-technology on 27/05/2019. 
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Standard probes Customised probes 
CD38 AluYa5 
CXCR5 AluYb9 












Table 2. 8 Additional genes (probes) included in the NanoString nCounter Human 
immunology V2 Panel. 
Due to the small numbers of ABCs I was able to sort from samples, when RNA was directly 
extracted from these cells it resulted in very small amounts of RNA purified. The amount 
of RNA was lower than the recommended amount, 100ng, to use in the NanoString assay. 
Using low amounts of RNA would lead to a loss of detection of low expressed genes, which 
could be very important for the characterisation of ABCs. I therefore, used whole cell 
lysates to load on the chip as the starting material. For each subset, 15,000 cells were sorted 
into a 1.5ml microcentrifuge tubes containing 280μl of RF10 (RPMI +10% FCS). After 
sorting, the cells were transferred into a 96-well plate and spun at 400g for 4 minutes. Cells 
were then resuspended in 1.6μl of RLT buffer (Qiagen, Germany), transferred, together 
with the residual RF10 volume, to a 0.2ml microcentrifuge tube and stored in the -80 freezer 
until all the samples were collected from recruited donors. Once the recruitment was 
finished and the NanoString plates were ready to run, a total volume of 5μl of lysate for 
each of the cell subsets was loaded into the chip and the protocol was followed according 
to standard nCounter instructions. 
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Each nCounter CodeSet includes 15 housekeeping genes used as an internal control due to 
their low variability across sample types and high counts to correct for differences in 
sample quality and amount of RNA.  
2.5.2 NanoString nCounter data analysis 
The analysis of the data generated with NanoString was performed by Najib Naamane, a 
bioinformatician in our group. R software version 3.5.3 was used in association with the 
Bioconductor repository (Huber et al., 2015) for this analysis.  
Data pre-processing and quality assessment 
A quality control step was conducted using the arrayQualityMetrics (Kauffmann et al., 
2009) Bioconductor package to detect and remove any outlier samples. This was done after 
normalisation to the NanoString housekeeping genes. For each sample, 
arrayQualityMetrics computes three different metrics: 1. The sum of the distances to all 
other samples, 2. The Kolmogorov-Smirnov statistic between the sample's distribution and 
the pooled distribution from all samples, and 3. The Hoeffding's statistic on the joint 
distribution of M (log-ratio) and A (mean of logarithms) values, corresponding to the gene 
counts of the studied sample and a "pseudo"-sample (i.e. the median across samples). A 
threshold is then determined for each metric based on the distribution of its values across 
all samples (i.e. the third quartile plus 1.5 times the interquartile range). Samples with at 
least two metrics exceeding the threshold were considered as outliers. Four samples were 
flagged as outliers and were thus excluded from further analysis. 
Lowly expressed genes were filtered out to improve the mean-variance relationship 
estimation and reduce the number of tests to be performed during downstream differential 
expression analysis, hence increasing the statistical power. A gene was considered to be 
expressed in a given sample if its counts were greater than the corresponding background 
estimate (i.e. the mean of the negative controls in that sample added by two standard 
deviations). Only genes that were expressed in all the samples of at least one condition (i.e. 
a cell subset of a disease group) were retained. 
Differential gene expression analysis 
The DESeq2 R package (Love et al., 2014) was used to compare the gene expression 
profiles between different B cell subsets and disease groups. DESeq2 tests for differential 
expression by fitting negative binomial generalized linear models (GLMs) to the data (Love 
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et al., 2014). The analysis was performed in three steps. First, sample-specific size factors 
were estimated using the median ratio method (Anders and Huber, 2010) implemented by 
the estimateSizeFactors function. Then, the gene-specific dispersions estimates were 
obtained using the estimateDispersions function. Finally, the nbinomWaldTest function 
was used to fit a GLM that uses the previously calculated size factors and dispersion 
estimates to normalize the raw count data for library size and compute the Wald statistics 
for the following comparisons: 
• ABCs against each cell type in early RA - each B cell subset was compared with 
the ABCs in patients with early RA. 
• Cell types in early RA against DC - each B cell subset was compared between early 
RA and disease controls. 
• Cell types in eRA against HC - each B cell subset was compared between early RA 
and age-matched healthy controls. 
Genes with a Benjamini-Hochberg adjusted p-value < 0.05 and a fold change > 1.5 were 
considered to be differentially expressed when comparing B cell subtypes within the same 
disease group while a less stringent cut-off (unadjusted p-value < 0.05 and a fold change > 
1.5) was required for disease group comparisons within the same cell subpopulation. 
2.6 Cell lines 
2.6.1 HEK293T cells 
The cell line HEK293T (Human Embryonic Kidney 293T, ATCC® CRL-3216™) was 
used. The HEK293T cell line, originally referred to as 293tsA1609neo, is a highly 
transfectable cell line which contains the SV40 T-antigen. It is a semi adherent cell line. 
Due to its high transfectable capacity and its ability to produce recombinant retroviruses, 
they were used to both check FcRLs antibody specificity and for FcRL3 retroviral particle 
assembly. 
HEK293T cells were cultured in Dulbecco’s Modified Eagle Medium with high glucose 
and L-Glutamine (all Gibco - Thermo Fisher Scientific, MA, USA), supplemented with 
100 U/ml penicillin, 100µl/ml streptomycin and 8% FCS.  
Upon thawing a cryovial of frozen HEK293T cells, cells were mixed and transferred drop 
wise to a universal container containing warmed (37 °C) culture medium DMEM with 8% 
FCS to a final volume of 25ml. These were then centrifuged at 400g for 8 minutes. The cell 
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pellet was resuspended in 20ml of warmed culture medium and centrifuged again at 400g 
for 8 minutes. Cells were resuspended in 12ml of warmed medium and transferred to a T75 
culture flask (Greiner Bio-one, Austria). The flask was incubated at 37 °C with 5% CO2 
until the cells were 80-90% confluent. When the cells were confluent, the media was 
removed, the cells were detached by flushing PBS and centrifuged at 400g for 8 minutes. 
The cell pellet was resuspended in 12ml of pre-warmed culture medium, and the cells were 
then split (1:10 or 1:20) and incubated at 37 °C with 5% CO2 until confluent or counted 
using a Burker counting chamber with Trypan Blue exclusion and used for their desired 
application.  
2.6.2 Ramos and Raji cells 
For the functional work with FcRL3, Ramos (RA 1, ATCC® CRL-1596™) and Raji 
(ATCC® CCL-86™) B cell lines were used. The Ramos B cell line was established from 
a Burkitt’s lymphoma of a 3-year-old Caucasian male and the Raji B cell line was 
established from a Burkitt's lymphoma of the left maxilla of an 11-year-old black male. 
Both cell lines grow in suspension and have a lymphoblast morphology. However, Raji B 
cells are positive for the presence of Epstein Barr virus (EBV) viral DNA sequences and 
EBNA protein whereas Ramos B cells are negative for EBV. 
Ramos and Raji cells were cultured in RPMI 1640 medium containing 2 mM L-glutamine, 
100 U/ml penicillin and 100 µg/ml streptomycin and supplemented with 10% FCS. 
Upon thawing a cryovial of frozen Ramos or Raji cells, cells were mixed and transferred 
drop wise to a universal container containing warmed (37 °C) culture medium RPMI 1640 
with 10% FCS to a final volume of 25ml. These were then centrifuged at 400g for 8 
minutes. The cell pellet was resuspended in 20ml of warmed culture medium and 
centrifuged again at 400g for 8 minutes. Cells were resuspended in 12ml of warmed 
medium and transferred to a T75 culture flask. The flask was incubated at 37 °C with 5% 
CO2 until the cell density was 80-90%. When the cell density was high, they were split 1:10 
or 1:20 by transferring the cells to a new T75 flask with warmed culture medium and 
incubated at 37 °C with 5% CO2. If the cells were needed for another application, these 
were counted using a Burker counting chamber with Trypan Blue exclusion after splitting 




2.7 FcRL family transfection of HEK293T cells 
The cell line HEK293T was used to check FcRLs antibody specificity. The plasmids 
containing transcripts for the FcRL family were kindly provided by Professor Nagata, 
Osaka University, Japan. Briefly, in order to have enough plasmid to test the antibody 
specificity, Escherichia coli (E. coli) bacteria were transformed and the plasmids were 
extracted. Then HEK293T cells were transfected with the plasmids using a lipid-based 
approach and stained for all the antibodies against the FcRL family members. 
2.7.1 Agar plates preparation and bacterial LB broth preparation  
Agar plates were used to grow transformed E. coli bacteria. To make 10 plates, 7.63g of 
Luria Broth (LB) containing 15g/L of agar (Sigma-Aldrich, MO, USA) was added to 250ml 
of distilled water in a 500ml glass bottle. The solution was mixed and autoclaved to 
sterilise. After autoclaving, the bottle was placed into a 55°C water bath and left for at least 
15 minutes to decrease the temperature. Then, under a Bunsen burner flame, to maintain 
sterility, ampicillin was added at a final concentration of 100µg/ml. Close to the open flame, 
25ml of sterile LB broth with agar and ampicillin was pipetted into previously labelled Petri 
dishes. The Petri dishes were left to set and were parafilmed and store at 4°C (in the cold 
room) upside down for future use.  
2.7.2 Bacteria transformation 
Plasmid concentration and quality were determined using a NanoDrop ND-1000 
spectrophotometer (NanoDrop Technologies, DE, USA). E. coli competent cells, LS2001 
(Promega, WI, USA), were used for all the bacterial transformations. Close to an open 
Bunsen burner flame, 100µl of competent cells were transferred to a chilled sterile tube. 
Plasmid DNA was then added to the E. coli. For the positive control, 0.1ng of control DNA 
was used, and for the plasmids of interest 50ng was used. The competent cells with the 
DNA were placed on ice and incubated for 10 minutes. After this time, the bacteria were 
heat-shocked by placing the tubes in a water bath at exactly 42°C for 50 seconds. After the 
50 seconds, bacteria were placed immediately back on ice and incubated for 2 minutes 
before the addition of 900µl of cold SOC medium (Sigma-Aldrich, MO, USA). The 
competent cells were then incubated for 1 hour at 37°C with shaking at 300rpm. After this 
incubation period, each transformation reaction was diluted with warm SOC medium 
before plating. For the positive control, bacteria were diluted 1:10, and for the plasmid of 
interest transformations bacteria were diluted 1:10 and 1:100. Finally, 100µl of the diluted 
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transformed bacteria was pipetted into an agar plate with ampicillin and the bacteria was 
spread using a glass spreader previously sterilised in 90% ethanol. Plates were incubated 
upside down in a bacterial incubator at 37°C for 12-14 hours. The next morning, plates 
were checked, parafilmed and stored at 4°C (cold room) upside down until future use.  
2.7.3 Plasmid extraction 
For the FcRLs antibody specificity checking (Chapter 4.4.5), the plasmids were extracted 
using the PureLinkTM HiPure Plasmid DNA Purification Kit – MidiPrep (Invitrogen - 
Thermo Fisher Scientific, MA, USA) according to manufacturer’s protocol. Briefly, 
transformed cells were grown overnight. Cells were pelleted, lysed and loaded into the kit’s 
column. The column was washed and the plasmid was eluted. Then the eluate was 
precipitated with isopropanol and washed with ethanol. Finally, the pellet was air-dried and 
resuspended in RNase/DNase-free water (Sigma-Aldrich, MO, USA). The extracted 
plasmids were stored in the -20 °C freezer.  
2.7.4 Concentration of plasmids 
For downstream applications, such as transfecting cells, the generated plasmids were 
needed at a high concentration. Upon thawing of the plasmids, the microcentrifuge tube 
caps were cut and the tube was covered with parafilm (Bemis, WI, USA). Using a 25G BD 
MicolanceTM needle (Becton Dickinson, NJ, USA), holes were placed in the parafilm to 
allow controlled evaporation. The microcentrifuge tube was centrifuged using the DNA 
120 SpeedVac system (Thermo Fisher Scientific, MA, USA) until about 10-15µl volume 
remained. The plasmid concentration was then quantified using a NanoDrop ND-1000 
spectrophotometer (NanoDrop Technologies, DE, USA) and was re-frozen at -20 °C until 
further use. 
2.7.5 Restriction enzyme digestion 
For the antibody specificity checking, the plasmids were digested to check that the insert 
length was the expected one. All the restriction enzymes used were purchased from Thermo 
Fisher Scientific, MA, USA. As described in Table 2.9, plasmids encoding for FcRL4 and 
FcRL3 were digested using the restriction enzymes EcoRV and NotI, plasmids encoding 
FcRL5 and FcRL2 were digested using BamHI and NotI, and the plasmid encoding FcRL1 
was digested using EcoRI and NotI. Figure 2.4 shows a scheme of the restriction enzyme 
digestion protocol. Each plasmid was digested with both enzymes to check that the insert 
length was the expected one. However, a single digestion with only one of the enzymes 
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was also performed to linearize the plasmid and check for the total plasmid length. Plasmid 
concentration was determined using a NanoDrop ND-1000 spectrophotometer. In a 
microcentrifuge tube, for each digestion, 1µg of each plasmid was added, together with 1x 
O buffer and 20 units of enzyme (see Table 2.9 for enzyme compatibility with buffer). 
Because the plasmids concentration was low, and in order to not have to dilute the 
enzymatic reaction by adding big volumes of plasmids, all the volumes were scaled up to 
80µl final volume. The tubes were topped up to 80µl final volume with RNase/DNase free 
water. The reactions were mixed gently and incubated at 37°C overnight. The next 
morning, the restriction enzymes were heat-inactivated at 65°C for 20 minutes. Finally, 5µl 
of the restriction enzyme digestion and 2µl of undigested plasmid were run in a 1% agarose 
gel with a DNA ladder, to check that the gene and the plasmid sizes were the correct ones 
(see section 2.8.2 for detailed protocol).   
 
 FcLR1 FcLR2 FcLR3 FcLR4 FcLR5 
5’ enzyme EcoRI BamHI EcoRV EcoRV BamHI 
3’ enzyme NotI NotI NotI NotI NotI 
Buffer used O buffer O buffer O buffer O buffer O buffer 













6,790 bp 7,027 bp 7,525 bp 7,048 bp 8,434 bp 
FcRL 
transcript size 
1,290 bp 1,527 bp 2,205 bp 1,548 bp 2,934 bp 
Table 2. 9. Restriction enzymes and buffers used to digest each of the FcRLs plasmids, 




Figure 2. 4. Scheme of restriction enzyme digestion of the plasmids coding the FcRL family members. Each plasmid coding one FcRL family 
member was digested using the correspondent restriction enzymes for a 3’ and a 5’ digestion. After the incubation time, each restriction enzyme 
digestion was run in a 1% agarose gel with a DNA ladder (lane 1). For each plasmid, a single digestion, shown in lane 2, was performed to linearize 
the plasmid and check for the total plasmid length. Additionally, as shown in lane 3, a double digestion was performed, resulting in two bands in 
the gel: one corresponding to the plasmid backbone (pcDNA3) and the other corresponding to the size of the FcRL family member transcript 
examined. Created with Biorender.com. 
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2.7.6 HEK293T cells transfection 
To check specificity of each FcRL antibody, HEK293T cells were transfected using a lipid-
based approach. Lipofectamine ®LTX and Plus™ Reagent (Thermo Fisher Scientific, MA, 
USA) were used to transfect the cells with each FcRL family member plasmid.  
Between 2-0.5 x 105 HEK293T cells were cultured into a 24-well plate (CoStar, DC, USA) 
in a final volume of 500µl of DMEM with 8% FCS. The cells were incubated at 37°C with 
5% CO2 overnight, so the next day they were 70-90% confluent. As for the manufacturer’s 
protocol, when cells were confluent, 50µl of serum free medium and 4µl of lipofectamine 
were added to a microcentrifuge tube. In another tube, 250µl of a serum free medium was 
mixed with 5µl of plus reagent and 5µg of the plasmid. For the final mix, in a new 
microcentrifuge tube, 50µl of the mix containing lipofectamine was combined with 50µl 
of the mix containing the plasmid and the plus reagent. This mix was then incubated for 5 
minutes at RT and a final volume of 50µl was added dropwise to the cells in the plate. Cells 
were incubated for one day at 37°C with 5% CO2. The next day, cells were harvested by 
pipetting up and down to detach them, transferred into a universal flask and spun at 400g 
for 8 minutes. Cell were then resuspended in FACS buffer and transferred to a 96-well plate 
for antibody staining. To reduce background staining, the cells were blocked with 2% 
mouse serum for 15 minutes at 4°C. Cells were then washed and resuspended in the FcRL1 
to FcRL5 antibody mixes (Tables 2.10 and 2.11) at the pre-titrated dilution in FACS buffer. 
Cells were incubated for 30 minutes at 4°C in the dark. After this time, cells were washed 
and resuspended in 100μl of PBS containing 1μl of Zombie UV to stain dead cells. Cells 
were incubated at 4°C for 15 minutes in the dark, then washed twice with FACS buffer, 
resuspended in a final volume of 300μl of FACS buffer and fixed in 1% formaldehyde 
before acquisition on a BD LSR Fortessa X20. 
Surface 
marker 
Fluorophore Clone Dilution factor Company 
FcRL3 BB515 H5 1:200 BD Biosciences, CA, USA 
FcRL4 PE 413D12 1:100 Biolegend, CA, USA 
FcRL5 APC 509f6 1:50 Biolegend, CA, USA 






Fluorophore Clone Dilution factor Company 
FcRL2 PE REA474 1:20 Miltenyi Biotech, Germany 
FcRL1 APC REA440 1:100 Miltenyi Biotech, Germany 
FcRL2 PE B24 1:100 Gift from Prof Nagata, Japan 
Table 2. 11 Fluorophore labelled antibodies used for the specificity check (FcRL1-2). 
 
2.8 FcRL3 cloning 
The FcRL3 transcript from the pcDNA3 plasmid was cloned into the pIG plasmid in order 
to create retroviral particles and transduce the Ramos and Raji cell lines. See Figure 2.5 for 
an overview of the cloning steps. 
2.8.1 Polymerase chain reaction (PCR) 
Standard PCR was used to amplify the FcRL3 transcript in order to clone it into the 
retroviral pMSCV PIG plasmid (referred to as pIG). Primers were designed to amplify a 
product containing the start and stop codons of the FcRL3 transcript with the introduction 
of restriction enzyme digestion sites for two different restriction enzymes at the 5’ and the 
3’ end of the product (Table 2.12). The restriction enzyme sites were identical to two sites 
within the pIG plasmid. From the pcDNA3 plasmid, 2ng were mixed with 2.5μl of 10μM 
of forward and reverse primers (Sigma-Aldrich, MO, USA), 1μl of 10mM of dNTPs and 
10μl of 5x Phusion HF buffer (both from Invitrogen - Thermo Fisher Scientific, MA, USA). 
The volume of the reaction was then topped up with RNase/DNase free water to a final 
volume of 50μl. Finally, 0.5μl of 2 U/μl of Phusion Hot Start II DNA Polymerase 
(Invitrogen - Thermo Fisher Scientific, MA, USA) was added. The mixture was covered 
with a StarSeal adhesive lid (StarLab, Germany) and pulse spun to >800g before being 
placed in a PCRmax alpha thermal cycler (PCRmax, UK). The following cycle was 
performed after preheating the lid to 98 °C: an initial denaturation at 98 °C for 30 seconds 
and then 25 cycles of denaturation at 98 °C for 10 seconds and annealing and extension at 
72 °C for 45 seconds, finally a final extension at 72 °C for 5 minutes. All the PCR product 
was loaded onto an agarose gel to check for the correct size and extract the amplified 





2.8.2 Gel electrophoresis and fragment purification 
The PCR amplification product was run in an agarose gel in order to check the size of the 
amplicon and purify the fragment. A 1% weight/volume agarose gel was made by mixing 
1g of agarose (Sigma-Aldrich, MO, USA) with 100ml of 1x TAE (made of 2M Tris base 
(Sigma-Aldrich, MO, USA), 0.5M EDTA (Thermo Fisher Scientific, MA, USA), 1M acetic 
acid (Fisher Scientific, NH, USA) and up to 1L with distilled water). The agarose mix was 
heated in the microwave until melted, when cool to touch 5µl of 10mg/ml ethidium bromide 
(Sigma-Aldrich, MO, USA) were added and the mix was poured in the gel tank and left 
until solid. For fragment purification steps downstream, all the PCR product, 50µl, was 
loaded onto the gel mixed with 8µl of 6x loading dye (Thermo Fisher Scientific, MA, 
USA). A 1Kb DNA ladder (Thermo Fisher Scientific, MA, USA) was used to assess the 
band sizes. The gel was run at 100 V for 1 hour and 30 minutes and visualised under the 
UV light using an Odyssey Fc Imaging System (Licor Biosciences, NE, USA). 
Fragment purification was performed using the Wizard® SV Gel and PCR Clean-Up 
System (Promega, WI, USA) as per manufacturer’s instructions. The DNA fragment of 
interest was cut from the gel, dissolved in a ratio of 10µl of Membrane Binding Solution 
from the kit per 10mg of agarose gel slice, and incubated at 60°C until the gel slice was 
completely dissolved. The solution was loaded on the SV Minicolumn provided in the kit 
and spun at 16,000g. Then the column was washed twice with Membrane Wash Solution 
previously diluted with 95% ethanol (Thermo Fisher Scientific, MA, USA). Finally, DNA 







Table 2. 12 FcRL3 forward and reverse primer sequences used to clone the FcRL3 
transcript. The XhoI restriction enzyme site is highlighted in yellow in the forward primer. 
The HpaI restriction enzyme site is highlighted in green in the reverse primer Start codon 
is underlined in the forward primer and the stop codon is underlined in the reverse primer.  
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2.8.3 Restriction enzyme digestion 
For the cloning of the FcRL3 transcript into the pIG plasmid, both the FcRL3 transcript 
and the pIG plasmid were restriction enzyme digested in order to be able to ligate the FcRL3 
transcript into the pIG plasmid. The two restriction enzymes used, XhoI and HpaI, were 
purchased from New England Biolabs, MA, USA. As for the other plasmids, a single 
digestion, to check the size of the whole plasmid (size of 9,874 bp) and a double digestion, 
to check the insert length was performed (plasmid backbone size was 7,649 bp and FcRL3 
transcript size was 2,225 bp). For this restriction enzyme digestion, 500ng of plasmid was 
used, together with 10 units of each enzymes and 1x CutSmart buffer (New England 
Biolabs, MA, USA). The tubes were topped up to a final volume of 50µl with RNase/DNase 
free water. The reactions were mixed gently and incubated at 37°C for 1 hour. After this 
time, the restriction enzymes were heat-inactivated at 65°C for 20 minutes. The digestion 
products were all loaded onto a 1% agarose gel and purified as described in section 2.8.2.  
2.8.4 DNA ligation 
The products of the restriction enzyme digestion were ligated in order to introduce the 
FcRL3 transcript sequence into the pIG plasmid. The concentration of both digestion 
products was determined using a NanoDrop ND-1000 spectrophotometer. The New 
England Biolabs Ligation Calculator (NEBs, MA, USA) was used to calculate the mass of 
insert required to ligate 50ng of vector DNA. Two ratios of insert: vector were used, 2:1 
and 5:1. A higher ratio of FcRL3 gene to plasmid increases the chances of FcRL3 being 
inserted in the plasmid. 
In a microcentrifuge tube on ice, the calculated amount of plasmid and FcRL3 for the two 
ratios reaction was added, together with 1x T4 DNA ligase buffer (10x stock) and 400 Units 
of T4 DNA ligase (stock at 400,000 U/ml; both from New England Biolabs, MA, USA). 
The reaction was topped up to a final volume of 20µl with RNase/DNase free water. The 
contents were mixed by pipetting up and down and the tubes were incubated at RT for 2 
hours. After this time, the T4 DNA ligase was heat-inactivated at 65°C for 10 minutes. The 
tubes were then chilled on ice, then frozen at -20°C and stored. The reaction product was 





2.8.5 Plasmid extraction 
To check if the plasmid incorporated into the bacteria in the colonies that grew on the agar 
plate had the correct inserted FcRL3 transcript, a QIAprep® Spin Miniprep Kit (Qiagen, 
Germany) was used following manufacturer’s instructions for the high-yield protocol. 
After checking all the colonies using restriction enzyme digestion analysis (see section 
2.8.3), one colony was picked and a Maxiprep, using the PureYieldTM Plasmid Maxiprep 
System (Promega, WI, USA) following the manufacturer’s protocol, was performed to 
obtain high amounts of the plasmid.  
2.8.6 Plasmid sequencing 
The two FcRL3 plasmids, FcRL3-pcDNA3 and the FcRL3-pIG, were sent for sequencing, 
to make sure that the FcRL3 transcript was the correct one and the sequence did not contain 
any mutations. Two labelled 1.5ml microcentrifuge tubes with plasmids were prepared: 
One for the forward sequencing, and the other for the reverse sequencing. 100 ng of plasmid 
in a final volume of 20µl of RNase/DNase free water were sent to GATC Services (Eurofins 
Scientific, Luxembourg) for sequencing in both directions. The primers were designed 
using Primer3Plus (Free Software Foundation, MA, USA) and their synthesis was ordered 
from GATC Services (Eurofins Scientific, Luxembourg). For primers details see Tables 
2.13 and 2.14. 






















FcRL3 - pIG 
Forward primers 











MSCV rev CAGCGGGGCTGCTAAAGCGCATGC 





Figure 2. 5. Overview of protocol used to clone the FcRL3 transcript into the pIg plasmid. The FcRL3 transcript was amplified from the 
pcDNA3 plasmid by PCR. The primers contained the start and the stop codons, as well as two different restriction enzyme sites. These restriction 
enzymes were identical to two sites within the pIG plasmid. Both the PCR product containing FcRL3 transcripts and the pIG plasmid were 
restriction enzyme digested to create sticky ends. Finally, the two digestion products were ligated using a T4 DNA ligase, resulting in the FcRL3 
transcript being incorporated in the pIG plasmid. The ligation product was checked by transforming bacteria and digesting the plasmid grown by 
selected colonies. A colony showing the right restriction enzyme digestion was picked and the plasmid was sent for sequencing to check that the 
transcript sequence was the same as the reference one. After validation of the sequence, the FcRL3-pIG plasmid was used to transduce a Ramos 
B cell line. Created with Biorender.com.
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2.9 FcRL3 transfection/transduction of Ramos B cells 
2.9.1 Ramos and Raji cells Neon® Kit Transfection  
The Neon® Transfection System (Invitrogen - Thermo Fisher Scientific, MA, USA) was 
used for the transfection of Ramos and Raji B cells with the FcRL3-pcDNA3 plasmid using 
electroporation. Cells from each cell line were harvested and washed in PBS. Then, the 
cells were resuspended in Resuspension Buffer R to a final density of 2 × 107 cells/ml. 
Cells were resuspended up and down gently to ensure a single cell suspension and 9µl were 
transferred to a tube with 3µg of FcRL3-pcDNA3 plasmid, making up a final volume of 
10µl. Then, using the Neon® Pipette with a 10µl Neon® Tip the cell-DNA suspension was 
slowly aspirated, carefully avoiding air bubbles. The Neon® Tip was then vertically 
inserted into the Neon® Tube which was previously filled with 3ml of Electrolytic Buffer 
(Buffer E). Next, the desired pulse conditions were set; the pulse conditions used were 
tested and optimised for Ramos and Raji cells by Invitrogen and were as following: a pulse 
voltage of 1,350V, a pulse width of 30ms and a pulse number of 1. After the electroporation, 
the Neon® Tip was slowly removed from the Neon® Pipette Station and cells were 
immediately transferred to a previously prepared 24-well plate containing 0.5ml of pre-
warmed RF10 (RPMI +10% FCS). Cells were incubated for three days at 37°C with 5% 
CO2 in RF10 without any antibiotics. After the three days, the selection antibiotic G418 
(Geneticin, Thermo Fisher Scientific, MA, USA) was added at a final concentration of 
600μg/ml. The cells which were successfully transfected would be resistant to G418 as the 
FcRL3-pcDNA3 plasmid contained a neomycin resistance gene. Transfection efficiency 
was assessed by expression of FcRL3 using flow cytometry.  
2.9.2 HEK293T cells retroviral transfection 
Lipofectamine ®LTX and Plus™ Reagent was also tested for its ability to transfect 
HEK293T cells with the plasmids to assemble the FcRL3 retroviral particles needed to 
transduce the B cell lines. See Figure 2.6 for an overview of the protocol.  
To create the retroviral particles, three plasmids were used. Two of the plasmids, VSVG 
and pCGP create the viral particles: VSVG codes for the vesicular stomatitis virus G-
protein making the envelope, and the pCGP plasmid codes for the Gag protein, a major 
component of the virus capsid and the Pol protein, responsible for synthesis of viral DNA 
and integration into the host genome. The third plasmid used is the pIG transfer plasmid 
(Puromycin IRES GFP plasmid), this plasmid is packed into the retroviral particles and 
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once in the transduced cells the puromycin resistance gene confers puromycin resistance 
and the IRES (Internal Ribosome Entry Site) induces GFP production and in the case of 
the FcRL3-pIG plasmid of GFP and FcRL3, as two separate protein products.  
2.5 x 106 HEK293T cells were cultured in a 6-well plate (CoStar, DC, USA) in a final 
volume of 10ml of DMEM with 8% FCS. The cells were incubated at 37°C with 5% CO2 
overnight, so the next day they were 70-90% confluent. As for the manufacturer’s protocol, 
when cells were confluent, 150µl of the mix containing serum free medium and 15µl of 
lipofectamine was combined with 150µl of a mix containing serum free medium, 14µl of 
plus reagent and 14µg of the FcRL3-pIG transfer plasmid, the pCGP packaging plasmid 
and the VSVG envelope plasmid. As a control, the empty pIG transfer plasmid was added 
together with the packaging and the envelope plasmids to generate control viral particles 
that will do not contain the FcRL3 transcript and will only express GFP. The final mixes 
were incubated for 5 minutes at RT and a final volume of 250µl was added dropwise to the 
cells in the plate. Cells were incubated for two days at 37°C with 5% CO2. After two days, 
cells were harvested by pipetting up and down to detach them, transferred into a universal 
tube and spun at 400g for 10 minutes. Supernatants were collected and used on the same 
day to transfect the Ramos and Raji cell lines.  
2.9.3 Ramos and Raji cells retroviral transduction 
Cells from each cell line were harvested and count Burker counting chamber with Trypan 
Blue. 0.5 x 106 cells from each cell line, were cultured in a 12-well plate (CoStar, DC, 
USA) in a final volume of 1ml of RPMI 1640 with 10% FCS. Mastermixes containing 
8µg/ml of polybrene and various volumes (250µl, 500µl, 750µl and 1000µl) of either only 
RF10, or 48-hour HEK293T cell culture supernatants from cells transfected either with the 
control retroviral particles or the FcRL3 retroviral particles, were added to the cell lines. 
Cells were then centrifuged at 600g for 2 hours at RT in order to force the retroviral 
particles towards the cells at the bottom of the plate. Cells were then incubated for 72 hours 
at 37°C with 5% CO2. After 3 days, cells were harvested and centrifuged at 400g for 8 
minutes. Cells transduced with either the control retroviral particles or the FcRL3 retroviral 
particles, were resuspended in pre-warmed RPMI 1640 containing 10% FCS and 
supplemented with 1μg/ml puromycin. Cells were split and plated at a cell density of 0.5 x 
106 cells/well of a 12-well plate. A control well with wild-type cells from each cell line was 
cultured in RPMI 1640 containing 10% FCS without puromycin. The cells which were 
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successfully transduced would be resistant to puromycin as the pIG plasmid contained a 
puromycin resistance gene. Cells were incubated for an additional 72 hours. After these 
three days, cells were harvested, layered under 10ml of Lymphoprep and centrifuged at 
700g for 10 minutes at RT (acceleration 9, deceleration 0). Live cells deposited at the 
interface were harvested and the cells were washed twice in RPMI 1640 with 10% FCS to 
remove any contaminating Lymphoprep. The first wash centrifugation spin was at 600g for 
8 minutes and the second at 400g for 8 minutes. Cells were then resuspended in 5ml of 
RPMI 1640 with 10% FCS and 1μg/ml of puromycin and transferred to a T25 culture flask 
(Greiner Bio-one, Austria). Once confluent, cells were transferred to a T75 culture flask 
and were kept in culture in the presence of puromycin to select the transduced cells. 





Figure 2. 6. Overview of protocol used to transduce Ramos cells using a retroviral approach. HEK293T cell were transfected using 
lipofectamine with the three plasmids needed to create the retroviral particles. After two days, supernatants containing the virus particles were 
collected. Ramos cell lines were then incubated with the HEK293T supernatants containing the viruses. Selection of the infected cells was achieved 
by the addition of puromycin three days post-transfection. Created with Biorender.com. 
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Due to the presence of a heterogeneous mixed population in the FcRL3 Ramos transduced 
cells, expressing either GFP alone or both GFP and FcRL3, flow cytometry cell sorting was 
used to purify the double positive population (GFP+FcRL3+). 30 x 106 cells were stained 
for FcRL3-PE (Biolegend, CA, USA) and the lineage marker CD19-BV421 (Biolegend, CA, 
USA). Cells were stained with 2μl of Zombie UV in 100μl of PBS for exclusion of dead 
cells. Cells were transferred to a FACS tube and the volume was made up to 2ml with 
FACS buffer, resulting in a cell density of 10 x 106 cells/ml. 
Immediately before sorting, the cells were transferred into a new FACS tube and strained 
through a 50μm cell strained (CellTrics - Sysmex, IL, USA). The BD FACSARIA II with 
a 100μm nozzle was used to sort three cell subsets: GFP bright cells (GFP high FcRL3-), 
GFP intermediate cells (GFP+ FcRL3-) and double positive cells (GFP+ FcRL3+). Around 
0.8 x 106 cells per subset were sorted into 350μl of RLT Plus Lysis Buffer from Qiagen 
RNeasy Plus Micro Kit, to which β-mercaptoethanol had been added at ratio 1:100. Cells 
were sorted into RLT as FcRL3 expression was also checked at the mRNA level (see 
sections 2.9.4-6). The lysate was then added to a QIAshredder column (Qiagen, Germany) 
and spun at full speed (1,700g) for 2 minutes. The eluate was then frozen at -80 °C prior to 
RNA extraction. The rest of the cells, about 1 x 106 cells, were sorted into RF20 (RPMI 
1640 medium containing 20% (v/v) Foetal Calf Serum and supplemented with 2 mM L-
glutamine, 100 U/ml penicillin and 100 µg/ml streptomycin) for cell culture. The sorting 
gating strategy is shown in Chapter 7, Figure 7.5. After sorting, cells were spun at 400g for 
8 minutes at RT and resuspended in 5ml of RPMI 1640 with 10% FCS and 1μg/ml of 
puromycin and transferred to a T25 culture flask.  
Transduction efficiency was assessed throughout the process of expanding the transduced 
population, by GFP fluorescence using a fluorescent microscope (Invitrogen™ EVOS™ 
FL Digital Inverted Fluorescence Microscope - Life Technologies - Thermo Fisher 
Scientific, MA, USA), as well as by flow cytometry, acquiring the cells on a BD LSR 
Fortessa X20™. In addition to GFP detection, transduction was assessed by flow cytometry 
staining transduced cells with the FcRL3 antibody (FcRL3 – PE clone H5/FcRL3, from 
Biolegend CA, USA). 
2.9.4 RNA extraction  
Transduced Ramos cells were flow cytometry sorted straight into 350μl of RLT Plus Lysis 
Buffer containing β-mercaptoethanol at ratio 1:100. Sorting straight into RLT buffer 
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increases RNA recovery and integrity. The lysate was then added to a QIAshredder column 
and spun at full speed (1,700g) for 2 minutes. The eluate was then frozen at -80 °C prior to 
RNA extraction. 
The Qiagen RNeasy Mini Kit (Qiagen, Germany) was used to extract the RNA following 
manufacturer’s instructions apart from one modification. To ensure that any DNA 
contamination was removed, the optional DNase digestion steps were performed as 
described in the appendix D protocol in the Qiagen RNeasy Mini Kit Handbook. Extracted 
RNA was eluted in 30μl of RNase-free water (provided in the kit). The concentration of 
RNA in this final eluate was determined using the NanoDrop ND-1000 spectrophotometer 
and the RNA was frozen at -80 °C if not used immediately for downstream applications. 
2.9.5 Reverse Transcription 
Reverse transcription (cDNA synthesis) was performed in a 0.2ml PCR strip. Due to 
different amounts of extracted RNA, the same total amount of RNA, 160 ng, was reverse 
transcribed for each sample used in a volume of 10μl.  Two negative controls were 
included, a water control where RNA was replaced with RNase/DNase-free water and a 
reverse transcriptase (RT) control where RT enzyme (SuperScript II, Thermo Fisher 
Scientific, MA, USA) was replaced with RNase/DNase-free water. To all wells 1μl of 
random hexamers (1 μg/μl, Integrated DNA Technologies, Inc, IA, USA) was added and 
the mixture was covered with a StarSeal adhesive lid (StarLab, Germany) and pulse spun 
to >800g. In a PCRmax alpha thermal cycler (PCRmax, UK) the strip was heated to 70 °C 
for 10 minutes and then chilled at 4 °C for an extra 10 minutes. A mastermix containing 
0.01M DTT, 0.25mM dNTP, 1 unit SuperScript II and 2.2X First Strand Buffer (all 
Invitrogen - Thermo Fisher Scientific, MA, USA) was generated and 9μl of the mastermix 
were added in each well except the RT negative control, giving a final volume of 20 μl. For 
the RT negative controls, an additional mastermix was made up where the SuperScript II 
was replaced by RNase/DNase-free water. The strip was then heated for 1 hour at 42 °C in 
the PCRmax thermal cycler. The synthesised cDNA was diluted down to 1:2.5 and 1:100 
with RNase/DNase-free water and stored at -20 °C until used for downstream applications.  
2.9.6 Quantitative Polymerase chain reaction (q-PCR) 
qPCR was used to check FcRL3 expression on the transfected cell lines. A mastermix 
containing 0.2μl of 10μM Universal ProbeLibrary probe (Roche, Switzerland), 0.4μl of 
10mM forward and reverse primers (Sigma-Aldrich, MO, USA), 4μl RNase/DNase Free 
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water and 10μl 2X TaqMan® Gene Expression Mastermix (Life Technologies - Thermo 
Fisher Scientific, MA, USA) was prepared and 15μl were mixed with 5µl of 1:2.5 diluted 
cDNA in a MicroAmp Fast Optical PCR plate (Applied Biosystems - Thermo Fisher 
Scientific, MA, USA). Probe and primer sequences for FcRL3 are shown in Table 2.15. 
The expression of the housekeeper gene, 18S, was used to normalise the results. For the 
18S expression, 5μl of a separate mastermix containing 0.1μl of 10μM 18S Probe (Sigma-
Aldrich, MO, USA), 0.1μl of 10mM forward and reverse primers (Sigma-Aldrich, MO, 
USA), and 4.7μl of 2X TaqMan® Gene Expression Mastermix were added to 5μl of 1:100 
diluted cDNA. Probe and primer sequences for the 18S gene are shown in Table 2.15.  
mRNA expression was quantified using a TaqMan 7900HT fast-real time PCR system (Life 
Technologies - Thermo Fisher Scientific, MA, USA) with the thermal cycler set to 50 °C 
for 2 minutes, 95 °C for 10 minutes and then 95 °C for 15 seconds and 60 °C for 1 minute 
repeated for 40 cycles. 
 
 
2.10 FcRL3 functional work 
2.10.1 Apoptosis assay 
Untransduced (wild type) and transduced Ramos cells (Ramos GFP control cells and 
Ramos FcRL3+ cells) were plated at a cell density of 1 x 106 cells per well in 24-well plate 
in a final volume of 1ml of RF10 with or without 1μg/ml of puromycin. A separate plate 
was used for each of the three time points: Day 1, Day 2 and Day 3. The LEAF™ Purified 
anti-human CD95 (Fas) antibody (clone EOS9.1; Biolegend, CA, USA) was used to induce 




Roche Universal Probe Library Number 64 




Table 2. 15 FcRL3 and housekeeper 18S primer and probe information.  
79 
 
100ng/ml and 200ng/ml. Cells were cultured for different days at 37°C with 5% CO2 prior 
to assessment by flow cytometry. After the different time points, cells were harvested from 
the culture plate and transferred to a previously labelled 1.5ml microcentrifuge tube. The 
tubes were then spun at 400g for 8 minutes at RT, supernatants were discarded and cells 
were resuspended and transferred to a 96-well v-bottom plate (CoStar, DC, USA) for flow 
cytometry staining. The plate was centrifuged at 400g for 3 minutes, blotted and 
resuspended in 100μl of PBS containing 1μl of Zombie UV to stain dead cells. Cells were 
incubated at 4°C for 15 minutes in the dark, then washed once with FACS buffer. Cells 
were then resuspended in 100μl of 1x Binding Buffer (10x stock containing 0.1 M HEPES 
(at pH 7.4), 1.4 M NaCl, 25 mM CaCl2) containing 5μl of Annexin V – APC (Biolegend, 
CA, USA). Cells were incubated at room temperature for 15 minutes in the dark. After the 
incubation time, cells were washed with 100μl of 1x Binding Buffer and resuspended in a 
150μl of 1x Binding Buffer and fixed in 1% formaldehyde through the addition of 50μl of 
4% formaldehyde.   
2.10.2 Cell Trace Violet staining 
2 x 106 untransduced and (wild type) and transduced Ramos cells (Ramos GFP control cells 
and Ramos FcRL3+ cells) were resuspended in a final volume of 1ml of warmed PBS and 
stained with CellTrace™ Violet (CTV; ThermoFisher Scientific, MA, USA). CellTrace 
dyes are used for in vivo labelling of cells to trace multiple generations using dye dilution 
by flow cytometry. CellTrace dyes easily cross the plasma membrane and covalently bind 
to all free amines on the surface and inside cells. Due to their high stability and well-
retained fluorescence, these dyes provide a consistent signal, even after several days in a 
cell culture environment. When a cell divides, the amount of dye in their membrane is 
divided by half, allowing for proliferation measurement by successive halving of the 
fluorescent dye intensity. As per manufacturer’s instructions, a vial of CTV was 
reconstituted by adding 20μl of DMSO (included in the CTV Kit) to a final concentration 
of 5 mM, immediately prior to use. The recommended final concentration of CellTrace™ 
dye per 1 x 106 cells is of 5μM, therefore a 2x stock of 10μM in warm PBS was prepared 
by mixing 2μl of CTV and 1ml of warm PBS. Finally, the 2x stock solution was mixed 
with an equal volume of the cells giving a final concentration of 5μM CTV per 1 x 106 
cells/ml. The mixture was gently mixed and incubated at 37°C for 30 minutes (in an 
incubator), protected from light. After the incubation time, at least 5x the staining volume 
of complete culture medium, RF10, was added and incubated at 37°C for 5 minutes to 
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quench any remaining dye. After 5 minutes, cells were spun at 400g for 8 minutes at RT. 
Supernatants were discarded, and cells were resuspended in 12ml of RPMI 1640 with 10% 
FCS with or without 1μg/ml of puromycin and transferred to a T75 culture flask. At the 
different time points, a 500μl aliquot of cells were transferred to a FACS tube topped to 
2ml with FACS buffer and spun at 400g for 8 minutes. The supernatant was blotted and the 
cells were resuspended in a final volume of 200μl of FACS buffer and fixed in 1% 
formaldehyde before acquisition on a BD LSR Fortessa X20™. 
2.10.3 Cell Stimulation 
Untransduced (wild type) and transduced Ramos cells (Ramos GFP control cells and 
Ramos FcRL3+ cells) were plated at a cell density of 250,000 cells per well in 24-well plate 
in a final volume of 1ml of RF10 with or without 1μg/ml of puromycin, respectively. Cells 
were stimulated with two different cocktails: Stimulus 1 was a combination of the TLR7 
ligand, Imiquimod (1μg/ml), TLR9 agonists ODN 2216 – CpG A and ODN 2006 – CpG B 
(both 1μg/ml), PWM (5μg/ml), anti-CD40 antibody (10μg/ml, clone HB14), human IL-21 
(0.05μg/ml), human IL-4 (0.05μg/ml) and IFN-gamma (0.02μg/ml). Stimulus 2 was the 
same stimulation reagents as stimulus 1 but no IL-4 was added to the mastermix. Cells were 
cultured for 3 days at 37°C with 5% CO2 prior to assessment by flow cytometry. For the 
staining protocols see section 2.4.3 for surface staining and 2.4.2 for intracellular staining. 
For information on the antibodies used see Tables 2.16-2.18. Supernatants were frozen at -
80°C prior to further analysis by MSD assay.  
Surface 
marker 
Fluorophore Clone Dilution factor Company 
FcRL3 PE H5/FcRL3 1:25 Biolegend CA, USA 
CD19 BUV395 SJ25C1 1:100 BD Biosciences, CA, USA 
HLA-DR PerCP L203 1:20 RnD Systems, MN, USA 
FcRL4 APC 413D12 1:10 Biolegend CA, USA 
CD69 APC-Vio770 FN-50 1:20 Miltenyi Biotech, Germany 
CD40 BV421 5C3 1:20 Biolegend CA, USA 
CD86 BV711 IT2.2 1:50 Biolegend CA, USA 






Fluorophore Clone Dilution factor Company 
FcRL3 PE H5/FcRL3 1:25 Biolegend CA, USA 
CD19 BUV395 SJ25C1 1:100 BD Biosciences, CA, USA 
IgM PerCP-Cy5.5 MHM-88 1:20 Biolegend CA, USA 
FcRL5 APC 509f6 1:50 Biolegend CA, USA 
IgD AF700 IA6-2 1:50 Biolegend CA, USA 
CD11c BV421 B-LY6 1:20 BD Biosciences, CA, USA 
IgG BV786 G18-145 1:50 BD Biosciences, CA, USA 




Fluorophore Clone Dilution factor Company 
FcRL3 PE H5/FcRL3 1:25 Biolegend CA, USA 
CD19 BUV395 SJ25C1 1:100 BD Biosciences, CA, USA 
CD55 APC JS11 1:25 Biolegend CA, USA 
CD5 PE-Cy7 UCHT2 1:50 eBioscience, CA, USA 
T-bet BV421 O4-46 1:10 BD Biosciences, CA, USA 
CD27 BV650 O323 1:10 Biolegend CA, USA 
Ki67 BV711 Ki-67 1:10 Biolegend CA, USA 
CD97 BV786 VIM3b 1:25 BD Biosciences, CA, USA 
Table 2. 18. Fluorophore labelled antibodies used for the intracellular panel. 
 
2.11 Statistical analysis 
For the flow cytometric analyses percentage positive cells and MFI values were visualised 
as graphs using GraphPad Prism (version 8, GraphPad Software, CA, USA). Various 
statistical analyses were carried out on the data of three replicates or more. For statistical 
tests where a non-parametrical analysis was performed due to the non-normal distribution 
of the data, two tests were used: a Mann-Whitney U test to compare 2 groups and a Kruskal-
Wallis test for 3 or more groups. For the Kruskal-Wallis test a subsequent Dunn’s test was 
used to perform multiple comparisons and assess which comparisons are significantly 
different. For frequency data, like the percentage of females in each cohort, a non-
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parametric test like the Fisher exact probability test was used to compare 2 groups and a 
Chi-squared test to compare more than 2 groups. To study linear correlations, like the 
correlation of ABC frequency with inflammation markers, a Pearson Correlation 
coefficient was calculated to assess if there is a correlation and if this correlation is positive 
or negative. These tests were performed using GraphPad Prism and significance was 
defined when p<0.05.  
As mentioned above, for the NanoString transcriptomic analysis, R core (The R 
Foundation) was used together with the Bioconductor repository both to analyse and plot 
the data. 
Some tests were performed using JMP Statistical Visualization Software (version 13, SAS 
Inc, NC). Functional work readouts from RA patients and healthy control B cell subsets 
were analysed using the JMP Software. Data was transformed to ranks permitting 
parametric tests, such as a Two-way ANOVA, comparing established RA patients and 
healthy controls, to be performed. Also using JMP Software, a regression analysis was 
performed to evaluate the influence of key patient variables on ABC frequency. These data 
was logit transformed to take into account that the lower bound is zero, as for some patients 
the frequency of ABCs is in the range of 0 (from 0.5 to 1) the logit transformation was used 
to change these values so a fitted Full Model assessing the contribution of each variable to 









Different groups have recently identified a novel subset of B cells named age-associated B 
cells (ABCs), which are linked to aging and autoimmunity (Hao et al., 2011; Rubtsov et 
al., 2011). Studies to characterise this subset have been done in mice models, as well as in 
healthy individuals and autoimmune patients. Because of their increased frequencies in 
autoimmune patients, these cells have been hypothesised to potentially be involved in 
autoimmune pathogenesis due to their ability to produce antibodies, cytokines and present 
antigens. 
In mice, Rubtsov et al., described these cells as CD11c and CD11b positive but CD21 
negative and found them in increased frequencies in mice prone to autoimmune diseases 
like lupus-like disease and systemic autoimmunity (NZB/WF1 and Mer-/- mice) when 
compared to age-matched healthy mice (C57BL/6 mice) (Rubtsov et al., 2011).  
In autoimmune patients suffering from SLE and autoimmune cytopenia, a similar 
population of B cells has been identified as CD21-CD19high B cells (Warnatz et al., 2002; 
Wehr et al., 2004). However, unlike in mice, only a proportion of autoimmune patients 
displayed high frequencies of CD21low B cells in peripheral blood. Rubtsov et al., also 
investigated human ABCs, defined as CD21-CD11c+CD19high B cells, in the peripheral 
blood of RA, SSc and SLE patients and found high frequencies of this subset in a proportion 
of patients with RA and SSc (Rubtsov et al., 2011). The expanded ABC population was 
observed at a higher frequency in women suffering from RA compared to younger women 
and men of any age. Other studies also compared healthy, age- and sex- matched controls 
with patients with RA and found that the patients had higher frequencies than the controls 
(Shimabukuro-Vornhagen et al., 2017). The CD21low population has also been studied in 
synovial fluid of patients with active RA, where it has been demonstrated that the CD21low 
B cell subset is a major B cell subset (Illges et al., 2000; Thorarinsdottir et al., 2019). 
CD21low B cells have been described in different diseases ranging from infections to 
autoimmunity (Charles et al., 2011; Thorarinsdottir et al., 2015). The common feature in 
all of these diseases is chronic immune stimulation. However, none of the published papers 
have correlated ABCs frequency with clinical parameters as markers of inflammation and 
disease activity scores.  
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Therefore, I assessed the frequency of ABCs in peripheral blood and synovial fluid in early 
and established RA patient cohorts compared to other disease controls as well as age-
matched healthy controls.   
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3.2 Chapter hypothesis and aims 
In this chapter, I hypothesised that ABCs are found in increased frequencies in patients 
with RA and they correlate with inflammation markers and disease activity.  
Therefore, the aims of this chapter were to: 
1. Assess the frequency of ABCs in peripheral blood and synovial fluid in early and 
established RA patient cohorts compared to other disease controls and age-matched 
healthy controls. 
2. Correlate the frequency of these cells with the patients’ clinical parameters. 
The specific objectives were: 
1. Determine the best staining protocol to assess ABC frequency by flow cytometry. 
2. Compare ABC frequency in peripheral blood in different inflammatory arthritides 
as well as healthy controls.  
3. Correlate the frequency of these cells with different clinical parameters such as 
disease activity and inflammation markers.  





3.3.1 Flow cytometry gating strategy used to determine the frequency of ABCs  
ABC frequency in blood of patients and healthy controls was determined by flow 
cytometry. See methods chapter 2 for staining protocols from whole blood and from 
previously isolated PBMCs (sections 2.5.1 and 2.5.3 respectively). The flow cytometry data 
were analysed using the software FlowJo Version 10 (Treestar Inc, OR, USA).  
Figure 3.1 shows an example of the gating strategy used to determine the percentage of 
ABCs from the total B cell population from an RA patient. First, doublets and 
autofluorescent cells were excluded. Lymphocytes were gated using SSC-A vs FSC-A, and 
from the lymphocyte gate, the B cells were gated. A dump channel was used to exclude 
other cell types, CD3 for T cells, CD16 and CD14 for all monocytes, CD56 for NK cells 
and most importantly CD33 for dendritic cells. Exclusion of dendritic cells is very 
important as these cells are positive for CD11c and could contaminate our ABC population. 
From the B cell gate, ABCs were identified as CD11c+CD21- and, from the non-ABC B 
cells, CD5+ cells were gated as CD5+CD19+. From the CD5- fraction, naïve B cells 





Figure 3. 1. Gating strategy for each B cell subset. Example of the gating strategy used to create 
each of the B cell subsets of interest from whole blood from an RA patient. Singlet cells are gated 
first using SSC-A against SSC-W, then autofluorescent cells are excluded. From the AF- gate, 
the lymphocyte gate is created on a SSC-A against FSC-A. Then B cells are gated excluding NK 
cells, T cell, monocytes and most importantly dendritic cells with a dump channel. From the B 
cell gate, ABCs were identified as CD11c+CD21- and from the non-ABCs, CD5+ B cells were 
identified as CD5+CD19+. From the CD5- populations, naïve cells are identified as IgD+CD27- 





3.4.1 Detection of ABCs using different staining techniques and centrifugation medium 
Using flow cytometry, ABCs were identified as CD19+CD11c+CD21- in the peripheral 
blood of patients and healthy controls (Figure 3.1), as previously described by other groups 
(Rubtsov et al., 2011). 
I have demonstrated that ABCs are detectable in peripheral blood using flow cytometry. 
However, as I planned to isolate ABCs for downstream analysis, I needed to determine 
whether ABCs were detectable after PBMCs isolation using a density centrifugation 
medium. ABCs have previously been described as slightly larger than other B cell subsets 
(Rubtsov et al., 2011). Due to their larger size, it is possible that I might lose some ABCs 
when isolating PBMCs with a density centrifugation medium, such as Lymphoprep. This 
technique uses the cell density to isolate mononuclear cells from red blood cells and 
granulocytes, which are denser and pass through the Lymphoprep solution and sediment 
during centrifugation. If ABCs are bigger and denser than other B cells it would be possible 
that they also sediment and therefore are lost from the isolated PBMC fraction.  
To test this, an ABCs detection panel was used to stain cells isolated using different density 
centrifugation medium. From the same sample, an aliquot of whole blood was stained with 
an antibody panel to detect ABCs, and the remaining blood was used to isolate mononuclear 
cells with different density centrifugation medium and stained with the same panel of 
antibodies. ABCs frequency, as a percentage of total CD19+ B cells was used to determine 
if there was any cell loss during cell isolation.  
There were no significant differences between the frequency of ABCs detected from 
stained whole blood and different centrifugation media (Figure 3.2.A). When comparing 
whole blood and Lymphoprep in matched donors, no differences were seen in the 
percentage of ABCs detected (Figure 3.2.B). I therefore used whole blood flow cytometry 
to detect and phenotype the different B cell populations as this involves minimal 
manipulation of the cells. When isolating cells for downstream work, the centrifugation 





Figure 3. 2. Determination of ABCs frequency using different staining protocols. A. 
ABCs were detected by flow cytometry from whole blood staining and from different 
centrifugation media protocols used to isolate PBMCs. The frequency of ABCs is shown 
as a percentage of total CD19+ B cells. N numbers vary between each method: whole blood 
n = 4, Lymphoprep n = 3, Histopaque n = 2, Polymorphoprep n = 2 and Percoll n = 2. B. 
ABCs were detected in the same donor by flow cytometry from whole blood staining (n = 
11) and from Lymphoprep isolated peripheral blood mononuclear cells (n = 11). The 
frequency of ABCs is shown as a percentage of total CD19+ B cells. Samples are from HCs 




3.4.2 ABCs frequency and cohorts’ demographical data 
Using the ABCs gating strategy described in Figure 3.1, percentages of ABCs in peripheral 
blood were determined. The percentage of ABCs found in blood was measured in four 
different cohorts: early drug naïve RA (eRA), established RA (estRA), early drug naïve 
other inflammatory arthitides (disease controls, DC) and age-matched healthy controls 
(HC).  
There were 50 patients in the early RA cohort. The demographical and clinical data are 
shown in Table 3.1. All patients met the 2010 ACR/EULAR RA classification criteria. For 
the early disease control cohort with the other inflammatory arthritides, 39 patients were 
recruited. The comparison between the different disease groups is shown in Table 3.2. 
There were statistically significant differences between the groups in terms of sex. Analysis 
of the participants’ age in each group revealed significant differences between the cohorts. 
There were differences in disease activity between the early and the established RA cohorts. 
Regarding seropositive status the differences between the groups were also significant.     
The percentage of ABCs present in peripheral blood in the different cohorts was assessed 
by flow cytometry. There were no significant differences between early RA patients when 
compared to other cohorts (Figure 3.3). However, established RA patients had significantly 
higher percentages of ABCs in peripheral blood than ACPA+ patients and the 




Early RA patients Number = 50 
Age (years; median and range) 68 (21 - 89) 




DAS28 (median and range) 4.47 (1.33 – 8.53) 
CRP (mg/ml; median and range) 9 (4 - 127) 
ESR (mm/hr; median and range) 28 (2 - 116) 
Tender joint count (median and 
range) 
3 (0 - 25) 
Swollen joint count (median and 
range) 
4 (0 – 21) 
Patient VAS (median and range) 50 (2 – 100) 
Anti-CCP positive 
(n and percentage) 
30 (60%) 
Rheumatoid factor positive 
(n and percentage) 
31 (62%) 
Seropositive – anti-CCP+ or RF+ 
(n and percentage) 
34 (68%) 
Smoker (n and percentage) 29 (58%) 
 
Table 3. 1. Demographic characteristics of the early RA cohort. Demographical data 
for the drug naïve RA patients’ cohort used to determine the frequency of ABCs in 
peripheral blood. All patients were diagnosed with rheumatoid arthritis following the 2010 
ACR/EULAR classification criteria. All these patients were naïve to disease modifying 
anti-rheumatic drugs (DMARDs) at the time that blood was taken. CRP = C - reactive 
protein, ESR = erythrocyte sedimentation rate, anti- CCP = anti-cyclic citrullinated peptide 
antibody, RF = rheumatoid factor. 
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Table 3. 2. Demographic characteristics for all the cohorts. Demographical data for the disease cohorts: early RA patients, n=50; established 
RA patients, n=12; Psoriatic Arthritis patients, n=17; ACPA+ arthralgia patients, n=3; Undifferentiated Arthritis patients, n=7 and the healthy 
control cohort (n=13) used to determine the frequency of ABCs in blood. # Kruskal-Wallis test with Dunn’s multiple comparisons. + Chi-square 
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Figure 3. 3. Detection of ABCs in different disease groups and age-matched healthy 
controls. ABCs frequency in healthy controls older than 50 years old (HC, n=13), early 
RA patients (eRA, n=50), established RA patients (estRA, n=12), Psoriatic Arthritis 
patients (PsA, n=17), ACPA+ patients (ACPA+, n=3) and Undifferentiated Inflammatory 
Arthritis patients (UIA, n=7). ABCs were detected by flow cytometry using whole blood. 
The frequency of ABC is shown as a percentage of total CD19+ B cells. The median value 
is represented by the horizontal line for each group. Statistical significance was assessed 
using a Kruskal-Wallis test with Dunn’s multiple comparisons of each group against the 




3.4.3 ABCs frequency and patients’ serostatus in RA patients 
Due to the implication of B cells in autoantibody production in autoimmune diseases, all 
early RA patients (n=50) and established RA patients (n=12) were then separated by 
serostatus as defined by their RF and anti-CCP titres, which were positive or negative as 
determined by the clinical labs’ standards. Patients were further split into double negative 
(anti-CCP-, RF-), and positive, including both single positive for either autoantiboy (anti-
CCP+, RF- and anti-CCP-, RF+) as well as double positive (anti-CCP+, RF+). There were 
no significant differences in the frequency of ABCs found in blood and the serostatus of 
the patients (Figure 3.4).  
 
Figure 3. 4. ABCs frequency in early RA patients separated by their serostatus. Early 
RA patients were divided in seronegative (double negative, anti-CCP-, RF-) where n=16 
or in seropositive, including single positive (anti-CCP+, RF- and anti-CCP-, RF+) as well 
as double positive (anti-CCP+, RF+), where n=34. The median is represented by the 




3.4.4 ABCs frequency and correlation with age and sex in the RA cohort 
Due to significant differences in age and sex between the cohorts, RA patients were 
separated by sex and age into four groups, females younger than 54 years, females older 
than 55 years, males younger than 54 years and males older than 55 years. An age range of 
over or below 55 was chosen based on other published work reporting higher frequencies 
in young females compared to young males (Shimabukuro-Vornhagen et al., 2017), and 
because it was a cut-off that give enough number of patients in each group to compare. 
There were no significant differences in the percentage of ABCs found in peripheral blood 
in each of the groups (Figure 3.5). 
Nevertheless, when RA patients were separated by sex, higher frequencies of ABCs were 
seen in females compared to male patients (Figure 3.6).  
 
Figure 3. 5. ABCs frequency in RA patients separated by age and sex. Both early and 
established RA patients were separated according to their age and sex: females younger 
than 54 years old (n=11); females older than 55 years old (n=32); males younger than 54 
years old (n=4); and males older than 55 years old (n=15). The median value is represented 
by the horizontal line for each group. Statistical significance was assessed using a Kruskal-








Figure 3. 6. ABCs frequency in RA patients separated by sex. Both early and established 
RA patients were separated according to their sex.  Females (n=34) and males (n=16). The 
median value is represented by the horizontal line for each group. Statistical significance 
was assessed using a Mann- Whitney U test; * p < 0.05. 
 
3.4.5 ABCs frequency and correlation with inflammatory markers in eRA patients 
The correlation of inflammatory markers, erythrocyte sedimentation rate (ESR) and C - 
reactive protein (CRP), in early RA patients with ABCs frequencies was also assessed. ESR 
and CRP values were determined by the clinical labs according to their standards. 





Figure 3. 7. Correlation of the frequency of ABCs with the ESR value. ABCs frequency 
in early RA patients were correlated with the patients’ ESR value as determined by the 
clinical labs; n=47. Pearson R test was used. 
 
 
Figure 3. 8. Correlation of the frequency of ABCs with the CRP value. ABCs frequency 
in early RA patients were correlated with the patients’ CRP value as determined by the 
clinical labs; n=49. Pearson R test was used.  
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3.4.6 ABCs frequency and correlation with disease activity in eRA patients 
Early RA patients (n= 50) were then separated by disease activity at the time of the visit in 
three groups, patients with a low disease activity (DAS28 < 3.2), patients with moderate 
disease activity (DAS28 ≥ 3.2 but < 5.1) and patients with high disease activity (DAS28 ≥ 
5.1). There were no significant differences between the ABCs frequencies in each of the 
disease activity groups (Figure 3.9). There were also no significant differences when 
patients’ DAS28 score was correlated with the frequency of ABCs (Figure 3.10).  
 
Figure 3. 9. ABCs frequency in early RA patients separated by the disease activity at 
the time of the visit. Early RA patients were separated by their disease activity depending 
on their DAS28 score in patients with a low disease activity (DAS28 < 3.2; n=10), and 
patients with moderate disease activity (DAS28 ≥ 3.2 but < 5.1; n=22) and patients with 
high disease activity (DAS28 ≥ 5.1; n=18). The horizontal lines represent the median value. 
Statistical significance was assessed using a Kruskal-Wallis test with Dunn’s multiple 




Figure 3. 10. Correlation of the number of ABCs with the disease activity score, 
DAS28. ABCs frequency in early RA patients were correlated with the patients’ DAS28 
score; n=47 using a Pearson R test. 
3.4.7 Regression analysis 
In order to integrate all the patient variables and assess which effect they have on the ABC 
frequency, a single regression analysis was performed using JMP Software. The variables 
analysed were age, sex, RF positivity, CCP positivity, CRP value, ESR value, DAS28 
score, disease activity and smoking status. The data was logit transformed in order to take 
into account that the lower bound is zero. A fitted Full Model was run assessing the effect 
of each variable. As seen in Figure 3.11, the only significant effect was found on sex, which 
confirms the results found when the variables were analysed separately.  
 
Figure 3. 11. Summary of the effect of each variable in ABC frequency using a single 
regression analysis. The contribution of each variable in the frequency of ABCs was 
assessed using a fitted full model in JMP. The blue line is set at a p value of 0.01. After 
adjustment for differences in age, smoking status and other covariates, there is a significant 
difference in sex: ABCs were more prevalent in females (p<0.05).  
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3.4.8 ABCs frequency in synovial fluid from patients with inflammatory arthritides 
Other groups (Amara et al., 2017; Thorarinsdottir et al., 2019) reported that ABC 
frequencies were much higher in synovial fluid than in peripheral blood. I, therefore, 
wanted to replicate this in my own inflammatory arthritis cohort. Synovial fluid 
mononuclear cells from inflammatory arthritis patients collected throughout three years 
were thawed and stained for the detection of ABCs. Patients were separated by disease 
diagnosis into early RA patients (n=3), established RA patients (n=6), Psoriatic Arthritis 
patients (n=3), Other Inflammatory Arthritis patients (n=5), Juvenile Idiopathic Arthritis 
patients (n=2), ACPA+ patients (n=1) and Reactive Arthritis patients (n=1). There were no 
significant differences in patients’ demographics between all the disease groups regarding 
sex (Table 3.3). However, differences were seen in terms of age between the cohorts. 
Unfortunately, serostatus was not available for these patient samples. No differences were 
seen in age and sex when the patients were separated in early inflammatory arthritis and 
established inflammatory arthritis (Table 3.4).  
The flow cytometry gating strategy used was the same as for the blood samples (Figure 
3.1). There were no significant differences between the different inflammatory arthritides 
groups (Figure 3.12). However, when all the patients were separated into early drug naïve 
and established patients, there were higher frequencies of ABCs in the synovium of patients 
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Table 3. 3. Demographic characteristics for all the cohorts. Demographical data for the disease cohorts: early RA patients (n=3), established 
RA patients (n=6), Psoriatic Arthritis patients (n=3), Other Inflammatory Arthritis patients (n=5), Juvenile Idiopathic Arthritis patients (n=2), 
ACPA+ patients (n=1) and Reactive Arthritis patients (n=1) used to determine the frequency of ABCs in synovial fluid. # Kruskal-Wallis test with 




Table 3. 4. Demographic characteristics for all the cohorts. Demographical data for the 
disease cohorts separated into early Inflammatory Arthritis patients (n=6), established 





Figure 3. 12. ABCs detection in synovial fluid in different disease groups. ABCs 
frequency in early RA patients (eRA, n=3), established RA patients (estRA, n=6), Psoriatic 
Arthritis patients (PsA, n=3), Other Inflammatory Arthritis patients (OIA, n=5), Juvenile 
Idiopathic Arthritis patients (JIA, n=2), ACPA+ patients (ACPA+, n=1) and Reactive 
Arthritis patients (Reactive, n=1). ABCs were detected by flow cytometry from isolated 
synovial fluid mononuclear cells. The frequency of ABC is shown as a percentage of total 
CD19+ B cells. The median value is shown as a horizontal line for each group. Statistical 
significance was assessed using a Kruskal-Wallis test with Dunn’s multiple comparisons 
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Figure 3. 13. ABCs detection in synovial fluid in patients with inflammatory arthritis 
separated into early and established disease. ABCs frequency in early Inflammatory 
Arthritis patients (n=7) and in established Inflammatory Arthritis patients (n=10). The 
median value is shown as a horizontal line for each group. Statistical significance was 




In this chapter, I explored the frequency of ABCs in the peripheral blood of RA patients, 
disease controls and healthy controls. I found that the percentage of ABCs in early and 
established RA patients is not significantly higher than in age-matched healthy controls. 
However, I did see an increase in the percentage of ABCs in females with RA compared to 
males. The frequency of ABCs did not correlate with disease activity or with blood 
inflammatory markers. Importantly, high percentages of ABCs were found in the synovial 
fluid of patients with inflammatory arthritides, especially in those with established disease. 
Previous studies found that these cells were slightly larger than follicular B cells. They 
were also reported to have high expression of granzymes and could have a granular 
appearance (Rubtsov et al., 2011; Shimabukuro-Vornhagen et al., 2017). For that reason, I 
first investigated if due to their bigger size and granularity these cells would pass through 
the density centrifugation medium, as happens with granulocytes, and therefore we would 
lose them from the PBMC preparation. Consequently, I determined the frequency of these 
cells comparing whole blood and PBMCs isolated with Lymphoprep and found no 
significant differences between the two isolation methods (Figure 3.2). I subsequently used 
whole blood for the phenotyping of these cells. This only requires a small amount of blood, 
which is advantageous as samples are shared between different researchers; reassuringly, 
however, my data suggested that I could use Lymphoprep isolated PBMCs to sort ABCs 
for transcriptome analysis and functional assays, which would reduce flow sorting time and 
costs. For PBMC isolation I also compared different density centrifugation media and 
found a similar frequency of ABCs between them, I decided to use Lymphoprep for 
downstream work as this is the standard density centrifugation medium used in the lab. 
Multiple studies have shown increased frequencies of ABCs in patients with RA compared 
to healthy donors (Isnardi et al., 2010; Shimabukuro-Vornhagen et al., 2017; Wang et al., 
2018). However, I could not replicate these results (Figure 3.3). This could be due a few 
differences in the studies. None of the other groups used age-matched healthy controls, 
therefore if their healthy controls were younger, they could have lower percentages of 
ABCs in blood purely reflecting their age, and explaining the difference from RA patients. 
Finding healthy controls to match the patients was difficult as I had to match patients who 
were over the age of 75. This age group are hard to find and most volunteers of this age 
have comorbidities which could influence the data. Recently NIHR Newcastle Biomedical 
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Research Centre has established a “healthy ageing” bioresource, which provides a 
recallable population of elderly patients willing to provide blood samples for studies such 
as mine.  
Furthermore, there is no consensus on how to gate ABCs in humans. Each group uses 
different markers; some groups describe them as CD21-/low B cells (Shimabukuro-
Vornhagen et al., 2017), others use CD19+ and CD11c+ B cells but do not look at CD21 
expression (Wang et al., 2018) and others use CD11c+ CD21- B cells (Rubtsov et al., 
2011). In this project, I defined the ABCs as CD11c+ and CD21- CD19+ B cells as 
described initially by Rubtsov et al., in mice spleen (Rubtsov et al., 2011) (Figure 3.1). 
Nonetheless, I could not replicate the results shown by Rubtsov et al., with RA patients 
having significantly higher percentages of ABCs in the blood compared to healthy controls. 
Other studies found that CD11c+ double negative B cells (CD27- IgD-), which have a 
similar phenotype to ABCs, were increased in a cohort of patients with a predominance of 
African-American ethnicity (Jenks et al., 2018). Although Rubtsov et al., did not described 
the ethnicity of the population used in their study, differences in ethnicity could be the 
reason I was unable to replicate their data. Therefore, there could be differences in the 
accumulation of these cells in different ethnic groups.  
A common feature seen in all studies is the variability in ABCs frequency. As shown in 
Figure 3.3, the percentage of ABCs is variable between individuals. Most of the patients 
have similar percentages of ABCs in blood, ranging from 0.5 to 3% but a small number of 
patients have higher than 5%, especially in early RA, established RA and PsA patients. 
Similar results can also be seen in the RA cohorts used by different groups (Isnardi et al., 
2010; Rubtsov et al., 2011; Shimabukuro-Vornhagen et al., 2017). In order to reduce 
“noise” due to inherent variability seen in human studies, more patients and healthy 
controls could be recruited. However, due to time limitations and the finite timing of the 
PhD that was not possible. 
In terms of the association of ABC frequency with sex and age, these cells have been 
reported to be increased in the spleen of elderly female mice (Hao et al., 2011; Rubtsov et 
al., 2011). Rubtsov et al., checked ABC frequencies in RA patients and found that these 
cells were increased in females and, furthermore, in females their frequency correlated with 
age. However, I could only detect an increase in the frequency of ABCs in females 
compared to males but no differences in age was found (Figure 3.5-6). Other groups also 
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reported sex and age differences in healthy controls; however, Shimabukuro-Vornhagen et 
al observed an increase frequency of CD21low CD86+ cells in young female 
(Shimabukuro-Vornhagen et al., 2017). All these differences could be explained by the use 
of different markers in each study used to define ABCs or, as explained before, due to 
discrepancies in ethnicity. 
Since ABCs are known to play an important role in clearing viral infections (Charles et al., 
2011) and are reported to be increased in autoimmune diseases (Thorarinsdottir et al., 
2019), I hypothesised that these cells could be associated with inflammatory state and I 
further investigated if their frequency correlated with disease activity or with blood 
inflammatory markers. It has been reported before that the frequency of ABCs in SLE 
patients correlates with the disease activity score SLEDAI (Wang et al., 2018). 
Nevertheless, I was unable to reproduce this correlation in patients with RA, finding no 
correlation between the frequency of ABCs and the DAS28 score or inflammatory markers 
(Figure 3.7-10).  
Because many variables could potentially affect the frequency of ABCs, a single regression 
analysis was used to assess the effect of each variable in the frequency of ABCs (Figure 
3.11). Unfortunately, the only variable showing a significant effect was sex, as shown in 
the separated analysis. 
The lack of differences between the frequency of ABCs in HCs and RA patients, it could 
be the case that peripheral blood is not the most appropriate organ to study these cells. 
Murine studies have looked at the spleen instead of the blood (Hao et al., 2011; Rubtsov et 
al., 2011; Rubtsov et al., 2013), however, in patients the most accessible tissue is blood. A 
possibility to keep in mind would be the hypothesis that these cells are harboured in the 
spleen and when they reach a certain threshold they appear in the blood. This would explain 
why ABCs are only detected in the peripheral blood of elderly women, as it could be that 
they are present in the spleen in younger women but are not detected until they egress into 
peripheral blood during aging. However, in inflammatory conditions, ABCs could be 
migrating from the spleen to inflammatory sites as reported previously in RA synovial fluid 
(Illges et al., 2000; Yeo et al., 2015) and in multiple sclerosis central nervous system (van 
Langelaar et al., 2019).  
The frequencies of ABCs in synovial fluid of patients with inflammatory arthritides was 
much higher than the frequencies found in blood, reaching almost 90% of the total B cell 
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population (Figure 3.12). These results are in line with other previously published studies 
(Illges et al., 2000; Yeo et al., 2015; Amara et al., 2017). A better option would have been 
obtaining matched PBMCs and SFMCs in order to correlate the frequencies seen in blood 
and synovial fluid, however, this has proven difficult and only one patient had matched 
samples. Interestingly, this patient showed a small frequency of ABCs in peripheral blood, 
of around 1% but very high percentages in synovial fluid, reaching up to 72%.  
The reason for this increase in ABCs in the synovial fluid is unknown. The high 
vascularisation and release of proinflammatory mediators in the joints increases 
mononuclear cells recruitment in the synovial tissue (Ziff, 1989). The migration of cells 
into the synovial fluid could be due to the presence of chemokines, ligands and antigens 
facilitating cell activation and inflammation. 
Even though ABCs are found in much higher frequencies in synovial fluid than in blood, 
further research is needed to understand their origin. It is still unknown if ABCs migrate 
from the blood into the tissue or if B cells from the blood infiltrate the inflammatory tissue 




I assessed the frequency of ABCs in different arthritic diseases. I hypothesised that ABCs 
are present in peripheral blood of patients and controls and that they can be found in 
increased frequencies in patients suffering from RA. The frequency of these cells, due to 
their contribution to inflammation, might correlate with disease activity and inflammation. 
I also hypothesised that the frequency of these cells in the synovial fluid is increased 
compared to peripheral blood. 
I showed that ABCs are detectable in blood from patients and controls by flow cytometry. 
I described ABCs as CD11c+ CD21- CD19+ B cells. Contrary to my hypothesis, 
assessment of the frequency of B cells with this phenotype showed no significant 
differences in patients with RA compared to other arthritic diseases and age-matched 
healthy controls. Moreover, no correlation was found with inflammation and disease 
activity. In addition, the previously described correlation between the age and sex of RA 
patients and the frequency of these cells could not be reproduced.  However, I did see a 
much higher frequency of these cells in synovial fluid of patients with arthritides, 
composing almost all the B cell population found in the joint of some patients.  
In summary, I could not demonstrate a higher frequency of ABCs in RA patients. However, 
these cells constitute a unique subset of B cells which are of interest in inflammatory 
conditions and therefore more research on their phenotype and their function is needed to 













In addition to determining the frequency of ABCs in blood and synovial fluid of patients 
with RA, I also aimed to characterise this subset of B cells in terms of surface and 
intracellular expression of relevant markers. 
Studies in mice mainly described ABCs as expressing CD11b and CD11c but lacking CD21 
(Rubtsov et al., 2011). Characterisation of these cells revealed that they were positive for 
CD5 and expressed high levels of CD80, CD86 and MHC class II. When stimulated by 
TLR7 agonist, these cells produced high amounts of anti-chromatin IgG autoantibodies 
compared to other B cell subsets, demonstrating that ABCs may be a source of 
autoantibodies (Rubtsov et al., 2013). 
In humans, ABCs have been described by different groups generally as CD21low B cells. 
However, some studies reported these cells as being functionally exhausted and anergic, 
whereas others have described them as activated B cells. The discrepancies in expression 
of several surface molecules could be justified by the presence of more than one subset 
within the CD21low population. Focusing on RA, two CD21low B cell subsets have been 
found to be expanded in peripheral blood: one expresses CD27 while the other lacks 
expression of this receptor (Thorarinsdottir et al., 2015). Rubtsov et al., found that the 
CD27+ subset also expresses CD11c and CD5 in addition to activation markers such as 
CD80 and CD86, and were considered to be memory cells as they were class-switched 
(Rubtsov et al., 2011). The CD27- cells, characterised by Isnardi et al., also expressed 
CD11c but displayed unmutated IgM (Isnardi et al., 2010). Besides some differences, the 
CD21low B cell subset described by all the different groups had high expression of CD86, 
CD80 and HLA-DR (Isnardi et al., 2010; Rubtsov et al., 2011; Shimabukuro-Vornhagen 
et al., 2017).  
These CD21-CD11c+ B cells also expressed the transcription factor T-bet (Rubtsova et al., 
2017). T-bet expression in B cells has been proven to play a critical role during anti-viral 
immune responses (Rubtsova et al., 2013), however, their role in human autoimmunity is 
still understudied (Rubtsov et al., 2017).  
Studies have also investigated expression of Ig by ABCs to determine if these cells have 
undergone class switching, in addition to determining their replicative ability. The subset 
described by Shimabukuro-Vornhagen et al., had a large fraction of proliferating cells, 
assessed by the expression of Ki67, and a high degree of class-switching cells (IgM- and 
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IgD-negative) (Shimabukuro-Vornhagen et al., 2017). In line with these results, Rubtsov 
et al., found that ABCs were negative for IgD and IgM but positive for IgG (Rubtsov et al., 
2011). However, Isnardi et al., found that CD21low B cells from RA patients preferentially 
expressed IgM and/or IgD, whereas CD21low B cells from healthy donors were switched-
class B cells (Isnardi et al., 2010). 
Moreover, a subset of synovial fluid B cells described as FcRL4+ B cells showed a similar 
phenotype to the ABCs as they had low expression of CD21 and high expression of CD11c. 
These cells also showed expression of the co-stimulatory molecules CD80 and CD86 in 
addition to expression of CD27, IgG and IgA (Yeo et al., 2015; Amara et al., 2017). 
Therefore, I assessed expression of different activation markers as well as intracellular 
molecules by flow cytometry on the ABC population (CD19+CD11c+CD21-) compared to 
the other three B cell subsets, CD5+ B cells (CD19+CD5+), naïve B cells 
(CD19+IgD+CD27-) and memory B cells (CD19+IgD-CD27+).   
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4.2 Chapter hypothesis and aims 
The underlying hypothesis for the work detailed in this chapter is: the involvement of ABCs 
in RA pathogenesis can be confirmed if they have an activated phenotype and are class-
switched, actively proliferating B cells.  
Therefore, the aims of this chapter were to: 
1. Characterise the phenotype of ABCs compared to other B cell subsets. 
2. Determine if the phenotype of ABCs is different between different diseases, as well 
as healthy controls.  
The specific objectives were: 
1. Measure expression of different markers (co-stimulatory, activation, transcription 
factors, immunoglobulin, etc.) using flow cytometry.  
2. Compare expression of those markers between ABCs and other B cell subsets.  
3. Compare expression of the markers in ABCs from different disease groups as well 





4.3.1 Flow cytometry gating strategy for the determination of expression of phenotypic 
markers in the different B cell subsets  
I designed 5 different antibody panels to investigate the expression of a range of phenotypic 
markers. Each of the panels included the markers used to identify B cells and exclude other 
cell types, as well as the markers to create the four B cell subsets: ABCs 
(CD19+CD11c+CD21-), CD5+ B cells (CD19+CD5+), naïve B cells (CD19+IgD+CD27-
) and memory B cells (CD19+IgD-CD27+). In addition, the different phenotypic markers 
were included in the various panels to be able to determine the percentage of positive cells 
in each subset for each marker. See section 2.5.1 in the methods chapter for whole blood 
staining protocol and tables 2.1 to 2.5 for the antibodies used. The gating strategy used is 
shown in Figure 4.1, showing an RA patient as an example. First, following the gating 
strategy explain in Chapter 3 Figure 3.1, the different B cell subsets were created. Then, 
expression of each of the phenotypic markers in each of the subsets was determined by 
creating a quadrant gate in the lymphocytes population of the marker against CD19 and 
copying that gate into the subsets to assess the number of positive cells for that marker in 
each subset. Most of the phenotypic marker’s gate were set using an FMO. However, for 





Figure 4. 1. Gating strategy for all the phenotypic markers. The gating strategy for 
determination of FcRL3 expression in B cell subsets from an RA patient is shown as an example. 
A similar strategy was used for all the other phenotype markers. Dead cells and doublets were 
excluded. Lymphocytes were selected based on their forward and sideward scatter signal, B cells 
were identified as CD19+ and negative for CD3, CD33, CD14, CD16 and CD56. Among the 
selected B cells the four B cell subsets were defined. From the lymphocyte gate, the phenotypic 
marker against CD19 expression is gated and the phenotypic marker gate is copied in each B cell 
subset, allowing determination of expression of a set of markers in each subset. The phenotypic 
marker’s gate is set on the expression of that marker in the CD19- fraction of cells. If the CD19- 
population also expresses the phenotypic marker, for example with FcRL3, the FMO strategy was 




4.4.1 ABCs have high expression of HLA-DR but low expression of the co-stimulatory 
molecule CD40  
As expected, all B cell subsets have high expression of the antigen presentation MHC class 
II molecule, HLA-DR (Figure 4.2.A-C). However, MFI values showed that ABCs have 
significantly higher expression of HLA-DR compared to the memory B cells (Figure 
4.2.D).  
In terms of CD40 expression, all B cells are positive for this co-stimulatory molecule 
(Figure 4.3). Nevertheless, significantly lower percentages of positive cells are found in the 
ABC population compared to the naïve B cells and the CD5+ subsets (Figure 4.3.C). 
However, no significant differences were seen in terms of MFI values (Figure 4.3.D). 
4.4.2 In the ABC population there are higher percentages of cells positive for activation 
markers 
Expression of B cell activation markers was assessed. CD80, a co-stimulatory molecule 
that is upregulated on activated B cells was highly expressed in the memory and ABC 
population (Figure 4.4). There were significantly higher percentages of positive cells in the 
ABCs compared to naïve and CD5+ cells (Figure 4.4.C). Moreover, CD80 expression, 
measured as a MFI value, was also higher in ABCs compared to naïve and CD5+ cells 
(Figure 4.4.D). 
Another co-stimulatory molecule, which is also upregulated on B cells after stimulation, is 
CD86. A higher percentage of CD86 positive B cells was found on the ABCs population 
(Figure 4.5. A-C), these differences were significant in ABCs compared to naïve and CD5+ 
B cells. CD86 expression was also higher in ABCs compared to naïve and CD5+ cells 
(Figure 4.5.D). 
Finally, CD69 expression was also assessed (Figure 4.6). CD69 is an early indicator of 
leukocyte activation and although being more variable between patients, there are 
significantly higher percentages of positive cells in the ABC population compared to the 
memory B cell subset (Figure 4.6.C). CD69 expression is also higher in ABCs than in 





Figure 4. 2. Expression of the antigen-presentation molecule HLA-DR in each B cell 
subset in early RA patients. A. Flow cytometry plots for each B cell subset. HLA-DR 
expression against CD19, gate set from the lymphocyte population. B. HLA-DR expression 
overlay for each of the subsets. Naïve B cells are shown in orange; memory B cells in red, 
CD5+ B cells in purple and ABCs are shown in blue. The peaks are normalised to the same 
height to normalise different numbers of cells in each population. C. Percentage of HLA-
DR positive cells in the B cell subsets (n=8). The bar represents the median. D. HLA-DR 
median fluorescence intensity (MFI) in the different B cell subsets (n=8). The bar represents 
the median. Statistical significance was assessed using a Kruskal-Wallis test with Dunn’s 
multiple comparisons of the ABCs against the other subsets; * p < 0.05. Kruskal-Wallis test 





Figure 4. 3. Expression of the co-stimulatory molecule CD40 in each B cell subset in 
early RA patients. A. Flow cytometry plots for each B cell subset. CD40 expression 
against CD19, gate set from the lymphocyte population. B. CD40 expression overlay for 
each of the subsets. Naïve B cells are shown in orange; memory B cells in red, CD5+ B 
cells in purple and ABCs are shown in blue. The peaks are normalised to the same height 
to normalise different numbers of cells in each population. C. Percentage of CD40 positive 
cells in the B cell subsets (n=8). The bar represents the median. D. CD40 median 
fluorescence intensity (MFI) in the different B cell subsets (n=8). The bar represents the 
median. Statistical significance was assessed using a Kruskal-Wallis test with Dunn’s 
multiple comparisons of the ABCs against the other subsets; **p < 0.01, **** p < 0.0001. 




Figure 4. 4. Expression of the co-stimulatory molecule CD80 in each B cell subset in 
early RA patients. A. Flow cytometry plots for each B cell subset. CD80 expression against 
CD19, gate set from the lymphocyte population. B. CD80 expression overlay for each of the 
subsets. Naïve B cells are shown in orange; memory B cells in red, CD5+ B cells in purple 
and ABCs are shown in blue. The peaks are normalised to the same height to normalise 
different numbers of cells in each population. C. Percentage of CD80 positive cells in the B 
cell subsets (n=8). The bar represents the median. D. CD80 median fluorescence intensity 
(MFI) in the different B cell subsets (n=8). The bar represents the median. Statistical 
significance was assessed using a Kruskal-Wallis test with Dunn’s multiple comparisons of 
the ABCs against the other subsets; **p < 0.01, *** p < 0.001. Kruskal-Wallis test p < 





Figure 4. 5. Expression of the co-stimulatory molecule CD86 in each B cell subset in 
early RA patients. A. Flow cytometry plots for each B cell subset. CD86 expression against 
CD19, gate set from the lymphocyte population. B. CD86 expression overlay for each of 
the subsets. Naïve B cells are shown in orange; memory B cells in red, CD5+ B cells in 
purple and ABCs are shown in blue. The peaks are normalised to the same height to 
normalise different numbers of cells in each population. C. Percentage of CD86 positive 
cells in the B cell subsets (n=8). The bar represents the median. D. CD86 median 
fluorescence intensity (MFI) in the different B cell subsets (n=8). The bar represents the 
median. Statistical significance was assessed using a Kruskal-Wallis test with Dunn’s 
multiple comparisons of the ABCs against the other subsets; *** p < 0.001. Kruskal-Wallis 





Figure 4. 6. Expression of the activation molecule CD69 in each B cell subset in early 
RA patients. A. Flow cytometry plots for each B cell subset. CD69 expression against 
CD19, gate set from the lymphocyte population. B. CD69 expression overlay for each of 
the subsets. Naïve B cells are shown in orange; memory B cells in red, CD5+ B cells in 
purple and ABCs are shown in blue. The peaks are normalised to the same height to 
normalise different numbers of cells in each population. C. Percentage of CD69 positive 
cells in the B cell subsets (n=8). The bar represents the median. D. CD69 median 
fluorescence intensity (MFI) in the different B cell subsets (n=8). The bar represents the 
median. Statistical significance was assessed using a Kruskal-Wallis test with Dunn’s 
multiple comparisons of the ABCs against the other subsets; **p < 0.01, *** p < 0.001. 
Kruskal-Wallis test p = 0.0133 for percentages; p = 0.0014 for MFI values. 
123 
 
4.4.3 A high percentage of the ABC population is actively proliferating 
In order to assess cell proliferation, an intracellular staining was performed. Ki67 was used 
as a cell proliferation marker as it is expressed during all the phases of the cell cycle but 
not in resting cells (Schwarting et al., 1986). As expected, in the memory B cell population 
there was a small proportion of cells positive for Ki67, and in the ABC population there 
was a similar percentage of positive cells (Figure 4.7). This high percentage of positive 
cells in the ABC subset was significant when compared to the naïve and the CD5+ cells 
(Figure 4.7.C). However, no significant differences were seen in terms of MFI values 
between the populations (Figure 4.7.D). 
4.4.4 A high percentage of the ABC population expresses the transcription factor T-bet 
The T cell-associated transcription factor T-bet has been described as a specific 
transcription factor for the ABC-like subset (Rubtsov et al., 2011; Rubtsova et al., 2015; 
Karnell et al., 2017), therefore I explored this in RA patients. T-bet expression was 
determined by flow cytometry using the intracellular staining protocol (Figure 4.8). The 
percentage of T-bet positive B cells was very low in the naïve and CD5+ B cell populations, 
but in the ABC subset there was a significantly higher number of B cells expressing this 
transcription factor (Figure 4.8.C). MFI values also showed that T-bet expression was 






Figure 4. 7. Expression of the proliferation marker Ki67 in each B cell subset in early 
RA patients. A. Flow cytometry plots for each B cell subset after intracellular staining. Ki67 
expression against CD19, gate set from the lymphocyte population. B. Ki67 expression 
overlay for each of the subsets. Naïve B cells are shown in orange; memory B cells in red, 
CD5+ B cells in purple and ABCs are shown in blue. The peaks are normalised to the same 
height to normalise different numbers of cells in each population. C. Percentage of Ki67 
positive cells in the B cell subsets (n=11). The bar represents the median. D. Ki67 median 
fluorescence intensity (MFI) in the different B cell subsets (n=11). The bar represents the 
median. Statistical significance was assessed using a Kruskal-Wallis test with Dunn’s 
multiple comparisons of the ABCs against the other subsets; **p < 0.01, **** p < 0.0001. 





Figure 4. 8. Expression of the transcription factor T-bet in each B cell subset in early 
RA patients. A. Flow cytometry plots for each B cell subset after intracellular staining. T-
bet expression against CD19, gate set from the lymphocyte population. B. T-bet expression 
overlay for each of the subsets. Naïve B cells are shown in orange; memory B cells in red, 
CD5+ B cells in purple and ABCs are shown in blue. The peaks are normalised to the same 
height to normalise different numbers of cells in each population. C. Percentage of T-bet 
positive cells in the B cell subsets (n=11). The bar represents the median. D. T-bet median 
fluorescence intensity (MFI) in the different B cell subsets (n=11). The bar represents the 
median. Statistical significance was assessed using a Kruskal-Wallis test with Dunn’s 
multiple comparisons of the ABCs against the other subsets; **p < 0.01, **** p < 0.0001. 
Kruskal-Wallis test p < 0.0001 for percentages; p = 0.0025 for MFI values. 
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4.4.5 ABCs resemble a memory B cell population regarding class switch immunoglobulin 
expression 
In order to assess the immunoglobulin expression on each of the B cell subsets, PBMCs 
were isolated from EDTA blood and stained with the immunoglobulin panel for flow 
cytometry analysis. Isolated PBMCs were used instead of whole blood due to circulating 
IgG and IgM present in plasma that would bind the flow cytometry antibodies and therefore 
reduce staining of the cells. 
As expected, most of the cells in the naïve and the CD5+ population are positive for IgM 
(Figure 4.9). However, in the ABC population there was significantly lower percentages of 
cells expressing IgM compared to the CD5+ subset but higher percentages of positive cells 
than in the memory population (Figure 4.9.C). In terms of MFI, ABCs have significant 
lower expression of IgM compared to the naïve and CD5+ B cells (Figure 4.9.D). 
Expression of IgD was also assessed. IgD is expressed in mature B cells until somatic 
hypermutation and class switching occurs (Treanor, 2012). Accordingly, the percentage of 
positive cells for IgD was significantly higher in naïve (expected as this subset is gated on 
IgD expression) and CD5+ B cells (Figure 4.10). In the ABC population there was a 
significantly lower percentage of cells expressing IgD compared to the naïve subset but 
higher percentages of positive cells than in the memory population (Figure 4.10.C). MFI 
values show that ABCs have significantly lower expression of IgD than naïve and CD5+ B 
cells but higher than memory B cells (Figure 4.10.D).  
I also evaluated expression of the class switched immunoglobulins, IgG and IgA. Both IgG 
and IgA are immunoglobulins expressed after B cells are antigen-activated and undergo 
somatic hypermutation and class switching (Treanor, 2012). Regarding IgG expression, in 
the naïve and the CD5+ B cells there very few cells positive for IgG (Figure 4.11). As 
expected, in the memory B cells we found around half of the cells positive for IgG. 
However, in the ABC population there are also significantly higher percentages of positive 
cells for this class switched immunoglobulin compared to the naïve and the CD5+ subsets 
(Figure 4.11.C). In addition, ABCs have significantly higher expression of IgG than naïve 
B cells (Figure 4.11.D).  
Expression of another class switched immunoglobulin, IgA, showed that higher 
percentages of positive cells were found in the memory subset (Figure 4.12). Nevertheless, 
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the ABC population has significantly higher percentages and higher expression of IgA 






Figure 4. 9. IgM expression in each B cell subset in early RA patients. A. Flow 
cytometry plots for each B cell subset after PBMCs isolation and staining. IgM expression 
against CD19, gate set from the lymphocyte population. B. IgM expression overlay for 
each of the subsets. Naïve B cells are shown in orange; memory B cells in red, CD5+ B 
cells in purple and ABCs are shown in blue. The peaks are normalised to the same height 
to normalise different numbers of cells in each population. C. Percentage of IgM positive 
cells in the B cell subsets (n=15). The bar represents the median. D. IgM median 
fluorescence intensity (MFI) in the different B cell subsets (n=15). The bar represents the 
median. Statistical significance was assessed using a Kruskal-Wallis test with Dunn’s 
multiple comparisons of the ABCs against the other subsets; * p < 0.05, **p < 0.01, *** 





Figure 4. 10. IgD expression in each B cell subset in early RA patients. A. Flow cytometry 
plots for each B cell subset after PBMCs isolation and staining. IgD expression against 
CD19, gate set from the lymphocyte population. B. IgD expression overlay for each of the 
subsets. Naïve B cells are shown in orange; memory B cells in red, CD5+ B cells in purple 
and ABCs are shown in blue. The peaks are normalised to the same height to normalise 
different numbers of cells in each population. C. Percentage of IgD positive cells in the B 
cell subsets (n=15). The bar represents the median. D. IgD median fluorescence intensity 
(MFI) in the different B cell subsets (n=15). The bar represents the median. Statistical 
significance was assessed using a Kruskal-Wallis test with Dunn’s multiple comparisons of 
the ABCs against the other subsets; * p < 0.05, **p < 0.01, **** p < 0.0001. Kruskal-Wallis 





Figure 4. 11. Expression of class switch IgG in each B cell subset in early RA patients. 
A. Flow cytometry plots for each B cell subset after PBMCs isolation and staining. IgG 
expression against CD19, gate set from the lymphocyte population. B. IgG expression 
overlay for each of the subsets. Naïve B cells are shown in orange; memory B cells in red, 
CD5+ B cells in purple and ABCs are shown in blue. The peaks are normalised to the same 
height to normalise different numbers of cells in each population. C. Percentage of IgG 
positive cells in the B cell subsets (n=15). The bar represents the median. D. IgG median 
fluorescence intensity (MFI) in the different B cell subsets (n=15). The bar represents the 
median. Statistical significance was assessed using a Kruskal-Wallis test with Dunn’s 
multiple comparisons of the ABCs against the other subsets; * p < 0.05, **p < 0.01, **** 





Figure 4. 12. Expression of class switch IgA in each B cell subset in early RA patients. 
A. Flow cytometry plots for each B cell subset after PBMCs isolation and staining. IgA 
expression against CD19, gate set from the lymphocyte population. B. IgA expression 
overlay for each of the subsets. Naïve B cells are shown in orange; memory B cells in red, 
CD5+ B cells in purple and ABCs are shown in blue. The peaks are normalised to the same 
height to normalise different numbers of cells in each population. C. Percentage of IgA 
positive cells in the B cell subsets (n=15). The bar represents the median. D. IgA median 
fluorescence intensity (MFI) in the different B cell subsets (n=15). The bar represents the 
median. Statistical significance was assessed using a Kruskal-Wallis test with Dunn’s 
multiple comparisons of the ABCs against the other subsets; * p < 0.05, **p < 0.01, **** p 
< 0.0001. Kruskal-Wallis test p < 0.0001 for percentages; p = 0.0003 for MFI values. 
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4.4.6 Expression of members of the FcRL family is enriched in the ABC population 
In view of my supervisor’s work in Birmingham on FcRL4+ cells in the synovial fluid of 
RA patients and their similar phenotype to peripheral blood ABCs (Yeo et al., 2015), I 
designed a panel to assess FcRL4 expression in blood. Moreover, due to FcRL3 implication 
in RA (Lin et al., 2016) and FcRL5 in IgG binding (Franco et al., 2013), these two other 
FcRLs were included in the panel.  
Considering the high homology present between each of the members of the FcRLs family 
(Li et al., 2014b), I first needed to validate that the antibodies used to determine expression 
of these markers were specific for each of the FcRLs and were not cross-reacting and 
binding another FcRL family members. In order to check the antibodies’ specificity, I 
transfected HEK293T cells with individual plasmids coding each of the FcRLs (kind gift 
from Professor Nagata, Osaka University) and stained transfected cells with each of the 
antibodies.  
In Figure 4.13, the rows show each of the transfected cell lines and the columns the FcRLs 
antibody clones used to stain the transfected cells. The antibodies raised against each FcRLs 
are only recognised by their cognate FcRL. However, the FcRL2 antibody, in addition to 
recognising FcRL2 transfected cells, it also binds cells transfected with the FcRL3 and 
FcRL5 plasmid; meaning that FcRL2 antibody clone REA474 apart from partially binding 
FcRL2 also binds FcRL3 and FcRL5 (Figure 4.13).  
In the view of these results, a previously verified FcRL2 antibody by the Nagata’s group 
was tested and FcRL2 expression was assessed using the transfected HEK293T cells. 
FcRL2 antibody clone B24 was a kind gift from Professor Nagata (Osaka University). As 
shown in Figure 4.14, the new FcRL2 clone was specific and there was no binding of the 




Figure 4. 13. FcRLs antibodies check using transfected HEK293T cells expressing a 
single FcRL. Rows show each of the HEK293T cells transfected with a single FcRLs. 
Columns show staining of the cells with each of FcRLs antibody clones. The diagonal 
marks each of the antibodies recognising the correspondent FcRL. Gates were set based on 




Figure 4. 14. New FcRL2 clone B24 antibody check using transfected HEK293T cells 
expressing a single FcRL. Rows show each of the HEK293T cells transfected with a single 
FcRLs. Columns show staining of the cells with each of FcRLs antibody clones. The 
diagonal marks each of the antibodies recognising the correspondent FcRL. Gates were set 
based on isotype controls.  
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Once the antibodies were validated, early RA patients were recruited and expression of the 
FcRL family members in each of the B cell subsets of interest was determined.  
FcRL4 expression is scarce on circulating B cell subsets (Figure 4.15) but there were 
significantly higher percentages of positive cells in the ABC population compared to naïve 
and CD5+ subsets (Figure 4.15.C). However, no significant differences were seen in terms 
of MFI values between the populations (Figure 4.15.D).  
In terms of FcRL5 expression, there were significantly higher percentages of FcRL5 and 
higher expression in the ABC population compared to the naïve and the memory B cell 
subsets (Figure 4.16).  
Regarding FcRL3 expression, this marker is more widely expressed by peripheral B cells 
than FcRL4 and FcRL5, as around 60% of the cells in each subset expressed FcRL3. 
However, in the ABC population, all the cells are positive for FcRL3 (Figure 4.17). There 
are significantly higher percentages of FcRL3 positive cells in the ABCs population 
compared to all the other subsets (Figure 4.17.C). The MFI shows that FcRL3 is 
significantly expressed in ABCs compared to all the other B cell subsets (Figure 4.17.D).  
FcRL1 and FcRL2 are also expressed in B cells (Miller et al., 2002), therefore expression 
of these other two FcRLs was also assessed. FcRL1 is highly expressed on all the B cells, 
although memory B cells and ABCs have lower expression (Figure 4.18). The percentage 
of ABCs positive for FcRL1 is significantly lower compared to naïve and the CD5+ B cells 
(Figure 4.18.C). However, no significant differences were seen in terms of MFI values 
between the populations (Figure 4.18.D).  
FcRL2 was expressed at a low level in peripheral B cells but in the ABCs population a 
significantly higher percentage of FcRL2 positive cells compared to all the other B subsets 
was found (Figure 4.19.C).  Moreover, MFI values revealed significantly higher expression 






Figure 4. 15. Expression of FcRL4 in each B cell subset in early RA patients. A. Flow 
cytometry plots for each B cell subset after whole blood staining. FcRL4 expression against 
CD19, gate set from the lymphocyte population. B. FcRL4 expression overlay for each of 
the subsets. Naïve B cells are shown in orange; memory B cells in red, CD5+ B cells in 
purple and ABCs are shown in blue. The peaks are normalised to the same height to 
normalise different numbers of cells in each population. C. Percentage of FcRL4 positive 
cells in the B cell subsets (n=11). The bar represents the median. D. FcRL4 median 
fluorescence intensity (MFI) in the different B cell subsets (n=11). The bar represents the 
median. Statistical significance was assessed using a Kruskal-Wallis test with Dunn’s 
multiple comparisons of the ABCs against the other subsets; * p < 0.05, ** p < 0.01, *** p 






Figure 4. 16. Expression of FcRL5 in each B cell subset in early RA patients. A. Flow 
cytometry plots for each B cell subset after whole blood staining. FcRL5 expression against 
CD19, gate set from the lymphocyte population. B. FcRL5 expression overlay for each of 
the subsets. Naïve B cells are shown in orange; memory B cells in red, CD5+ B cells in 
purple and ABCs are shown in blue. The peaks are normalised to the same height to 
normalise different numbers of cells in each population. C. Percentage of FcRL5 positive 
cells in the B cell subsets (n=11). The bar represents the median. D. FcRL5 median 
fluorescence intensity (MFI) in the different B cell subsets (n=11). The bar represents the 
median. Statistical significance was assessed using a Kruskal-Wallis test with Dunn’s 
multiple comparisons of the ABCs against the other subsets; * p < 0.05, ** p < 0.01, *** p 





Figure 4. 17. Expression of FcRL3 in each B cell subset in early RA patients. A. Flow 
cytometry plots for each B cell subset after whole blood staining. FcRL3 expression against 
CD19, gate set from the lymphocyte population. B. FcRL3 expression overlay for each of 
the subsets. Naïve B cells are shown in orange; memory B cells in red, CD5+ B cells in 
purple and ABCs are shown in blue. The peaks are normalised to the same height to 
normalise different numbers of cells in each population. C. Percentage of FcRL3 positive 
cells in the B cell subsets (n=11). The bar represents the median. D. FcRL3 median 
fluorescence intensity (MFI) in the different B cell subsets (n=11). The bar represents the 
median. Statistical significance was assessed using a Kruskal-Wallis test with Dunn’s 
multiple comparisons of the ABCs against the other subsets; * p < 0.05, **p < 0.01, *** p < 






Figure 4. 18. Expression of FcRL1 in each B cell subset in early RA patients. A. Flow 
cytometry plots for each B cell subset after whole blood staining. FcRL1 expression against 
CD19, gate set from the lymphocyte population. B. FcRL1 expression overlay for each of 
the subsets. Naïve B cells are shown in orange; memory B cells in red, CD5+ B cells in 
purple and ABCs are shown in blue. The peaks are normalised to the same height to 
normalise different numbers of cells in each population. C. Percentage of FcRL1 positive 
cells in the B cell subsets (n=9). The bar represents the median. D. FcRL1 median 
fluorescence intensity (MFI) in the different B cell subsets (n=9). The bar represents the 
median. Statistical significance was assessed using a Kruskal-Wallis test with Dunn’s 
multiple comparisons of the ABCs against the other subsets; * p < 0.05, **p < 0.01, *** p 






Figure 4. 19. Expression of FcRL2 in each B cell subset in early RA patients, tested 
using the specific FcRL2 antibody. A. Flow cytometry plots for each B cell subset after 
whole blood staining. FcRL2 expression against CD19, gate set from the lymphocyte 
population. B. FcRL2 expression overlay for each of the subsets. Naïve B cells are shown 
in orange; memory B cells in red, CD5+ B cells in purple and ABCs are shown in blue. 
The peaks are normalised to the same height to normalise different numbers of cells in 
each population. C. Percentage of FcRL2 positive cells in the B cell subsets (n=11). The 
bar represents the median. D. FcRL2 median fluorescence intensity (MFI) in the different 
B cell subsets (n=11). The bar represents the median. Statistical significance was assessed 
using a Kruskal-Wallis test with Dunn’s multiple comparisons of the ABCs against the 
other subsets; * p < 0.05, **p < 0.01, *** p < 0.001, **** p < 0.0001. Kruskal-Wallis test 
p < 0.0001 for percentages; p < 0.0001 for MFI values. 
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4.4.7 Phenotypically, ABCs from eRA patients are similar to ABCs from other disease 
controls and healthy controls 
To determine whether ABCs from early RA patients were phenotypically different from 
ABCs from RA patients with established disease, as well as ABCs from disease controls 
and healthy controls, I recruited donors for each group and assessed ABCs phenotype using 
flow cytometry. See Appendix A.3 and A.4 for the tables showing demographic differences 
between each group in each of the panels used. Due to the donors in each cohort being 
recruited longitudinally over two years, MFI values variate substantially and therefore only 
percentage of positive cells are used to assess phenotypical differences in ABCs from 
different disease controls and healthy controls. 
Regarding percentage of positive cells for the MHC class II molecule, HLA-DR, there were 
no significant differences between the different groups (Figure 4.20.A). Comparing the 
percentage of positive cells for the co-stimulatory molecule CD40 revealed no differences 
between the different groups (Figure 4.20.B).  
Expression of molecules upregulated after activation such as CD80 and CD86, also 
demonstrated no significant difference between the groups (Figure 4.21. A-B). Expression 
of the activation marker CD69 showed a trend for increased expression in RA patients 
compared to healthy controls, however, these differences did not reach significance (Figure 
4.21.C).  
With regard to expression of intracellular markers as Ki67 in ABCs, there were no 
significant differences between the groups (Figure 4.22.A). In terms of T-bet expression, 
the ABC-associated transcription factor, ABCs from established patients had significantly 
fewer positive cells than the age-matched healthy controls (Figure 4.22.B).  
Immunoglobulin expression on these cells in the different groups was also assessed. IgM 
expression was not significantly different among the groups although established RA 
patients showed a trend for decreased IgM positive cells in the ABC population that did not 
reach significance (Figure 4.23.A). However, more established patients are needed to 
confirm this trend as n = 4. IgD expression was very similar between the groups (Figure 
4.23.B). The percentage of IgG positive cells was slightly increased in established RA 
patients compared to the other group, but these differences were not significant (Figure 




Figure 4. 20. HLA-DR and CD40 expression in ABCs from different diseases and 
healthy control groups. Disease controls and healthy controls donors were recruited and 
whole blood was stained for different flow cytometry panels. Percentage of HLA-DR 
positive cells (A) and CD40 positive cells (B) in the ABC subset in early RA patients (n=8), 
established RA patients (n=8), disease controls (n=14) and age-matched healthy controls 
(n=6). The bar represents the median. Statistical significance was determined using a 
Kruskal-Wallis test with Dunn’s multiple comparisons of each groups against the others. 
 
Figure 4. 21. Expression of the co-stimulatory molecules, CD80 and CD86 and the 
activation marker CD69 in ABCs from different diseases and healthy control groups. 
Disease controls and healthy controls donors were recruited and whole blood was stained 
for different flow cytometry panels. Percentage of CD80 positives (A), of CD86 positives 
(B) and of CD69 positives (C) in the ABC population in early RA patients (n=8), 
established RA patients (n=8), disease controls (n=14) and age-matched healthy controls 
(n=6). The bar represents the median. Statistical significance was assessed using a Kruskal-





Figure 4. 22. Expression of the proliferation marker Ki67 and the transcription factor 
T-bet in ABCs from different diseases and healthy control groups. Disease controls and 
healthy controls donors were recruited and whole blood was stained for different flow 
cytometry panels. Percentage of Ki67 positive cells (A) and percentage of T-bet positive 
cells (B) in the ABC population in early RA patients (n=11), established RA patients 
(n=10), disease controls (n=15) and age-matched healthy controls (n=8). The bar represents 
the median. Statistical significance was determined using a Kruskal-Wallis test with 
Dunn’s multiple comparisons of each groups against the others. * p < 0.05. 
 
Figure 4. 23. Expression of the immunoglobulin markers in ABCs from different 
diseases and healthy control groups. Disease controls and healthy controls donors were 
recruited and whole blood was stained for different flow cytometry panels. Percentage of 
IgM positive cells (A), percentage of IgD positive cells (B), percentage of IgG positive 
cells (C) and percentage of IgA positive cells (D) in the ABC subset in early RA patients 
(n=15), established RA patients (n=4), disease controls (n=13) and age-matched healthy 
controls (n=8). The bar represents the median. Statistical significance was determined using 
a Kruskal-Wallis test with Dunn’s multiple comparisons of each groups against the others. 
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Regarding FcRLs expression in the different groups, there were no significant differences 
in FcRL3, FcRL4 and FcRL5 expression in ABCs among the groups (Figure 4.24).  
In addition, expression of FcRL1 and FcRL2 in the ABC population from the different 
groups was very similar and there were no differences (Figure 4.25).  
 
Figure 4. 24. Expression of the FcRL3 to FcRL5 in ABCs from different diseases and 
healthy control groups. Disease controls and healthy controls donors were recruited and 
whole blood was stained for different flow cytometry panels. Percentage of FcRL3 positive 
cells (A), percentage of FcRL4 positive cells (B) and percentage of FcRL5 positive cells 
(C) in the ABC subset in early RA patients (n=11), established RA patients (n=8), disease 
controls (n=15) and age-matched healthy controls (n=8). The bar represents the median. 
Statistical significance was determined using a Kruskal-Wallis test with Dunn’s multiple 





Figure 4. 25. Expression of the FcRL1 and FcRL2 in ABCs from different diseases 
and healthy control groups. A. Disease controls and healthy controls donors were 
recruited and whole blood was stained for different flow cytometry panels. Percentage of 
FcRL1 positive cells in the ABC subset in early RA patients (n=9), established RA patients 
(n=10), disease controls (n=7) and age-matched healthy controls (n=8). B. Percentage of 
FcRL2 positive cells in the ABC subset in early RA patients (n=10), established RA 
patients (n=5), disease controls (n=10) and age-matched healthy controls (n=6). The bar 
represents the median. Statistical significance was assessed using a Kruskal-Wallis test 





In this chapter, I characterised the ABC subset from RA patients phenotypically in depth, 
using several flow cytometry panels. Their high expression of activation markers like CD80 
and CD69 suggests that they are an activated cell population. Moreover, expression of the 
cell cycle marker, Ki67, indicated that some cells in the ABC subset are actively replicating 
and that, as reported before. B cells with this phenotype express the T-bet transcription 
factor. Immunoglobulin expression analysis showed that most of these cells are class-
switched B cells expressing IgG. Interestingly, expression of FcRL molecules is elevated 
in ABCs compared to the other B cell subsets. Despite the differences between cell types, 
no major differences were seen between ABCs in different arthritic diseases and the healthy 
controls.  
In the initiation of an adaptive immune response, the first signal for the engagement of an 
antigen-presenting cell and a T cell is interaction of MHC class II molecules bound with 
peptide to the T cell receptor (Katikaneni and Jin, 2019). HLA-DR is an MHC class II 
molecule found on the surface of antigen-presenting cells such as dendritic cells and B 
cells. In the view of this, HLA-DR is considered a marker of antigen-presenting cells, and 
the fact that it is highly expressed in ABCs (Figure 4.2) confirms the hypothesis that one 
of the functions of these cells might be to present antigens to T cells, thus initiating and 
directing immune responses, although specific functional work is needed to confirm this 
hypothesis. This result fits with published literature as other studies, in mice and in 
autoimmune patients, also reported ABCs to have higher expression of the MHC class II 
molecule HLA-DR (Isnardi et al., 2010; Rubtsov et al., 2011).  
Subsequent signals to initiate the immune response include co-stimulatory receptors 
binding their ligands. One of these co-stimulatory molecules is CD40, which is expressed 
by antigen-presenting cells and it binds its ligand CD40L on activated T cells (Elgueta et 
al., 2009). These two signals together with other complementary cytokine signals lead to 
an activation of the antigen-presenting cells, such as B cells. I investigated CD40 
expression on ABCs compared to other B cells subsets and interestingly in the ABC 
population I found fewer cells positive for this marker (Figure 4.3). Contrary to the HLA-
DR, expression of CD40 suggest that ABCs may not be capable of productive interactions 
with T cells expressing CD40L. Low CD40 expression was also reported before on B cells 
from SLE patients with a similar ABC phenotype described as CD11c+ B cells (Wang et 
147 
 
al., 2018). These cells in the Wang et al., study quickly differentiated into plasma cells that 
produced IgG when co-cultured with T cells, suggesting that ABCs may already be 
activated B cells in a translation state between germinal centre B cells and early 
plasmablasts. Other studies suggested that ABCs arise from conventional B cells after a 
sustained CD40 stimulation (Shimabukuro-Vornhagen et al., 2017). This chronic CD40 
stimulation could therefore result in the CD40 downregulation seen on ABCs.  
Two other co-stimulatory receptors found on B cells are CD80 and CD86. These co-
stimulatory molecules are upregulated upon B cell activation and are therefore used as 
markers of activation (Shimabukuro-Vornhagen et al., 2017). My results show higher 
expression of these molecules in ABCs compared to naïve B cells in addition to a high 
expression by memory B cells (Figure 4.4-5). These results are in line with other published 
phenotyping studies (Isnardi et al., 2010; Rubtsov et al., 2011; Shimabukuro-Vornhagen et 
al., 2017). These results together with the HLA-DR expression results, strengthen the 
hypothesis that these cells are potentially potent antigen-presenting cells. 
CD69 has also been described as an activation marker. Kinetic studies show this marker to 
increase early after infection in mice (Purtha et al., 2008) and decrease during the course 
of infection in B cells. My results show that higher percentages of CD69+ B cells can be 
found in the ABC population (Figure 4.6). The only other group to assess CD69 expression 
on ABC-like cells was Isnardi et al., which found that CD21low B cells failed to induce 
CD69 after BCR and CD40 triggering (Isnardi et al., 2010). A possible explanation for the 
contradictory results is that my results are on resting ABCs, whereas Isnardi et al., 
stimulated the cells. In addition, Isnardi et al., described these cells only using CD21 and 
therefore, it is not possible to confirm that their CD21low B cell is the same as my ABC 
subset. The CD69 results reinforces the hypothesis that these cells are activated cells which 
may function as antigen-presenting cells.   
I next assessed if there were actively proliferating cells in the ABC population (Figure 4.7). 
My results do show a fairly high percentage of cells in the ABC subset are positive for the 
proliferation marker Ki67, the percentages are similar to memory B cells which are known 
to proliferate. Ki67 expression is strictly associated with cell proliferation. This protein is 
expressed during all phases of the cell cycle except in resting cells (Scholzen and Gerdes, 
2000). Only one other group has investigated Ki67 expression in ABC-like cells 
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(Shimabukuro-Vornhagen et al., 2017); the results were in accordance with mine, with very 
similar percentages of positive cells in their ABC-like cells.  
T-bet was originally described as a transcription factor skewing T cells towards a Th1 
linage (Szabo et al., 2000). However, in the last years expression of T-bet has been reported 
in other cell types such as dendritic cells, NK cells and B cells (Rubtsov et al., 2017). Most 
of the published work on ABC-like cells, found that these cells express the transcription 
factor T-bet (Isnardi et al., 2010; Rubtsov et al., 2011). Because most of the T-bet+ B cells 
also express CD11c and these cells have similar expression of other activation markers as 
well as a similar chemokine receptor profile, T-bet+ B cells have also been called ABCs 
(Karnell et al., 2017). For this reason, I assessed expression of T-bet in my ABC population. 
My results showed that T-bet is lowly expressed by B cells but high percentages of positive 
cells are found in the ABC-like population (Figure 4.8). On B cells, groups have focused 
on the requirement of T-bet for class-switching to IgG2a on mice (Gerth et al., 2003), as 
well as elucidating which receptors are needed for its expression (Liu et al., 2003). 
Nonetheless, the role of T-bet expression on B cells is still under investigation. It has been 
demonstrated to play an important function on viral clearance (Rubtsova et al., 2013) as 
well as in controlling chronic viral infections (Barnett et al., 2016). Additionally, T-bet 
expression has also been reported to play an important role in autoimmunity. ABCs 
expressing T-bet+ were increased in autoimmune-prone mice (Rubtsov et al., 2011) and 
these cells were able to produced autoantibodies (Rubtsov et al., 2013). In humans, some 
studies showed increase frequencies of these cells in patients with scleroderma, RA and 
SLE (Rubtsova et al., 2017; Shimabukuro-Vornhagen et al., 2017; Wang et al., 2018). The 
main question still to be answered is why these cells are involved both in protective humoral 
responses and autoimmune diseases. Although most of the times these cells are described 
as CD11c+ or T-bet+ B cells, not all the CD11c+ B cells are T-bet+ and not all the T-bet+ 
cells are CD11c+. Therefore, there is some heterogeneity within this subset regarding origin 
and function of these cells that could explain these contrasting roles (Myles et al., 2019).  
I also explored the immunoglobulin expression profile of ABCs. Studies in mice 
demonstrated that after TLR7 agonist stimulation, ABCs produced some IgM and high 
amounts of IgG (Rubtsov et al., 2011). Moreover, this IgG could recognise chromatin, 
proving that ABCs could be a source of autoantibodies. As described before, T-bet+ ABCs 
also produced IgG2a in response to viral infections (Rubtsova et al., 2013). However, in 
humans, some discrepancies have been reported. Both subsets reported by Shimabukuro-
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Vornhagen et al., and Rubtsov et al., described these cells as IgD-IgM- but IgG+, being 
therefore, class-switched B cells (Rubtsov et al., 2011; Shimabukuro-Vornhagen et al., 
2017). On the contrary, Isnardi et al., found that CD21low B cells from RA patients 
preferentially expressed IgM and/or IgD, whereas CD21low B cells from healthy donors 
were switched-class B cells enriched for polyreactive and autoreactive clones (Isnardi et 
al., 2010). My results show that around half the population of ABCs are IgG+ (Figure 4.11). 
However, in this population there are still some cells positive for IgM and IgD (Figure 4.9-
10). I think that these results show that the ABC population found in the blood could be 
heterogeneous. This is confirmed by the discrepancies in expression of other markers such 
as CD27 or T-bet in my ABC subset compared to other ABC subsets (Thorarinsdottir et 
al., 2015). As explained before about T-bet expression, these studies defined ABCs as 
CD21low B cells, so no expression of CD11c was assessed. Not all the CD21low B cells 
are positive for CD11c, therefore the CD21 low population is a different population with a 
different phenotype to my ABCs. However, taking all the studies into account, ABCs as 
described in this thesis are more similar to the studies describing them as class-switched, 
as half of the cells are IgG+, rather than Isnardi’s cells which look more like exhausted B 
cells which are not class-switched.  
Focusing on the FcRLs, I successfully tested all the antibody clones and made sure that 
these are specific for each FcRL (Figure 4.14). This is very important as due to the high 
homology between the FcRLs, antibodies could be cross-reacting and giving false positive 
results (Sullivan et al., 2015).  
FcRL4 expression on blood cells is very scarce, which is in accordance to other published 
studies (Ehrhardt and Cooper, 2011). FcRL4 expression is limited to a subset of memory 
B cells found in mucosal-associated lymphoid tissues (Falini et al., 2003). Transcriptome 
analysis of this subset of FcRL4+ B cells revealed expression of similar genes to ABCs, as 
they had low expression of CD21 and had high expression of CD80 and CD11c (Ehrhardt 
et al., 2005). Additionally, a subset of B cells characterised by the expression of FcRL4 
was described by my supervisor in Birmingham, Professor Dagmar Scheel-Toellner (Yeo 
et al., 2015). These cells had a phenotype similar to blood ABCs, with low expression of 
CD21 and high expression of CD11c. The common expression of FcRL4 by mucosal B 
cells and synovial fluid B cells and the enrichment of IgA expressing cells reinforces the 
hypothesis that RA pathogenesis could start within mucosal inflammation in the gum, the 
gut and the lungs (Catrina et al., 2014). However, additional studies are needed to 
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determine if these FcRL4+ B cells are generated in the mucosa and later migrate to the 
synovia to contribute to RA pathogenesis. Another interesting role for FcRL4, shared by 
ABCs, is its ability to attenuate BCR signalling but augment B cell activation through TLR9 
signalling (Sohn et al., 2011). The ligand for FcRL4 has been postulated to be heat-
aggregated IgA (Wilson et al., 2012) and the ligand for TLR9 is DNA fragments containing 
CpG motifs. Interestingly, both these ligands are found in the synovial fluid of patients with 
RA (Hajizadeh et al., 2003; Aleyd et al., 2016), so it is feasible that FcRL4 in RA, may 
enhance immune activation through TLR9 signalling.  
FcRL5 has been reported to be expressed by naïve and memory B cells from the blood, 
with high expression levels found on plasma cells from the spleen, the bone marrow and 
the tonsils (Polson et al., 2006). There are some discrepancies between FcRL5 expression 
in blood in the literature; Polson et al detected expression in blood B cells, however, other 
studies showed no expression on primary B cells (Ise et al., 2005). These differences could 
be due to different antibody clones used in each study, as both groups generated their 
antibodies. My results showed low expression of FcRL5 on most of the B cell subsets 
except for the ABCs, with about half the cells positive for this receptor (Figure 4.16). 
FcRL5 expression on ABCs have been previously described by other groups at the mRNA 
levels and the protein levels (Isnardi et al., 2010; Lau et al., 2017; Wang et al., 2018). 
FcRL5 function is still under investigation and there is some disagreement on whether this 
receptor inhibits B cell activation (Haga et al., 2007) or if it is able to enhance B cell 
proliferation and drive the development of IgG+ and IgA+ B cells (Dement-Brown et al., 
2012). These differences could be due to the use of different cells, as one study used cell 
lines and the other used primary B cells from blood.  
My results for FcRL3 expression by ABCs are especially interesting. Some studies reported 
very low expression of FcRL3 on peripheral blood B cell (Polson et al., 2006), however, 
other studies show some expression of FcRL3 by circulating B cells with an increase in 
expression by memory B cells (Li et al., 2013). However, my results, while confirming 
some expression on memory, as well as naïve and CD5+ B cells, show that FcRL3 
expression on ABCs is extremely high and that all the ABCs have expression of this 
receptor (Figure 4.17). Studies that have investigated FcRL3 expression on B cells reported 
a potential role for FCRL3 in memory B cells with innate‐like characteristics (Li et al., 
2013). The influence of FcRL3 on innate-like responses has shown that FcRL3 engagement 
increased TLR9 triggered peripheral blood B cell activation, survival and activation 
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markers expression. On the contrary, this signal inhibited antibody production and plasma 
cell differentiation (Li et al., 2013). These findings together with the fact that ABCs are not 
fully differentiated into plasma cells and have high expression of HLA-DR and co-
stimulatory molecules, reinforces the hypothesis that ABCs are potential antigen-
presenting cells which respond to innate-like stimuli via TLRs. Another fascinating aspect 
of FcRL3 is its implication in autoimmune diseases. For a variety of disorders, disease risk 
associations for single nucleotide polymorphisms (SNP) located in regions of FcRL genes 
have been reported (Kochi et al., 2005). A SNP on the FcRL3 promoter region generated a 
more orthodox NF-κB binding sequence that exerted a regulatory effect on FcRL3 
transcript and protein expression as well as on auto-antibody production (Gibson et al., 
2009). Moreover, our group has reported that site-specific DNA methylation upstream of 
the FcRL3 gene mediates expression of this gene (Clark et al., 2020). Due to its very high 
expression on ABCs and its potential role as an innate mediator, together with its 
association in autoimmune disease, I decided to further investigate the role of FcRL3 in B 
cell function (see Chapter 7).  
FcRL1 expression is present on all B cells and for this reason, it can be considered a pan B 
cell marker. It appears at the pre-B cell stage and it increases with maturation, peaking on 
naïve and memory B cells (Polson et al., 2006). My results show that FcRL1 is expressed 
by all the B cell subsets (Figure 4.18); however, we see lower numbers of FcRL1+ cells in 
the memory and the ABC population. FcRL1 is the only FcRLs family member with two 
ITAM-like sequences and appears to act as a co-activation receptor. Its ligation by receptor-
specific monoclonal antibodies results in its tyrosine phosphorylation (pTyr) and stimulates 
human B cell proliferation (Leu et al., 2005). Moreover, crosslinking FcRL1 with the BCR 
enhances calcium flux augmenting B cell activation and proliferation. Accordingly, the 
lower expression of FcRL1 seen in ABCs is in line with other studies showing that ABCs 
do not respond to BCR stimulation, but they do respond to TLRs (Rubtsov et al., 2011). 
FcRL1 acts as a co-activator in adaptive signals, however, other FcRLs such as FcRL3, 
which are increased in ABCs, tend to respond together with colligation of TLRs and would 
be better at amplifying innate immune responses (Ehrhardt and Cooper, 2011). These 
findings support a role for ABCs as innate immune cells (Rubtsov et al., 2017).  
Lastly, FcRL2 expression in peripheral blood has been described in circulating CD20+ B 
cells (Polson et al., 2006). My results show that most of these B cells are found on the 
memory B cell subset and in the ABCs (Figure 4.19). This is the first time FcRL2 protein 
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expression is reported on ABCs, as all the previous studies have only checked expression 
of FcRL3-5 (Isnardi et al., 2010; Lau et al., 2017; Wang et al., 2018). FcRL2 function is 
still unknown. There are some studies investigating FcRL2 function together with FcRL3 
and FcRL5 and mutated receptors which indicate that FcRL2 co-engagement with the BCR 
leads to an inhibition of BCR signalling (Jackson et al., 2010). More studies investigating 
the role of FcRL2 in B cell function, are needed. This is especially important because 
FcRL2 is highly expressed on malignant B cell leukaemia and it could, therefore, be a 
potential therapeutic target (Ise et al., 2005).  
In terms of phenotypic expression in the different disease groups, there are no differences 
in expression of the different phenotypic markers I assessed (Figure 4.20-25). As explained 
in Chapter 3, one of the reasons for this finding could be that the blood is not the most 
informative tissue to investigate. In patients with RA, it has been demonstrated that most 
of the B cells that infiltrate the synovia have a similar phenotype as ABCs, with high 
expression of CD11c and low expression of CD21 (Amara et al., 2017). Therefore, I 
hypothesised that circulating ABCs found in peripheral blood are similar phenotypically 
between HCs and inflammatory arthritis patients, but in inflammatory arthritis, ABCs also 
migrate to sites of inflammation where they become activated and contribute to pathology 
and joint damage.  
The only difference between ABCs from HCs and RA patients was in T-bet expression 
(Figure 4.22). Even though expression seems to be quite variable between individuals in 
all the disease groups, there is significantly higher expression in healthy controls compared 
to established RA patients. In addition, RA and disease controls with early disease also 
have higher expression of T-bet than established patients, although these differences are 
not significant. This could be due to the treatment the patients with established disease 
receive. It is difficult to record the treatment established patients are receiving, due to the 
structure of the established clinics. These patients with chronic disease are treated with 
immune system suppressant drugs and these could influence ABCs function and alter their 
transcriptional profile, as it has been reported before on T cells (Ponchel et al., 2005). 
Interestingly, three patients with low percentages of T-bet positive cells had been treated 
with steroids, being therefore a possible explanation for their low expression of the 
transcription factor. T-bet has been shown to induce CXCR3 expression in T cells (Koch 
et al., 2009), and CXCR3 promotes cell migration into sites of inflammation (Groom and 
Luster, 2011b). Another explanation for the decreased T-bet expression in established 
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patients would be that cells with higher expression of T-bet, would have higher expression 
of CXCR3 and therefore migrate into the inflamed joints. These results are in line with my 
results from Chapter 3, which show that established patients have higher percentages of 




In this chapter, I performed an extensive phenotypic characterisation of the ABCs subset 
using flow cytometry. Based on previously published literature, I hypothesised that ABCs 
are activated B cells with a potential capacity for antigen presentation. 
I confirmed this hypothesis and showed that ABCs have high expression of co-stimulatory 
and activation molecules, like CD80, CD86 and CD69. Moreover, a high proportion of B 
cells in the ABC subset are actively proliferating and express the transcription factor T-bet. 
Immunoglobulins expression analysis revealed that the ABCs population is heterogeneous. 
A high percentage of ABCs, similar to memory B cells, are class-switched IgG-expressing 
B cells. However, some ABCs also express IgD and IgM. This reinforces the hypothesis 
that, although being a heterogeneous population, some of these cells are antigen-
experienced B cells and could be producing antibodies. Additionally, to my knowledge, 
this is the first time that a deep phenotyping looking at all five FcRL receptors has been 
performed on ABCs at a protein level. My results showed a very high expression of FcRL2-
5 and a lower expression of FcRL1 on ABCs compared to the other B cell subsets. As 
discussed before, the effect of FcRL2-5 signalling in conjunction to BCR and TLRs is still 
under investigation. Nevertheless, FcRL2-5 engagement seems to enhance TLRs signalling 
and therefore potentially marks an innate-like B cell subset which is in concordance to 
ABCs responding to TLR7 and TLR9. Differences in the ABC phenotype in different 
diseases and healthy controls was not found; ABCs from different disease groups have a 
similar protein expression profile. 
In summary, I confirmed the hypothesis that ABCs are an active, proliferating and class-
switched B cell subset with a potential role in antigen presentation. Despite the surface 








Alongside characterisation of ABC surface marker expression in early RA patients and 
controls, I also aimed to assess the transcriptome profile of these cells and compare gene 
expression between the different B cell subsets, as well as between RA patients and 
controls. 
Murine studies showed that ABCs express transcripts of Ig heavy chain, transcription 
factors involved in plasma cell differentiation and the marker CD138, supporting their role 
as a unique precursor of antibody-secreting plasma cells (Rubtsov et al., 2011). Curiously, 
ABCs also expressed genes found in helper and cytotoxic T cells such as T-bet, perforin 
and granzyme A as well as high expression of adhesion molecules such as integrins. 
Human studies in ABCs/CD21low B cells from healthy donors showed that these cells had 
high expression of chemokine receptors and adhesion molecules involved in extravasation 
and recruitment to sites of inflammation, such as CD11a, CCR3, CCR5, CCR10 and 
CXCR2 (Shimabukuro-Vornhagen et al., 2017). In addition, their expression of lymph node 
homing receptors was low. Transcriptome analysis of ABCs from patients with SLE 
confirmed that these cells have highly upregulated plasma cell transcripts such as BLIMP1, 
AID and XBP1. Nevertheless, their low expression of CD38 and CD138 suggests that these 
cells may be precursors of plasmablasts (Wang et al., 2018). In addition, these cells had 
upregulation of inflammation homing chemokine receptors such as CXCR3 and 
downregulation of lymph node homing receptors such as CXCR4 and CXCR5, confirming 
the conclusions of other groups.  
Alternatively, some studies described CD21low B cells as anergic and found that this subset 
downregulated genes encoding survival and activation proteins, as well as cytokine and 
chemokine receptors (Isnardi et al., 2010). In contrast, this subset up-regulated inhibitory 
receptors known to suppress B cell activation and proliferation. Other studies also showed 
that CD11c+T-bet+ B cells had high expression of inhibitory receptors such as FcRLs, 
CD72 and CD32B, in contrast to low expression of markers associated with B cell 
activation such as CD40 and NFKBIA (Karnell et al., 2017). This would support the idea 
that ABCs poorly respond to BCR stimulation. In addition, these cells had upregulation of 
apoptosis-related transcripts such as caspases, suggesting they are prone to cell death. This 
together with their downregulation of survival genes such as cyclins, supports the 
suggestion that these cells might have reduced survival and proliferation (Isnardi et al., 
157 
 
2010; Saadoun et al., 2013). Additionally, some studies showed that ABCs had high 
expression of TNF and IFN receptors, reinforcing the hypothesis that these cells play an 
important role in autoimmune diseases (Isnardi et al., 2010; Saadoun et al., 2013).  
Transcriptional analysis of the FcRL4+ B cell subset with a similar phenotype as the ABCs 
showed high expression of the cytokines RANKL and TNF-α (Yeo et al., 2015). Moreover, 
these cells had high expression of the chemokine receptors CCR1 and CCR3 which would 
explain their homing and retention to the inflamed synovium. In support of this finding, 
RNA sequencing confirmed that FcRL4 expressing B cells had high expression of RANKL 
and CD11c as well as inflammatory recruitment chemokine receptors such as CCR1 
(Amara et al., 2017). Nonetheless, these cells showed low expression of BLIMP1 and XBP1 
suggesting that these cells are not differentiating into antibody-secreting plasma cells. 
All in all, although the discrepancies in whether these cells are an anergic or an activated 
subset, gene expression analysis revealed high expression of adhesion molecules and 
inflammatory chemokine receptors suggesting that ABCs are able to migrate into inflamed 
tissue. Moreover, all the studies conclude that these cells are not plasma cells but probably 
a precursor of them. The origin of ABCs remains unknown, studies in the generation of T-
bet+ B cells show that they would be generated via BCR stimulation together with 
triggering of endosomal TLRs in a Th1 cytokine milieu composed of IL-21 and IFN-γ and 
absence of IL-4 (Knox et al., 2019). 
Additionally, previous work done in our group compared expression of six retrotransposons 
in different white blood cells from early RA patients (Cooles et al., unpublished results). 
Higher expression of these retrotransposons was found in the B cell and the CD4+ T cell 
populations compared to CD14+ monocytes, plasmacytoid DCs and myeloid DCs (Figure 
5.1 and 5.2). In the case of the endogenous retrovirus sequence LTR5 5’ expression on B 
cells was significanlty higher compared to all the other cell subsets (Figure 5.1.A). 
Interestingly, retroelements have been shown to be transcribed to RNA and bind and signal 
through TLRs (Mu et al., 2016). These results together with the evidence showing that 
ABCs are generated through TLR7 signalling (Rubtsov et al., 2011; Rubtsov et al., 2013) 
lead to the hypothesis that the high expression of retrotransposons could activate TLR7 in 
the B cells and drive ABC skewing. Accordingly, expression of these retroelements would 
be higher in ABCs compared to other B cells. Moreover, previous work done on RA and 
retrotransposons showed high expression of the LINE-1 retroelement in RA synovial tissue 
158 
 
compared to reactive arthritis’ synovium (Neidhart et al., 2000; Ali et al., 2003). Therefore, 
expression of retroelements in the different subset of B cells as well as in the different 
cohorts was evaluated. 
Due to the lack of studies of ABCs from RA patients, I used NanoString Technologies to 
analyse the gene expression profile of the ABC subset from RA patients and compare this 
to other B cell subsets from RA patients. I also compared the ABC transcriptome from RA 
patients to the ABC transcriptome from psoriatic arthritis (PsA) patients and age-matched 
healthy controls, to identify RA-specific gene expression in this novel B cell subset.  
 
Figure 5. 1. Expression of non-long terminal repeat retroelements in different immune 
cell subsets in early RA. Peripheral blood immune cells (plasmacytoid dendritic cells, 
pDCs; myeloid dendritic cells, mDCs; B cells, CD4+ T cells, CD4; CD8+ T cells, CD8; 
CD14+ monocytes, CD14) from early RA patients (n=8) were flow cytometry cell sorted 
and cellular RNA was analysed using NanoString nCounter technology for non-long 
terminal repeat retroelements. A. AluYa5 activity. B. AluYb9 activity. C. L1-5’UTR 
activity. D. L1-ORF2 activity. Data are presented as box and whisker plots, in which the 
horizontal line represents the median value, the box represents upper and lower quartiles 
and the error bars represent range. Kruskal-Wallis test. ** p<0.01, ***p<0.001. Taken from 




Figure 5. 2. Expression of long terminal repeat retroelements in different immune cell 
subsets in early RA. Peripheral blood immune cells (plasmacytoid dendritic cells, pDCs; 
myeloid dendritic cells, mDCs; B cells, CD4+ T cells, CD4; CD8+ T cells, CD8; CD14+ 
monocytes, CD14) from early RA patients (n=8) were flow cytometry cell sorted and 
cellular RNA was analysed using NanoString nCounter technology for non-long terminal 
repeat retroelements. A. LTR5 5’ activity. B. LTR5 3’ activity. Data are presented as box 
and whisker plots, in which the horizontal line represents the median value, the box 
represents upper and lower quartiles and the error bars represent range. Kruskal-Wallis test. 





5.2 Chapter hypothesis and aims 
The work described in this chapter addresses the hypothesis that ABCs have a unique 
transcriptome compared to other B cell subsets and that ABCs from RA patients show a 
different gene expression profile to ABCs from PsA disease controls and healthy controls.   
Therefore, the aims of this chapter were to: 
1. Characterise the gene expression profile of ABCs compared to other B cell subsets. 
2. Determine if the ABC transcriptome from RA patients is different to that from PsA 
patients and age-matched healthy controls.  
3. Determine if ABCs show higher expression of retroelements compared to other B 
cell subsets.  
4. Determine if eRA B cells have higher expression of retroelements compared to B 
cells from PsA and healthy controls.  
The specific objectives were: 
1. Optimise the sorting of pure B cell populations. 
2. Compare gene expression between ABCs and other B cell subsets in RA patients. 
3. Compare gene expression between ABCs from RA patients and ABCs from PsA 
patients and healthy controls. 
4. Compare gene expression of the retroelements between ABCs and other B cell 
subsets in RA patients. 
5. Compare gene expression of the retroelements between B cells from RA patients 





5.3.1 Flow cytometry cell sorting of B cell subsets for NanoString analysis 
Briefly, isolated PBMCs were resuspended in cold FACS buffer to a final concentration of 
20 x 106 cells/ml. To each tube, 1ml of this cell suspension was added and centrifuged at 
400g for 8 minutes at 4°C. The cell pellet was resuspended in the fluorophore labelled 
antibody mix (see table 2.6 in Chapter 2 for the list of antibodies used). After the staining 
time, cells were stained for Zombie UV (Biolegend, CA, USA) in PBS to identify dead 
cells. Cells were incubated at 4°C for 15 minutes in the dark and then washed twice with 
FACS buffer. Cells from each tube were transferred to a FACS tube and the volume was 
made up to 2ml with FACS buffer, resulting in a cell density of 10 x 106 cells/ml. 
Right before sorting, the cells were strained through a 30μm cell strainer (CellTrics - 
Sysmex, IL, USA). This was performed immediately prior to sorting to avoid small cell 
clumps blocking the sorter’s nozzle. The BD FACSARIA II (Becton Dickinson, NJ, USA) 
with a 70μm nozzle was used to sort the four immune cell subsets.  
The gating strategy used to sort the four subsets is shown in Figure 5.3. After excluding 
dead cells and doublets using two doublet gates, lymphocytes were gated using SSC-A vs 
FSC-A. From the lymphocyte gate, B cells were gated using CD19 vs CD3/CD33, therefore 
excluding T cells and dendritic cells. From the B cell gate, the ABCs were gated using 
CD11c vs CD21. From the rest of the cells, CD5+ cells were gated using CD5 and CD19. 
Finally, from the CD5- fraction, naïve (IgD+CD27-) and memory (IgD-CD27+) B cells 
were gated. 
5.3.2 Post-sorting sample preparation for NanoString analysis 
For each subset, 15,000 cells were sorted into 1.5ml microcentrifuge tubes containing 280μl 
of RF10 (RPMI +10% FCS) at 4°C. After sorting, the cells were transferred into a 96-well 
plate and spun at 400g for 4 minutes. The supernatant was removed by flicking and blotting 
the plate. Cells were then resuspended in 1.6μl of RLT buffer, transferred, together with 
the residual RF10 volume (resulting in 5µl total volume), to a 0.2ml PCR tube and stored 
in the -80 freezer until all the patients were recruited. Once the recruitment was completed 
and the NanoString chips were ready to run, a total volume of 5μl of lysate for each of the 
cell subsets was loaded onto the NanoString chip and the protocol was followed according 
to standard nCounter instructions. 
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See Chapter 2 section 2.5 on NanoString Technologies for the methodology, the genes 
analysed and the computational analysis performed in collaboration with our group’s 




Figure 5. 3. Gating strategy used for the sorting of each B cell subset for gene expression analysis. Example of the gating strategy used to 
sort the four B cell populations for the gene expression analysis. After excluding dead cells and doublets twice, lymphocytes were gated using 
SSC-A vs FSC-A. From the lymphocyte gate, B cells were gated using CD19 vs CD3/CD33. From the B cell gate, the ABCs were gated using 
CD11c vs CD21. From the rest of the cells, CD5+ cells were gated using CD5 and CD19. Finally, from the CD5- fraction, naïve (IgD+CD27-) 
and memory (IgD-CD27+) B cells were gated. Gates were set based on an initial FMO and every time that a donor was recruited the gates were 




5.4.1 Sorted B cell populations show a purity greater than 85% 
For the gene expression analysis, the four B cell subsets had to be isolated from the rest of 
the PBMC fraction. For this reason, I flow cytometry cell sorted the four B cell subsets; 
naïve, memory, CD5+ B cells and ABCs. However, due to the importance for high purity 
sorting, the gating strategy was optimised to make sure highly pure populations were 
isolated. In order to check whether the sorted cells were pure, some of the sorted cells were 
reacquired on the FACSAria II sorter to check their purity (Figure 5.4). Figure 5.4.A shows 
the gates for each subset before sorting, from the mixed population. Figure 5.4.B shows 
each of the purified B cell subsets after reacquisition. The purity of ABCs was greater than 
85%, the purity of CD5+ B cells was 91.3%, the naïve B cell purity was 98.6% and the 
memory B cells 93.2%. These purities may be underestimated due to slight changes in 
morphology and fluorescence of sorted cells causing spreading of the population.  
In addition to purity checks, the cells were cytospun and stained with a Wright-Giemsa 
staining in order to assess cell morphology and appearance (Figure 5.5). The Wright-
Giemsa staining colours the cytoplasm light pink and the nuclei dark purple. Examples of 
naïve B cells are shown in Figure 5.5.A. Memory B cells are shown in Figure 5.5.B; these 
cells are slightly bigger than naïve B cells. Similar to naïve B cells, CD5+ B cells (Figure 
5.5.C) are round and smaller than memory B cells. ABCs are shown in Figure 5.5.D; ABCs 
are very much like memory B cells in terms of size. Moreover, memory and ABCs show a 




Figure 5. 4. Purity check of the sorted B cell subsets. A. Flow cytometry plots of the gates used to sort each of the B cell subsets from the pre-
sorted mixed population of B cells. Subsets of interest are squared in blue. B. After sorting, some cells from each of the subsets were rerun in the 
FACSAria II sorter to check if the sorted populations were pure. Each sorted population is found in the correct gate. Gates for the pre-sorting were 





Figure 5. 5. Cytospin images of the sorted B cell subsets. Cytospin pictures to assess 
morphology and appearance were performed on the four sorted B cell subsets. Cytospins 
were stained with Wright-Giemsa stain, which stains the cytoplasm light pink and the 
nucleus dark purple. A. Naïve B cells, B. Memory B cells, C. CD5+ B cells and D. Age-





5.4.2 Cohorts demographics 
Once I had confirmed that the sorted populations were pure, I recruited early RA and PsA 
patients, as well as age-matched healthy controls for B cell subset sorting. Early RA 
patients were recruited from the Newcastle Early Arthritis Clinic (NEAC) and were 
therefore naïve to any DMARDs or other drug treatment. These patients were double 
positive for RF and anti-CCP antibodies. As a disease control, patients diagnosed with 
psoriatic arthritis were used; these patients were also early-untreated patients. Early PsA 
patients were double negative for RF and anti-CCP antibodies. Healthy controls were 
volunteers who had no personal history of rheumatological or autoimmune disease. 
Demographic data are shown in Table 5.1. There were no significant differences between 
the age and the sex of the groups. There was a significant difference, as expected, in the 
autoantibody seropositivity between the two disease groups. The differences between 
groups for the age and the sex were calculated comparing all three groups, however, for the 











Number 4 4 4 - 
Age (years; median 
and range) 
70 
(60 - 80) 
70 
(63 - 79) 
63 
(61 - 73) 
>0.9# 
Percentage of 









DAS28 (median and 
range) 
5.74 
(4.65 - 6.37) 
- - - 
Seropositive – anti-
CCP+ and RhF+ 






Table 5. 1. Demographic characteristics for all the cohorts used for NanoString gene 
expression analysis. Flow cytometry cell sorting was performed on the disease cohorts 
(early RA patients, n = 4 and early PsA patients, n = 4) and the healthy control cohort (n = 
4) to assess gene expression using NanoString Technologies. # Kruskal-Wallis test with 




5.4.3 Data pre-processing and quality assessment 
Before performing differential gene analysis, data quality was assessed using the 
arrayQualityMetrics (Kauffmann et al., 2009) Bioconductor package to detect and remove 
any outlier samples. An overview of the bioinformatics performed can be found in Chapter 
2 section 2.5. NanoString, like other methods to assess gene expression, uses gene counts 
to quantify gene expression, meaning it counts the number of times a gene is detected. First, 
the gene counts for each sample are normalised to the housekeeping genes to correct for 
differences in amounts of mRNA. Then, for each normalised sample, arrayQualityMetrics 
computes three different metrics corresponding to the gene counts. Samples with at least 
two metrics exceeding the threshold were considered as outliers. After running the 
arrayQualityMetrics and excluding the outliers, the normalisation was run again and further 
outliers were also removed. On the third cycle of arrayQualityMetrics, no outliers exceeded 
the threshold, in total four samples were flagged as outliers (2 ABCs samples from disease 
controls, 1 ABC sample from a healthy control and 1 memory B cell sample from a disease 
control) and were excluded from further analysis. Because the gene counts dataset is a 
multivariate data set with a lot of variables, a PCA plot helps extracting the important 
information and plotting it in new variables called principal components. These new 
variables correspond to a combination of the original variables, therefore, PCA reduces the 
dimensionality of a multivariate data to two principal components that can be visualised in 
a graph. The PCA plot shown in Figure 5.6 represent one of the metrics used to assess data 
quality. These plots show variance in the data set, allowing for the detection of outlier 
samples. Figure 5.6.A shows the results of the first cycle of arrayQualityMetrics. In this 
cycle, three ABCs samples, two from PsA patients and one from a HC were flagged 
(circled). Figure 5.6.B shows the results of the second cycle. One more sample was flagged 
and excluded, it corresponded to memory B cells from a PsA patient. Figure 5.6.C shows 
the last cycle of quality control, no outliners were detected in more than two methods 





Figure 5. 6. Principal component analysis of the normalised samples. Principal 
component analysis was run on the normalised data from the NanoString chip using the 
arrayQualityMetrics Bioconductor package in R software. Each dot represents a donor and 
the cell types can be distinguished by the colour code. A. PCA plot generated after the first 
round of quality control. Circled samples show high and significant variance in the data set 
as assessed by this metric. These samples were, therefore, excluded. B. PCA plot generated 
after the second round of quality control. Another outlier was detected and excluded from 
further analysis. C. PCA plot generated after the third round of quality control. No outliers 




5.4.4 Differential gene expression in the distinct B cell subsets from early RA patients 
After assessing data quality and excluding outliers, ABCs gene expression was compared 
with this of the other B cell subsets in early RA. An overview of the bioinformatics analysis 
can be found in Chapter 2 section 2.6. Briefly, the DESeq2 R package (Love et al., 2014) 
was used to compare the gene expression profiles between different B cell subsets and 
disease groups. DESeq2 package was chosen as it is a standard method for the analysis of 
count data. This package estimates the dispersion and the fold change of the counts to 
enable for a more quantitative analysis focused on the strength of the differential expression 
rather than the simple presence of differential expression. Differences were regarded 
significant when the Benjamini-Hochberg adjusted p value was <0.05 and the fold change 
was >1.5. 
Heatmaps were used to visualize clustering differences between cell types (Figure 5.7). 
Figure 5.7.A shows that ABCs and naïve B cells are two distinct subsets with different gene 
expression profiles. The same is shown for the comparison of ABCs to CD5+ B cells 
(Figure 5.7.B) and memory B cells (Figure 5.7.C). The ABCs display different gene 
expression profiles to the rest of the B cell subsets.  
Differentially expressed genes between the ABCs and the naïve B cells were assessed 
(Figure 5.8). The differentially expressed genes identified are shown in the volcano plot 
(Figure 5.8.A). This analysis revealed a wide range of downregulated genes such as CR2 
and CR1, which encode CD21 and CD35 respectively, and chemokine receptors which 
mediate recruitment to lymphoid organs such as CCR7, CXCR4 and CXCR5 (Figure 5.8.B). 
Moreover, the upregulated genes were mainly enriched for previously described ABC 
markers such as integrins (ITGAX, ITGB2), adhesion molecules (CD97) and TBX21, which 
encodes T-bet (Figure 5.8.C). 
ABCs’ gene expression was compared to the CD5+ B cells’ gene profile (Figure 5.9). 
Differentially expressed gene analysis between the two subsets is shown in the volcano plot 
(Figure 5.9.A). Gene expression analysis revealed a similar profile of downregulated genes 
as compared to naïve B cells, with downregulation of chemokine receptors mediating 
recruitment to lymphoid organs and CD21 (Figure 5.9.B). Additionally, upregulated genes 
comprised T-bet, integrins and adhesion molecules as with the naïve B cells (Figure 5.9.C). 
Finally, ABCs’ gene expression was also compared to the memory B cells’ gene profile 
(Figure 5.10). The volcano plot shows the differentially expressed genes between the two 
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subsets (Figure 5.10.B). Downregulated genes include complement receptors and 
regulators such as CR1, CR2, and CD59, in addition to the plasma cell marker CD138 and 
CD38 (Figure 5.10.C). Upregulated genes comprised integrin genes, CD19 and the coding 
T-bet gene. Moreover, there was upregulation of inhibitory receptors such as LAIR1 and 





Figure 5. 7. Heatmap of the differentially expressed genes between ABCs and the other subsets of B cells. B cell subsets from early RA 
patients were sorted by flow cytometry. Cells were lysed and the cell lysates were loaded to the NanoString nCounter Technologies chip to assess 
gene expression. Raw counts were normalised to the housekeeping genes. Sample quality was then assessed using the arrayQualityMetrics package 
and 4 outliers were excluded. Gene expression profiles between different B cell subsets was assessed using the DESeq2 R package. Gene expression 
intensities were log10 transformed and are displayed as colours ranging from yellow to red as shown in the key. A. Heatmap of the differentially 
expressed genes between naïve B cells and ABCs. ABCs are shown in purple and naïve B cells in pink. B. Heatmap of the differentially expressed 
genes between CD5+ B cells and ABCs. ABCs are shown in purple and CD5+ B cells in pink. C. Heatmap of the differentially expressed genes 





Figure 5. 8. Gene expression analysis of sorted ABCs compared to naïve B cells from early RA patients. Cell lysates from sorted ABCs and 
naïve B cells from early RA patients were loaded to the NanoString nCounter Technologies chip to assess gene expression. Raw counts were 
normalised to the housekeeping genes. Sample quality was then assessed using the arrayQualityMetrics package and 4 outliers were excluded. 
Gene expression profiles between different B cell subsets was assessed using the DESeq2 R package. Genes achieved statistical significance when 
the adjusted p value was <0.05 (FDR corrected) and the fold change was >1.5. A. Volcano plot showing the Log2Fold change against the –log10 
Adjusted p value where genes plotted in red are upregulated and genes in green are downregulated in ABCs compared to naïve. B. Table showing 
the 10 most significant downregulated genes, with their fold change and adjusted p value. C. Table showing the 10 most significant upregulated 




Figure 5. 9. Gene expression analysis of sorted ABCs compared to CD5+ B cells from early RA patients. Cell lysates from sorted ABCs and 
CD5+ B cells from early RA patients were loaded to the NanoString nCounter Technologies chip to assess gene expression. Raw counts were 
normalised to the housekeeping genes. Sample quality was then assessed using the arrayQualityMetrics package and 4 outliers were excluded. 
Gene expression profiles between different B cell subsets was assessed using the DESeq2 R package. Genes achieved statistical significance when 
the adjusted p value was <0.05 (FDR corrected) and the fold change was >1.5. A. Volcano plot showing the Log2Fold change against the –log10 
Adjusted p value where genes plotted in red are upregulated and genes in green are downregulated in ABCs compared to CD5+ B cells. B. Table 
showing the 10 most significant downregulated genes, with their fold change and adjusted p value. C. Table showing the 10 most significant 




Figure 5. 10 Gene expression analysis of sorted ABCs compared to memory B cells from early RA patients. Cell lysates from sorted ABCs 
and memory B cells from early RA patients were loaded to the NanoString nCounter Technologies chip to assess gene expression. Raw counts 
were normalised to the housekeeping genes. Sample quality was then assessed using the arrayQualityMetrics package and 4 outliers were excluded. 
Gene expression profiles between different B cell subsets was assessed using the DESeq2 R package. Genes achieved statistical significance when 
the adjusted p value was <0.05 (FDR corrected) and the fold change was >1.5. A. Volcano plot showing the Log2Fold change against the –log10 
Adjusted p value where genes plotted in red are upregulated and genes in green are downregulated in ABCs compared to memory B cells. B. Table 
showing the 10 most significant downregulated genes, with their fold change and adjusted p value. C. Table showing the 10 most significant 
upregulated genes, with their fold change and adjusted p value.
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5.4.5 Expression of selected genes of interest in B cell subsets 
Considering the previous results showing different gene expression between ABCs and the 
other B cell subsets, I decided to further investigate some of the enriched and previously 
reported pathways.  
Further inspection of the genes which were differentially expressed by ABCs compared to 
the other B cell subsets revealed that the high expression of some of the previously assessed 
protein phenotypic markers were confirmed at the mRNA level. The markers comprising 
the ABC phenotype were CD19, ITGAX (CD11c), TBX21 (T-bet), CR2 (CD21), MS4A1 
(CD20) and CD27 (Figure 5.11.A).  
Gene expression analysis of genes related to B cell differentiation and activation markers 
showed higher expression of genes involved in plasma cell differentiation (AICDA, 
PRDM1 (BLIMP1) and XBP1) compared to naïve B cells, although lower expression 
compared to memory B cells (Figure 5.11.B), supporting the idea that ABCs might be 
precursors of plasma cells. However, low expression by ABCs of molecules associated to 
B cell activation, for example NFKBIA and NFKBIZ support the notion that ABCs might 
be unresponsive to BCR stimulation (Figure 5.11.B). 
 
Figure 5. 11. Expression of selected genes of interest in the different B cell subsets 
from RA patients. Heat map showing expression pattern of representative genes with 
relevant functions. A. Group of genes encoding the ABCs phenotype. B. Genes encoding 
B cell differentiation and activation factors. For plotting, median log2 expression for each 
cell population was used. Red indicates higher expression, and blue indicates lower 
expression. Colour bar indicates Z score or adjusted p value. 
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Furthermore, analysis of migration and adhesion molecules showed high expression of 
alpha and beta integrins (like ITGAL and ITGB1) as well as NCAM1, but not PECAM 
(Figure 5.12.A).  
Moreover, the gene expression results confirm a unique ABC-expression profile of 
cytokine receptors. These cytokines include the gamma-c family receptor IL2RB, members 
of the TNF receptor super family (TNFRSF1B and TNFRSF13B) and the interferon alpha 
receptor 2, IFNAR2 (Figure 5.12.B). The unique chemokine receptor profile includes high 
expression of chemokine receptors which mediate recruitment to inflammatory sites and 
low expression of chemokine receptors which mediates migration of leukocytes into 
lymphoid organs (Figure 5.12.B). 
 
Figure 5. 12. Expression of selected genes of interest in the different B cell subsets 
from RA patients. Heat map showing expression pattern of representative genes with 
relevant functions. A. Group of genes encoding adhesion molecules. B. Genes encoding 
cytokines and chemokines receptors. For plotting, median log2 expression for each cell 
population was used. Red indicates higher expression, and blue indicates lower expression. 




Moreover, ABCs also show high expression of apoptosis-related genes as expression of 
caspases (CASP8 and CASP1), the apoptotic antigen FAS, and the apoptosis regulator 
MCL1, primarily compared to naïve B cells (Figure 5.13.A). 
Interestingly, gene expression results demonstrated very high expression of genes 
associated with NK cell cytotoxicity. ABCs upregulate genes encoding granzymes (GZMA, 
GZMB and GNLY) and perforin (PRF1) as well as Killer cell Lectin like Receptors (KLRC3, 
KLRF1 and KLRD1) and Killer cell Immunoglobulin-like Receptor (KIR3DL1) (Figure 
5.13.B). 
 
Figure 5. 13. Expression of selected genes of interest in the different B cell subsets 
from RA patients. Heat map showing expression pattern of representative genes with 
relevant functions. A. Group of genes related to apoptosis. B. Genes involved in NK cell 
cytotoxicity. For plotting, median log2 expression for each cell population was used. Red 
indicates higher expression, and blue indicates lower expression. Colour bar indicates Z 





Additionally, ABCs show high expression of inhibitory receptors such as FCGR, and 
LILRB, as well as immunomodulatory molecules including TLR9, CD80 and CD86 (Figure 
5.14).  
 
Figure 5. 14. Expression of selected genes of interest in the different B cell subsets 
from RA patients. Heat map showing expression pattern of representative genes with 
relevant functions. A. Group of genes encoding inhibitory receptors and immune 
modulators. For plotting, median log2 expression for each cell population was used. Red 
indicates higher expression, and blue indicates lower expression. Colour bar indicates Z 




As a different way to compare key pathways between the B cell subsets, gene expression 
after normalisation to housekeeping genes was compared using dot plots. Figure 5.15 
highlights genes involved in cellular migration. 
Analysis of chemokine receptor gene expression showed high expression of the chemokine 
receptors which mediate migration into inflammatory sites (Figure 5.15.A-B). High 
expression on ABCs was significant when compared to naïve B cells for CXCR3 and 
memory B cells for CX3CR1. On the contrary, expression of chemokine receptors known 
to mediate recruitment to lymphoid organs such as CXCR4 and CXCR5, was significantly 
downregulated in ABCs compared to naïve B cells (Figure 5.15.C-D). 
Additionally, expression of ITGB2, an integrin also known as CD18 and involved, together 
with CD11c, in B cell attachment to fibrinogen (Postigo et al., 1991), was plotted as a 
representative of the different integrins and adhesion molecules upregulated in ABCs 
compared to other subsets. ITGB2 expression was significantly higher in ABCs compared 
to memory B cells (Figure 5.16.A). Expression of the adhesion and activation marker CD97 
was also assessed (Figure 5.16.B). CD97 expression was higher in ABCs than the other 




Figure 5. 15. Normalised gene expression of chemokine receptors in the different B 
cell subsets in early RA patients. A-B. Normalised gene expression of chemokine 
receptors which mediate recruitment of cells to inflammatory sites (n=4). C-D. Normalised 
gene expression of chemokine receptors which mediate recruitment of cells to lymphoid 
organs (n=4). The bar represents the median. Statistical significance was assessed using a 
Friedman test with Dunn’s multiple comparisons of the ABCs against the other subsets; * 
p < 0.05, **p < 0.01. Friedman test p = 0.0009 for A, p = 0.0190 for B, p = 0.0027 for C 





Figure 5. 16. Normalised gene expression of adhesion molecules in the different B cell 
subsets in early RA patients. A. Normalised gene expression of the adhesion receptor 
integrin subunit β2 in the different B cell subsets (n=4). B. Normalised gene expression of 
the adhesion molecule CD97 in each of the B cell subsets (n=4). Statistical significance 
was assessed using a Friedman test with Dunn’s multiple comparisons of the ABCs against 
the other subsets; * p < 0.05, **p < 0.01, **** p < 0.0001. Friedman test p = 0.0016 for A 




5.4.6 Validation of transcriptomic data at the protein level 
Considering the previous results showing different gene expression between ABCs and 
other B cell subsets, I validated the expression of selected genes at the protein level, using 
flow cytometry. 
CXCR3 expression, known to recruit cells into sites of inflammation, showed higher 
percentages of CXCR3 positive cells in the ABC population (Figure 5.17.A-C), confirming 
the gene expression analysis. These differences were significant in ABCs compared to 
naïve and CD5+ B cells (Figure 5.17.C). CXCR3 expression, as measured by MFI, was 
also higher in ABCs compared to naïve and CD5+ B cells (Figure 5.17.D). 
CXCR4 expression, a chemokine receptor that recruits cells into lymph nodes, was 
downregulated in the ABC population (Figure 5.18.A-B). There were significantly lower 
percentages of positive cells in the ABCs compared to naïve and CD5+ B cells (Figure 
5.18.C). Moreover, CXCR4 expression, as measured by MFI, was also lower in ABCs 
compared to naïve and CD5+ B cells (Figure 5.18.D). 
Another chemokine receptor which recruits lymphocytes into lymphoid organs is CXCR5. 
A lower percentage of CXCR5 positive B cells was found on the ABCs population (Figure 
5.19.A-C), these differences were significant in ABCs compared to naïve and CD5+ B 
cells. CXCR5 expression was also higher in ABCs compared to the rest of the B cell subsets 
(Figure 5.19.D). 
Expression of the death receptor CD95 (Fas) was also validated. CD95 expression was 
highly expressed in the memory and ABC population (Figure 5.20.A-C). There were 
significantly higher percentages of positive cells in the ABCs compared to naïve and CD5+ 
cells (Figure 5.20.C). Moreover, CD95 expression, as measured by MFI, was also higher 
in ABCs compared to naïve and CD5+ cells (Figure 5.20.D). 
Expression of the adhesion and activation marker CD97 was additionally validated. Higher 
percentages of CD97 positive cells can be found in the ABC population compared to naïve 
and CD5+ B cells (Figure 5.21. A-C). MFI values confirmed the higher expression of CD97 





Figure 5. 17. Expression of CXCR3 in each B cell subset in early RA patients. A. Flow 
cytometry plots for each B cell subset after whole blood staining. CXCR3 expression 
against CD19, gate set from the lymphocyte population. B. CXCR3 expression overlay for 
each of the subsets. Naïve B cells are shown in orange; memory B cells in red, CD5+ B 
cells in purple and ABCs are shown in blue. The peaks are normalised to the same height 
to normalise different numbers of cells in each population. C. Percentage of CXCR3 
positive cells in the B cell subsets (n=6). The bar represents the median. D. CXCR3 median 
fluorescence intensity (MFI) in the different B cell subsets (n=6). The bar represents the 
median. Statistical significance was assessed using a Kruskal-Wallis test with Dunn’s 
multiple comparisons of the ABCs against the other subsets; * p < 0.05, **p < 0.01, **** 





Figure 5. 18. Expression of CXCR4 in each B cell subset in early RA patients. A. Flow 
cytometry plots for each B cell subset after whole blood staining. CXCR4 expression 
against CD19, gate set from the lymphocyte population. B. CXCR4 expression overlay for 
each of the subsets. Naïve B cells are shown in orange; memory B cells in red, CD5+ B 
cells in purple and ABCs are shown in blue. The peaks are normalised to the same height 
to normalise different numbers of cells in each population. C. Percentage of CXCR4 
positive cells in the B cell subsets (n=6). The bar represents the median. D. CXCR4 median 
fluorescence intensity (MFI) in the different B cell subsets (n=6). The bar represents the 
median. Statistical significance was assessed using a Kruskal-Wallis test with Dunn’s 
multiple comparisons of the ABCs against the other subsets; **p < 0.01, *** p < 0.001, 





Figure 5. 19. Expression of CXCR5 in each B cell subset in early RA patients. A. Flow 
cytometry plots for each B cell subset after whole blood staining. CXCR5 expression 
against CD19, gate set from the lymphocyte population. B. CXCR5 expression overlay for 
each of the subsets. Naïve B cells are shown in orange; memory B cells in red, CD5+ B 
cells in purple and ABCs are shown in blue. The peaks are normalised to the same height 
to normalise different numbers of cells in each population. C. Percentage of CXCR5 
positive cells in the B cell subsets (n=6). The bar represents the median. D. CXCR5 median 
fluorescence intensity (MFI) in the different B cell subsets (n=6). The bar represents the 
median. Statistical significance was assessed using a Kruskal-Wallis test with Dunn’s 
multiple comparisons of the ABCs against the other subsets; * p < 0.05, **p < 0.01. 





Figure 5. 20. Expression of CD95 in each B cell subset in early RA patients. A. Flow 
cytometry plots for each B cell subset after whole blood staining. CD95 expression against 
CD19, gate set from the lymphocyte population. B. CD95 expression overlay for each of 
the subsets. Naïve B cells are shown in orange; memory B cells in red, CD5+ B cells in 
purple and ABCs are shown in blue. The peaks are normalised to the same height to 
normalise different numbers of cells in each population. C. Percentage of CD95 positive 
cells in the B cell subsets (n=6). The bar represents the median. D. CD95 median 
fluorescence intensity (MFI) in the different B cell subsets (n=6). The bar represents the 
median. Statistical significance was assessed using a Kruskal-Wallis test with Dunn’s 
multiple comparisons of the ABCs against the other subsets; **p < 0.01. Kruskal-Wallis 





Figure 5. 21. Expression of CD97 in each B cell subset in early RA patients. A. Flow 
cytometry plots for each B cell subset after whole blood staining. CD97 expression against 
CD19, gate set from the lymphocyte population. B. CD97 expression overlay for each of 
the subsets. Naïve B cells are shown in orange; memory B cells in red, CD5+ B cells in 
purple and ABCs are shown in blue. The peaks are normalised to the same height to 
normalise different numbers of cells in each population. C. Percentage of CD97 positive 
cells in the B cell subsets (n=13). The bar represents the median. D. CD97 median 
fluorescence intensity (MFI) in the different B cell subsets (n=13). The bar represents the 
median. Statistical significance was assessed using a Kruskal-Wallis test with Dunn’s 
multiple comparisons of the ABCs against the other subsets; *** p < 0.001, **** p < 





Two NK cell related genes were also validated at the protein level using intracellular flow 
cytometry staining.  
Granzyme B, a serine protease that induces apoptosis in target cells, was expressed by all 
NK cells (Figure 5.22.A). NK cells were gated by the exclusion of the CD19 and the CD3 
and CD33 cells to assess staining. The higher mRNA expression of this protease in ABCs 
could not be confirmed at the protein level (Figure 5.22.B). Granzyme B expression in the 
NK cell population was very high, however, no differences in the MFI values were seen 
between B cell subsets (Figure 5.22.C). 
The higher mRNA expression of perforin, another cytotoxic protein which mediates pore 
formation in target cells, by ABCs could also not be validated by flow cytometry (Figure 
5.23). Perforin expression in NK cells confirmed that the staining worked as most of the 
cells were positive for perforin (Figure 5.23.A). Unfortunately, there were no perforin 
positive cells in any of the B cell subsets (Figure 5.23.B). Moreover, no differences in the 





Figure 5. 22. Expression of Granzyme B in each B cell subset in early RA patients. A. 
Flow cytometry plot showing expression of granzyme B against SSC-A in the NK cell 
population after intracellular staining. Gate set using an FMO. B. Flow cytometry plots for 
each B cell subset after intracellular staining. Granzyme B expression against CD19, gate 
set using an FMO C. Granzyme B expression overlay for each of the subsets. Naïve B cells 
are shown in orange; memory B cells in red, CD5+ B cells in purple, ABCs in blue and NK 
cells in green. The peaks are normalised to the same height to normalise different numbers 





Figure 5. 23. Expression of perforin in each B cell subset in early RA patients. A. Flow 
cytometry plot showing expression of perforin against SSC-A in the NK cell population 
after intracellular staining. Gate set using an FMO. B. Flow cytometry plots for each B cell 
subset after intracellular staining. Perforin expression against CD19, gate set using an FMO 
C. Perforin expression overlay for each of the subsets. Naïve B cells are shown in orange; 
memory B cells in red, CD5+ B cells in purple, ABCs in blue and NK cells in green. The 





5.4.7 Differential gene expression in ABCs from early RA patients compared to early 
PsA patients and healthy controls 
A comparison of ABCs’ gene expression between the different groups, eRA, ePsA and 
healthy controls was also performed. The DESeq2 R package (Love et al., 2014) was used 
to compare the gene expression profiles between different B cell subsets and disease 
groups. For this analysis a less stringent cut-off was used. Differences were regarded 
significant when the unadjusted p value was < 0.05 and the fold change was > 1.5. 
Unadjusted p values were used as applying adjusted p values did not result in any 
differentially expressed genes between the RA patients and the two control groups. This is 
probably due to the small number of samples per group, as only four donors were recruited 
in each group, and not all samples passed quality controls. Further validation in a bigger 
cohort is needed to confirm these exploratory results. 
Heatmaps were used to visualize clustering differences between the RA patients and the 
disease controls and the healthy controls (Figure 5.24). Figure 5.24.A shows that ABCs 
from eRA patients and ePsA patients cluster separately, with the exception of one eRA 
patient. As explained before, two ABC samples from ePsA patients did not pass quality 
control and were therefore excluded, leaving only two ePsA ABC samples. For the 
comparison of ABCs from eRA patients and healthy controls, cells from each group cluster 
separately (Figure 5.24.B). An ABC sample from a healthy control was also excluded as it 
did not pass quality control. 
Differentially expressed genes between eRA and ePsA ABCs were assessed (Figure 5.25). 
The differentially expressed genes identified are shown in the volcano plot (Figure 5.25.A). 
This analysis revealed a few downregulated genes in eRA, such as the transcription factors 
BCL6 and SOCS3, as well as extracellular receptors such as IFNAR2, FCGRT and LILRB4 
(Figure 5.25.B). Moreover, the genes upregulated in eRA were coding for subunits of 
interleukin receptors such as IL2RG and IL13RA1, as well as the killer cell receptor 
KIR3DL1 (Figure 5.25.C). Interestingly, two of the upregulated genes were related to the 
chemerin pathway, with upregulation of retinoid acid receptor (RARRES3) and of the 
chemerin receptor (CMKLR1). 
ABCs’ gene expression in eRA patients was also compared to that in age-matched healthy 
controls (Figure 5.26). Differentially expressed gene analysis between the two groups is 
shown in the volcano plot (Figure 5.26.A). Gene expression analysis revealed 
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downregulation in eRA of the transcription factors BATF and IRF5, as well as the adhesion 
molecule PECAM (Figure 5.26.B). Upregulated genes in eRA comprised interleukin 
receptors such as IL4R and IL13RA1, the chemokine receptor CXCR4 and the transcription 
factor IRF1 and transcriptional co-activator BCL3 (Figure 5.26.C). 
Figure 5.27.A shows the upregulated genes when each of the disease groups are compared. 
There were 12 genes that were shown to be upregulated in ABCs from eRA patients when 
compared to healthy controls but also upregulated in eRA patients compared to PsA disease 
controls. The upregulated genes coded for proteins involved in leukocyte activation and 
migration to inflammatory sites such as CD6, as well as receptors related to NK cell 
cytotoxicity like KIRs and KLRs (Figure 5.27.B). Interestingly, two of the upregulated 
genes in RA compared to other control groups, IL13RA1 and IL4R, encode a functional 
receptor for IL-13 (Figure 5.27.B). These genes could represent a RA-specific gene 
signature as they are increased in RA compared to both control groups. There were some 
differentially expressed genes in early RA and PsA compared to healthy controls (Figure 
5.27.A). As shown in Figure 5.27.B, 8 genes were upregulated in both arthritic diseases 
compared to healthy controls. Therefore, these genes could be related to general 
inflammation rather than being disease specific. The upregulated genes included the BCL2 
like 11 (BCL2L11) and the ligand for T cell activation ICOSLG and CD83, involved in 
antigen-presentation and lymphocyte activation. Interestingly, BCL3 and SOCS3 appeared 
upregulated in both disease groups compared to the healthy controls.  
Figure 5.28.A shows the downregulated genes when each of the disease groups are 
compared. There was only one downregulated gene common in the RA versus PsA 
comparison as well as the RA versus HC comparison (Figure 5.28.B). This gene is FCGRT; 
this gene codes a receptor that binds the Fc region of immunoglobulin G, thus protecting 
IgG from degradation in addition to facilitating its transport. There were 7 genes 
downregulated in both arthritic diseases compared to healthy controls. These genes 
comprised the transcription factors BATF and IRF5 and the inhibitory receptors FcRL4 and 
the Leukocyte Immunoglobulin-Like Receptor LILRA4. Additionally, the downregulated 





Figure 5. 24. Heatmap of the differentially expressed genes between ABCs from early RA patients, early PsA patients and age-matched 
healthy controls. Cell lysates from sorted ABCs were loaded to the NanoString nCounter Technologies chip to assess gene expression. Raw 
counts were normalised to the housekeeping genes. Sample quality was then assessed using the arrayQualityMetrics package Gene expression 
profiles between different disease groups and healthy controls was assessed using the DESeq2 R package. Gene expression intensities were log10 
transformed and are displayed as colours ranging from yellow to red as shown in the key. A. Heatmap of the differentially expressed genes between 
ABCs from eRA patients in pink and ABCs from ePsA patients in purple. B. Heatmap of the differentially expressed genes between ABCs from 




Figure 5. 25. Gene expression analysis of sorted ABCs from eRA patients compared to ABCs from ePsA patients. Cell lysates from sorted 
ABCs were loaded to the NanoString nCounter Technologies chip to assess gene expression. Raw counts were normalised to the housekeeping 
genes. Sample quality was then assessed using the arrayQualityMetrics package Gene expression profiles between different disease groups and 
healthy controls was assessed using the DESeq2 R package. Genes achieved statistical significance when the unadjusted p value was <0.05 and 
the fold change was >1.5. A. Volcano plot showing the Log2Fold change against the –log10 p value where genes plotted in red are upregulated 
and genes in green are downregulated in ABCs from eRA patients compared to ABCs from ePsA patients. B. Table showing the 10 most significant 





Figure 5. 26. Gene expression analysis of sorted ABCs from eRA patients compared to ABCs from healthy controls. Cell lysates from sorted 
ABCs were loaded to the NanoString nCounter Technologies chip to assess gene expression. Raw counts were normalised to the housekeeping 
genes. Sample quality was then assessed using the arrayQualityMetrics package Gene expression profiles between different disease groups and 
healthy controls was assessed using the DESeq2 R package. Genes achieved statistical significance when the unadjusted p value was <0.05 and 
the fold change was >1.5. A. Volcano plot showing the Log2Fold change against the –log10 p value where genes plotted in red are upregulated 
and genes in green are downregulated in ABCs from eRA patients compared to ABCs from healthy controls. B. Table showing the 10 most 
significant downregulated genes, with their fold change and p value. C. Table showing the 10 most significant upregulated genes, with their fold 





Figure 5. 27. Venn diagram of overlapping upregulated genes in early RA, early PsA and healthy controls. Cell lysates from sorted ABCs 
were loaded to the NanoString nCounter Technologies chip to assess gene expression. Raw counts were normalised to the housekeeping genes. 
Sample quality was then assessed using the arrayQualityMetrics package Gene expression profiles between different disease groups and healthy 
controls was assessed using the DESeq2 R package. Genes achieved statistical significance when the unadjusted p value was <0.05 and the fold 
change was >1.5. A. Venn diagram of overlapping upregulated genes in the different disease groups. The red circles and the red arrows mark the 






Figure 5. 28. Venn diagram of overlapping downregulated genes in early RA, early PsA and healthy controls. Cell lysates from sorted ABCs 
were loaded to the NanoString nCounter Technologies chip to assess gene expression. Raw counts were normalised to the housekeeping genes. 
Sample quality was then assessed using the arrayQualityMetrics package Gene expression profiles between different disease groups and healthy 
controls was assessed using the DESeq2 R package. Genes achieved statistical significance when the unadjusted p value was <0.05 and the fold 
change was >1.5. A. Venn diagram of overlapping downregulated genes in the different disease groups. The green circles and the green arrows 




5.4.8 Retroelement expression in different B cell subsets and disease groups 
Expression of retroelement sequences in the different B cell subsets and disease and healthy 
controls was assessed (Figure 5.29.A). When expression of the retroelements is split by B 
cell subset and donors are pooled, memory B cells show very low expression of the 
retroelements (Figure 5.29.A). Higher expression is seen in naïve and CD5+ B cells (Figure 
5.29.A). Contrary to my hypothesis, ABCs showed low expression of all the 
retrotransposons (Figure 5.29.A). 
Donors were separated into disease and healthy control groups, and expression of the 
retroelements assessed (Figure 5.29.B-D). In eRA patients, naïve B cells showed higher 
expression of the retroelements, whereas lower expression was seen in memory B cells and 
ABCs (Figure 5.29.B). In ePsA patients, higher expression was seen in CD5+ B cells and 
ABCs while memory B cells showed lower expression (Figure 5.29.C). In heathy controls, 
higher expression was shown in CD5+ B cells and low expression in memory B cells 
(Figure 5.29.D). 
Expression in each subset comparing the different disease groups and the healthy controls 
was also examined (Figure 5.30). Naïve B cells showed higher expression of retroelements 
in eRA patients, whereas expression in ePsA patients was very low (Figure 5.30.A). In 
memory B cells, high expression was seen in eRA and healthy controls compared to the 
disease controls which showed very low expression (Figure 5.30.B). CD5+ B cells 
exhibited a similar pattern, with higher expression in eRA patients and healthy controls 
compared to disease controls (Figure 5.30.C). Finally, in ABCs, higher expression was seen 
in healthy controls, while eRA and ePsA patients showed low expression of the 





Figure 5. 29. Retroelement expression in the different B cell subsets from all the disease groups as well as the healthy controls. Heat map 
showing expression pattern of the endogenous retroelements. A. Expression of the group of retroelements in the different B cell subsets from all 
the samples, eRA, ePsA and HC. B. Expression of the group of retroelements in the different B cell subsets from only eRA patients. C. Expression 
of the group of retroelements in the different B cell subsets from only ePsA patients. D. Expression of the group of retroelements in the different 
B cell subsets from only healthy controls. For plotting, median log2 expression for each cell population were used. Red indicates higher expression, 




Figure 5. 30 Retroelement expression in the different disease groups and healthy 
controls plotted by B cell subsets. Heat map showing expression pattern of the 
endogenous retroelements. A. Expression of the group of retroelements in the naïve B cells 
from each disease group and healthy control group. B. Expression of the group of 
retroelements in the memory B cells from each disease group and healthy control group. 
C. Expression of the group of retroelements in the CD5+ B cells from each disease group 
and healthy control group. D. Expression of the group of retroelements in the ABCs from 
each disease group and healthy control group. For plotting, median log2 expression for 
each cell population were used. Red indicates higher expression, and blue indicates lower 




In this chapter I examined the transcriptome profile of ABCs and compared them to other 
B cell subsets, as well as assessing differences between arthritic diseases and healthy 
controls. I first optimised a protocol for the sorting of each of the B cell subsets to obtain 
pure populations for the use in the NanoString Technologies gene expression analysis. 
NanoString results showed that ABCs are a distinct B cell population with unique 
transcriptome profile that differs from other B cell subsets. Moreover, ABCs from eRA 
patients differ from those from PsA patients, as well as healthy controls. 
Due to ABCs being found in very low percentages in peripheral blood, I was limited by the 
number of cells I could obtain after sorting, even when using the largest volume of blood I 
could obtain under the project ethics (80ml). The NanoString transcriptomic analysis can 
use RNA or cell lysates as input material. After sorting the highest number of ABCs, which 
was around 20,000 cells, RNA was extracted and quantified. However, the amount of RNA 
extracted from these low number of cells was very low (on average 5ng (data not shown)). 
Because NanoString requires 100ng of purified RNA to run the chip, using such low 
amounts of RNA would result in the loss of low-expressed genes, which could be very 
important for the ABCs characterisation. I, therefore, used a cell lysate approach to run the 
transcriptome analysis. Importantly, for the use of cell lysates, lower numbers of cells are 
needed (between 5,000 and 10,000). This was an advantage when studying rare subsets, so 
I optimised a protocol for the sorting and the preparation of the cell lysates from 15,000 
cells to load on the chip (see Chapter 2, section 2.5.1 for detailed protocol).  
Purity checks were performed in order to make sure that the sorted cells were pure enough 
as contamination with other cells would lead to erroneous results (Figure 5.4). Although 
the percentage of positive cells were about 85% in some subsets such as the ABCs, the 
sorted population was considered pure because the sorted cells had “spread” in terms of 
fluorescence and the gates were not moved to take this into account. It is known that cells 
can appear to change fluorescence slightly during sorting, fluorochromes are excited by the 
flow cytometer sorter and, when they are re-excited during purity checking, their emission 
can vary slightly with reduced fluorescence intensity (Cossarizza et al., 2017). Moreover, 
the cells might also change in terms of morphology after sorting, and the way the population 
appears in the flow cytometry plots can also vary when only sorted cells are plotted. This 
can result in the cells being slightly outside of the original gates. However, due to the efforts 
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made to ensure high purity, like the filtering of the cells right before sorting to ensure a 
single-cell suspension, as well as the use of two excluding doublets gates, purity 
percentages of 85% were taken to indicate pure populations were being sorted. In addition, 
gene expression analysis confirmed that the populations were pure as the markers used to 
sort the cells appeared in the highly expressed gene lists.  
Cytospin slides were prepared for the sorted populations to visualise the different subsets 
of B cells (Figure 5.5). No major differences were seen between the cells, as expected, 
because all subsets are B cells and there are no major differences detectable by light 
microscopy. However, there is a hint that naïve and CD5+ B cells are smaller with less 
cytoplasm (Arce et al., 2001) than memory B cells and ABCs. These results fit with current 
dogma, as memory B cells are larger due to the fact that when they activate, they blast and 
increase protein production and therefore, these cells have a larger cytoplasm (Huggins et 
al., 2007). Because ABCs are phenotypically similar to memory B cells, it was expected 
that they would look similar to the memory B cells. Moreover, previous studies in mice 
reported ABCs as slightly larger and more granular than follicular B cells (Rubtsov et al., 
2011). These findings are confirmed by the cytospin images compared to naïve B cells. No 
differences were seen with memory B cells. However, caution needs to be taken when 
interpreting these results as after sorting, some cells may die or become stressed from the 
process, and the cytospin process itself may cause some additional physical stress. 
Therefore, sorting and cytospins could influence the morphology and appearance of cells. 
Nevertheless, these results further confirm that ABCs resemble memory B cells in terms of 
morphology and appear to be large and granular cells.  
For the gene expression analysis, differences in the expression of 628 genes in the different 
B cell subsets from early drug-naïve RA patients were examined. My results show that 
ABCs are a unique B cell subset, which clusters separately from the rest of the B cell subsets 
analysed (Figure 5.7). Moreover, there is a high number of up and downregulated genes 
between ABCs and the other B cells (Figure 5.8-10). Further analysis of the involved 
pathways reveals some interesting potential roles for ABCs. However, it is important to 
keep in mind that these results are derived from transcriptomic data and gene expression at 
the mRNA level does not always equate to the protein level. There is not always a relevant 
link between mRNA expression and function, which is why transcriptomic analysis is 
usually used as a hypothesis generating tool. Transcriptomics analysis is useful to create an 
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idea of the function and possible role of cells; however, additional functional work is 
needed to confirm the role of ABCs in health and disease. 
Notwithstanding these caveats, the NanoString results show overexpression of some 
interesting genes, some of which have previously been reported in the literature and support 
a relevant role for ABCs in health and disease. Compared to other B cell subsets, ABCs 
show high expression of adhesion molecules such as integrins, as reported before (Isnardi 
et al., 2010; Wang et al., 2018). My results report high expression of alpha and beta 
integrins as well as other adhesion molecules (Figure 5.12). Integrins play a critical role in 
regulating the interaction between a cell and the microenvironment to control cell fate 
(Anderson et al., 2014). Integrins initiate a wide range of changes which result in cells 
attaching to the extracellular matrix and migrating through it to other tissues. Each integrin 
is formed through the non-covalent association of one α-subunit and one β-subunit 
(Harburger and Calderwood, 2009). ABCs showed high expression of the two β-subunits, 
ITGB1 and ITGB2 and the α-subunits, ITGAX, ITGAL and ITGAM. The combination of 
these subunits results in an integrin that can bind different ICAM molecules as well as the 
iC3b complement fragment and fibrinogen. These combinations have been associated with 
leukocyte adhesion and transmigration (Bai et al., 2017). The high expression of adhesion 
molecules by ABCs supports the idea that ABCs might migrate into inflammatory sites, 
like the synovial fluid in RA, which has been shown to have high percentages of these cells 
(see Figure 3.11-12 in Chapter 3 and (Amara et al., 2017)). However, integrin function is 
more complex, and overexpression of integrins does not prove that these molecules will be 
functionally active. It has been reported that most of the integrins expressed on circulating 
leukocytes are found in the inactive or low affinity form, until the ligand triggers signalling 
and adhesion and migration starts (Schittenhelm et al., 2017).  
Interestingly, CD97 expression, another adhesion molecule, was increased in ABCs 
compared to the other B cell subsets (Figure 5.16). This finding is novel and was confirmed 
at the protein level when comparing ABCs to naïve and CD5+ B cells (Figure 5.21). CD97 
is a member of the EGF-TM7 subfamily of G protein-coupled adhesion receptors; it is 
known to mediate cell-cell interactions and play a role in cell adhesion, leukocyte 
recruitment, cell activation and migration to sites of inflammation (Hamann et al., 2010). 
Moreover, CD97 has been shown to be a receptor for several ligands, including CD55 
(Hamann et al., 2016). CD55 is highly expressed by fibroblast-like synoviocytes (FLS) 
located in the lining layer of the synovium and has been shown to interact with CD97-
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expressing macrophages in the rheumatoid synovium (Hamann et al., 1999). Therefore, my 
findings are consistent with the hypothesis that this receptor-ligand interaction results in 
the recruitment and retention of CD97-expressing ABCs in the synovium, perpetuating the 
pro-inflammatory state. I am currently testing this hypothesis with a small grant from the 
JGW Patterson Foundation, a local charity. 
Other differentially expressed pathways included chemokine receptors (Figure 5.12 and 
Figure 5.15). As shown previously, ABCs show low expression of chemokine receptors 
that mediate migration to lymphoid organs (Isnardi et al., 2010; Jenks et al., 2018; Wang 
et al., 2018). My results confirmed these findings with low expression of CXCR4 and 
CXCR5, as well as CCR7, by ABCs. These results were also confirmed at the protein level 
(Figure 5.17-19), supporting the hypothesis that ABCs are not recruited into lymphoid 
organs; ligands for these three receptors, CCL19 and CCL21, are found in high 
concentrations in lymphoid tissues (Mcheik et al., 2019). IL-21, together with IFN-γ, 
induces an ABC-like phenotype in B cells, and also downregulates CXCR4 expression on 
centrocytes from germinal centres (Yoshida et al., 2011). This could explain the low 
expression of this chemokine receptor by ABCs. Conversely, ABCs had high expression 
of the chemokine receptors, CXCR3 and CX3CR1, both at the RNA and the protein level. 
These receptors mediate migration into inflammatory sites. Interestingly, CXCR3+ T-bet+ 
B cells have been reported in other inflammatory diseases, such as multiple sclerosis (van 
Langelaar et al., 2019). These cells were shown to be enriched in different central nervous 
system (CNS) compartments of MS patients. Moreover, this study proved that TLR9 
triggering upregulated T‐bet and CXCR3 and was essential for IgG1 class-switching. This 
could link ABC expression of T-bet and CXCR3 with the TLR9 and TLR7 responsiveness 
of ABCs (Rubtsov et al., 2011; Rubtsov et al., 2013). The CX3CR1 ligand, CX3CL1, is 
expressed on the surface of endothelial cells near inflamed tissues, attracting  CX3CR1+ 
circulating cells (Lee et al., 2018). Interestingly, some studies have shown that CX3CL1 
levels in serum and synovial fluid of patients with RA are higher than in other inflammatory 
arthritides (Blaschke et al., 2003; Yano et al., 2007). These results support the hypothesis 
that ABCs migrate into inflammatory sites and promote disease pathogenesis. 
The NanoString results also showed high expression of TNF and IFN receptors (Figure 
5.12), indicating that ABCs might respond to TNF and IFN stimulation, known to play an 
important role in autoimmune diseases. Moreover, ABCs overexpress IL21R compared to 
memory B cells. Taken together, these findings support the suggestion that ABCs are 
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generated through IL-21 and IFN-γ stimulation (Naradikian et al., 2016b). Moreover, TNF 
is an important pro-inflammatory cytokine, increased in RA synovial fluid, that contributes 
to the inflammation and joint destruction characteristic of RA (Bradley, 2008).  
Interestingly, the ABC transcriptome also showed high expression of genes involved in NK 
cell cytotoxicity, such as granzymes and NK cell receptors (Figure 5.13). Some of the 
granzyme genes and perforin were reported previously by others (Rubtsov et al., 2011). 
However, to my knowledge, this is the first time that NK cell receptors have been described 
in ABCs and B cells. Expression of some of these receptors outside the NK cell linage, 
such as the KIRs (Killer-cell Inhibitory Receptors), has been reported in a subset of 
activated CD8+ T cells (Moretta et al., 1996). These cells had a memory phenotype and the 
expression of KIRs inhibited TCR mediated functions (Mingari et al., 1998). Expression 
of the other overexpressed NK receptors, Killer Lectin-like Receptors (KLR), has also been 
reported in a subset of CD8+ T cells and that study showed that these receptors serve as an 
alternative pathway for cytotoxic T lymphocyte activation (Guma et al., 2005). These 
results are of interest as ABCs are known to be unresponsive to BCR stimulation, and KIRs 
and KLRs on ABCs could provide an alternative activation pathway. Granzyme B and 
perforin expression could not be validated at the protein level (Figure 5.22-23). It is well 
known that RNA levels do not always correlate to protein expression levels (Liu et al., 
2016), as regulatory mechanisms can prevent RNA translation into protein. It is possible 
that ABCs express high RNA levels for these cytotoxic proteins but require a danger or 
activation signal to trigger protein translation. Nevertheless, granzyme B expression 
showed around 10-25% of positive cells, depending on the B cell subset (Figure 5.22). 
These percentages are surprisingly high and could be due to the intracellular staining 
increasing cells autofluorescence and producing a slight shift of the population that was not 
corrected when setting the gate based on the FMO. These results showing high expression 
of NK cell markers that could not be proven at the protein level, led me to consider that an 
NK cell contamination could have happen during sorting. However, this is improbable 
because although NK cells express CD11c and lack CD21 (like ABCs) they do not express 
CD19 and they would not be present in the B cell population used to then gate the ABCs 
as CD19+ CD11c+ CD21low B cells.  
Finally, ABCs showed high expression of genes related to apoptosis (Figure 5.13), such as 
FAS and caspases, as well as inhibitory receptors (Figure 5.14), such as FCGR and LILRB, 
raising the hypothesis that these cells are refractory to BCR activation and could be an 
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anergic and exhausted B cell subset. ABCs have been reported as an exhausted B cell subset 
by other groups (Isnardi et al., 2010). Moreover, high expression of apoptosis related genes 
supports the hypothesis that these cells might exhibit defective cell survival. Additionally, 
ABCs show low expression of genes involved in protection against complement-mediated 
cell lysis, such as CD59 and the complement receptors CR1 and CR2 (CD21). Thus, these 
cells may be more susceptible to complement lysis and reinforces their susceptibility to cell 
death (Karnell et al., 2017).  
Gene expression in ABCs from different diseases and healthy controls was also assessed 
(Figure 5.24-28). As disease controls, drug naïve patients newly diagnosed with PsA were 
recruited. PsA was chosen as a disease control because it is also an autoimmune disease 
which causes joint destruction and loss of function (Gladman, 2015). PsA is also a good 
disease control because its pathogenesis differs from RA. In PsA the HLA alleles associated 
with the disease are from the MHC class I complex rather than MHC class II as in RA 
(Merola et al., 2018). Moreover, most PsA patients are seronegative for autoantibodies. 
There were no differences between RA patients, PsA patients and healthy controls in terms 
of age and sex. The only significant difference, as expected, was in autoantibody 
seropositivity, as all RA patients recruited were double positive for RF and ACPA and the 
PsA patients were all seronegative.  
Upregulated genes in early RA compared to both control groups, showed enrichment for 
leukocyte activation and migration (CD6), NK cell cytotoxicity (KIRs and KLRs) and IL-
13 signalling (IL13RA1 and IL4R) (Figure 5.27). Because these genes are upregulated in 
RA only, they could represent a RA specific gene signature only found in ABCs from RA 
patients. Notably, the two upregulated genes IL13RA1 and IL4R form a functional receptor 
for IL-13 (Murata et al., 1998). Moreover, genetic variants in the IL4R gene in RA have 
been linked to increased joint damage (Krabben et al., 2013). IL-13 has been shown to be 
increased in synovial fluid in patients with early RA compared to established RA patients 
and other inflammatory arthritides (Raza et al., 2005). Another study showed that IL-13 
decreased the production of pro-inflammatory cytokines by synovial fluid mononuclear 
cells (Isomaki et al., 1996). Although it has not been reported before, ABCs from RA 
patients may respond to the cytokines IL-4 and IL-13. However, these results are potentially 
inconsistent with studies that show that IL-4 antagonises expression of T-bet by B cells 
(Naradikian et al., 2016b). 
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Differentially expressed genes were also detected in early RA and PsA patients compared 
to healthy controls (Figure 5.27). STAT3-inducible genes like BCL3 and SOCS3 were 
upregulated. Interestingly, previous work in our group defined a CD4+ T cell gene 
signature which implicates interleukin 6-mediated STAT3 signalling in early RA (Pratt et 
al., 2012; Anderson et al., 2016; Anderson et al., 2019). Both BCL3 and SOCS3 were 
upregulated in CD4+ T cells from patients with early RA compared to other arthritic 
diseases. In contrast, my results show upregulation of these genes in ABCs from both RA 
and PsA patients compared to healthy controls. This discrepancy could reflect the 
examination of different cells (ABCs vs CD4+ T cells), or the inclusion of a healthy control 
group in my study. Intriguingly, downregulated genes included inhibitory receptors such 
as FcRL4, LAIR1 and LILRA4 (Figure 5.28). These receptors are usually associated with 
dampening of BCR signalling (van der Vuurst de Vries et al., 1999; Sohn et al., 2011). 
High expression of inhibitory receptors such as FCGR2B and LILRBs has been reported in 
ABCs before (Karnell et al., 2017), consistent with my results. My supervisor in 
Birmingham, Professor Dagmar Scheel-Toellner, characterised a subset of B cells with high 
expression of FcRL4 in the synovial fluid of patients with RA (Yeo et al., 2015), whereas 
I have found lower expression of FcRL4 in ABCs from patients with RA and PsA compared 
to HCs. This could reflect differences in the tissue studied (peripheral blood vs synovial 
fluid). For example, FcRL4 high cells may have higher migration capacity towards 
inflamed joints, with FcRL4 low B cells remaining in peripheral blood B cells. Also, the B 
cells studied by Dagmar are not identical to ABCs in other characteristics. However, it is 
interesting that these inhibitory receptors are downregulated in inflammatory arthritic 
diseases compared to healthy controls. This would reinforce the hypothesis that in 
inflammatory conditions these cells might be more pathogenic due to downregulation of 
inhibitory mechanisms. 
Retroviral expression analysis disproved the hypothesis that ABCs from RA patients have 
higher retroviral expression, which could have activated them via TLR7. Previous work 
from our group found higher expression of all six retrotransposons in B cell and CD4+ T 
cell populations in eRA compared to CD14+ monocytes, plasmacytoid DCs and myeloid 
DCs (Cooles et al., unpublished results). However, when B cells from eRA patients were 
split into subsets, the highest expression of these retroelements was seen in the naïve and 
CD5+ B cell subsets (Figure 5.30). Expression of retroelements in ABCs and memory B 
cells was low. These results are consistent with the fact that a high proportion of peripheral 
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blood B cells are naïve B cells (Perez-Andres et al., 2010). The percentage of ABCs in 
peripheral blood is very low and their gene expression would be masked by that of more 
abundant subsets. Previous work reported that retroelements are strongly induced during B 
cell activation (Kassiotis and Stoye, 2016; Attig et al., 2017). This is not in line with my 
results as memory B cells, which are activated cells, had low expression of the endogenous 
retroviruses. It is possible, however, that expression of retroelements is transient upon B 
cell activation. ABCs from healthy controls showed higher expression of retroviral 
elements than eRA and ePsA patients. Previous studies in MS showed high expression of 
two human endogenous retrovirus (HERVs) envelop proteins in this neurological and 
autoimmune disease (Brudek et al., 2009). In contrast with my data, these two viral proteins 
were detected at higher levels in peripheral blood B cells of patients with active MS 
compared to healthy controls and other neurological controls. Some studies have described 
expression of LINE retroelements in RA synovial fluid and synovium (Neidhart et al., 
2000; Ali et al., 2003). However, expression of retroelements in RA synovial fluid B cells 
has not been assessed specifically and it may be a more informative tissue than peripheral 
blood B cells.      
A major consideration, with regard to my findings, is the small sample size used. Only 4 
individuals per group were recruited due to the need for age-matched healthy controls, and 
the isolation of sufficient numbers of subsetted B cells for analysis. Due to the high 
heterogeneity present in RA, high sample sizes are often needed to overcome individual 
variability, which needs to be recognised when studying my data. 
It is currently unclear whether the ABC subset is anergic or if it plays an important role in 
autoimmunity and disease pathogenesis. Gene expression analysis is consistent with ABC 
being a hyporesponsive B cell subset, although the high expression of activation markers, 
adhesion molecules and chemokine receptors, supports these cells playing an important 
role in inflammation and autoimmunity. Further functional studies are still needed to 





In this chapter, I optimised a protocol for sorting different B cell subsets to obtain pure 
populations. This allowed me to assess the expression of 628 gene using the NanoString 
Technology nCounter. The transcriptome of ABCs was compared to other B cell subsets. 
Moreover, I examined gene expression of ABCs from patients suffering from early RA and 
compared it to the ABC transcriptome in early PsA and age-matched healthy controls. 
Purity checks were performed in order to ensure that sorted populations contained the 
correct subset of B cells. Due to the limiting number of ABCs, cell lysates rather than 
mRNA were used as the input material for hybridisation chips used in NanoString analysis.  
Gene expression analysis of ABCs compared to other B cells revealed a different 
population of B cells with a unique transcriptome, enriched for adhesion molecules, such 
as integrins, chemokine receptors involved in leukocyte recruitment to sites of 
inflammation, and NK cell cytotoxicity enzymes and receptors. This supports the 
hypothesis that ABCs migrate to sites of inflammation, such as the synovium in RA 
patients, where they may promote disease pathogenesis. However, ABCs also displayed 
high expression of apoptosis molecules such as caspases, and inhibitory receptors like 
LILRs. These data reinforce previous findings that ABCs might be an exhausted and 
anergic B cell subset, unable to respond to BCR stimulation and prone to die by apoptosis. 
In addition, a few genes, such as KLRs, were differentially expressed in ABCs from eRA 
patients compared to ePsA and HCs. Other genes were also up or downregulated in eRA 
ABCs compared to the control groups, potentially highlighting them as RA specific genes; 
others were differentially expressed in both arthritic diseases compared to healthy controls, 
potentially suggesting an inflammation related signature. However, my small sample size 
means that this work must be viewed as preliminary and hypothesis generating; a bigger 
sample size would provide more definitive information on the role of ABCs in health and 
disease. 
In summary, ABCs are a novel B cell subset which shows a unique transcriptome profile. 
My analysis indicates that these cells may migrate to sites of inflammation. However, 









In addition to the characterisation of ABCs surface phenotype and gene expression, I aimed 
to investigate the role of these cells through functional studies.  
Studies in mice demonstrated that when ABCs were stimulated by a TLR7 agonist, they 
produced similar levels of IgM as other B cell subsets, but also produced higher levels of 
IgG (Rubtsov et al., 2013; Rubtsova et al., 2017). This IgG recognised chromatin, 
suggesting that ABCs may be a source of autoantibodies. Interestingly, simultaneous 
stimulation with TLR and BCR ligation produced the strongest response, resulting in 
extensive division and high numbers of responding cells (Hao et al., 2011). Moreover, these 
ABCs preferentially expressed IL-4 and IL-10 after TLRs stimulation as assessed by qPCR 
and polarised T cells towards a Th17 response. Studies in mice also showed that generation 
of CD11c+ T-bet+ B cells required TLR engagement together with a specific cytokine 
network (Naradikian et al., 2016b). In the absence of IFN-γ signalling, the ratio between 
IL-4 and IL-21 determines B cell expression of CD11c and T-bet, with low IL-4 and 
presence of IL-21 driving this expression. So, the generation of ABC-like B cells in 
autoimmunity and viral infection would depend on TLR engagement together with 
abundant IFN-γ and IL-21 in absence of IL-4. 
In humans only a few studies have investigated the functional role of ABC-like cells of a 
similar phenotype (CD21low B cells). Some studies showed that these CD21low B cells 
were unable to activate, proliferate and secrete antibodies after BCR triggering (Isnardi et 
al., 2010). Moreover, these cells were prone to die by apoptosis. In line with these results, 
another study found that CD21low CD86+ B cells have impaired BCR-induced signalling, 
as there was no calcium release detected when the BCR was cross-linked (Shimabukuro-
Vornhagen et al., 2017). Although these cells have been shown to be unresponsive to BCR 
and CD40 signalling, their responses were not globally impaired. In some autoimmune 
diseases, these cells have been shown to be responsive to TLR7-8 signalling in conjunction 
with other stimulatory signals such as BCR and IL-2 stimulation (Thorarinsdottir et al., 
2016). Overall, these studies suggest that instead of being unresponsive and anergic, these 
ABC-like cells might exhibit a different response profile, depending on a very specific 
cytokine milieu, than conventional naïve and memory B cells. Additionally, studies in SLE 
patients show that CD11c+ B cells were poised to become plasma cells after T cell 
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activation and had very high secretion of autoantibodies compared to memory B cells 
(Wang et al., 2018).  
Moreover, the FcRL4+ synovial fluid B cell subset with a similar phenotype as ABCs was 
shown by qPCR to produce RANKL and TNF-α (Yeo et al., 2015). These two cytokines 
are known to stimulate the differentiation and activation of osteoclasts, suggesting a 
potential role for FcRL4+ B cells in RA pathogenesis. 
However, there is a lack of studies investigating the cytokines secreted by ABC-like B 
cells. Some mice studies showed ABCs to preferentially secrete IL-4 and IL-10 after TLR7 
or TLR9 stimulation (Hao et al., 2011), and TNF-α after TLR4 stimulation (Ratliff et al., 
2013). For all that, studies of cytokine secretion after combined TLR and cytokine 
stimulation are needed to further investigate the role of ABCs in health and disease.  
Therefore, I sorted and cultured blood ABCs from patients and controls and assessed 
phenotype cell marker expression, cytokine production, and immunoglobulin secretion.   
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6.2 Chapter hypothesis and aims 
In this chapter I hypothesised that ABCs are a responsive B cell subset capable of producing 
proinflammatory cytokines as well as immunoglobulins in response to a B cell stimulation 
cocktail. Because I hypothesised that ABCs are antigen-experienced B cells and may 
already be class-switched, the aim was to assess the effect a potent B cell stimuli had on 
these cells. 
Therefore, the aims of this chapter were to: 
1. Determine if ABCs show a different cytokine and immunoglobulin production 
profile than other B cell subsets after potent B cell stimulation. 
2. Determine if ABCs from established RA patients respond differently to stimuli 
compared to those from age-matched healthy controls.  
The specific objectives were: 
1. Optimise the culturing conditions for the B cell subsets’ stimulation assays. 
2. Optimise a protocol for the sorting of the B cell subsets that reduced the sorting 
time.  
3. Characterise the phenotype of ABCs compared to other B cell subsets after potent 
stimulation. 
4. Determine the cytokine secretion profile of ABCs compared to other B cells. 
5. Compare the cytokine secretion profile in established RA patients and healthy 
controls. 
6. Determine the immunoglobulin production by ABCs and other B cell subsets. 






All the work completed in Chapter 5 – on ABCs RNA expression profiling was done by 
sorting B cells from PBMCs. The sorting time from total PBMCs was very long, therefore 
the cells were exposed to potentially high levels of stress resulting in high cell death. 
Because the cells were to be used in functional studies the stress the cells were placed under 
needed to be kept to a minimum to try and keep the cells healthy and viable. Therefore, a 
protocol was optimised to reduce the sorting time and keep it to a minimum. This was 
achieved by depleting all the CD3+ cells from the PBMCs fraction using a CD3 MicroBead 
Kit (Miltenyi Biotech, Germany). 
Briefly, PBMCs were isolated from EDTA blood using Lymphoprep (Axis-Shield 
Diagnostics Ltd, UK). T cells were then depleted using the positive selection CD3 
MicroBeads (see Chapter 2 Methods section 2.2.1 for more detail). Because B cells are 
found in the CD3- fraction, this fraction was then stained for surface antibodies and 
live/dead dye and sorted on the BD FACSARIA II (Becton Dickinson, NJ, USA). The 
antibodies used to identify each subset are shown in Table 2.6 in Chapter 2. 
Four populations of interest were sorted into 300µl of RF10: ABCs 
(CD19+CD11c+CD21), CD5+ cells (CD19+ CD5+), naïve B cells (CD19+IgD+CD27-) 
and memory B cells (CD19+IgD-CD27+). The sorting strategy is shown in Figure 6.1. 
After excluding dead cells and doublets using two doublet gates, lymphocytes were gated 
using SSC-A vs FSC-A. From the lymphocyte gate, B cells were gated using CD19 vs 
CD3/CD33, therefore excluding any remaining T cells and dendritic cells. From the B cell 
gate, the ABCs were gated using CD11c vs CD21 expression. From the rest of the cells, 
CD5+ cells were gated using CD5 and CD19 expression. Finally, from the CD5- fraction, 
naïve (IgD+CD27-) and memory (IgD-CD27+) B cells were gated. 
After sorting, cells were counted using a Burker counting chamber (Sigma-Aldrich, MO, 
USA). Cells were then centrifuged and each cell type was cultured at a density of 20,000 
cells per well in 96-well round-bottom plates in a final volume of 200µl of medium. At 
initiation of culture, B cells were stimulated with a combination of TLR7 ligand 
Imiquimod, TLR9 agonists ODN 2216 – CpG A and ODN 2006 – CpG B, Poke Weed 
Mitogen, anti-CD40, human IL-21, human IL-4 and IFN-gamma. B cells were cultured for 
5 days at 37°C with 5% CO2 prior to examination by flow cytometry. Supernatants were 




Figure 6. 1. Gating strategy for the sorting of each B cell subset from the CD3- fraction. Example of the gating strategy used to sort the B cell 
populations for the functional work. After excluding dead cells and doublets twice, lymphocytes were gated using SSC-A vs FSC-A. From the 
lymphocyte gate, B cells were gated using CD19 vs CD3/CD33. From the B cell gate, the ABCs were gated using CD11c vs CD21. From the rest 





6.4.1 Optimisation of the culture volume for sorted B cells 
For the functional work I was limited by the small numbers of ABCs in peripheral blood. 
Therefore, the plate chosen to culture the cells in was a 96-well round-bottom plate. A 
round bottom plate was chosen over a flat plate because in the round bottom plate the cells 
are forced closer together to the centre of the well and this is better when working with 
small number of cells. However, the final volume to culture the cells needed to be 
optimised. I tested two different culture volumes, 100µl and 200µl. For this, I sorted 
memory and naïve B cells and cultured the same number of cells, 20,000, in the two 
volumes with and without the stimulation cocktail. After 6 days, the cells were harvested 
and their viability was assessed. In addition, the culture supernatants were stored for 
quantification of IgG production by ELISA. IgG production was chosen over other 
cytokines as all memory B cells after stimulation are known to secrete class-switched 
immunoglobulins like IgG. Figure 6.2 shows the results for the memory B cells only. The 
results from the naïve B cells were not informative as the majority of the cells were dead 
by day 6 and stimulation for 6 days is not enough for the cells to class switch and produce 
IgG (data not shown). As shown in Figure 6.2.A, there is a trend for more reproducible and 
higher percentages of live cells in the stimulated memory B cells when cultured in 200µl 
compared to 100µl. Moreover, IgG production is also slightly higher and more reproducible 
in the 200µl volumes of stimulated cells compared to the smaller culture volume. Although 
being double the volume, IgG production was easily detected in the 200µl cultures, and 
counterintuitively the concentration detected in the 200µl cultures was not half the 
concentration detected in the 100µl cultures (Figure 6.2.B). Thus, memory B cells seem to 
be more viable and healthier and produce more consistent, reliable results in the 200µl 





Figure 6. 2. Effect of culture volume on cell viability and IgG production. 20,000 sorted 
memory B cells were plated in a final volume of 100µl or 200µl culture medium and either 
left unstimulated or stimulated with a cocktail of stimuli for 6 days. The stimuli cocktail 
contained TLR7 ligand Imiquimod, TLR9 agonists ODN 2216 – CpG A and ODN 2006 – 
CpG B, Poke Weed Mitogen, anti-CD40, human IL-21, human IL-4 and IFN-gamma. 
Unstimulated cells are shown in the filled bars and stimulated in the pattern bars. A. 
Percentage of live cells assessed by Zombie Aqua staining and flow cytometry. B. 
Immunoglobulin G production measured by ELISA from supernatants. No statistical test 
was performed due to low number of repeats; n = 2, mean values with SEM shown.        
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6.4.2 Optimisation of the number of cells cultured for the functional work 
Due to very small numbers of ABCs in peripheral blood, the number of cells used for the 
functional assays cell cultures needed to be the minimum which would still produce 
detectable cytokines and immunoglobulins. Following, the protocol in section 6.3, I sorted 
memory and naïve B cells and plated two different numbers of cells, 10,000 and 20,000 
cells. I then cultured the cells with and without stimulation in a 200µl culture volume for 6 
days. As described before, the majority of the naïve B cells died after 6 days, so only the 
results for the memory B cells are shown (Figure 6.3). There was no difference in the 
percentage of live cells in the 20,000 cells groups stimulated compared to the 10,000 cells 
(Figure 6.3.A). In terms of IgG production, there was also no clear difference between the 
20,000 stimulated cells compared to the culture containing 10,000 cells (Figure 6.3.A). 
However, the higher number of cells (20,000) enabled the detection of small concentration 
of spontaneous IgG production in the unstimulated cells. Consequently, cultures of 20,000 
cells were chosen as it would give increased confidence that production of cytokine and 
immunoglobulin would be within the detection range, and at the same time I would have 
sufficient numbers of ABCs to include both unstimulated and stimulated conditions.  
 
Figure 6. 3. Effect of the number of cultured cells on cell viability and IgG production. 
Two different numbers of memory B cells, 10,000 cells and 20,000 cells, were plated and 
either left unstimulated or stimulated with a cocktail of stimuli for 6 days. The stimuli 
cocktail contained TLR7 ligand Imiquimod, TLR9 agonists ODN 2216 – CpG A and ODN 
2006 – CpG B, Poke Weed Mitogen, anti-CD40, human IL-21, human IL-4 and IFN-
gamma. Unstimulated cells are shown in the filled bars and stimulated in the pattern bars. 
A. Percentage of live cells assessed by Zombie Aqua staining and flow cytometry. B. 
Immunoglobulin G production measured by ELISA from supernatants. No statistical test 
was performed due to low number of repeats; n = 2, mean values with SEM shown.  
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6.4.3 Optimisation of the culture time for the functional work 
The culturing time also needed to be optimised. Due to small numbers of ABCs, it was not 
possible to include different time points for the functional work. I therefore tested 
incubating naïve and memory B cells for 3 days or for 6 days. Following on from the 
previous optimisation experiments, naïve and memory B cells were sorted, and 20,000 cells 
were plated in a 200µl volume. As before, I used an unstimulated and a stimulated 
condition. Only memory B cells results are shown (Figure 6.4). The results from the naïve 
B cells were not informative as the majority of the cells were dead by day 6. The percentage 
of live cells, as expected, was higher after 3 days of culture compared to 6 days, especially 
in the stimulated B cells (Figure 6.4.A). By day 6, most of the unstimulated cells had died, 
but the stimulated conditions still had a reasonably high percentage of viable cells. In terms 
of IgG detection as a functional readout, by day 3 there was some IgG production following 
stimulation (Figure 6.4.B). Nevertheless, after 6 days, the detectable concentration of 
secreted IgG was doubled in the stimulated cells. Due to the higher detectable 
concentrations of IgG by day 6, this time point was chosen over the day 3 time point. 
However, due to clinic and sample time restrictions, this time point was unfeasible 
therefore, the final incubation time for the functional work was chosen as 5 days.  
 
Figure 6. 4. Effect of the incubation time on cell viability and IgG production. 20,000 
memory B cells were either left unstimulated or stimulated with a cocktail of stimuli for 3 
or 6 days. The stimuli cocktail contained TLR7 ligand Imiquimod, TLR9 agonists CpG A 
and CpG B, Poke Weed Mitogen, anti-CD40, human IL-21, human IL-4 and IFN-gamma. 
Unstimulated cells are shown in the filled bars and stimulated in the pattern bars. A. 
Percentage of live cells assessed by Zombie Aqua staining and flow cytometry. B. 
Immunoglobulin G production measured by ELISA from supernatants. No statistical test 
was performed due to low number of repeats; n = 2, mean values with SEM shown.  
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6.4.4 Sorting B cell subsets from a pre-enriched B cell population 
In order to get the maximum number of ABCs, a large number of PBMCs had to be isolated 
and sorted. This resulted in very long sorting hours, which in addition to being expensive, 
also had the potential to impact on cell viability and quality. In order to reduce the sorting 
time to enable the isolation of viable and healthy cells, I tested a method of sorting from 
previously enriched B cell population. I isolated PBMCs from the blood of a single donor 
and then split them in half: One half was used to enrich for B cells using Miltenyi MACS 
CD19 MicroBeads; the other half was left as PBMCs. Both populations were then stained 
using my pre-optimised B cell sorting panel and naïve and memory B cells were sorted 
from each cell preparation. Sorted naïve and memory B cell populations from cell 
preparations were incubated with and without stimulation. After 6 days, the cells were 
harvested and their viability and phenotype was assessed. In addition, the culture 
supernatants were stored for quantification of IgG production by ELISA.  
Figure 6.5.A shows the percentage of live cells in the naïve and the memory subsets when 
cells were sorted from either isolated PBMCs or pre-enriched CD19+ B cells. As expected, 
the percentage of live cells in the naïve B cell subset, irrespective of the isolation technique, 
is low, especially when the cells were left unstimulated. However, for the stimulated naïve 
B cell condition, cells sorted from the pre-enriched CD19+ B cells had a particularly low 
percentage of live cells compared to the corresponding cells sorted from PBMCs. A similar 
trend is seen for the memory B cells, although these had a much higher proportion of live 
cells than in naïve B cells, the difference between the two isolation techniques was minimal 
(Figure 6.5.A). An informative phenotypic marker which seem to be altered between the 
two isolation techniques was the co-stimulatory molecule CD40 (Figure 6.5.B). Because I 
used an anti-CD40 antibody in the stimulation cocktail, CD40 appears to be downregulated 
in the stimulated conditions. However, in the unstimulated cells sorted from pre-enriched 
CD19+ B cells, CD40 seems to be greatly downregulated, especially in the naïve B cells 
(Figure 6.5.B). In terms of IgG production, only the results from the memory B cells are 
shown, as there was no detectable IgG production by the naïve B cells from any condition 
(data not shown). IgG production is slightly higher in stimulated memory B cells sorted 
from PBMCs compared to those sorted from pre-enriched CD19+ B cells (Figure 6.5.C). 
Similar concentrations of IgG are detected in both isolation techniques for the unstimulated 
memory B cells.  
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Taken together, these data suggest that pre-enriching CD19+ B cells using CD19 
MicroBeads by positive selection may have an effect on B cell function, as expression of 





Figure 6. 5. Effect of sorting naïve and memory B cells from PBMCs compared to pre-enriched CD19+ cells on B cell function. Naïve and 
memory B cells were sorted using two different input populations, PBMCs or pre-enriched CD19+ B cells. Cells were cultured with or without 
stimulation for 6 days. The stimuli cocktail contained TLR7 ligand Imiquimod, TLR9 agonists CpG A and CpG B, Poke Weed Mitogen, anti-
CD40, human IL-21, human IL-4 and IFN-gamma. A. Percentage of live cells assessed by Zombie Aqua staining and flow cytometry in naïve and 
memory B cells sorted using both isolation techniques. B. Percentage of CD40 expressing cells determined by flow cytometry in naïve and memory 
B cells sorted using the two different isolation techniques. The gate was set from the lymphocyte population. C. Immunoglobulin G production 





6.4.5 Sorting B cell subsets from a CD3-depleted PBMC population 
In view of the above results that showed that cultured B cells are potentially altered, for 
example in terms of CD40 expression, when comparing cells sorted from PBMCs or from 
pre-enriched CD19+ B cells isolated using a positive selection method, I decided to try an 
alternative approach. This involved depleting PBMCs of CD3+ cells using Miltenyi MACS 
CD3 MicroBeads. By depleting the CD3+ cells from the PBMCs, a mix of B cells, NK 
cells and DCs will remain, with B cell accounting for a large proportion of the remaining 
cells. This significantly reduces the number of cells that need to be sorted, thus reducing 
the time, and also leaves the B cells untouched by MicroBeads. Therefore, I isolated 
PBMCs from the blood of a single donor and split them: One half was used to deplete CD3+ 
cells using the CD3 MicroBeads; and the other was left as PBMCs. Both populations were 
then stained using my pre-optimised B cell sorting panel, and naïve and memory B cells 
were sorted from each cell preparation. Sorted naïve and memory B cell populations from 
both cell preparations were incubated with and without stimulation. After 6 days, the cells 
were harvested and their viability and phenotyped was assessed. In addition, the culture 
supernatants were stored for quantification of IgG production by ELISA.  
Figure 6.6.A shows the percentage of live cells in the naïve and memory subsets when cells 
were sorted from either isolated PBMCs or from CD3-depleted PBMCs. Although the 
percentage of dead cells in the naïve B cells was high, there was no differences between 
the two different starting cell preparations. Memory B cells showed higher percentages of 
live cells than naïve B cells, as expected, and again, there were no differences when cells 
were sorted from the two different starting cell preparations. With regard to CD40 
expression, unlike naïve B cells sorted from pre-enriched CD19+ B cells (Figure 6.5.B), 
there was no difference in CD40 expression between cells sorted from PBMCs or CD3-
depleted PBMCs (Figure 6.6.B). There were also no differences in CD40 expression for 
the memory B cells. As explained before, in the stimulated conditions there is an apparent 
downregulation of CD40 because these cells were stimulated with an anti-CD40 antibody. 
Lastly, in terms of IgG production by the memory B cells (data for the naïve not shown due 
to low levels of production), there are no differences between the secretion of IgG by 
memory B cells sorted from PBMCs or CD3-depleted PBMCs (Figure 6.6.C).  
Taking all of these results into consideration, for the functional work presented in the rest 
of this chapter, the four B cell subsets of interest (naïve B cells, memory B cells, CD5+ B 
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cells and ABCs) were sorted from CD3-depleted PBMCs. This reduced the sorting time of 




Figure 6. 6. Effect of sorting naïve and memory B cells from PBMCs compared to CD3-depleted PBMCs on B cell function. Naïve and 
memory B cells were sorted using two different input populations, PBMCs or CD3-depleted PBMCs. Cells were cultured with or without 
stimulation for 6 days. The stimuli cocktail contained TLR7 ligand Imiquimod, TLR9 agonists CpG A and CpG B, Poke Weed Mitogen, anti-
CD40, human IL-21, human IL-4 and IFN-gamma. A. Percentage of live cells assessed by Zombie Aqua staining and flow cytometry in naïve and 
memory B cells sorted using both isolation techniques. B. Percentage of CD40 expressing cells determined by flow cytometry in naïve and memory 
B cells sorted using the two different isolation techniques. The gate was set from the lymphocyte population. C. Immunoglobulin G production 




6.4.6 Patients cohorts 
Once the protocol for sorting and culturing the B cell subsets was optimised, I started 
recruiting patients with established RA, as well as age-matched healthy controls. 
Established RA patients were double positive for RF and anti-CCP antibodies. These 
patients were receiving DMARD therapy but were not on any biological treatment. Healthy 
controls were age-matched volunteers from the lab who had no previous history of 
rheumatological or autoimmune disease. Demographic data is shown in Table 6.1. Patient 
and healthy control demographic data demonstrated no significant differences in the age 









Number 5 4 - 
Age (years; median 
and range) 
57.2 (31 - 72) 56 (50 – 62) 0.7# 
Percentage of 








CCP+ or RF+ 





Table 6. 1. Demographic characteristics for the cohorts used for functional work. 
Flow cytometry cell sorting and B cell culture was performed on two cohorts; RA 
patients, n = 5 and healthy controls, n = 4, for the functional characterisation of ABCs. # 




6.4.7 ABCs are less responsive to stimulation and die easily 
Viability analysis of the four B cell subsets after 5 days of culture showed that for the 
unstimulated conditions, almost all cells, no matter which B cell subset, die (Figure 6.7). 
For the stimulated conditions, a small percentage of cells in the naïve and the CD5+ 
populations survive the 5 day culture. As expected, memory B cells showed a high 
percentage of live cells (~60% average) after stimulation for 5 days (Figure 6.7.A). 
Surprisingly, although ABCs are phenotypically similar to memory B cells, the percentages 
of live cells in the ABC cultures from both established RA patients and healthy controls 
after stimulation for 5 days was low (~20% average) (Figure 6.7.A). The number of live 
cells in the ABC population was even lower than for the stimulated naïve and CD5+ B cells 
(~30% average for both) (Figure 6.7.A), suggesting that ABCs are potentially more 
susceptible to cell death or may be unresponsive to stimulation, resulting in fewer live cells.  
Viability analysis of each of the four B cell subsets, separately, from established RA 
patients and healthy controls showed no differences in the percentage of live cells either 
unstimulated or stimulated in CD5+ B cells, naïve B cells and memory B cells between the 
RA patients and the healthy controls (Figure 6.7.B-C and E). However, unstimulated 
memory B cells from established RA patients showed significantly higher percentages of 





Figure 6. 7. Percentage of live cells in sorted and cultured B cell subsets from established RA patients and healthy controls. The four 
populations of interest, CD5+ B cells, naïve B cells, memory B cells and ABCs were sorted from CD3-depleted PBMCs. From each subset, 20,000 
cells were cultured with or without stimulation (Imiquimod, CpG A, CpG B, PWM, anti-CD40, IL-21, IL-4 and IFN-γ) for 5 days. Cells were 
harvested and percentage of live cells was determined by flow cytometry using Zombie Aqua staining. A. Percentage of live cells in sorted cells 
from established RA patients are (n= up to 5). Statistical significance was assessed using a Kruskal-Wallis test (p=0.0003) with Dunn’s multiple 
comparisons of the two conditions in each B cell subset; **p < 0.01. B-E. Percentage of live cells in each sorted and cultured B cell subset from 
established RA patients (n= up to 5), shown as circles and healthy controls (n= up to 4), shown as squares. Statistical significance was assessed 
using a Fit Least Squares comparing RA patients and healthy controls in each B cell subset; *p < 0.05.
230 
 
6.4.8 Phenotypic characterisation of B cell subsets after stimulation  
Expression of certain markers previously used for the phenotypic characterisation of ABCs 
were used to assess responses of each B cell subset to stimulation. As expected, a large 
proportion of all B cell subsets from established RA patients express the antigen 
presentation MHC class II molecule, HLA-DR (Figure 6.8.A-B). Generally, levels of HLA-
DR increased after stimulation in all the B cells subsets from established RA patients 
(Figure 6.8.C), however, this increase was more pronounced in the naïve and the CD5+ B 
cell subsets (Figure 6.8.B-C). Interestingly, there was a trend for increased percentages of 
HLA-DR positive cells, and especially HLA-DR expression, as measured by MFI, in 
healthy controls compared to established RA patients in CD5+, naïve and memory B cells, 
both unstimulated and stimulated (Figure 6.9.A-B). Stimulated ABCs from healthy controls 





Figure 6. 8. Expression of HLA-DR in unstimulated or stimulated sorted B cell subsets from established RA patients. Sorted cells from 
established RA patients were incubated with or without stimulation (Imiquimod, CpG A, CpG B, PWM, anti-CD40, IL-21, IL-4 and IFN-γ) for 5 
days. The cell phenotype was then assessed by flow cytometry. A. HLA-DR expression overlay histograms for each B cell subset and stimulation 
condition. CD5+ B cells are shown in orange, naïve B cells are shown in red, memory B cells in purple and ABCs in blue. The peaks are normalised 
to the same height to standardise for different numbers of cells in each population. B. Percentage of HLA-DR positive cells in the B cell subsets. 
The bar represents the median. Gates were set using an unstained sample. C. HLA-DR median fluorescence intensity (MFI) in the different B cell 
subsets. The bar represents the median. N = up to 5. Statistical significance was assessed using a Kruskal-Wallis test (p=0.0002 for B, p=0.0019 




Figure 6. 9. Expression of HLA-DR in unstimulated or stimulated sorted B cell subsets from established RA patients and healthy controls. 
A. Percentage of HLA-DR positive cells in the B cell subsets. The bar represents the median. Gates were set using an unstained sample. B. HLA-
DR median fluorescence intensity (MFI) in the different B cell subsets. The bar represents the median. Established RA patients (n= up to 5) are 
shown as circles and healthy controls (n= up to 4) are represented with squares. Statistical significance was assessed using a Fit Least Squares 
comparing RA patients and healthy controls in each B cell subset; **p < 0.01, *** p < 0.001, **** p < 0.0001. 
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Expression of CD86, another co-stimulatory molecule, which is known to be upregulated 
on B cells after stimulation was investigated next. The percentage of CD86 positive cells 
in the unstimulated cells for all the B cell subsets was quite low, particularly in the naïve B 
cells and the CD5+ B cells (Figure 6.10.A-B). In keeping with my findings in Chapter 4 
(Figure 4.5), memory B cells and ABCs had higher percentages of CD86 positive cells than 
the other two B cell subsets (Figure 6.10.B). After stimulation, CD86 expression is greatly 
increased in all B cell subsets (Figure 6.10.B-C). When comparing sorted B cell subsets 
from established RA patients and healthy controls, only the percentage of CD86 positive 
cells in the unstimulated naïve B cell subset showed a significant decrease in established 
RA patients compared to healthy controls (Figure 6.11.A-B).  
The expression of the activation molecule, CD69 (a C-type lectin), was also assessed. 
Unstimulated cells for all B cell subsets showed low percentages of CD69 positive cells 
(Figure 6.12.A-B). These results are similar to my findings for phenotypic analysis of B 
cells from peripheral blood, although CD69 expression on ABC assessed using whole blood 
flow cytometry demonstrated a higher expression of CD69 than that seen here with sorted 
and cultured ABCs (Chapter 4, Figure 4.6). When the B cell subsets were stimulated, there 
was a significant increase in both the percentage of CD69 positive cells and CD69 
expression, as measured by MFI, in naïve and CD5+ B cells only (Figure 6.12.B-C). 
However, this increase was not seen in memory B cells and ABCs. No differences in 
percentage of CD69 positive cells and CD69 MFI values were seen in any of the B cell 
subsets when B cells from established RA patients were compared to B cells from healthy 
controls (Figure 6.13.A-B). 
The NanoString results (Chapter 5, section 5.4.4) demonstrated that ABCs had high 
expression of mRNA transcript for the activation molecule CD97 (a G-protein coupled 
receptor involved in cell adhesion). I therefore, analysed expression of this marker after B 
cell stimulation (Figure 6.14). Unstimulated B cells, with the exception, as predicated by 
the NanoString results, of ABCs, showed very low percentages of CD97 positive cells 
(Figure 6.14.A-B). This marker is greatly upregulated after B cell stimulation in all B cell 
subsets, but in particular in memory B cells and ABCs, where the percentages of positive 
cells reach more than 80% (Figure 6.14.B-C). Interestingly, the percentage of CD97 
positive cells in stimulated cells from all B cell subsets was higher in healthy controls 
compared to RA patients (Figure 6.15.A). Same results were found in terms of the MFI 




Figure 6. 10. Expression of the co-stimulatory molecule CD86 in unstimulated or stimulated sorted B cell subsets from established RA 
patients. Sorted cells from established RA patients were incubated with or without stimulation (Imiquimod, CpG A, CpG B, PWM, anti-CD40, 
IL-21, IL-4 and IFN-γ) for 5 days. The cell phenotype was then assessed by flow cytometry. A. CD86 expression overlay histograms for each B 
cell subset and stimulation condition. CD5+ B cells are shown in orange, naïve B cells are shown in red, memory B cells in purple and ABCs in 
blue. The peaks are normalised to the same height to standardise for different numbers of cells in each population. B. Percentage of CD86 positive 
cells in the B cell subsets. The bar represents the median. Gates were set using an unstained sample. C. CD86 median fluorescence intensity (MFI) 
in the different B cell subsets. The bar represents the median. N = up to 5. Statistical significance was assessed using a Kruskal-Wallis test 





Figure 6. 11. Expression of the co-stimulatory molecule CD86 in unstimulated or stimulated sorted B cell subsets from established RA 
patients and healthy controls. A. Percentage of CD86 positive cells in the B cell subsets. The bar represents the median. Gates were set using an 
unstained sample. B. CD86 median fluorescence intensity (MFI) in the different B cell subsets. The bar represents the median. Established RA 
patients (n= up to 5) are shown as circles and healthy controls (n= up to 4) are represented with squares. Statistical significance was assessed using 




Figure 6. 12. Expression of the activation marker CD69 in unstimulated or stimulated sorted B cell subsets from established RA patients. 
Sorted cells from established RA patients were incubated with or without stimulation (Imiquimod, CpG A, CpG B, PWM, anti-CD40, IL-21, IL-
4 and IFN-γ) for 5 days. The cell phenotype was then assessed by flow cytometry. A. CD69 expression overlay histograms for each B cell subset 
and stimulation condition. CD5+ B cells are shown in orange, naïve B cells are shown in red, memory B cells in purple and ABCs in blue. The 
peaks are normalised to the same height to standardise for different numbers of cells in each population. B. Percentage of CD69 positive cells in 
the B cell subsets. The bar represents the median. Gates were set using an unstained sample. C. CD69 median fluorescence intensity (MFI) in the 
different B cell subsets. The bar represents the median. N = up to 5. Statistical significance was assessed using a Kruskal-Wallis test (p=0.0001 





Figure 6. 13. Expression of the activation marker CD69 in unstimulated or stimulated sorted B cell subsets from established RA patients 
and healthy controls. A. Percentage of CD69 positive cells in the B cell subsets. The bar represents the median. Gates were set using an unstained 
sample. B. CD69 median fluorescence intensity (MFI) in the different B cell subsets. The bar represents the median. Established RA patients (n= 
up to 5) are shown as circles and healthy controls (n= up to 4) are represented with squares. Statistical significance was assessed using a Fit Least 




Figure 6. 14. Expression of the activation marker CD97 in unstimulated or stimulated sorted B cell subsets from established RA patients. 
Sorted cells from established RA patients were incubated with or without stimulation (Imiquimod, CpG A, CpG B, PWM, anti-CD40, IL-21, IL-
4 and IFN-γ) for 5 days. The cell phenotype was then assessed by flow cytometry. A. CD97 expression overlay histograms for each B cell subset 
and stimulation condition. CD5+ B cells are shown in orange, naïve B cells are shown in red, memory B cells in purple and ABCs in blue. The 
peaks are normalised to the same height to standardise for different numbers of cells in each population. B. Percentage of CD97 positive cells in 
the B cell subsets. The bar represents the median. Gates were set using an unstained sample. C. CD97 median fluorescence intensity (MFI) in the 
different B cell subsets. The bar represents the median. N = up to 5. Statistical significance was assessed using a Kruskal-Wallis test (p<0.0001 






Figure 6. 15. Expression of the activation marker CD97 in unstimulated or stimulated sorted B cell subsets from established RA patients 
and healthy controls. A. Percentage of CD97 positive cells in the B cell subsets. The bar represents the median. Gates were set using an unstained 
sample. B. CD97 median fluorescence intensity (MFI) in the different B cell subsets. The bar represents the median. Established RA patients (n= 
up to 5) are shown as circles and healthy controls (n= up to 4) are represented with squares. Statistical significance was assessed using a Fit Least 
Squares comparing RA patients and healthy controls in each B cell subset; * p < 0.05, ** p < 0.01. 
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Expression of the maturation marker CD27 was also assessed. As expected, on 
unstimulated cells, CD5+ and naïve B cells had lower expression of this marker than ABCs 
and memory B cells (Figure 6.16.A-C). In ABCs, around 50% of the cells were positive for 
this marker, and for the memory B cells all the cells were positive for the marker as this 
subset was sorted based on CD27 expression (i.e. CD19+IgD-CD27+) (Figure 6.16.B). 
When the B cells were stimulated, the percentage of CD27 positive cells in all the subsets 
increased, except in the memory B cells as all of the cells were positive initially (Figure 
6.16.B). Nevertheless, the MFI data showed that stimulation of memory B cells induced an 
upregulation of CD27 expression, with a similar effect, albeit not as pronounced, in ABCs 
(Figure 6.16.C). When comparing sorted B cell subsets from established RA patients and 
healthy controls, the percentage of CD27 positive cells in the unstimulated and stimulated 
naïve B cell subset showed a significant decrease in established RA patients compared to 
healthy controls (Figure 6.17.A). The percentage of CD27 positive cells in stimulated 
ABCs from established RA patients was also lower than stimulated ABCs from healthy 
controls (Figure 6.17.A). No differences in MFI values in established RA patients 
compared to healthy controls were seen in any of the subsets (Figure 6.17.B).  
Finally, assessment of surface IgG expression showed no changes in expression after 
stimulation (Figure 6.18). As expected, and reported in Chapter 4 (Figure 4.11), about 50% 
of the cells in the unstimulated condition for the memory B cell and the ABC population 
were IgG positive (Figure 6.18.A-B). The percentage of IgG positive cells in unstimulated 
and stimulated naïve B cells from RA patients was lower compared to healthy controls 
(Figure 6.19.A). In terms of the MFI values, there was higher IgG expression in 
unstimulated CD5+ B cells and stimulated naïve B cells from healthy controls compared 
to established RA patients (Figure 6.19.B). 




Figure 6. 16. Expression of the maturation marker CD27 in unstimulated or stimulated sorted B cell subsets from established RA patients. 
Sorted cells from established RA patients were incubated with or without stimulation (Imiquimod, CpG A, CpG B, PWM, anti-CD40, IL-21, IL-
4 and IFN-γ) for 5 days. The cell phenotype was then assessed by flow cytometry. A. CD27 expression overlay histograms for each B cell subset 
and stimulation condition. CD5+ B cells are shown in orange, naïve B cells are shown in red, memory B cells in purple and ABCs in blue. The 
peaks are normalised to the same height to standardise for different numbers of cells in each population. B. Percentage of CD27 positive cells in 
the B cell subsets. The bar represents the median. Gates were set using an unstained sample. C. CD27 median fluorescence intensity (MFI) in the 
different B cell subsets. The bar represents the median. N = up to 5. Statistical significance was assessed using a Kruskal-Wallis test (p=0.0004 





Figure 6. 17. Expression of the maturation marker CD27 in unstimulated or stimulated sorted B cell subsets from established RA patients 
and healthy controls. A. Percentage of CD27 positive cells in the B cell subsets. The bar represents the median. Gates were set using an unstained 
sample. B. CD27 median fluorescence intensity (MFI) in the different B cell subsets. The bar represents the median. Established RA patients (n= 
up to 5) are shown as circles and healthy controls (n= up to 4) are represented with squares. Statistical significance was assessed using a Fit Least 





Figure 6. 18. Expression of IgG in unstimulated or stimulated sorted B cell subsets from established RA patients. Sorted cells from 
established RA patients were incubated with or without stimulation (Imiquimod, CpG A, CpG B, PWM, anti-CD40, IL-21, IL-4 and IFN-γ) for 5 
days. The cell phenotype was then assessed by flow cytometry. A. IgG expression overlay histograms for each B cell subset and stimulation 
condition. CD5+ B cells are shown in orange, naïve B cells are shown in red, memory B cells in purple and ABCs in blue. The peaks are normalised 
to the same height to standardise for different numbers of cells in each population. B. Percentage of IgG positive cells in the B cell subsets. The 
bar represents the median. Gates were set using an unstained sample. C. IgG median fluorescence intensity (MFI) in the different B cell subsets. 
The bar represents the median. N = up to 5. Statistical significance was assessed using a Kruskal-Wallis test (p=0.0003 for B, p=0.0030 for C) 





Figure 6. 19.  Expression of IgG in unstimulated or stimulated sorted B cell subsets from established RA patients and healthy controls. A. 
Percentage of IgG positive cells in the B cell subsets. The bar represents the median. Gates were set using an unstained sample. B. IgG median 
fluorescence intensity (MFI) in the different B cell subsets. The bar represents the median. Established RA patients (n= up to 5) are shown as 
circles and healthy controls (n= up to 4) are represented with squares. Statistical significance was assessed using a Fit Least Squares comparing 
RA patients and healthy controls in each B cell subset; * p < 0.05, ** p < 0.01.
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6.4.9 Cytokine secretion profiles of each B cell subset after stimulation 
Supernatants from the sorted and cultured B cell subsets were analysed on an MSD U-
PLEX Custom Biomarker (human) plate. MSD assay allows for the detection of low 
concentrations of cytokines. The cytokines analysed were: GM-CSF, IL-2, IL-6, IL-10, IL-
12p70, IL-23 and TNF-alpha.   
Although T cells are considered a major source of IL-2, activated B cells also produce IL-
2, which has been proposed to act as an autocrine growth factor (Lagoo et al., 1990; 
Wojciechowski et al., 2009). In the unstimulated condition all of the B cell subsets 
produced very low levels of IL-2 (Figure 6.20.A). Production of IL-2 was slightly increased 
from all the B cell subsets when the B cells were stimulated, however, the concentrations 
produced were very low. Interestingly, there was increased production of IL-2 by the 
stimulated CD5+ and naïve B cells from established RA patients compared to heathy 
controls (Figure 6.20.B-C). Moreover, there was increased production of IL-2 in the 
unstimulated memory B cell subset from established RA patients compared to heathy 
controls (Figure 6.20.D).  
Another cytokine analysed was IL-6, important in germinal centre formation in 
autoimmune diseases (Arkatkar et al., 2017). As expected, production of IL-6 was low in 
the unstimulated conditions for all the B cell subsets (Figure 6.21.A). Interestingly, when 
the cells were stimulated only the CD5+ and naïve B cells produced significantly high 
levels of IL-6. There was a small increase in the production of IL-6 from memory B cells 
but no secretion by ABCs. These data suggest that IL-6 may be a cytokine produced at the 
initiation of an immune response by naïve B cells. No differences in IL-6 production were 
seen in any of the B cell subsets when B cells from established RA patients were compared 




Figure 6. 20.  Production of the cytokine IL-2 from unstimulated or stimulated sorted B cell subsets. Sorted cells from established RA patients 
were incubated with or without stimulation (Imiquimod, CpG A, CpG B, PWM, anti-CD40, IL-21, IL-4 and IFN-γ) for 5 days. A. The culture 
supernatants from established RA patients (n= up to 5) were harvested and the concentration of IL-2 was detected using a U-PLEX Custom 
Biomarker plate from MSD. The dotted line indicates the lower limit of detection. Statistical significance was assessed using a Kruskal-Wallis test 
(p=0.0004) with Dunn’s multiple comparisons of the two conditions in each B cell subset; *p < 0.05. B-E. IL-2 production from B cells from 
established RA patients (n= up to 5), shown as circles and healthy controls (n= up to 4), shown as squares. The dotted line indicates the lower limit 
of detection. Statistical significance was assessed using a Fit Least Squares comparing RA patients and healthy controls in each B cell subset; *p 





Figure 6. 21. Production of the cytokine IL-6 from unstimulated or stimulated sorted B cell subsets. Sorted cells from established RA patients 
were incubated with or without stimulation (Imiquimod, CpG A, CpG B, PWM, anti-CD40, IL-21, IL-4 and IFN-γ) for 5 days. A. The culture 
supernatants from established RA patients (n= up to 5) were harvested and the concentration of IL-6 was detected using a U-PLEX Custom 
Biomarker plate from MSD. The dotted line indicates the lower limit of detection. Statistical significance was assessed using a Kruskal-Wallis test 
(p<0.0001) with Dunn’s multiple comparisons of the two conditions in each B cell subset; **p < 0.01. B-E. IL-6 production from B cells from 
established RA patients (n= up to 5), shown as circles and healthy controls (n= up to 4), shown as squares. The dotted line indicates the lower limit 
of detection. Statistical significance was assessed using a Fit Least Squares comparing RA patients and healthy controls in each B cell subset. 
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Production of the anti-inflammatory cytokine IL-10 was also assessed. IL-10 has been 
proposed to act as potent growth and differentiation factor for activated B cells (Rousset et 
al., 1992), as well as acting as a B cell maturation suppressor, depending on the activation 
stage of the B cells (Itoh and Hirohata, 1995). As was observed for IL-2 and IL-6, 
production of IL-10 in the unstimulated condition for all the B cell subsets was very low 
(Figure 6.22.A). However, stimulation enhanced IL-10 production in naïve B cells, CD5+ 
B cells and memory B cells. Interestingly, stimulation of ABCs did not induce production 
of IL-10. No differences in IL-10 production were seen in any of the B cell subsets when 
B cells from established RA patients were compared to B cells from healthy controls 
(Figure 6.22.B-E). 
IL-12 production was also assessed due to its role in skewing T cells towards a Th1 
phenotype (Gee et al., 2009). Overall, the concentrations of IL-12p70 that are produced in 
both the unstimulated and stimulated conditions was quite low (Figure 6.23.A). Production 
in the unstimulated conditions for all the B cell subsets was almost undetectable. 
Nonetheless, production of IL-12p70 was slightly increased after stimulation by all the B 
cell subsets. There were no differences in IL-12p70 production by any of the B cell subsets 
between the established RA patients and the healthy controls (Figure 6.23.B-E). 
Production of IL-23, another cytokine important for T cell skewing, which drives T cell 
differentiation towards a Th17 phenotype, was assessed. IL-23 production was almost 
undetectable by the unstimulated cells (Figure 6.24.A). However, similar to IL-12p70, IL-
23 production increased when all the B cell subsets were stimulated. Nonetheless, there 
was increased production of IL-23 by the stimulated CD5+ and naïve B cells from 





Figure 6. 22. Production of the cytokine IL-10 from unstimulated or stimulated sorted B cell subsets. Sorted cells from established RA 
patients were incubated with or without stimulation (Imiquimod, CpG A, CpG B, PWM, anti-CD40, IL-21, IL-4 and IFN-γ) for 5 days. A. The 
culture supernatants from established RA patients (n= up to 5) were harvested and the concentration of IL-10 was detected using a U-PLEX 
Custom Biomarker plate from MSD. The dotted line indicates the lower limit of detection. Statistical significance was assessed using a Kruskal-
Wallis test (p=0.0002) with Dunn’s multiple comparisons of the two conditions in each B cell subset; *p < 0.05. B-E. IL-10 production from B 
cells from established RA patients (n= up to 5), shown as circles and healthy controls (n= up to 4), shown as squares. The dotted line indicates the 





Figure 6. 23. Production of the cytokine IL-12p70 from unstimulated or stimulated sorted B cell subsets. Sorted cells from established RA 
patients were incubated with or without stimulation (Imiquimod, CpG A, CpG B, PWM, anti-CD40, IL-21, IL-4 and IFN-γ) for 5 days. A. The 
culture supernatants from established RA patients (n= up to 5) were harvested and the concentration of IL-12p70 was detected using a U-PLEX 
Custom Biomarker plate from MSD. The dotted line indicates the lower limit of detection. Statistical significance was assessed using a Kruskal-
Wallis test (p=0.0003) with Dunn’s multiple comparisons of the two conditions in each B cell subset; *p < 0.05. B-E. IL-12p70 production from 
B cells from established RA patients (n= up to 5), shown as circles and healthy controls (n= up to 4), shown as squares. The dotted line indicates 





Figure 6. 24. Production of the cytokine IL-23 from unstimulated or stimulated sorted B cell subsets. Sorted cells from established RA 
patients were incubated with or without stimulation (Imiquimod, CpG A, CpG B, PWM, anti-CD40, IL-21, IL-4 and IFN-γ) for 5 days. A. The 
culture supernatants from established RA patients (n= up to 5) were harvested and the concentration of IL-23 was detected using a U-PLEX 
Custom Biomarker plate from MSD. The dotted line indicates the lower limit of detection. Statistical significance was assessed using a Kruskal-
Wallis test (p=0.0003) with Dunn’s multiple comparisons of the two conditions in each B cell subset; *p < 0.05. B-E. IL-23 production from B 
cells from established RA patients (n= up to 5), shown as circles and healthy controls (n= up to 4), shown as squares. The dotted line indicates the 
lower limit of detection. Statistical significance was assessed using a Fit Least Squares comparing RA patients and healthy controls in each B cell 
subset; **p < 0.01. 
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Production of GM-CSF, a cytokine involved in the activation of monocytes and 
macrophages (Ushach and Zlotnik, 2016), was also assessed. Production of this growth 
factor was low in the unstimulated conditions for all the B cell subsets (Figure 6.25.A). 
However, its production was slightly increased after stimulation in all the B cell subsets. 
Interestingly, production by the CD5+ B cells was more pronounced compared to the other 
B cell subsets. When the data from the established RA patients was compared to the healthy 
controls, there were no differences for any of the B cell subsets for either condition (Figure 
6.25.B-E). 
Finally, TNF-α production was also evaluated. TNF-α was shown to be produced by the 
synovial FcRL4+ B cell subset, suggesting a possible role for these ABC-like cells in 
osteoclast activation (Yeo et al., 2015). As for the all other cytokines, production of TNF-
α was very low in the unstimulated condition for all the B cell subsets (Figure 6.26.A). 
However, its production was slightly increased after stimulation in all the B cell subsets, 
especially in the CD5+ and the naïve B cells. The induction of TNF-α production following 
stimulation was smaller in ABCs than the other B cell subsets. However, there was 
increased production of TNF-α by the stimulated memory B cells from established RA 




Figure 6. 25. Production of the cytokine GM-CSF from unstimulated or stimulated sorted B cell subsets. Sorted cells from established RA 
patients were incubated with or without stimulation (Imiquimod, CpG A, CpG B, PWM, anti-CD40, IL-21, IL-4 and IFN-γ) for 5 days. A. The 
culture supernatants from established RA patients (n= up to 5) were harvested and the concentration of GM-CSF was detected using a U-PLEX 
Custom Biomarker plate from MSD. The dotted line indicates the lower limit of detection. Statistical significance was assessed using a Kruskal-
Wallis test (p=0.0001) with Dunn’s multiple comparisons of the two conditions in each B cell subset; **p < 0.01. B-E. GM-CSF production from 
B cells from established RA patients (n= up to 5), shown as circles and healthy controls (n= up to 4), shown as squares. The dotted line indicates 





Figure 6. 26. Production of the cytokine TNF-α from unstimulated or stimulated sorted B cell subsets. Sorted cells from established RA 
patients were incubated with or without stimulation (Imiquimod, CpG A, CpG B, PWM, anti-CD40, IL-21, IL-4 and IFN-γ) for 5 days. A. The 
culture supernatants from established RA patients (n= up to 5) were harvested and the concentration of TNF-α was detected using a U-PLEX 
Custom Biomarker plate from MSD. The dotted line indicates the lower limit of detection. Statistical significance was assessed using a Kruskal-
Wallis test (p<0.0001) with Dunn’s multiple comparisons of the two conditions in each B cell subset; **p < 0.01. B-E. TNF-α production from B 
cells from established RA patients (n= up to 5), shown as circles and healthy controls (n= up to 4), shown as squares. The dotted line indicates the 
lower limit of detection. Statistical significance was assessed using a Fit Least Squares comparing RA patients and healthy controls in each B cell 
subset; *p < 0.05.
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6.4.10 Immunoglobulin production by each B cell subset after stimulation 
Supernatants from the cultured B cell subsets were also analysed for the presence of 
immunoglobulins (total IgM, total IgG and total IgA) using The Isotyping Panel 1 
(Human/NHP) Kit from MSD.  
There were very low levels of IgM production in the unstimulated condition for all the B 
cell subsets (Figure 6.27.A). Following stimulation, the level of IgM secreted into the 
culture supernatant increased and this effect was more enhanced for the memory B cell 
population. When the data from the established RA patients was compared to the healthy 
controls, there were no differences for any of the B cell subsets for either condition (Figure 
6.27.B-E). 
Regarding IgG production, there was no production by the unstimulated condition for all 
the B cell subsets (Figure 6.28.A). Upon stimulation the CD5+ and naïve B cell subsets did 
not produce IgG. However, there was detectable levels of this class-switched 
immunoglobulin by both memory B cells and ABCs, with memory B cells displaying the 
highest level of induction. Interestingly, there was increased production of IgG by the 
stimulated ABCs from established RA patients compared to heathy controls (Figure 
6.28.E). 
In terms of IgA production, there was no detectable levels in the unstimulated conditions 
for the CD5+ B cells, naïve B cells and ABCs (Figure 6.29.A). Interestingly, there was 
some spontaneous production of IgA detected in the unstimulated memory cells. Following 
stimulation, only the memory B cells produced IgA. There were no differences in IgA 
production by any of the B cell subsets between the established RA patients and the healthy 




Figure 6. 27. IgM production from unstimulated or stimulated sorted B cell subsets. Sorted cells from established RA patients were incubated 
with or without stimulation (Imiquimod, CpG A, CpG B, PWM, anti-CD40, IL-21, IL-4 and IFN-γ) for 5 days. A. The culture supernatants from 
established RA patients (n= up to 5) were harvested and the concentration of IgM was detected using the Isotyping Panel 1 Kit from MSD. The 
dotted line indicates the lower limit of detection. Statistical significance was assessed using a Kruskal-Wallis test (p=0.0001) with Dunn’s multiple 
comparisons of the two conditions in each B cell subset; *p < 0.05. B-E. IgM production from B cells from established RA patients (n= up to 5), 
shown as circles and healthy controls (n= up to 4), shown as squares. The dotted line indicates the lower limit of detection. Statistical significance 




Figure 6. 28. IgG production from unstimulated or stimulated sorted B cell subsets. Sorted cells from established RA patients were incubated 
with or without stimulation (Imiquimod, CpG A, CpG B, PWM, anti-CD40, IL-21, IL-4 and IFN-γ) for 5 days. A. The culture supernatants from 
established RA patients (n= up to 5) were harvested and the concentration of IgG was detected using the Isotyping Panel 1 Kit from MSD. The 
dotted line indicates the lower limit of detection. Statistical significance was assessed using a Kruskal-Wallis test (p=0.0009) with Dunn’s multiple 
comparisons of the two conditions in each B cell subset; *p < 0.05. B-E. IgG production from B cells from established RA patients (n= up to 5), 
shown as circles and healthy controls (n= up to 4), shown as squares. The dotted line indicates the lower limit of detection. Statistical significance 





Figure 6. 29. IgA production from unstimulated or stimulated sorted B cell subsets. Sorted cells from established RA patients were incubated 
with or without stimulation (Imiquimod, CpG A, CpG B, PWM, anti-CD40, IL-21, IL-4 and IFN-γ) for 5 days. A. The culture supernatants from 
established RA patients (n= up to 5) were harvested and the concentration of IgA was detected using the Isotyping Panel 1 Kit from MSD. The 
dotted line indicates the lower limit of detection. Statistical significance was assessed using a Kruskal-Wallis test (p=0.0001) with Dunn’s multiple 
comparisons of the two conditions in each B cell subset. B-E. IgA production from B cells from established RA patients (n= up to 5), shown as 
circles and healthy controls (n= up to 4), shown as squares. The dotted line indicates the lower limit of detection. Statistical significance was 




In this chapter, I optimised a sorting protocol for the isolation of different B cell subsets 
and developed a protocol for the culture and stimulation of small numbers of B cells. This 
optimisation allowed me to perform a few selected functional studies on the ABC 
population and compare the readout to the other B cell subsets. I phenotyped the cells after 
culturing with or without a stimulation cocktail containing Imiquimod, CpG A, CpG B, 
Poke Weed Mitogen, anti-CD40, human IL-21, human IL-4 and IFN-γ, to check for 
activation marker expression. This stimulation cocktail mimicked signals from a T cell-
dependent response such as PWM, which stimulates BCR, and anti-CD40, as well as 
mimicking innate signals, for a T cell-independent response, using the TLR ligands, 
Imiquimod and CpG A and B. IL-21 was chosen as it has been shown to induce plasma cell 
differentiation and Ig secretion (Ettinger et al., 2005). IL-4 is known to induce B cell 
survival and protect B cells from apoptosis (Wurster et al., 2002), and IFN-γ was added 
due to its wide range of functions on B cells, such as promoting B cell survival and B cell 
differentiation into immunoglobulin producing cells (Jurado et al., 1989). In addition to 
investigating the phenotype of the stimulated cells, I quantified a wide range of cytokines 
produced by B cells, as well as the profile of immunoglobulins secreted by these cells. 
Additionally, I compared all these readouts in established RA patients B cell subsets and 
age-matched healthy controls B cell subsets, albeit there was little difference between the 
two cohorts.  
In order to optimise a protocol for the sorting and culture of B cell subsets, I first tested 
multiple culture conditions using naïve and memory B cells, as these were readily available 
in sufficient numbers for optimisation experiments. The first variable I tested was the 
culture volume. Due to the small numbers of B cells cultured the plate I chose to use was a 
96-well round-bottom plate. The reason I wanted to test a smaller volume was due to the 
fact that culturing low numbers of B cells will likely result in the production of low 
concentrations of secreted mediators, such as immunoglobulins and cytokines, in the 
culture supernatant. Therefore, if a too large culture volume is used it would dilute the 
secreted mediators and could potentially make detection difficult. However, the 
concentration of IgG detected in the 200µl volumes is slightly higher, and more 
reproducible, than in the 100µl volumes (Figure 6.2.B). This is probably due to the fact that 
the cells appeared to be more viable and healthier in the larger volume of culture medium, 
possibly due to the increased amount of nutrients. Additionally, the slightly reduced 
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viability of the cells in the lower culture volume could be due to evaporation of culture 
volume from the plate. There is always some evaporation during incubation at 37°C, but 
smaller volumes evaporate at a higher rate, resulting in a large reduction of the final volume 
of culture medium (Esser and Weitzmann, 2011). However, the differences in the detected 
concentration of secreted IgG in the two culture volumes are very modest and could simply 
be due to slight differences in the cell composition between the two cultures, i.e. by chance 
one of the conditions may contain more plasma cells, which would produce more IgG, or 
may have more responsive cells. Unexpectedly, the concentration of IgG in the 200µl 
cultures volumes was not half the concentration in the 100µl cultures volumes (Figure 
6.2.B). This could be due to the provision of extra nutrients in the 200µl cultures volumes 
and the cells being healthier and more viable and therefore producing more IgG than the 
100µl cultures volumes. From these data I concluded that the 200µl culture volume was 
optimal, which was further supported by the pragmatic reasoning that having a larger 
volume of culture supernatant guaranteed that enough supernatants would be available for 
analysis using two different MSD assays, with spare available for other tests.  
The second condition I wanted to optimise was the number of cells plated in each well. 
According to the manufacturer of the 96-well round-bottom plates, the minimum number 
of cultured cells in a 96-well plate are 10,000 cells. Once again, as the number of ABCs I 
could isolate from peripheral blood was very limited, I tested two low numbers (10,000 and 
20,000) of B cells to determine if such small cell numbers are able to produce detectable 
concentrations of cytokines and immunoglobulins. I found that the percentage of live cells 
was higher in the 20,000 B cell cultures, suggesting that cells are more viable and healthier 
when cultured in higher numbers (Figure 6.3.A). However, IgG production was slightly 
higher in the 10,000 B cells cultures (Figure 6.3.B). As explained before, these could be 
due to having more plasma cells or cells which responded better to stimulation and 
therefore produced more IgG, in the 10,000 cell cultures just by chance. Because the 
percentage of live cells was higher in the 20,000 cell cultures and because culturing larger 
numbers of cells should increase the concentration of detectable cytokines and 
immunoglobulins, I decided to use 20,000 cells per well for the functional work. 
Finally, the last variable I wanted to optimise was the culture time. I tested two different 
time points: 3 days and 6 days (Figure 6.4). A short time point of 3 days was chosen because 
B cells are very sensitive and die easily so I wanted to test if I could detect secreted IgG at 
a short time point. A longer time point of 6 days was chosen to see if a longer culture time 
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was needed for the cells to activate and secrete IgG and other cytokines. Some studies 
showed that around 8 days are required for primary B cells to class-switch (Su et al., 2016). 
Because I hypothesised that ABCs are antigen-experienced B cells and a large proportion 
has already class-switched, the aim was to assess the effect a potent B cell stimuli had on 
these cells, and therefore a time point longer than 6 days was deemed unnecessary. As 
expected, the percentage of live memory B cells was higher at day 3 compared to day 6, 
however, the live cells did not greatly decrease at day 6 when the memory B cells were 
stimulated (Figure 6.4.A). In terms of IgG production, secretion of this immunoglobulin 
was doubled at day 6 compared to day 3 (Figure 6.4.B). Because the number of live 
stimulated memory B cells did not dramatically decrease and the detection of secreted IgG 
was much higher at day 6, the later time point was chosen for the functional work. However, 
due to clinic timings and sample processing time restrictions, the final incubation time for 
the functional work had to be compromised to 5 days. This time point was chosen as it 
would provide sufficient culture time for the B cells to activate and secrete cytokines and 
immunoglobulins, and would maintain a high percentage of live cells when cells were 
stimulated.  
As explained before, in order to isolate a usable number of ABCs, a large volume of blood 
was needed. This resulted in high numbers of isolated PBMCs and therefore a large number 
of cells to stain and process through the flow cytometer sorter. This in turn, resulted in very 
long periods of time sorting the cells, which in addition to being expensive, also had the 
potential for damaging the sorted cells resulting in high levels of cell stress and ultimately, 
death. In order to reduce the sorting time, I tried sorting B cell subsets using two different 
approaches utilising Miltenyi MACS MicroBeads. Positive selection, in which CD19+ B 
cells are labelled with CD19 MicroBeads and are actively removed from the sample; and 
negative selection, in which the CD19+ B cells remain “untouched” by MicroBeads. A 
study comparing different methods, including the use of Miltenyi MACS isolations, found 
that there was high contamination of platelets when using the Miltenyi MACS system 
(Moore et al., 2019). This study concludes that the best method for isolating pure B cells 
for downstream functional assays is by flow cytometry sorting. Nonetheless, because I am 
interested in different B cell subsets, I needed to sort the cells anyway to obtain pure 
fractions of the different B cell subsets. Therefore, I tested sorting the subsets from a pre-
enriched CD19+ B cell population, obtained using CD19 Miltenyi MACS MicroBeads, as 
it would decrease the sorting time as only B cells were used as the starting sort population 
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compared to PBMCs. However, the results showed that B cells sorted from pre-enriched 
CD19+ B cells were not functionally the same as when sorted directly from PBMCs (Figure 
6.5). The B cell subset which seemed more affected were the naïve B cells. These cells 
showed higher cell death and CD40 downregulation in the unstimulated condition when 
sorted from the pre-enriched CD19+ B cell population compared to direct sorting from 
PBMCs. These results suggest that the CD19 MicroBeads isolation process could be 
inducing downregulation of CD40. A previous study described downregulation of CD20 
following CD40 stimulation (Anolik et al., 2003), so it could be possible that stimulation 
of CD19, via binding of a CD19 MicroBead, may also downregulate CD40. Moreover, 
production of IgG by the memory B cell subset was ever so slightly lower in cells sorted 
from the pre-enriched CD19+ B cell population. 
Because sorting from pre-enriched CD19+ B cells seemed to affect the function of the cells, 
a negative selection approach was tested. This method is advantageous as the pre-enriched 
CD19+ B cells remain untouched by MicroBeads, therefore, potentially functionally 
unaltered by this process. To this end, a Miltenyi MACS CD3 MicroBead kit was chosen 
to deplete the T cells from the PBMC fraction. The cells left in the CD3-depleted PBMC 
sample would include monocytes, NK cells, dendritic cells and B cells. Because T cells 
constitute around 70% of PBMCs (Corkum et al., 2015), the number of cells remaining for 
the flow cytometer sort is therefore significantly much less and sort time is significantly 
reduced. Unlike the results obtained using the B cells sorted from pre-enriched CD19+ B 
cells, B cells sorted from the CD3-depleted PBMCs showed no difference in B cell function 
compared to the cells sorted directly from PBMCs (Figure 6.6). Some studies in which 
functional work on ABC-like cells was performed also used a negative selection approach 
(Isnardi et al., 2010; Wang et al., 2018). Even though these studies did not just deplete 
CD3+ cells, other enrichment cocktails which depleted all types except B cells, leaving the 
B cells untouched, were employed. Taking all of this into account, the functional B cell 
work was performed using sorted B cell subsets from CD3-depleted PBMCs, allowing for 
shorter sorting times, and B cells which were functionally similar to the ones sorted directly 
from PBMCs. 
For the functional work, five established RA patients and four age-matched healthy controls 
were recruited. Because the established RA patients were recruited first, age- and sex-
matched healthy controls were picked specifically to match the patients and therefore no 
significant differences in age and sex were seen (Table 6.1).  
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In terms of cell viability after sorting and culturing, I expected to see a small number of 
live cells in the unstimulated conditions, as B cells are known to die quickly in culture if 
they are not stimulated (Researchgate, 2012). I have demonstrated in the previous chapters 
that ex vivo CD5+ B cells appear to be similar to the naïve B cell subset phenotypically and 
transcriptionally. In terms of cell viability following stimulation, CD5+ B cells also appear 
to be similar to naïve B cells as the percentages of live cells are almost identical in the two 
subsets. In addition, the phenotype and gene expression profile data I have previously 
shown, suggested that ABCs are quite similar to memory B cells. However, when the ABCs 
are stimulated, they do not respond as robustly as the memory B cells and they display a 
high level of cell death (Figure 6.7.A). This could be due to the ABCs being more sensitive 
to the pressure and stress of cell sorting, resulting in higher cell death. It is known that cell 
sorting can cause stress to the cells, and the choice of flow cytometer sorter can also 
influence this. The FACSAria system (BD Biosciences, CA, USA), which I used for this 
work, interrogates the cells in a cuvette and although it increases optical resolution, cells 
are slowed down and then sped up and this change in speed can increase cell stress 
(Harvard, n.d). On the other hand, other cell sorters, such as MoFlo Astrios (Beckman 
Coulter, CA, USA), maintain velocity, minimising cell stress and improving cell viability. 
Although all the B cell subsets have been through the same potential stress levels induced 
by the FACSAria system, ABCs could be more prone to die by apoptosis as highlighted by 
their expression of apoptotic genes I presented in Chapter 5, as well as in published 
literature (Isnardi et al., 2010). A study showed that flow cytometry sorting is the best 
method for transcriptomic analysis as it gives high purity cell yields and avoids the 
induction of cell stress (Beliakova-Bethell et al., 2014). However, this published study 
analysed gene expression immediately after sorting the leukocytes, so no assessment of 
changes which occur after a few days culture, post-sorting, were evaluated. Nevertheless, 
the only way to feasibly assess cytokine and immunoglobulin production in each of the 
subsets was by sorting. Another reason for the low cell viability in the ABC population, 
could be due to the use of IL-4 in the stimulation cocktail. As reported before, IL-4 
antagonises ABC formation and could be inhibiting ABC activation, thus leading to 
increased cell death (Naradikian et al., 2016b). Interestingly, unstimulated memory B cells 
from established patients showed slightly higher percentages of live cells than unstimulated 
memory B cells from healthy controls, suggesting that memory B cells from patients with 
RA may have enhanced survival (Figure 6.7.D). A study showed that in the RA synovia, 
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V-CAM expressing fibroblast regulated synovial memory B cell survival, preventing 
apoptosis (Reparon-Schuijt et al., 2000). 
A limitation of this experiment was that it was not possible to determine if the cells which 
responded to stimulation actually proliferated. For future work this could be done by and 
intracellular staining for Ki67 to assess the percentage of proliferating cells or by labelling 
the cells with a CellTrace dye. This will help to determine whether the higher percentage 
of live cells in the memory B cells is due to B cell proliferation or whether the live cells are 
just more robust and survive. 
With regard to the surface marker phenotype, in general, HLA-DR was upregulated 
following stimulation (Figure 6.8). This is not surprising as HLA-DR is involved in the B 
cell activation cascade both at an early and late stage (Giudizi et al., 1987). Interestingly, 
in both unstimulated and stimulated conditions, there is a trend for decreased percentages 
of HLA-DR+ cells, as well as expression of HLA-DR in all B cell subsets from RA patients 
compared to healthy controls (Figure 6.9). However, these results are not in line with other 
studies, which showed a positive correlation between the amount of HLA-DR gene 
transcripts and the presence of the RA risk alleles, suggesting a correlation between HLA-
DR expression and RA susceptibility (Kerlan-Candon et al., 2001; Kampstra and Toes, 
2017). 
Expression of another co-stimulatory molecule, CD86, which is known to increase after 
cell activation (Suvas et al., 2002) was assessed. As expected, CD86 expression was 
upregulated in all B cell subsets after stimulation (Figure 6.10). As reported in Chapter 4 
Figure 4.5, resting or unstimulated ABCs, and memory B cells to a lesser extent, have 
higher expression of CD86 than other resting B cell subsets. CD86 upregulation following 
stimulation was higher in memory B cells and ABCs, which is in line with a published 
study showing that CD86 is rapidly upregulated on B cells following activation by cross-
linking of the BCR or the addition of a variety of cytokines (Manzoor, 2015). The fact that 
expression is higher in ABCs and is heavily upregulated after stimulation reinforces the 
hypothesis that ABCs are an activated B cell subset with a potential role in antigen 
presentation. Unstimulated naïve B cells from healthy controls showed slightly higher 
percentages of CD86+ cells than the unstimulated naïve B cells from established RA 
patients (Figure 6.11.A), suggesting naïve cells from RA patients might require a stronger 
stimulation to respond and activate.  
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Expression of the activation marker CD69 was also evaluated. Interestingly, CD69 
expression was upregulated after stimulation only on CD5+ and naïve B cells (Figure 6.12). 
Memory B cells and ABCs showed no change in expression of this activation molecule. 
However, these results are in keeping with another study looking at the kinetics of CD69 
expression, which have shown that CD69 expression increases early after infection in mice 
(Purtha et al., 2008) and decreases during infection. Therefore, CD69 is an early activation 
marker, which is upregulated predominantly in naïve B cells. However, CD69 expression 
did not increase in memory B cells and ABCs following stimulation. This could be due to 
these cells being already in an activated state or even being exhausted or it might be the 
case that the kinetics for CD69 might be different in memory B cells and it could be more 
rapidly downregulated. However, no differences were seen in the percentage of CD69 
positive cells or CD69 expression, as measured by MFI, in any of the B cell subsets from 
established RA patients and healthy controls (Figure 6.13).  
Another activation marker, which was of interest based on my NanoString gene expression 
analysis from Chapter 5 was the activation marker CD97, a G-protein coupled receptor 
involved in cell adhesion. From my NanoString results CD97 transcript and protein 
appeared to be upregulated in ABCs compared to the other B cell subsets. Interestingly, 
CD97 was upregulated by all B cell subsets after stimulation (Figure 6.14). Moreover, as 
reported in Chapter 5, section 5.4.4, CD97 was highly expressed by resting ABCs, and as 
demonstrated here, CD97 is greatly upregulated after stimulation. To my knowledge this is 
the first time that expression of this adhesion molecule is reported in ABCs. Moreover, 
CD97 has been reported to be expressed at high levels on inflammatory cells and is thought 
to contribute to inflammation-mediated angiogenesis (Wang et al., 2005). These results, 
together with the data from Chapter 5 showing high expression of integrins and other 
chemokine receptors, supports a role for the migration of ABCs to inflammatory sites. 
Percentage of CD97 positive cells in the stimulated conditions from all the B cell subsets 
showed higher expression in B cells from healthy controls than established RA patients 
(Figure 6.15), suggesting that B cells from healthy controls have an increased upregulation 
of CD97 following stimulation. In terms of MFI values, CD97 expression in the 
unstimulated CD5+ B cells and memory B cells, as well as the stimulated naïve B cells is 
higher in healthy controls compared to established RA patients. This decreased expression 
of CD97 in established RA patients could be explained by the fact that these patients are 
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being treated with global immune suppressor drugs and activation of the cells could be 
affected by these.  
Expression of the memory B cell marker CD27 was also analysed. CD27 is a type I 
glycoprotein expressed globally and used to distinguish naïve from memory B cells 
(Agematsu et al., 2000). Memory B cells express CD27, although expression of this marker 
also went up with stimulation as CD27 is both a maturation and activation marker. As 
expected, naïve and CD5+ B cell subsets became positive for CD27 after stimulation, 
although expression of this marker was not massively upregulated (Figure 6.16). Memory 
B cells were already positive for CD27 as this marker was used as an identification marker 
to gate these cells, however, expression of this activation marker was also highly 
upregulated after stimulation in memory B cells, as evidenced by an increase in the MFI 
(Figure 6.16.C). Around half of the resting ABC subset were CD27+, however, the 
percentage of CD27 positive cells increased after stimulation and expression of CD27, 
measured as MFI, was also slightly upregulated. Interestingly, there was a small trend for 
unstimulated and stimulated naïve B cells and stimulated ABCs from established RA 
patients to have a lower percentage of CD27+ cells compared to healthy controls (Figure 
6.17.A). This could be due to the increased expression of CD70 by T cells in blood from 
RA patients (Park et al., 2014). CD70 is the ligand for CD27 and an increased expression 
in RA could possibly induce downregulation of its receptor, CD27, to help control B cell 
activation.  
The last phenotypic marker assessed was cell surface expression of IgG. IgG expression is 
not induced after stimulation of naïve and CD5+ B cells (Figure 6.18). These results are 
expected as 5 days of stimulation culture are not enough to induce class-switching of the 
naïve B cells (Su et al., 2016). Intriguingly, ABCs showed a similar percentage of IgG+ 
cells and expression, measured by MFI, of IgG as the memory B cells, supporting the role 
of ABCs as class-switched memory B cells. These results are in line with the phenotyping 
of resting ABCs shown in Chapter 4 Figure 4.11, where the percentages of class-switched 
IgG B cells in the ABC subset were as high as in the memory B cell population. 
Interestingly, the percentage of IgG positive cells in unstimulated and stimulated naïve B 
cells from RA patients was lower compared to healthy controls (Figure 6.19). Additionally, 
there was higher IgG expression, as measured by MFI, in unstimulated CD5+ B cells and 
stimulated naïve B cells from healthy controls compared to established RA patients (Figure 
6.19.B). Although these differences were significant, the percentage of IgG positive cells 
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and the MFI values in these subsets are very low compared to the memory B cell subset 
and the ABC population.  
In addition to cell surface markers I also assessed the production of cytokines following 
cell stimulation. IL-2 production was assessed as this cytokine acts as an autocrine growth 
factor, which has been proven important for B cell proliferation, as well as for T cell 
survival and for the development of Tregs (Lagoo et al., 1990; Malek, 2003). My results 
show little secretion of IL-2 by all the B cell subsets (Figure 6.20.A). However, it has been 
reported before that production of IL-2 by B cells occurs as a late event relative to their 
activation and proliferation (Kindler et al., 1995). This could explain why such small 
concentrations of IL-2 were detected from all B cell subsets. A solution to this could be 
increasing culturing time in order for the B cells to fully activate and secrete IL-2. 
Moreover, as IL-2 is a growth factor for B cells, it is possible that the B cells are consuming 
it and therefore small concentrations are detected. Interestingly, unstimulated memory B 
cells and stimulated CD5+ B cells and naïve B cells from established RA patients showed 
higher secretion of IL-2 compared to B cells from healthy controls (Figure 6.20.B-D). 
However, a study found that PBMCs from RA patients produced lower quantities of IL-2 
than PBMCs from healthy controls (Combe et al., 1985). Nevertheless, this study was done 
with PBMCs, so there was a mix of lymphocytes and production by a specific type of cell 
was not assessed. 
IL-6 was also assessed in the culture supernatants following cell stimulation. This cytokine 
was chosen due to the role it plays in the differentiation of T follicular helper cells and 
formation of germinal centres (Arkatkar et al., 2017), in addition to our interest in this 
cytokine stemming from previous work published from our group which described an IL-
6 gene signature in CD4 T cells from patients suffering from RA (Pratt et al., 2012; 
Anderson et al., 2016; Anderson et al., 2019; Ridgley et al., 2019). My results showed high 
production of IL-6 by naïve and CD5+ B cells after stimulation, however, secretion by 
memory and ABCs was very low (Figure 6.21.A). As IL-6 production by B cells has been 
shown to have a function in germinal centre formation and T follicular help cells 
differentiation, secretion of this cytokine by naïve and CD5+ cells is understandable as 
when these cells become activated, they should migrate to germinal centres and interact 
with T follicular helper cells to undergo class-switching (Stebegg et al., 2018). No 
differences in IL-6 production by all the B cell subsets in established RA patients compared 
to healthy controls were detected (Figure 6.21.B-E). 
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Regarding IL-10 production, secretion of this cytokine was assessed due to its properties 
as anti-inflammatory cytokine (Couper et al., 2008). IL-10 has been proposed to have a 
dual function, as depending on the activation stage of B cells, this cytokine can act as a 
growth and differentiation factor (Rousset et al., 1992) or can supress maturation of B cells 
(Itoh and Hirohata, 1995). Surprisingly, all the B cell subsets except the ABCs secreted this 
cytokine after stimulation (Figure 6.22.A). CD5+ B cells have been suggested to be potent 
producers of IL-10 (Dalloul, 2009), and my results showed that they do produce higher 
levels of this cytokine compared to other B cells. However, to my knowledge, IL-10 
production by ABCs have never been investigated, although a study reported CD21low B 
cells expressed high levels of IL-10 transcript after BCR and TLR stimulation (Hao et al., 
2011). Nevertheless, this study did not check secretion of the actual protein. This striking 
difference between ABCs and the other subsets supports the hypothesis that ABCs may be 
a pro-inflammatory B cell subset and lack anti-inflammatory capabilities. No differences 
in IL-10 production by all the B cell subsets in established RA patients compared to healthy 
controls were detected (Figure 6.22.B-E). 
IL-12p70 secretion was also assessed. IL-12 is composed of two subunits, p35 and p40, 
which combined form the bioactive IL-12p70. Due to the ability of IL-12 to induce IFN-γ 
production this cytokine is involved in the skewing of T cells towards a Th1 phenotype 
(Gee et al., 2009). My results showed induction of IL-12p70 production following 
stimulation by all the B cell subsets (Figure 6.23.A). Although IL-12 production by B cells 
has been previously reported, the study used much higher numbers of cultured tonsillar B 
cells rather than peripheral blood B cell subsets (Schultze et al., 1999). Moreover, IL-
12p70, the active form peaked on day 2 after stimulation and decreased by day 4, 
demonstrating that by day 5 of culture, as I used, there might not be very high levels of 
active IL-12 due to degradation over time. This is in fitting with the low pg/ml levels 
detected in my B cell subset cultures. As for IL-6 and IL-10, no differences in IL-12p70 
production by all the B cell subsets in established RA patients compared to healthy controls 
were detected (Figure 6.23.B-E). 
Another cytokine assessed was IL-23. IL-23 is of interest due to its implication in inducing 
Th17 cells (Gee et al., 2009). In addition, IL-23 has been proven to play a role in the 
pathogenesis of different inflammatory conditions, as well as being found in skin lesion in 
psoriatic arthritis and the synovial membrane in RA patients joints (Duvallet et al., 2011). 
IL-23 production by stimulated B cells was generally high, however the concentrations 
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produced by the different B cell subsets were quite similar (Figure 6.24.A). Interestingly, 
IL-23 production by stimulated CD5+ and naïve B cells from established RA patients was 
higher than stimulated CD5+ and naïve B cells from healthy controls (Figure 6.24.B-C). 
Higher levels of serum IL-23 have been reported in RA patients compared to healthy 
controls (Zaky and El-Nahrery, 2016), therefore, CD5+ and naïve B cells, probably 
together with other blood cells, might be contributing to the increased levels of IL-23 in 
serum from RA patients.  
Production of GM-CSF was also evaluated. GM-CSF is involved in activation of 
monocytes and macrophages, as well as mediating their differentiation to other cell types 
such as dendritic cells (Ushach and Zlotnik, 2016). Although my results showed very low 
levels of production of GM-CSF (Figure 6.25.A), in the low pg/ml range, upon stimulation, 
other groups have discovered a subset of B cells in multiple sclerosis that is able to produce 
GM-CSF (Li et al., 2015). However, in that study GM-CSF production was assessed after 
a 2 day culture, so as previously mentioned in connection with IL-12, it may be the case 
that in my cultures by day 5, the GM-CSF secreted by the B cells had been degraded. Even 
though the amounts of GM-CSF produced were very low, there was a trend for increased 
production by stimulated CD5+ B cells. As explained before, CD5+ B cells are thought to 
produce IL-10 (Dalloul, 2009), and some studies in autoimmune diseases have shown that 
low doses of GM-CSF expand the IL-10 producing regulatory B cells (Sheng et al., 2014). 
Therefore, CD5+ B cells could be involved in GM-CSF production following activation, 
which may work in an autocrine manner. No differences in GM-CSF production by all the 
B cell subsets in established RA patients compared to healthy controls were detected 
(Figure 6.25.B-E). 
The last cytokine assessed was TNF-α. TNF-α is of interest because previous work done 
by my supervisor in Birmingham (Professor Dagmar Scheel-Toellner) described an 
FcRL4+ B cell subset, with an ABC-like phenotype. This FcRL4+ B cell subset was found 
in the synovial fluid of RA patients and had high expression of TNF-α mRNA (Yeo et al., 
2015). This high expression of TNF-α, together with the expression of RANKL, suggested 
a possible role for these cells in osteoclast differentiation and activation. Production of 
TNF-α by all the B cell subsets was very low after stimulation, levels were only in the low 
pg/ml range (Figure 6.26.A). In addition, memory B cells and ABCs showed lower 
production of this cytokine compared to naïve B cells and CD5+ B cells. This is in line 
with studies in mice which evaluated the production of TNF-α by ABCs compared to 
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follicular B cells and did not find a significant increase in TNF-α expression in ABCs 
(Frasca et al., 2012). Interestingly, stimulated memory B cells from established RA patients 
showed higher TNF-α production than stimulated memory B cells from healthy controls 
(Figure 6.26.D). High levels of TNF-α have been found in synovial fluid of patients with 
RA and it has been proven to play an important role in inflammation and joint destruction 
(Choy and Panayi, 2001). Moreover, anti-TNF therapies have proven effective in the 
treatment of RA (Feldmann and Maini, 2001), highlighting the importance of this cytokine 
in RA.   
In terms of immunoglobulin production, IgM secretion was assessed. IgM is expressed on 
naïve B cells and it is the antibody formed during an initial response to an antigen (Goding, 
1978). It is a marker of non-class-switched B cells. As expected, my results showed 
secretion of IgM from all the subsets after stimulation, with memory B cells showing higher 
secretion (Figure 6.27.A). A study reported CD5+ B cells produced polyreactive IgM, 
natural antibodies recognising autoantigens (Duan and Morel, 2006). Nevertheless, in my 
study no increased production of IgM was seen by these cells compared to other subsets, 
yet no evaluation assessing which epitopes the secreted antibodies recognised was done. 
Supernatants from stimulated memory and ABCs were sent to the Newcastle clinical 
laboratories (Newcastle Hospitals NHS Trust) for the detection of RF and CCP antibodies. 
However, no autoantibodies were detected probably due to the low cell numbers used. 
Moreover, no differences in IgM production by all the B cell subsets in established RA 
patients compared to healthy controls were detected (Figure 6.27.B-E). 
IgG secretion was also investigated. Contrarily to IgM, IgG is expressed and secreted by 
antigen-activated B cells which have undergone isotype switching (Rich et al., 2019). 
Because naïve and CD5+ B cells are not class-switched cells, the low secretion of IgG seen 
after stimulation was expected (Figure 6.28.A). On the contrary, high production of IgG by 
memory B cells was as predicted. Regarding the ABCs, as shown before in Chapter 4, 
Figure 4.11 and in Figure 6.14, around 50% of the B cells in the ABC population showed 
IgG surface expression. The percentage of IgG+ B cells in the ABC population was similar 
to the memory B cells, however, secretion of this immunoglobulin was much higher in 
memory B cells than in ABCs. These results indicate that in the ABC population there are 
not a lot of effective antibody producing cells, as seen in the memory B cell subset. This 
lower production of IgG by ABCs could also be due to the low number of live cells after 
culture. A study describing ABCs as CD11c+ T-bet+ IgM memory B cells demonstrated 
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that these cells are memory B cells which express IgM but respond quickly to antigen 
challenge and can undergo class-switching in germinal centres (Winslow et al., 2017). 
Therefore, the ABC subset found in the peripheral blood may be a heterogeneous 
population with cells which have undergo isotype class-switching in germinal centres and 
others which have not. This may also explain the discrepancies reported by other studies in 
expression of other markers, such as CD27 or T-bet (Thorarinsdottir et al., 2015). 
Interestingly, stimulated ABCs from established RA patients showed higher IgG 
production than stimulated ABCs from healthy controls (Figure 6.28.E). These results may 
suggest that the ABC population in RA patients have a higher percentage of class-switched 
cells or that these ABCs from RA patients may be more responsive to stimulation, leading 
to higher concentrations of IgG produced.   
Lastly, IgA production was also assessed. This immunoglobulin is of interest for its 
implication in mucosal immunity, as some studies point at mucosal sites as the trigger of 
autoimmunity (Catrina et al., 2014). IgA is also expressed and secreted after isotype 
switching. As expected, naïve B cells and CD5+ B cells secreted very low levels of IgA, 
even after stimulation (Figure 6.29.A). ABCs showed a similar result. However, the 
memory B cell population demonstrated some level of IgA secretion upon stimulation and 
even some without stimulation, suggesting that some spontaneous IgA producing B cells 
where found in this population. No differences in IgA production by all the B cell subsets 





In this chapter, I performed a functional characterisation of ABCs and other B cell subsets 
isolated from established RA patients and healthy controls. Previous studies on the 
functionality of ABCs show discrepancies when describing these cells as an exhausted or 
an activated B cell subset. Considering, the phenotypic and gene expression 
characterisation showed in previous chapters, I hypothesised that the ABC subset can 
respond to a B cell stimulation cocktail and produce immunoglobulins and pro-
inflammatory cytokines.  
Due to the limiting numbers of ABCs in blood, I optimised a protocol for the sorting and 
culturing of small numbers of B cells. Culturing 20,000 cells with a B cell stimulation 
cocktail for 5 days in a final volume of 200µl allowed for the detection of secreted IgG 
using ELISA. In addition, I optimised a protocol to reduce the sorting time compared to 
sorting directly from PBMCs, which did not alter the B cell function. After the optimisation 
of a protocol for the functional work, I sorted and cultured the different B cell subsets from 
established RA patients and healthy controls, I phenotyped the cells and analysed the 
supernatants for the detection of secreted immunoglobulins and cytokines. Analysis of the 
cells after 5 days of culture showed high cell death even in the stimulated conditions for 
CD5+ B cells, naïve B cells and ABCs. Phenotyping of the stimulated B cell subsets 
showed upregulation of activation markers, such as CD86, CD97 and CD27, as well as 
increased expression of the MHC class II molecule, HLA-DR. However, IgG expression 
was unchanged suggesting that 5 days of stimulation was not enough for the B cells to 
class-switch. Cytokine secretion revealed, in general, very low concentrations of most of 
the assessed cytokines, probably due to low cell numbers. Production of the cytokines by 
the different B cell subsets showed no differences except for the secretion of IL-10, which 
was mostly undetectable from ABCs. Analysis of the secretion of immunoglobulins 
showed production of IgM and IgG in ABCs although lower than the concentrations 
produced by memory B cells.  
In summary, to my knowledge this is the first time that cytokine production and 
immunoglobulin secretion by ABCs has been assessed following cell stimulation. 
Nevertheless, probably due to small numbers of cells, the amounts of cytokines detected 
was rather low. All in all, I cannot confirm the hypothesis that ABCs are an active and 
responsive B cell subset due to the high level of cell death seen. However, further studies 
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using large number of cells, different time points or different stimuli cocktails could give 















In Chapter 4, section 4.4.6 I assessed expression of the FcRL family of molecules on the 
ABC population. I demonstrated that higher percentages of cells positive for FcRL2, 
FcRL3, FcRL4 and FcRL5 were found in the ABC population. Following on from this 
discovery I next wanted to focus on the functional consequences of this expression.  
FcRL1-5, all expressed by B cells, are located in the human FcRL1-5 cluster, in 
chromosome 1. This cluster encodes transmembrane glycoproteins with extracellular Ig-
like domains and cytoplasmic tails with immunoreceptor tyrosine-based activating 
(ITAM), switch (ITSM) and/or inhibitory (ITIM) motifs (Davis et al., 2002) (Figure 7.1). 
The cytoplasmic properties of FcRLs are complex. The cytoplasmic tail of most FcRLs 
possess both ITAM-like and ITIM elements. The possession of these intracellular 
sequences indicates that most of these molecules may be capable of exerting a dual 
modulation. However, the exact mechanism of how their dual-regulation modulates TLR 
versus BCR activation of B cells and impacts innate and adaptive immune responses still 
needs to be explored (Kochi et al., 2009; Sohn et al., 2011). Moreover, expression of FcRLs 
have been implicated to have potential roles in certain diseases. Several FcRLs have been 
found upregulated among lymphocyte populations in individuals with chronic viral 
diseases (Moir et al., 2008) as well as in patients with combined variable immunodeficiency 
(CVID) (Rakhmanov et al., 2009). Furthermore, disease risk associations for single 
nucleotide polymorphisms (SNP) located in regions of FcRLs genes have arisen in a variety 
of disorders (Kochi et al., 2005). 
In light of the fact that my supervisor at the University of Birmingham, Professor Dagmar 
Scheel-Toellner, works on FcRL4+ B cells from RA joints, I decided to focus on one of the 
others FcRLs and further investigate its potential role in B cell function. Out of the 
remaining FcRLs that are highly expressed on ABCs I chose to investigate the role of 
FcRL3 due to the implication that a certain FcRL3 polymorphism acts as a risk factor in 
RA (Lin et al., 2016). Additionally, previous work published by our group, which 
reinforces the suggestion that FcRL3 polymorphisms may be risk factors for RA, identified 
both a methylation and an expression quantitative trait locus (mQTL and eQTL, 
respectively) in the FcRL3 region on B cells and T cells from patients with RA (Clark et 
al., 2020).  
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FcRL3 highest expression is found on memory B cells in the periphery and it marks a 
circulating innate-like marginal zone (MZ) B cell equivalent (Li et al., 2013). However, 
FcRL3 is also expressed outside the B cell lineage by subpopulations of cytotoxic NK and 
CD8+ T cells as well as a dysfunctional population of CD4+ regulatory T cells (Nagata et 
al., 2009). It has already been reported that FcRL3 engagement augmented TLR9 triggered 
blood B cell proliferation, survival, and induction of activation markers, in addition to 
inhibiting Ig production and halting the differentiation of antibody-secreting cells (Li et al., 
2013). To expand on this work, I aimed to further investigate the role of FcRL3 on B cell 
function.  
In order to achieve this aim, I created a Ramos B cell line overexpressing FcRL3 to aid in 
the exploration of B cell function, as well as provide a tool that could aid in the 
identification of a ligand for FcRL3. 
 
 
Figure 7. 1. Protein structure of the human FcRL family molecules. In the extracellular 
space, immunoglobulin domains are shown as circles. These are colour-coded to indicate 
their phylogenetic relationships. FcRL cytoplasmic tails possess consensus sequences for 
immunoreceptor tyrosine-based activating motifs (ITAM) in red, immunoreceptor 
tyrosine-based inhibitory motifs (ITIM) in green and immunoreceptor tyrosine-based 




7.2 Chapter hypothesis and aims 
In this section of my project, I addressed the hypothesis that overexpression of FcRL3 has 
an impact on B cell proliferation, apoptosis susceptibility and cytokine and 
immunoglobulin production.  
Therefore, the aims of this chapter were to: 
1. Stably transduced a B cell line to overexpress FcRL3. 
2. Explore the potential role for FcRL3 on B cell function. 
The specific objectives were: 
1. Stably transduce a B cell line, like the Ramos cell line to overexpress FcRL3.  
2. Determine if FcRL3 overexpression changes the Ramos cell phenotype. 
3. Determine whether FcRL3 overexpression has any effect on cell proliferation. 
4. Investigate if FcRL3 overexpression affects apoptosis susceptibility.  
5. Determine if FcRL3 overexpression alters the response of Ramos B cells to stimuli.  
6. Assess changes in phenotype, cytokine secretion profile and immunoglobulin 




7.3.1 FcRL3 overexpression in a B cell line using a retroviral approach  
In order to further investigate the role of FcRL3 in B cell biology, I wanted to establish a 
B cell line which overexpresses FcRL3. Because I already had an expression plasmid 
(pcDNA3) containing the FcRL3 transcript sequence (a kind gift from Professor Nagata, 
Osaka University, Japan), I first verified that the FcRL3 transcript sequence in the pcDNA3 
expression plasmid was the correct sequence (see Appendix A.5 for sequence BLAST 
against the reference gene). The sequence in the plasmid was identical to the reference 
sequence. 
Next, two B cell lines were chosen to overexpress FcRL3: Ramos B cells, and Raji B cells. 
Both B cell lines come from a Burkitt’s lymphoma, but Ramos are EBV negative, whereas 
Raji B cells are EBV positive. The approach used to transfect the cell lines was 
electroporation using the Neon Kit (Thermo Fisher). The pcDNA3 plasmid contained a 
neomycin resistance gene, confirming resistance to the G-418 antibiotic to successfully 
transfected cells. I cultured the transfected cells in culture medium containing G-418 to 
select only the cells containing the plasmid. Transfection efficacy was checked via flow 
cytometry using an FcRL3 antibody. Figure 7.2 shows transfection efficiency in the Ramos 
cells (Figure 7.2.A) and the Raji cells (Figure 7.2.B). For both cell lines, the transfection 
efficiency was low as the percentage of FcRL3 positive cells at day 3 after selection were 
less than 1%. Selection with the concentration of G-418 used did not kill the non-
transfected cells and, therefore did not select for the transfected cells because the 
percentage of FcRL3 positive cells did not increase at day 9 or day 18. In Ramos B cells, 
there was a small increase at day 12 to 14, however the expression was lost in the following 
days of culture. Due to the fact that the Raji cell line was prone to apoptosis following the 
transfection procedure (data not shown), and  also seemed to have low endogenous 





Figure 7. 2. The transfection efficacy of Ramos cells and Rajis cells using electroporation. 2x105 Ramos or Raji cells were transfected with a 
pcDNA3 expression plasmid (at a concentration of 3µg/µl) containing the FcRL3 transcript sequence using the Neon electroporator. After resting 
the cells for 3 days, the transfected cells were cultured in medium containing G-418 (at a concentration of 600µg/ml). A. FcLR3 expression check 
by flow cytometry of transfected Ramos B cells at day 3, day 12 and day 18 post antibiotic selection. Firstly, dead cells and doublets were excluded 
and from the cell population, FcRL3 was gated against CD19. Gates were set based on the cells transfected with no plasmid. The graph on the 
right shows the percentage of FcRL3 positive cells over time in transfected and untransfected cells in Ramos B cells. B. FcRL3 expression 
assessment using flow cytometry on transfected Raji B cells at day 3, day 12 and day 18 post antibiotic selection. As in A, FcRL3 expression was 
gated against a B cell marker CD19 after excluding dead and doublet cells. Gates were set based on the cells transfected with no plasmid. The 
graph on the right shows the percentage of FcRL3 positive cells over time in transfected and untransfected Raji cells.
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Because electroporation did not work and I could not establish a stably transfected cell line, 
I decided to try another approach to transfect the cells. Previously in our group, a protocol 
to transfect Jurkat T cells using a retroviral approach was optimised. In order to create 
retroviral particles which carried the expression plasmid for FcRL3, I had to clone the 
FcRL3 gene into the retroviral plasmid pIG (Puro IRES GFP, kind gift from Dr Carmody, 
Glasgow University, UK). Through the IRES sequence this plasmid enables the expression 
of the protein of interest (FcRL3), along with expression of GFP as a separate protein 
product. The plasmid also contains a puromycin resistance gene, allowing for cell selection 
to create stably transfected cell lines.  
A forward and a reverse primer were designed to incorporate restriction enzyme sites, Xho 
I and Hpa I contained within the pIG plasmid, at the 5’ and 3’ end of the FcRL3 transcript 
sequence, respectively (see Chapter 2 methods section 2.8.5 for primers sequence). First, 
the FcRL3 gene was amplified from the pcDNA3 plasmid (data not shown) and purified 
from the agarose gel. The gene was then restriction enzyme digested with Xho I and Hpa 
I, alongside the pIG plasmid to linearise it and create the sticky ends that would allow the 
gene to be ligated into the plasmid. The digestion products for both the plasmid and FcRL3 
gene are shown in Figure 7.3.A. The bands marked by the squares were cut and purified 
from the agarose gel and then used in a ligation assay with the DNA ligase T4 enzyme. The 
ligation assay product was then used to transform E. coli bacteria which was then cultured 
on an ampicillin containing agar plate. From the colonies that grew overnight (data not 
shown), 12 were picked and the plasmid was extracted using a MiniPrep Kit. Purified 
plasmids from each colony were restriction enzyme digested with Xho I and Hpa I and ran 
on a gel (Figure 7.3.B). Only one colony, number 8 (the gel image for colonies 1 to 6 not 
shown) showed two bands which had the expected size for the FcRL3 gene (2,225 bp) and 
the pIG plasmid backbone (7,649 bp), therefore, colony 8 was transformed with the correct 
plasmid containing the gene. However, to make sure that the FcRL3 transcript sequence 
was the correct one and did not contain any mutations, I sent the plasmid for sequencing of 
the FcRL3 transcript (see Appendix A.6 for sequence BLAST against the reference). The 




Figure 7. 3. Restriction enzyme digestion products for cloning of FcRL3 into the retroviral plasmid pIG. A. FcRL3 was PCR amplified from 
the pcDNA plasmid using primers to incorporate an Xho I site at the 5’ end of the product and an Hpa I site at the 3’ end of the product. Both 
amplified FcRL3 product and the pIG plasmid were restricted enzyme digested with Xho I and Hpa I and the resultant digests were ran on an 
agarose gel. Lane 1 and 8 show the DNA size ladder. In lane 2, in blue, the FcRL3 product (expected size of 2,225 bp). Lane 3 is empty. The 
plasmid was loaded in the lanes marked in green. Different controls were used; one undigested plasmid (lane 4) and a single digested plasmid (lane 
5) and double digested plasmid (lane 7) both with an expected size of ~7,649 bp (as the two restriction enzyme sites are only separated by 8 bp in 
the plasmid). B. Plasmids from 12 different transformed E.coli colonies were digested with both the restriction enzymes, Xho I and Hpa I, to check 
that the FcRL3 was successfully ligated in the plasmid. The resultant digestions were run on an agarose gel. The first and last lanes show the DNA 
ladders. For each colony, labelled with numbers, a single digestion (SD) and a double digestion (DD) were loaded in the gel. Colony number 8 
was the only one with the expected size for the plasmid; for the single digestion 9,874 bp was expected and for the double digestion two bands 
were expected, one corresponding to the plasmid backbone (7,649 bp) and the other one corresponding to the FcRL3 gene (2,225 bp). 
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After making sure that the plasmid contained the correct sequence of the FcRL3 transcript, 
I proceeded to the generation of the retroviral particles. In order to create the retroviral 
particles, I transfected HEK293T cells, a highly transfectable derivate of the human 
embryonic kidney 293 cell line, with the three plasmids: pIG-FcRL3, pCGP (coding Gag-
Pol) and VSVG (coding the vesicular stomatitis glycoprotein) using Lipofectamine 
(Thermo Fisher). These last two plasmids are translated into protein and the cells then 
produce retroviral particles containing the pIG-FcRL3 plasmid. The retroviral particles are 
released by the cells into the culture supernatant. I collected the culture supernatant and 
added them to the Ramos cells. As a control I also generated retroviral particles containing 
an empty pIG plasmid. This should result in the overexpression of GFP but no expression 
of FcRL3 in the successfully transduced cells. These cells will also be puromycin resistant, 
and were used as a control as they had been through the same transduction process as the 
FcRL3 overexpressing cells. 
As the successful transduction of the pIG plasmid leads to expression of GFP, transfection 
efficiency of the Ramos cells was assessed by analysis of GFP fluorescence by fluorescent 
microscopy and flow cytometry. The expression of FcRL3 was also assessed by flow 
cytometry using an anti-FcRL3 antibody. Transfected cells were selected using the 
antibiotic puromycin. 8 days after the addition of puromycin, as expected, untransduced 
Ramos cells (wild type) were double negative (GFP- FcRL3-), Ramos cells transfected with 
the empty pIG plasmid (termed Ramos GFP control cells) were only positive for GFP 
(GFP+ FcRL3-), whereas about 50% of the Ramos cells transfected with the FcRL3 
plasmid (termed Ramos FcRL3+ cells) were double positive for FcRL3 and GFP (GFP+ 
FcRL3+), with the other 50% of cells only expressing GFP (GFP+ FcRL3-) (Figure 7.4.A). 
The fluorescent microscopy image in Figure 7.4.B shows that the Ramos FcRL3+ cells 
express GFP although some are brighter than others, as confirmed by flow cytometry. 
Figure 7.4.C shows the change in FcRL3 and GFP expression in the Ramos FcRL3+ cells 
over time. Because the percentage of double positive cells seemed to decrease over time, 
possibly due to overgrowth of the culture by the cells only expressing GFP, I decided to 
flow cytometry sort the different populations to try and enrich for the double positive cells 
(GFP+ FcRL3+).  
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Figure 7. 4. Retroviral transduction efficacy in Ramos B cells was assessed using flow cytometry and fluorescence microscopy. 5x105 Ramos 
B cells were either left untransduced (wild type) or were transduced with a HEK293T cell culture supernatant (various volumes: 250µl, 500µl, 
750µl and 1000µl) containing retroviral particles expressing an FcRL3 plasmid (Ramos FcRL3+ cells), or as a control, an empty plasmid (Ramos 
GFP control cells). Both plasmids will lead to expression of GFP and puromycin resistance but only the FcRL3 plasmid will lead to FcRL3 
expression. After resting the cells for 3 days the transduced cells were cultured in medium containing puromycin at 1μg/ml. A. Transduction 
efficacy at day 8 post puromycin selection was checked by flow cytometry after staining cells with an anti-FcRL3 antibody and a viability dye. 
Dead cells and doublets were excluded, and from the alive cell gate, GFP was gated against FcRL3. Gates were set based on the untransduced 
cells. In red, gating of untransduced cells (wild type), in green empty plasmid transduced cells (Ramos GFP control), and in blue the gating for the 
FcRL3 plasmid transduced (Ramos FcRL3+ cells) is shown. B. Ramos FcRL3+ cells seen under the fluorescence microscope. Image from day 16 
post transfection using the 10x objective. C. Ramos FcRL3+ cells were assessed for expression of both GFP and FcRL3 over time after the addition 
of the selection antibiotic puromycin. Dead cells and doublets were excluded, and from the alive cell gate, GFP was gated against FcRL3. Gate 
based on untransduced cells.
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The gating strategy used to sort the transduced Ramos cells is shown in Figure 7.5.A. Three 
populations were sorted: GFP bright cells (GFP bright FcRL3-), GFP intermediate cells 
(GFP+ FcRL3-) and double positive cells (FcRL3+ GFP+). Figure 7.5.B shows the sorted 
populations 12 days after sorting. Some of the GFP intermediate cells seem to become 
double positive, whereas GFP bright cells stayed only positive for GFP. The FcRL3+GFP+ 
Ramos cells kept expression of both GFP and FcRL3 (Figure 7.5. B).  
Expression of both GFP and FcRL3 was also checked at a later time point (60 days after 
sorting), and the Ramos cells appear to have stable expression of both GFP and FcRL3 
(Figure 7.6.A). The Ramos GFP control cells also had stable expression of only GFP 
(Figure 7.6.B).  
FcRL3 expression in untransduced Ramos cells (wild type), Ramos GFP control cells, and 
sorted Ramos FcRL3+ cells was also assessed by TaqMan qPCR to confirm overexpression 
at the gene level (Figure 7.6.C). Normalised expression as compared to wild type cells 
shows high expression of FcRL3 mRNA by the Ramos FcRL3+ cells (about 150 times 
more than the wild type), whereas Ramos GFP control cells transfected with the empty 




Figure 7. 5. The gating strategy used to sort the FcRL3 transduced Ramos cells and the FcRL3 expression check after sorting. A. Dead 
cells and doublets were excluded. Alive cells were gated using the SSC-A against the FSC-A. From the cells gate, GFP expression was plotted 
against FcRL3 expression and three population were gated and sorted: GFP bright cells (GFP bright FcRL3-), GFP intermediate cells (GFP+ 
FcRL3-) and double positive cells (FcRL3+ GFP+). B. GFP and FcRL3 expression was assessed 12 days after of the sort by flow cytometry for 





Figure 7. 6. GFP and FcRL3 expression in the double positive (GFP+ FcRL3+) sorted Ramos cells. A-B. GFP and FcRL3 expression check 
on double positive (GFP+ FcRL3+) sorted Ramos FcRL3+ cells (A) and GFP control transduced Ramos B cells (B), 12 and 60 days after sorting 
as assessed by flow cytometry following staining with an anti-FcRL3 antibody. The plots shown are gated cells after excluding dead cells and 
doublets. Gates were set from the untransduced Ramos cells. C. FcRL3 gene expression was checked using TaqMan qPCR. Wells were run in 
duplicate and normalised to the housekeeping gene, POLR2A, followed by normalisation to the wild type cells. 
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7.3.2 FcRL3 overexpression does not influence the phenotype of Ramos cells 
After I had generated a stable Ramos cell line that overexpressed FcRL3 (Ramos FcRL3+ 
cells), as well as a stable GFP control cell line (Ramos GFP control cells), I firstly wanted 
to assess if expression of FcRL3 in the transduced cells had an effect on the Ramos 
phenotype. Therefore, I stained the different cell lines with pre-optimised antibody panels 
to compare expression of different B cell markers in the Ramos wild type cells, the Ramos 
GFP control cells, and the Ramos FcRL3+ cells.  
Figure 7.7 shows expression of HLA-DR, co-stimulatory molecules and activation 
markers. In terms of the percentage of the antigen-presenting molecule, HLA-DR, there 
was variation in expression as not all the cells were positive for this marker (Figure 7.7.A). 
Moreover, there was little difference in the expression of HLA-DR between the wild type 
cells and the two transduced cell lines, although the Ramos GFP control cells appeared to 
have a bigger variation of HLA-DR expression within the population. All Ramos cell lines 
were positive for the co-stimulatory molecule, CD40, (Figure 7.7.B), and, there was no 
difference in expression between the different cell lines. Expression of the activation 
marker, CD69, was low on all the Ramos cell lines, and its expression did not change 
between the wild type cells and the two transduced cell lines (Figure 7.7.C). All the Ramos 
cell lines were also positive for the co-stimulatory molecule, CD86, and again, there was 
no difference in expression between the different cell lines (Figure 7.7.D).  
FcRL4 was expressed at very low levels on all the Ramos cell lines (Figure 7.8.A), while 
none of the Ramos cell lines expressed FcRL5 (Figure 7.8.B). There was no difference in 
expression of either of these markers between the different Ramos cell lines.  
As expected for a cell line, Ki67 was highly expressed in all the Ramos cell lines (Figure 
7.9.A), and no difference in Ki67 expression was found between the different cell lines. In 
addition, all the Ramos cell lines, were negative for the transcription factor T-bet (Figure 




Figure 7. 7. HLA-DR, co-stimulatory molecule and activation marker’ expression on Ramos wild type, FcRL3+ cells and GFP control 
cells. Ramos cell lines were stained with a pre-optimised flow cytometry panel and assessed by flow cytometry. The cells were gated to exclude 
dead cells and doublets. Gates were set using the unstained cells. An exemplar flow cytometry plot showing HLA-DR expression (A, left panel), 
CD40 expression (B, left panel), CD69 expression (C, left panel) and CD86 expression (D, left panel) in Ramos FcRL3+ cells. Overlay histograms 
for each of the cell lines is shown for HLA-DR expression (A, right panel), CD40 expression (B, right panel), CD69 expression (C, right panel) 
and CD86 expression (D, right panel). For all the overlay histograms, the peaks are normalised to the same height to standardise for different 
numbers of cells in each population. MFI values are shown in the histograms. Ramos wild type cells are shown in red; Ramos GFP control are 




Figure 7. 8. FcRLs expression on Ramos wild type, FcRL3+ cells and GFP control cells. Ramos cell lines were stained with a pre-optimised 
flow cytometry panel and assessed by flow cytometry. The cells were gated to exclude dead cells and doublets. Gates were set using the unstained 
cells. An exemplar flow cytometry plot showing FcRL4 expression (A, left panel) and FcRL5 expression (B, left panel) in Ramos FcRL3+ cells. 
Overlay histograms for each of the cell lines is shown for FcRL4 expression (A, right panel) and FcRL5 expression (B, right panel). For all the 
overlay histograms, the peaks are normalised to the same height to standardise for different numbers of cells in each population. MFI values are 











Figure 7. 9. Intracellular markers, Ki67 and T-bet, expression on Ramos wild type, FcRL3+ cells and GFP control cells. Ramos cell lines 
were stained with a pre-optimised flow cytometry panel and assessed by flow cytometry. The cells were gated to exclude dead cells and doublets. 
Gates were set using the unstained cells. An exemplar flow cytometry plot showing Ki67 expression (A, left panel) and T-bet expression (B, left 
panel) in Ramos FcRL3+ cells. Overlay histograms for each of the cell lines is shown for Ki67 expression (A, right panel) and T-bet expression 
(B, right panel). For all the overlay histograms, the peaks are normalised to the same height to standardise for different numbers of cells in each 
population. MFI values are shown in the histograms. Ramos wild type cells are shown in red; Ramos GFP control are shown in green and Ramos 
FcRL3+ cells are shown in blue. 
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As previously reported in the literature (Upton and Unniraman, 2011), Ramos cells were 
all positive for IgM surface expression and there was no difference between expression in 
the Ramos wild type cells and both the transduced cell lines (Figure 7.10.A). In terms of 
IgD expression, all of the Ramos cell lines were negative for this immunoglobulin (Figure 
7.10.B). The Ramos cell lines were also negative for the class-switched immunoglobulin, 
IgG (Figure 7.10.C).  
In terms of CD5 expression, none of the Ramos cell lines were found to express this marker 
(Figure 7.10.D).  
I also assessed the B cell lineage markers I used to identify different B cell subsets. CD11c, 
a marker of ABCs, was expressed at very low levels in all the Ramos cell lines (Figure 
7.11.A), and there was no change in expression between the Ramos wild type cells and the 
two transduced cell lines, although the Ramos GFP control cells appeared to have a small 
increase in CD11c expression, as measured by the MFI. All the Ramos cell lines were close 
to 100% positive for the activation markers CD27 and CD97 (Figure 7.11.B-C), and no 





Figure 7. 10. Immunoglobulin expression on Ramos wild type, FcRL3+ cells and GFP control cells. Ramos cell lines were stained with a pre-
optimised flow cytometry panel and assessed by flow cytometry. The cells were gated to exclude dead cells and doublets. Gates were set using the 
unstained cells. An exemplar flow cytometry plot showing IgM expression (A, left panel), IgD expression (B, left panel) and IgG expression (C, 
left panel) in Ramos FcRL3+ cells. Overlay histograms for each of the cell lines is shown for IgM expression (A, right panel), IgD expression (B, 
right panel) and IgG expression (C, right panel). For all the overlay histograms, the peaks are normalised to the same height to standardise for 
different numbers of cells in each population. MFI values are shown in the histograms. Ramos wild type cells are shown in red; Ramos GFP control 





Figure 7. 11. Phenotypic marker’s expression on Ramos wild type, FcRL3+ cells and GFP control cells. Ramos cell lines were stained with 
a pre-optimised flow cytometry panel and assessed by flow cytometry. The cells were gated to exclude dead cells and doublets. Gates were set 
using the unstained cells. An exemplar flow cytometry plot showing CD11c expression (A, left panel), CD27 expression (B, left panel), CD97 
expression (C, left panel) and CD5 expression (D, left panel) in Ramos FcRL3+ cells. Overlay histograms for each of the cell lines is shown for 
CD11c expression (A, right panel), CD27 expression (B, right panel), CD97 expression (C, right panel) and CD5 expression (D, right panel). For 
all the overlay histograms, the peaks are normalised to the same height to standardise for different numbers of cells in each population. MFI values 




7.3.3 Control retroviral transduction increases cell proliferation, whereas FcRL3 
overexpression retroviral transduction returns cell proliferation to wild type levels 
I assessed cell proliferation using the cell proliferation tracking dye, CellTrace Violet 
(CTV), to determine whether overexpression of FcRL3 had any effect on cell proliferation 
and replication. Cells from each of the Ramos cell lines (wild type, GFP control and 
FcRL3+) were stained with CTV and cultured as normal. At different time points, an 
aliquot of the cell cultures was removed and the cells were assessed on a flow cytometer to 
determine CTV dilution, which is indicative of cell proliferation. 
Interestingly, the Ramos GFP control cells had a much higher proliferative rate after 12, 24 
and 76 hours as compared to the Ramos FcRL3+ cells and Ramos wild type cells (Figure 
7.12.A-C). There was no clear difference in the proliferative rate of the Ramos FcRL3+ 
cells compared to the Ramos wild type cells at these time point. By day 5, most of the cells 
from all the Ramos cell lines were dim for CTV, indicating that the majority of the cells 
had undergone multiple rounds of proliferation (Figure 7.12.D).  
The Ramos GFP control cells had a higher proliferative rate over time compared to the 
Ramos FcRL3+ cells and Ramos wild type cells (Figure 7.12.E). However, FcRL3+ Ramos 





Figure 7. 12. Cell proliferation of Ramos FcRL3+ cells and control cells. The Ramos cell lines were labelled with CellTrace Violet (CTV) and 
cultured as normal for 24 hours (A), 48 hours (B), 72 hours (C) and 5 days (D). CTV expression overlay histograms are shown with Ramos wild 
type cells in red, Ramos GFP control cells in green and Ramos FcRL3+ cells in blue. The cells were gated to exclude dead cells and doublets. For 
all the overlay histograms, the peaks are normalised to the same height to standardise for different numbers of cells in each population. E. 
Percentage of divided cells (CTV dim or negative) in the four time points. Ramos wild type cells are shown in red, Ramos GFP control cells are 
shown in green and Ramos FcRL3+ cells are shown in blue. N = 1.
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7.3.4 FcRL3 overexpression increases the susceptibility of Ramos cells to Fas ligand-
induced apoptosis 
Evidence from the literature suggests that FcRL3+ Tregs might be predisposed to apoptosis 
due to their high expression of the apoptosis-inducing marker CD95/Fas (Swainson et al., 
2010). I decided to investigate whether FcRL3 overexpression had an effect on apoptosis 
susceptibility in the Ramos cell lines. Cells from each of the Ramos cell lines were 
incubated without or with different concentrations of an anti-CD95 antibody for 24 hours. 
Cell death was assessed by flow cytometry using Annexin V and Zombie UV (ZUV) 
staining. Cells which are only positive for Annexin V (Annexin V+ ZUV-) are in early 
apoptosis, whereas double positive cells (Annexin V+ ZUV+) are dead.  
For the Ramos wild type cell cultures, around 7% of the cells die (are ZUV+ AnnexinV+) 
without any addition of an anti-CD95 antibody (Figure 7.13.A). However, when the cells 
were cultured with 100ng/ml of anti-CD95 antibody the percentage of dead cells nearly 
doubled to 11%. The percentage of early apoptotic cells increases slightly from 1% without 
anti-CD95 antibody to 1.6% with the anti-CD95 antibody. Similar results were seen for the 
Ramos GFP control cells, which had 6% dead cells and 1.1% early apoptotic cells without 
the anti-CD95 antibody and 11% dead cells and 2.3% early apoptotic cells with the anti-
CD95 antibody (Figure 7.13.B).  Interestingly, the percentage of dead cells in the Ramos 
FcRL3+ cell cultures without the addition of an anti-CD95 antibody was nearly double that 
seen in the Ramos GFP control cells and the wild type cells (14% compared to 7% and 6%, 
respectively) (Figure 7.13.C). The percentage of early apoptotic cells without the addition 
of anti-CD95 antibody (1.6%) was similar to the Ramos wild type cells and Ramos GFP 
control cells. When the Ramos FcRL3+ cells are cultured with 100ng/ml of anti-CD95 
antibody, the percentage of dead and early apoptotic cells increased considerably to 20% 
and 3.6% respectably (Figure 7.13.C). Overall Ramos FcRL3+ cells had a higher 
percentage of early apoptotic cells and dead cells and were more prone to apoptosis both in 
a resting state and when stimulated via Fas/CD95 than the Ramos wild type cells and the 
Ramos GFP control cells (Figure 7.14.A-B). 
Of general note, Ramos cells appear to be quite resistant to CD95-induced apoptosis as the 
percentage of dead cells and early apoptotic cells after addition of anti-CD95 antibody was 




Figure 7. 13. Evaluation of apoptosis induction and cell death following addition of an anti-CD95 antibody to the Ramos cell lines. 1x106 
Ramos cell were cultured without or with 100ng/ml anti-CD95 antibody for 24 hours, after which apoptosis and cell death were assessed by flow 
cytometry. The cells were gated to exclude doublets. An exemplar flow cytometry plot showing Zombie UV against Annexin V in untreated (no 





Figure 7. 14. Evaluation of apoptosis induction and cell death following addition of an anti-CD95 antibody to the Ramos cell lines. 1x106 
Ramos cell were cultured without or with 100ng/ml anti-CD95 antibody for 24 hours, after which apoptosis and cell death were assessed by flow 
cytometry. The cells were gated to exclude doublets. A. Percentage of early apoptotic cells (Annexin V+ only) using different concentrations of 
anti-CD95 antibody in the three Ramos cell lines. B. Percentage of dead cells (ZUV+ Annexin V+) using different concentrations of anti-CD95 
antibody in the three Ramos cell lines. N = 1.  
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7.3.5 Changes in the phenotype, cytokine secretion profile, and immunoglobulin 
production of Ramos FcRL3+ cells after B cell stimulation  
In order to assess if FcRL3 overexpression alters the Ramos cell response I firstly tested 
two different stimulation cocktails on Ramos FcRL3+ cells. Stimulation cocktail 1 was the 
optimised cocktail used for the other B cell stimulation assays using sorted B cell subsets. 
This stimulation cocktail contained TLR7 ligand Imiquimod, TLR9 agonists ODN 2216 – 
CpG A and ODN 2006 – CpG B, Poke Weed Mitogen, anti-CD40, human IL-21, human 
IL-4 and IFN-gamma. Stimulation cocktail 2 contained all the above stimuli but no IL-4. 
IL-4 was excluded from the stimulation cocktail as it has been shown to inhibit expression 
of CD11c and T-bet in B cells (Naradikian et al., 2016b). Cells were stimulated for 3 days 
after which the cell phenotype was assessed by flow cytometry. 
Following stimulation with the two different stimulation cocktails there were changes in 
certain markers with both stimulation conditions (Figure 7.15). There appears to be a slight 
downregulation in HLA-DR expression (Figure 7.15.A). Although CD86 was already 
highly expressed in the unstimulated Ramos FcRL3+ cell line, it was slightly increased 
upon stimulation (Figure 7.15.B). Expression of CD11c was increased (Figure 7.15.C), 
whereas CD27 expression was decreased with both stimulation cocktails (Figure 7.15.D). 
IgM appears to be slightly downregulated with both stimulation cocktails (Figure 7.15.E). 
IgD expression, however, did not change after stimulation (Figure 7.15.F). Even though 
CD97 expression was high in unstimulated cells, expression of this marker increased after 




Figure 7. 15. Phenotypic marker expression on unstimulated and stimulated Ramos FcRL3+ cells. 2.5x105 Ramos FcRL3+ cells were left 
unstimulated or were stimulated with either stimulation cocktail1 (Imiquimod, CpG A and CpG B, PWM, anti-CD40, IL-21, IL-4 and IFN-γ) or 
stimulation cocktail 2 (Imiquimod, CpG A and CpG B, PWM, anti-CD40, IL-21 and IFN-γ) for 3 days. The cells were then stained with a pre-
optimised flow cytometry panel and assessed by flow cytometry. The cells were gated to exclude dead cells and doublets. Flow cytometry overlay 
histograms are shown displaying unstimulated cells (red), cells stimulated by stimulation cocktail 1 (blue), and cells stimulated by stimulation 
cocktail 2 (orange) for expression of HLA-DR (A), CD86 (B), CD11c (C), CD27 (D), IgM (E), IgD (F), CD97 (G), and T-bet (H). For all the 
overlay histograms, the peaks are normalised to the same height to standardise for different numbers of cells in each population. N = 1. 
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After testing the two different stimulation cocktails on Ramos FcRL3+ cells I decided to 
use stimulation cocktail 2 for assessing the phenotype, the cytokine secretion profile and 
the immunoglobulin production. This cocktail contained TLR7 ligand Imiquimod, TLR9 
agonists ODN 2216 – CpG A and ODN 2006 – CpG B, Poke Weed Mitogen, anti-CD40, 
human IL-21 and IFN-gamma. The different Ramos cell lines were stimulated for 3 days 
after which the phenotype was assessed by flow cytometry, and culture supernatants were 
collected for secreted immunoglobulin and cytokine detection.  
Figure 7.16 shows expression of the phenotype markers, as displayed in Figure 7.15, 
comparing Ramos wild type cells, Ramos GFP control cells, and Ramos FcRL3+ cells 
following stimulation. When the expression profiles of the Ramos wild type cell, Ramos 
GFP control cells, and Ramos FcRL3+ cells were compared following stimulation there 
was very little difference between the cell lines for the majority of the markers analysed 
(Figure 7.16). The only small difference seen was slightly less expression of HLA-DR on 
the Ramos GFP control and the Ramos FcRL3+ cells compared to the Ramos wild type 
cells, however, this difference was also seen without stimulation (Figure 7.7.A) so may not 
be a consequence of stimulation.  
In summary, stimulation of the different Ramos cell lines, was not very informative for 
assessing the effect of FcRL3 overexpression on B cell function. This is possibly due to the 





Figure 7. 16. Phenotypic marker expression on stimulated Ramos cell lines. The different Ramos cell lines were stimulated with stimulation 
cocktail 2 (Imiquimod, CpG A and CpG B, PWM, anti-CD40, IL-21 and IFN-γ) for 3 days. The cells were then stained with a pre-optimised flow 
cytometry panel and assessed by flow cytometry. The cells were gated to exclude dead cells and doublets. Flow cytometry overlay histograms are 
shown displaying Ramos wild type cells (red), Ramos GFP control cells (green), and Ramos FcRL3+ cells (blue) for expression of HLA-DR (A), 
CD86 (B), CD11c (C), CD27 (D), IgM (E), IgD (F), CD97 (G), and T-bet (H). For all the overlay histograms, the peaks are normalised to the 
same height to standardise for different numbers of cells in each population. N = 1. 
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Culture supernatants from the different stimulated Ramos cell lines were used for the 
detection of secreted immunoglobulins and cytokines. As previously reported in the 
literature (Benjamin et al., 1982), the Ramos wild type cells were found to spontaneously 
secrete high levels of IgM (Figure 7.17.A). Stimulation of the cells had no effect on the 
production of IgM. There were no major differences between the different Ramos cell lines. 
In terms of IgG secretion, the concentrations detected were very low (Figure 7.17.B), 
compared to the stimulated primary memory B cells (Chapter 6, Figure 6.30). The amount 
of IgA produced, similar to IgG, was very low (Figure 7.17.C) when compared to the 
concentration detected from primary memory B cells (Chapter 6, Figure 6.31). Generally, 
the Ramos cell lines did not produce IgA, even with stimulation, however, the stimulated 
Ramos GFP control cells produced a small amount of IgA. Unexpectedly, the unstimulated 
Ramos wild type cells also produced a small amount of IgA.  
Focusing on the cytokines produced by the Ramos cell lines, IL-2 levels were very low 
(Figure 7.18.A). Interestingly, IL-10 production from the stimulated condition is lower in 
Ramos FcRL3+ cells compared to the Ramos GFP control and the Ramos wild type cells 
(Figure 7.18.B). Similar to IL-2, IL-6, IL-23, GM-CSF and TNF-α production was also 




Figure 7. 17. Immunoglobulin production by unstimulated and stimulated Ramos cell 
lines. The different Ramos cell lines were left unstimulated or were stimulated with 
stimulation cocktail 2 (Imiquimod, CpG A and CpG B, PWM, anti-CD40, IL-21 and IFN-
γ) for 3 days. The culture supernatants were harvested and the concentrations of IgM (A), 
IgG (B) and IgA (C) were detected using the Isotyping Panel 1 Human Kit from MSD. 
Unstimulated cells are shown in light blue and cells stimulated with stimulation cocktail 2 
are shown in dark blue. The dotted line indicates the lower limit of detection for each 




Figure 7. 18. Cytokine production by unstimulated and stimulated Ramos cell lines. The different Ramos cell lines were left unstimulated or 
were stimulated with stimulation cocktail 2 (Imiquimod, CpG A and CpG B, PWM, anti-CD40, IL-21 and IFN-γ) for 3 days. The culture 
supernatants were harvested and the concentrations of IL-2 (A), IL-10 (B), IL-6 (C), IL-23 (D), GM-CSF (E) and TNF-α (F) were detected using 
a U-PLEX Custom Biomarker plate from MSD. Unstimulated cells are shown in light blue and cells stimulated with stimulation cocktail 2 are 




I have generated a stably transduced Ramos cell line that overexpresses FcRL3, as well as 
a Ramos GFP control cell line. These stable B cell lines have enabled me to perform my 
preliminary experiments to further investigate the effect of FcRL3 overexpression on B cell 
function, such as apoptosis and cell death, cytokine secretion, and immunoglobulins 
production. Based on my highly preliminary observation, further work will be needed to 
bring a deeper understanding of the role of FcRL3 in B cell function, which in turn will aid 
in determining why ABCs abundantly express FcRL3. 
The main aim of this work was to generate a stable transduced B cell line that overexpressed 
FcRL3. In a stably transfected cell, the introduced genetic material is passed to their 
daughter cells, either because the introduced genetic material is inserted into the host 
genome, or, sometimes via stable inheritance of nongenomic DNA. This allows for a 
sustained expression even after the cell replicates (Kim and Eberwine, 2010). The first 
approach I used to create a stably transfected cell line overexpressing FcRL3 was 
electroporation. Electroporation was tried because I already had access to a plasmid 
containing the FcRL3 transcript sequence (a kind gift from Professor Nagata, Osaka 
University, Japan). Although I previously used a chemical transfection reagent 
(lipofectamine) to successfully transfect HEK293T cells with the pcDNA3 FcRL3 plasmid 
(Chapter 4, section 4.4.6), it has been reported that cells which grow in suspension, like 
Ramos cells, do not transfect efficiently with lipofectamine (Rahimi et al., 2018). 
Therefore, I tried a physical method (electroporation) to transfect two different B cell lines, 
Ramos and Raji cells, with the pcDNA3 FcRL3 plasmid. A group had previously reported 
success in stably transfecting Ramos B cells with a pcDNA3.1 plasmid using 
electroporation, followed by selection of transfected cells with G-418 (Zhang et al., 2019a). 
Unfortunately, even though the protocol followed was as per the manufacturers’ 
instructions and was optimised for Ramos cells, the transfection efficacy I managed to 
achieve was very low and I could not generate a stably transfected cell line using this 
method (Figure 7.2).  
Previous work done in our group, resulted in the development of an optimised protocol for 
retroviral transduction of a T cell line, the Jurkat cell line (Natasha West, Newcastle 
University). Through our RACE collaboration with the University of Glasgow, Dr Ruaidhri 
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Carmody’s group kindly supplied the envelope, packaging and pIG-GFP transfer plasmids 
(VSVG, pCGP and pIG, respectively) for the retroviral generation.  
I successfully cloned the FcRL3 transcript sequence into the pIG-GFP plasmid (Figure 7.3). 
I used the retroviral transduction protocol developed for the Jurkat cell line and successfully 
transduced the Ramos cell line to overexpress FcRL3 (Figure 7.6).  
Puromycin selection of the transduced cells resulted in a significant number of transduced 
cells expressing FcRL3, as well as the reporter protein, GFP. Unfortunately, the cultures of 
transduced cells were heterogeneous, apart from the cell double positive for GFP and 
FcRL3, a second population expressing only GFP was present (Figure 7.4). One possible 
explanation for this could be that as the GFP translation is controlled by an IRES element, 
this may be stronger, resulting in more protein product, than translation of the FcRL3 gene 
(Addgene, 2014). In addition, GFP is easily visible and has a long half-life at both the 
mRNA level and the protein level, so expression of GFP may be visible even when the 
mRNA transcript, which would also include FcRL3, which may not have a long protein 
half-life, is not actively transcribed or translated anymore (Researchgate, 2013b). Other 
people have reported that when sorting GFP bright transduced cells, these cells died and 
had difficulties in expanding to sufficient cell numbers (Researchgate, 2013a). A possible 
explanation for this phenomenon is these cells are only focused on producing GFP and 
therefore do not replicate, resulting in cell death. Hence, the recommendation is that only 
the GFP+ cells, but not the brightest GFP expressing cells, are flow cytometry sorted.  
I decided not to use the Raji cell line for the transduction with the FcRL3 plasmid because 
after the transfection using electroporation the cell viability was very low. Moreover, after 
the electroporation process, which causes cell stress, the control cells transfected with no 
plasmid upregulated FcRL3 expression. Raji cells have been reported to be FcRL5 positive 
(Shabani et al., 2014) and lymphoma cells have high expression of FcRL family members 
(Polson et al., 2006; Li et al., 2014a). Moreover, Raji cells contain EBV DNA and although 
DNA synthesis is defective in this cell line, early antigens are expressed (Hatfull et al., 
1988). This could interfere with B cell activation and function. For these reasons, Raji cells 
were not a good cell line to use for overexpression of FcRL3 and this cell line was not 
transduced with the retrovirus. 
Focusing on the outcome of the functional work, I reported that there was no difference in 
the phenotype of Ramos cells that overexpressed FcRL3 compared to the GFP control cells 
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(Figure 7.7-11). Ramos cells transduced to overexpress FcRL3 showed the same expression 
pattern of B cell markers and activation markers as the Ramos wild type and the Ramos 
GFP control cells. These results could be explained by the fact that the cells have not been 
stimulated to induce a B cell response, which would lead to potentially alterations in the 
expression of certain markers.  
I therefore, investigated whether FcRL3 overexpression changed how the Ramos cells 
responded to a B cell stimulation cocktail. Stimulation cocktail 1 contained  TLR7 ligand 
Imiquimod, TLR9 agonists ODN 2216 – CpG A and ODN 2006 – CpG B, Poke Weed 
Mitogen, anti-CD40, human IL-21, human IL-4 and IFN-gamma. This stimulation cocktail 
mimicked signals from a T cell-dependent response such as PWM and anti-CD40, as well 
as innate signals such as TLR ligands (T cell-independent response). Stimulation cocktail 
2 contained all the above stimuli but no IL-4. IL-4 was excluded from the stimulation 
cocktail as it has been shown to inhibit expression of CD11c and T-bet in B cells 
(Naradikian et al., 2016b). These potent stimulation cocktails were chosen to make sure the 
cells were fully activated. Although there were no differences in cell activation using the 
two stimulation cocktails (Figure 7.15), I decided to use stimulation cocktail 2 for the 
phenotype assessment, the cytokine secretion profile and the immunoglobulin production 
as this cocktail would more closely resemble the signals that drive the ABC-like phenotype. 
The differences seen in the stimulated, as compared to the unstimulated cells, confirm that 
Ramos cells do respond to a B cell stimulation cocktail as there was upregulation of 
activation markers, such as CD86 and CD97 (Figure 7.15). Sadly, there were no striking 
differences in expression of co-stimulatory and activation markers between the Ramos wild 
type, the Ramos GFP control, and the Ramos FcRL3+ cell lines (Figure 7.16). One 
explanation as to why I did not see any difference in the phenotype between the cells 
overexpressing FcRL3, as compared to the controls, may be due to the fact that the FcRL3 
receptor is not being engaged by its ligand and is therefore not actively signalling and 
exerting an effect. Thus, without ligation of the FcRL3 receptor no effect on B cell effector 
function, as measured by changes in the cell phenotype, can be seen. The ligand for FcRL3 
has been recently postulated to be secreted IgA (Agarwal et al., 2020). This is in line with 
the proposed ligands for other FcRL family members, as FcRL4 is proposed to bind IgA 
and FcRL5 to bind IgG (Wilson et al., 2012). These experiments were done using heat-
aggregated serum IgA and IgG, however, the IgA found to bind FcRL3 was secretory IgA 
from human colostrum.  
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A more informative experiment for future work would be ligating FcRL3 in conjunction 
with the addition of a B cell stimuli, such as stimulation of the BCR or addition of TLR 
ligands, and then assessing B cell phenotype and function. As the ligand for FcRL3 has just 
been described it would be sensible to try and cross-link FcRL3 using an anti-FcRL3 
antibody to induce stimulation of this receptor. A similar experiment was done on TLR9 
activated primary B cells (Li et al., 2013). As a different TLR, TLR7, has been proven to 
be important for ABC generation (Rubtsov et al., 2013), combined with the fact that ABCs 
have very high expression of FcRL3, elucidating the effect FcRL3 ligation may have on 
the response to TLR7 stimulation would be very interesting.  
In addition to assessing the effect FcRL3 overexpression may have on cell phenotype I also 
assessed the effect it had on both immunoglobulin production and cytokine secretion 
(Figure 7.17-18). I found that the Ramos cell lines all had very low production of IgA and 
IgG, even after stimulation. This is in accordance with another study describing Ramos 
cells as non-class-switched IgM+ IgD+ B cells (Dussault et al., 2008). However, as 
reported previously (Benjamin et al., 1982), Ramos cells produced high amounts of IgM. 
My results showed that this IgM production not only happens after stimulation, but Ramos 
cells spontaneously secrete this immunoglobulin.  
The majority of the cytokines assessed in the culture supernatants following stimulation of 
the Ramos cell lines were found at very low levels (Figure 7.18). IL-10 was the only 
cytokine detected at a high level. IL-10 was produced at a lower level in the FcRL3 
overexpressing Ramos cells than in the Ramos wild type and the Ramos GFP controls cells. 
Intriguingly, these results are in line with IL-10 production by FcRL3+ ABCs, which as 
reported in Chapter 6, section 6.4.9, is almost non-existent. This could mean that FcRL3 
expression is a marker of a pro-inflammatory subset of B cells rather than an anti-
inflammatory subset. It should be noted that the low levels of secreted cytokines were not 
surprising, as another study has demonstrated that Ramos cells stimulated with other 
stimuli, such as an anti-CD40 antibody, produce very little cytokine, and similar to my 
findings only IL-10 and low levels of TNF-α were detected (Grammer et al., 1998). In 
addition, it has previously been reported that, Ramos cells, as well as other cancerous B 
cell lines, exhibit defects in cytokine and immunoglobulin production, and for this reason 




As final readouts of B cell function, I decided to investigate if FcRL3 overexpression 
affected the Ramos cell line in terms of cell proliferation, as well as apoptosis and cell 
death. 
My results investigating cell proliferation showed that the Ramos GFP control cells were 
proliferating at a faster rate than the Ramos FcRL3+ cell, as well as the Ramos wild type 
controls (Figure 7.12). This may indicate that retroviral infection of B cell lines may 
increase cell proliferation. However, the Ramos FcRL3+ cells had been through the same 
retroviral infection protocol and did not have increased levels of proliferation. In fact, they 
were similar to the Ramos wild types in terms of proliferation capacity. Therefore, it may 
be the case that the overexpression of FcRL3 counteracts and reduces the enhanced 
proliferative effect induced by the retroviral infection. It has been reported previously that 
in primary B cells some retroviruses stimulate the host cell cycle, increasing cell 
proliferation (Coffin et al., 1997). However, there are no reports on retroviruses used to 
transduce having an effect by increasing cell proliferation. The results from the 
proliferation assay are intriguing as FcRL3 overexpression seems to have some influence 
on B cell proliferation. Unfortunately, due to time constraints, the functional work using 
the Ramos cell lines could only be performed once. Future work needs to focus on repeating 
this experiment to determine reproducibility and robustness of the result.  
The apoptosis and viability results highlighted two things: Firstly, FcRL3 overexpressing 
cells naturally died more easily compared to the two control cell lines; and secondly, when 
apoptosis was induced using an anti-CD95 antibody, FcRL3 overexpressing cells were 
more prone to apoptosis (Figure 7.13-14). The method used to induce apoptosis was by 
directly inducing CD95/FasR cell death by adding an anti-CD95 antibody to the cell 
cultures. The anti-CD95 antibody stimulates the Fas receptor and activates downstream 
signalling leading to caspase-induced apoptosis (Nagata, 1999). As shown in my results, 
induction of apoptosis in Ramos cells using the anti-CD95 antibody was not very effective. 
It has been reported previously, that CD95 is expressed on activated B cells but not on 
resting ones (Nagata, 1999). Studies using Ramos cells, found that stimulation with anti-
CD40 induced expression of CD95 on these cells (Schattner et al., 1995), perhaps 
suggesting that Ramos cells do not endogenously express CD95 at a high level. Moreover, 
a study found that the Ramos cells have different sensitivities to apoptosis and that it was 
possible to select the ones resistant to CD95-induced apoptosis (Lens et al., 1998). These 
reports may explain why I see only a small induction of apoptosis in Ramos cells with an 
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anti-CD95 antibody, even when the cells were left for a few days in culture (data not 
shown). Prior stimulation of the cells with an anti-CD40 antibody could lead to a better 
response to an anti-CD95 antibody and could bring more insight into whether FcRL3 
overexpression in B cells makes them more sensitive to apoptosis induction. The fact that 
the Ramos FcRL3+ cells are, in general, more prone to cell death, could also be influencing 
the proliferation results I discussed earlier. For example, if the Ramos FcRL3+ cells die 
more easily than the Ramos GFP control cells, this may explain why the proliferation rate 
is reduced. Of interest, there are studies on T cells connecting FcRL3 expression to cell 
death. A study described a subpopulation of naturally-occurring regulatory T cells (Tregs) 
characterised by FcRL3 expression, which are unresponsive to the effects of IL-2 (Nagata 
et al., 2009). Another study showed that FcRL3 expressing Tregs are dysfunctional and 
have high expression of the cell death marker Programmed Cell Death-1, PD-1 (Swainson 
et al., 2010). Although all of these studies have been done in T cells, my results showed 
that FcRL3 expressed on B cells could have a similar effect and could cause the cells to 
become more prone to apoptosis and cell death. However, all these results need to be 





This chapter illustrates the process of creating a stably transduced FcRL3 overexpressing 
B cell line using a retroviral approach in order to further investigate the role of FcRL3 in B 
cell function. Once the cell line was stably overexpressing FcRL3, I performed a few 
preliminary experiments, checking for differences between the FcRL3 overexpressing cells 
and control cells. 
I demonstrated that when trying to generate a stable FcRL3 overexpressing B cell line the 
approach which gave the highest transduction efficiency and was the most successful, was 
a retroviral transduction protocol. I also showed that transduction can result in a 
heterogeneous population, with cells expressing different levels of FcRL3, as well as the 
GFP reporter. In order to obtain a pure population of cells overexpressing FcRL3, flow 
cytometry sorting to enrich for FcRL3+GFP+ cells was needed. Moreover, I confirmed that 
simply overexpressing FcRL3 had no effect on the Ramos cell phenotype. I also showed 
that, although the proliferation rate seems to be enhanced in retroviral infected cells, this 
appears to be reduced in cells overexpressing FcRL3. Furthermore, induction of apoptosis 
is affected in cells overexpressing FcRL3, with higher susceptibility to apoptosis seen in 
FcRL3+ cells. Nevertheless, no differences in phenotype, cytokine secretion and 
immunoglobulins production between FcRL3 overexpressing cells and the control cells 
were found when cells were stimulated with a B cell stimulation cocktail. The reason why 
no differences were seen may be due to the fact that in these cultures FcRL3 was not 
engaged by its ligand. Further work is needed to clarify how ligation of FcRL3, possibly 
by cross-linking the receptor, affects B cell function.  
In summary, I created a B cell line which stably overexpresses FcRL3. This will allow for 
future work to further explore on how FcRL3 signalling impacts B cell function. Moreover, 
it may provide insights into why FcRL3 is highly expressed on ABCs and will help 








8.1 General discussion   
For the work performed in this thesis, I used three surface markers, CD19, CD11c and 
CD21, to identify the ABC subset in peripheral blood. I investigated the frequency of these 
cells in patients suffering from inflammatory arthritides and healthy controls. Furthermore, 
I characterised ABCs in depth, phenotypically, by analysing gene expression and 
functionally, by assessing immunoglobulin and cytokine production. The main outcomes 
are discussed below. 
8.1.1 ABCs activated phenotype 
Several studies have investigated ABCs in order to elucidate their potential role in health 
and disease (Karnell et al., 2017). However, there is a lack of consensus in the way these 
cells are described. Some studies simply use lack of CD21 expression (Wehr et al., 2004; 
Thorarinsdottir et al., 2019), others describe them using CD11c expression (Rubtsov et al., 
2011), while others define them by the expression of the transcription factor T-bet together 
with CD11c (Naradikian et al., 2016b; Karnell et al., 2017; Wang et al., 2018). Moreover, 
as reported in several literature reviews, the name “age-associated B cells”, is not very 
appropriate for three reasons: cells with a similar phenotype also appear in autoimmunity 
and viral infections, this population is heterogeneous, and their function appears to be 
distinct in different situations (Phalke and Marrack, 2018). For my PhD project I decided 
to define the ABC subset as CD11c+CD21- B cells (CD19+CD11c+CD21-) (Rubtsov et 
al., 2013). The combination of two surface markers, CD11c and CD21, was used in order 
to make the gated subset more defined because not all CD21- cells are positive for CD11c, 
and vice versa, not all CD11c+ B cells are negative or low for CD21. Therefore, using two 
markers I analysed a more distinct population of B cells.  
I designed comprehensive flow cytometry panels to fully characterise the ABCs subset and 
compare these cells with other B cell populations. As reported before in the literature, 
ABCs have high expression of MHC class II molecules together with co-stimulatory 
molecules and activation markers. Furthermore, I assessed the expression of the FcRL 
family on ABCs, which I believe is the first time that a full protein characterisation of this 
receptor family has been assessed on ABCs. FcRL family member expression on atypical 
memory B cells (CD10-CD19+CD20+CD21lowCD27-CD11chigh) was reported 
previously (Portugal et al., 2015), however, other studies have only analysed expression of 
one or two members of the FcRL family on ABC –like cells (Jenks et al., 2018; Wang et 
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al., 2018; Thorarinsdottir et al., 2019; Zumaquero et al., 2019). My results show that a 
higher proportion of ABCs express FcRL2 to FcRL5 compared to the other B cell subsets. 
I also assessed the proliferative marker, Ki67, and found that ABCs contain a high 
proportion of Ki67 positive cells, indicating that these cells are actively proliferating. A 
high percentage of ABCs were also positive for the transcription factor T-bet, confirming 
it as a specific marker for this subset (Rubtsov et al., 2017). However, my results show that 
not all the cells from the ABC population express T-bet, and this expression varies between 
individuals. Finally, analysis of immunoglobulin expression revealed that a high proportion 
of ABCs are class switched B cells as they express IgG. However, a proportion of ABCs 
are also IgM and/or IgD positive. Figure 8.1 summarises all the markers expressed by 
ABCs as described in Chapter 4. 
Among the described phenotypes, the cells described in this thesis are largely similar to the 
ABCs described by Rubtsov et al., and differ from the exhausted CD19+CD21- B cells 
described by Hao et al., in mice and by Isnardi et al., in humans (Isnardi et al., 2010; Hao 
et al., 2011; Rubtsov et al., 2011). This is due to their high expression of activation and co-
stimulatory molecules, such as CD80, CD86, and MHC class II molecules. The CD21low 
cells described by Hao et al., in mice and by Isnardi et al., in humans showed similar 
expression levels of these molecules to FO B cells and CD21+ B cells, respectively. 
Moreover, due to the high percentage of class switched cells in the ABC population, my 
results, in line with the work by Rubtsov et al., confirm that the ABCs are an antigen-
experienced population (Rubtsov et al., 2011).   
The data from the literature, as well as my work presented in this thesis, highlight the fact 
that the cell subset we define as ABC is in fact a heterogeneous population (Phalke and 
Marrack, 2018; Knox et al., 2019). The best example to illustrate this heterogeneity is the 
expression of immunoglobulins on ABCs. My results from Chapter 4 show that around half 
of the cells in the ABC subset are positive for IgD, however, when assessing IgG expression 
around half of the cells are also positive for this immunoglobulin. IgD+ cells are not 
positive also for IgG, therefore the ABCs population is heterogeneous and includes class-
switched (IgG+) and non-class switched (IgD+) B cells. This is in line with the 
discrepancies seen in the different studies, as some groups describe these cells as being 
class-switched (Rubtsov et al., 2011; Shimabukuro-Vornhagen et al., 2017), while others 
report them to be naïve (Isnardi et al., 2010). Moreover, when assessing expression of other 




Figure 8. 1. Phenotypic marker expression by ABCs. Graphical representation of the ABCs expression profile determined by flow cytometry. 
ABCs have high expression of co-stimulatory molecules, CD80 and CD86, in addition to high expression of MHC class II molecules. Moreover, 
they express the activation markers CD69 and CD97, but have low expression of CD40. ABCs have high expression of FcRLs family members 
FcRL2 to FcRL5, with a very high expression of FcRL3. In terms of immunoglobulin secretion and expression, some cells in the ABC population 
are class-switched IgG expressing cells, whereas others express IgD and IgM. Finally, ABCs have high expression of the transcription factor T-
bet and are actively proliferating as indicated by Ki67 expression. Created with Biorender.com. 
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8.1.2 Functional role of ABCs 
The role of ABCs both in healthy donors as well as in patients suffering from autoimmune 
diseases is still unknown. Phenotypic characterisation of these cells has given some insight 
into what their function may be. The potential roles for ABCs in health and disease, based 
on my findings, are summarised in Figure 8.2. My work supports the role of ABCs as 
antigen presenting cells, as they have high expression of co-stimulatory molecules, CD80 
and CD86, and high expression of the antigen presentation molecule MHC class II. 
However, this is an extrapolation from their phenotype while their presentation of antigen 
and interaction with T cells is yet to be directly tested.  
Additionally, the characterisation of surface immunoglobulins expression gives insights 
into the potential role of ABCs as precursors of antibody secreting plasma cells. Although 
these cells are not yet plasma cells, as shown by the gene expression analysis, they might 
be a precursor of antibody secreting cells which rapidly differentiate and secrete antibodies 
after B cell re-stimulation. Functional work in mice demonstrated that after stimulation, 
ABCs rapidly differentiate into antibody secreting plasma cells, which produce IgG2a/c 
despite their high expression of surface IgM and IgD (Rubtsova et al., 2013; Du et al., 
2019). ABCs in mice were also shown to contribute to the reduction of B cell 
lymphopoiesis seen with age and to secrete TNF-α which contributes to the inhibition of 
survival of the B lineage precursors (Ratliff et al., 2013; Riley et al., 2017). Although ABCs 
correlate with autoantibody production, B cell development and T cell function, causality 
is still to be determined (Naradikian et al., 2016a). My transcriptomic and functional results 
reinforce some of the previously hypothesised role for ABCs, nevertheless, in vitro 
functional work is needed in order to fully determine the function of ABCs.  
As shown in Chapter 3, I did not replicate previously published results showing increased 
frequency of ABCs in patients with RA (Rubtsov et al., 2011; Shimabukuro-Vornhagen et 
al., 2017). This may be due to the relatively small size of the cohort tested. Nevertheless, I 
did show that the frequency of ABCs is very high in synovial fluid of patients with 
inflammatory arthritides, as reported before in the literature (Illges et al., 2000; Yeo et al., 
2015; Thorarinsdottir et al., 2019). These results support the hypothesis that ABCs might 
be migrating into inflammatory sites. Moreover, the results from the gene expression 
analysis in Chapter 5 showed upregulation of genes involved in cell migration, such as 
adhesion molecules and chemokine receptors, further supporting the migratory potential of 
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these cells into inflammatory sites. Additionally, other studies showed that T-bet+ B cells 
with high expression of CXCR3, akin to the ABCs reported in this thesis, were increased 
in cerebrospinal fluid from patients with MS and had a higher migration capacity, as 
assessed in transwell assays (van Langelaar et al., 2019). Interestingly, the cells with a 
higher migration capacity were also IgG1+, which is the human equivalent to the mouse 
class switched isotype, IgG2a, shown to be promoted by T-bet expression in B cells 
(Rubtsova et al., 2013). 
The high expression of CD97 by ABCs compared to naïve and CD5+ B cells lead me to 
hypothesise that these cells may have the ability to interact with synovial fibroblasts. In 
order for the ABCs to interact with synovial fibroblasts they would need to migrate to the 
inflamed joint. This migration may be triggered by the high integrin expression, such as 
CD11c and CD18 and adhesion molecules, such CD97, which would allow them to adhere 
to the endothelium and migrate through the cell layer (Humphries et al., 2015). The high 
expression of CXCR3 by ABCs, together with the evidence of increased ligand expression, 
CXCL10, in RA joints (Patel et al., 2001), would attract these cells to inflammatory sites. 
Once in the joints, the CD97-expressing ABCs have the potential ability to interact with 
CD55-expressing fibroblast, as CD97 is known to bind CD55, in addition to another joint 
component, chondroitin sulfate (Hamann et al., 2016). Further investigation of ABCs 
migratory ability and their potential interaction with synovial fibroblasts is needed. 
Furthermore, my gene expression analysis demonstrated a possible role for cytotoxic 
activity of ABCs. My NanoString results showed high expression of granzyme A and B, as 
well as perforin and granulysin. This, together with a high expression of NK cell receptors, 
supports a potential cytotoxic role for ABCs. Unfortunately, these gene expression results 
could not be confirmed at the protein level. This could be due to the cells possibly requiring 
an additional stimulus to initiate translation of the mRNA into protein. Nevertheless, 
cytotoxic B cells, resulting from insufficient T cell help, have been reported before (Hagn 
et al., 2012). This study showed that in the absence of CD40L signalling, IL-21 induces 
differentiation of B cells into granzyme B secreting B cells. These results are in line with 
the published evidence that ABCs are generated through IL-21 signalling, in addition to 
IFN-γ and TLR signalling (Naradikian et al., 2016b; Wang et al., 2018).  
Intriguingly, my gene expression analysis showed high expression of pro-apoptotic 
molecules. Expression at the protein level was confirmed for CD95/Fas, reinforcing the 
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hypothesis that ABCs may be susceptible to cell death by apoptosis. These findings were 
reported before in literature by other groups, who suggested that the unresponsiveness seen 
in the ABC population, together with the high expression of caspases and CD95/Fas would 
lead to death of these cells (Isnardi et al., 2010; Rubtsov et al., 2011; Wang et al., 2018; 
Du et al., 2019). Functional work using apoptosis assays or B cell stimulation would help 
determine whether these cells are more prone to apoptosis.  
My gene expression results and my phenotypic characterisation showed that ABCs have 
high expression of the transcription factor T-bet, as confirmed in the literature by others 
(Rubtsova et al., 2015; Rubtsov et al., 2017). T-bet expression on B cells is induced through 
IL-21 signalling, together with IFN-γ and in the absence of IL-4 (Naradikian et al., 2016b). 
Moreover, TLR signalling can also drive T-bet expression in B cells (Knox et al., 2019; 
Zumaquero et al., 2019). T-bet promotes expression of T-bet inducible genes such as 
CXCR3, as shown in CD8+ T cells (Groom and Luster, 2011a), which supports a possible 
role for ABCs migration into inflammatory sites. Additionally, murine studies showed that 
T-bet expression promotes IgG2a class-switching on B cells (Gerth et al., 2003), which is 
the equivalent to IgG1 in humans. Figure 8.3 summarises the proposed mechanisms of 
ABCs generation, and the role T-bet may play in the functional role of ABCs. In the context 
of autoimmunity, such as in RA, ABCs generated through IL-21, IFN- γ and TLR signalling 
would lead to T-bet expression, which in turn would drive expression of CXCR3 and class-





Figure 8. 2.  The potential role of ABCs. Graphical summary of the possible functions of ABCs in health and disease. The high expression of 
both co-stimulatory molecules and HLA-DR suggests a potential role for ABCs in antigen presentation.  Due to a high percentage of class-switched 
ABCs, these cells may be antibody secreting cells or precursors to these cells. Their high expression of integrins and chemokine receptors indicate 
that ABCs may migrate from the blood into tissues. Once in the inflamed joint, ABCs may interact with synovial fibroblasts through the interaction 
of CD97 on the ABC with CD55 on the synovial fibroblasts. Finally, gene expression analysis showed high expression of NK cell related cytotoxic 




Figure 8. 3. The proposed mechanism involved in ABCs generation. Graphical summary of the generation of ABCs. IFN-γ, together with IL-
21 signalling and TLR engagement, in the absence of IL-4, leads to the expression of T-bet. T-bet promotes expression of T-bet inducible genes, 
leading to expression of the inflammatory homing chemokine receptor, CXCR3, as well as class-switching of the cell to an IgG1 isotype. In the 
context of autoimmunity, these cells may recognise autoantigens and therefore produce autoantibodies. Created with Biorender.com.   
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8.1.3 Expression of FcRL family protein on ABCs  
I became interested in the FcRL family of receptors and the potential role they play in ABCs 
function due to the work conducted by my supervisor in Birmingham on a subset of 
synovial B cells that express FcRL4, which have a similar phenotype to the ABCs (Yeo et 
al., 2015), in addition to the work performed in our group identifying a mQTL and eQTL 
for FcRL3 in B cells and T cells from RA patients (Clark et al., 2020). Interestingly, I found 
that FcRL2-5 expression was enriched in ABCs compared to the other B cell subsets. 
Expression of certain FcRL members, such as FcRL3, FcRL4 and FcRL5 has previously 
been reported in ABCs, although mostly at the mRNA level (Isnardi et al., 2010; Lau et al., 
2017; Wang et al., 2018). However, none of the studies checked the protein expression of 
all the FcRL family members, thus my thesis is the first to assess this. 
The function of the FcRL family members is still unknown. The presence of both ITAM 
and ITIM domains in their intracellular tails indicates that most of these receptors may be 
capable of exerting a dual-modulation by activating or inhibiting responses (Ehrhardt et al., 
2007). Some studies have shown that stimulation of the BCR together with one of the FcRL 
family members (FcRL2-5) leads to an attenuation of antigen receptor-mediated calcium 
mobilisation and MAPK activation, which results in apoptosis (Haga et al., 2007; Kochi et 
al., 2009; Jackson et al., 2010). Conversely, in TLR9 activated B cells when FcRL4 and 
FcRL3 were engaged, there was an enhancement of TLR9-induced proliferation, survival 
and B cell activation (Sohn et al., 2011; Li et al., 2013). As it has been reported that ABCs 
do not respond to BCR stimulation but do respond well to TLR engagement (Naradikian et 
al., 2016b; Thorarinsdottir et al., 2016; Johnson et al., 2019), it may be the case that the 
high expression of FcRL family members on ABCs contribute to the responsiveness of 
these cells to TLR ligands.  
FcRL3 expression on T cells have been shown to mark an exhausted regulatory T cell 
subset (Nagata et al., 2009). Interestingly, recent work on Tregs expressing FcRL3 
demonstrated that FcRL3 engagement mediates transition of these Tregs to a pro-
inflammatory Th17-like phenotype (Agarwal et al., 2020). This would suggest a role for 
FcRL3 in possibly driving cells to a pro-inflammatory program. Moreover, the authors 
suggest secretory IgA is a specific FcRL3 ligand which could limit Treg function at 
mucosal sites in order to control infection. In light of these results, further work is needed 
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to investigate if secretory IgA binds to FcRL3 on B cells, and, if it does, what the functional 
outcome of this interaction is.  
A subset of memory B cells with a similar phenotype as the ABCs have been described in 
viral infections. These cells are called atypical memory B cells (Portugal et al., 2017) and 
express CD11c and T-bet, and lack expression of CD21 (Chang et al., 2017; Obeng-Adjei 
et al., 2017). Interestingly, these atypical memory B cells have high expression of some of 
the FcRL family members, such as FcRL3, FcRL4 and FcRL5 (Moir et al., 2008; Sullivan 
et al., 2015). Additionally, these cells, similar to ABCs, are not a homogeneous population 
of B cells and show significant heterogeneity between different chronic infections. 
However, the main reported difference between ABCs and the atypical memory B cell 
population is in their response to stimulation. Atypical memory B cell are unresponsive to 
BCR engagement but also do not respond to TLR and cytokine stimulation (Moir et al., 
2008; Chang et al., 2017), unlike ABCs which do respond to TLR ligation, IFN-γ and IL-




8.2 Strengths and weaknesses 
The main strengths and weaknesses of this project are summarised in Table 8.1. The main 
strength of this project is the use of relevant human samples to perform the translational 
research reported here. Specifically access to peripheral blood samples from early drug 
naïve RA patients and established RA patients, as well as disease and age-matched healthy 
controls, allowed a detail characterisation of the ABC population. Although some of the 
weaknesses would not have been an issue when using animal models, for example isolating 
sufficient numbers of cells would not have been a challenge, the use of patient samples 
allowed for a more relevant and accurate characterisation of these cells in human 
autoimmunity. However, the inclusion of synovial fluid ABCs for phenotypic 
characterisation and functional work may have been even more informative than peripheral 
blood ABCs, as blood may be less relevant in RA, which manifests mainly in the joints. 
Furthermore, RA is a highly heterogeneous disease with a high level of gene – environment 
interaction. This creates a huge variability between patients and this variability is 
challenging, requiring sufficiently sized cohorts for both the discovery and the validation 
of observations. With this in mind, one other weakness of this study is the low numbers of 
patients and controls used – increased numbers would have enabled more in depth analysis 
and confidence in the conclusions drawn. Due to the high heterogeneity of human samples, 
it could have been useful to calculate the sample size prior to recruiting patients. With a 
few patients recruited as a pilot study, a sample size calculation could have been performed 
using a statistical test as the 2-Sample t-test. Calculating the sample size would take into 
account the sample variability and the power of the study and would have allowed me to 
estimate how many patients are needed to detect significant differences between the 
frequency of ABCs in the different disease controls and healthy controls. Regarding the 
FcRL3 functional work, the use of a cell line provides an easy way to overexpress and study 
the unknown function of proteins. Having a stably transfected B cell line overexpressing 
FcRL3 will allow for future work which will help elucidating the role of FcRL3 in B cell 
function. However, cell lines are cancerous cells and their functional properties are altered, 
therefore it is challenging to use them for functional work. 
One of the challenges encountered during this work has been the low number of ABCs that 
I was able to isolate from peripheral blood. As ABCs are a rare subpopulation of B cells 
(between 0.5% and 8% of the total B cell population), using the maximum amount of blood 
that I could collect under our ethical approval, I could only isolate around 40,000 ABCs 
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per donor. With this number of cells, functional work was very difficult as the number of 
cultured cells and the production and secretion of cytokines and immunoglobulins was very 
low. Previous published functional work on ABCs, done in mice, isolated cells from the 
spleen so cell numbers were not a limiting factor (Hao et al., 2011; Rubtsov et al., 2011; 
Naradikian et al., 2016b). Other functional studies using human ABCs define this cell 
population using less phenotypic markers, for example just isolating CD21 low B cells, 
resulting in a less distinct population which is more abundant (Isnardi et al., 2010; 
Thorarinsdottir et al., 2019). Some other studies even pooled sorted ABCs from different 
donors together to reach sufficient cell numbers (Wang et al., 2018). 
With the emergence of new techniques, other approaches to investigate the role of ABCs 
could have been used. CyTOF or mass cytometry tags cells as in flow cytometry but using 
metals instead of fluorophores, overcoming the limitations of spectral overlap typical from 
flow cytometry. CyTOF allows for a high number of markers to be analysed in one sample. 
This would have been useful when phenotyping the ABCs as the number of markers 
assessed per sample would have been broader and would have allowed for a deeper 
characterisation of ABCs and discovery of new markers for this subset of B cells. 
The use of organoids could also have helped determine the function of ABCs. Organoids 
are simplified versions of organs produced in vitro and derived from stem cells. Organoids 
can be used for drug testing and for disease modelling. An organoid model of an RA knee 
could be highly informative to determine how ABCs contribute to joint damage. Moreover, 
this environment could be favourable for ABCs culturing, which would help elucidating 
the role of this B cell subset in disease. Organoids would also allow to see how ABCs react 





− Access to peripheral blood from 
early drug naïve patients 
− Access to peripheral blood from 
established RA patients 
− Use of synovial fluid from 
inflammatory arthritis patients for 
ABCs frequency determination 
− Access to peripheral blood from age-
matched disease and healthy controls 
− Peripheral blood ABCs used for 
characterisation work instead of 
synovial fluid ABCs 
− Use of NanoString Technology 
which allowed analysis of rare 
subsets and avoided amplification 
bias 
− Validation of NanoString 
transcriptomic candidates at the 
protein level using flow cytometry 
− Due to small patient and control 
numbers, insufficient power to 
correlate ABCs with disease 
− Small number of patients for the 
transcriptomic analysis 
 
− No validation by qRT-PCR of 
transcriptome findings 
− Use of MSD Technology allowed 
assessment of a multiple cytokines 
from a small volume of culture 
supernatant 
− Low number of cultured cells 
− Generation of a stably transduced 
FcRL3+ B cell line that can be used 
for future work 
− Use of cell lines for functional 
work 
− Insufficient replicates for FcRL3 
functional work on the FcRL3+ B 
cell line 
Table 8. 1. Summary of the strengths and the weakness of the work presented in this 
thesis.   
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8.3 Future work  
The results from the NanoString analysis shown in Chapter 5, demonstrating high 
expression of chemokine receptors and adhesion molecules further supports the hypothesis 
that ABCs may migrate into sites of inflammation. Moreover, this hypothesis was 
reinforced by the high percentages of B cells with an ABC phenotype in the synovial fluid 
of patients with inflammatory arthritides. In addition, the high expression of CD97, both at 
the mRNA and the protein level, in ABCs lead me to postulate that once in the joints, ABCs 
could possibly interact with CD55-expressing synovial fibroblasts, as CD55 is a ligand for 
CD97, and contribute to the pathogenesis of inflammatory arthritis. 
In order to further investigate this hypothesis, I successfully applied for a 1 year project 
grant from the JGW Patterson Foundation. In this funded project, I will try to elucidate the 
role of CD97 expression on ABCs in inflammatory arthritis. CD97 is a member of the EGF-
TM7 subfamily of adhesion G protein-coupled receptors, which is abundantly expressed 
on macrophages and dendritic cells, and is upregulated on lymphocytes following 
activation. CD97 is known to mediate cell-cell interactions and this protein is believed to 
play a role in cell adhesion, leukocyte recruitment, cell activation and migration to sites of 
inflammation (Hamann et al., 2010). Interestingly, CD97 neutralisation using a CD97 
monoclonal antibody in a murine collagen-induced arthritis model of arthritis (CIA), 
showed reduced joint damage and inflammation (Kop et al., 2006). Moreover, CD97 has 
been shown to be a receptor for several ligands other than CD55, including chondroitin 
sulfate B, CD90 and the integrins α5β1 and αvβ3 (Hamann et al., 2016). CD55 is a 
glycoprotein involved in the regulation of the complement cascade by accelerating the C3 
convertase decay and therefore protecting host cells from complement damage (Dho et al., 
2018). CD55 is highly expressed by fibroblast-like synoviocytes (FLS) located in the lining 
layer of the synovia, and it has been shown that CD55 on FLS interacts with CD97-
expressing macrophages in the rheumatoid synovia (Hamann et al., 1999). In addition, 
CD97 has been shown to bind chondroitin sulfate in the inflamed synovial tissue of patients 
with RA (Kop et al., 2005), suggesting another receptor-ligand interaction that may result 
in the recruitment and retention of CD97-expressing leukocytes in the synovium, thus 
perpetuating the pro-inflammatory state. These findings highlight a potential role for 
CD97-expressing ABCs interacting with CD55+ synovial fibroblasts in driving the 
pathogenesis of RA. 
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Furthermore, it has been reported that interaction of CD97 and CD55 plays an important 
role in the regulation of T cell responses (Capasso et al., 2006), and blockade of this 
interaction using monoclonal antibodies impairs both T-cell proliferation and effector 
cytokine production (Abbott et al., 2007). However, very little is known about the role of 
CD97-CD55 interactions on B cell function or fibroblast function. Therefore, I hypothesise 
that the increased expression of pro-inflammatory chemokine receptors and cell adhesion 
molecules on ABCs promotes their recruitment to sites of inflammation and once there, 
high expression of CD97 allows them to interact with CD55-expressing fibroblasts, leading 
to activation of both cell subsets and the promotion of joint inflammation and RA disease 
pathogenesis.  
During this funded project, in order to test this hypothesis, I will address the following 
aims: 1. Examine whether ABCs co-localise with synovial fibroblasts in RA synovial 
tissue; 2. Determine whether ABCs can migrate towards RA synovial fibroblasts; and 3. 
Investigate if interaction of ABCs and RA synovial fibroblasts can drive one or both cell 
types towards a pro-inflammatory phenotype that may contribute to the joint inflammation 
seen in RA. This study will provide insights into the interaction between immune cells and 
stromal cells in the inflamed joint and will elucidate how these cells promote inflammation 
and joint damage. 
Additionally, during this extra year, as a side project, I will also investigate the role of 
FcRL3 expression on B cell function. By the end of my PhD I managed to stably transfect 
a B cell line that overexpresses FcRL3 and GFP, as well as a control B cell line just 
overexpressing GFP. I will, with the help of Undergraduate and Masters students, 
investigate the effect of FcRL3 co-ligation on downstream phosphorylation cascades. 
Moreover, I will try to use B cell stimuli, such as TLR7 engagement, and compare the 
responses with and without FcRL3 ligation. Finally, we will also assess FcRL3 ligation on 
peripheral blood B cells and check proliferation and survival of the cells.  
Due to our group’s previous work on the mQTL and eQTL modulating FcRL3 expression 
on B and T cells from RA patients (Clark et al., 2020), I will also recruit early RA patients 
and check protein expression of FcRL3 on different B and T cell subsets. These patients 
will be genotyped to investigate correlation between the genotype and the FcRL3 protein 
expression in each subset of cells. This will also be done with the help of Masters students. 
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Additional future work would also include increasing the n numbers for some of the work, 
for example for the NanoString analysis of gene expression and for the functional work. 
Due to the heterogeneity of RA and the high variability of the human population, increased 
numbers of patients and controls would have enabled more in depth analysis and a higher 
confidence in the conclusions drawn.  
Moreover, repeating the characterisation and the functional work on synovial ABCs rather 
than peripheral blood ABCs would be more informative as RA manifests in the joints. I 
have already optimised several flow cytometry panels to assess expression of phenotypic 
markers, which could be used to phenotype matched PBMCs and SFMCs from the same 
patient and would allow to compare each marker in the ABC population from both tissues. 
Moreover, sorted cells from peripheral blood and synovial fluid could be cultured and 
stimulated and cytokine and immunoglobulin production assessed.  
The NanoString results could be validated either using qPCR, such as TaqMan PCR at the 
mRNA level or using flow cytometry to detect protein expression.  
Finally, the results from the FcRL3+ B cell line are very preliminary and it is necessary to 
increase the n numbers. As the B cell line overexpressing FcRL3 is stably transfected, the 
apoptosis assay could be repeated. Moreover, other experiments crosslinking the FcRL3 





8.4 Final conclusions  
In conclusion, I have shown that although my study did not show significant differences in 
the frequency of peripheral blood ABCs between RA patients and other disease and healthy 
controls, the percentage of cells with an ABC phenotype in the synovial fluid is very high 
in patients suffering from inflammatory arthritides. I characterised these cells 
phenotypically and confirmed that they have high expression of activation and co-
stimulatory molecules, in addition to expressing high levels of T-bet and the members of 
the FcRL family (i.e. FcRL2-5). Moreover, these cells are actively proliferating and a high 
proportion of them have a class-switched memory B cells phenotype expressing IgG. 
Interestingly, the transcriptome analysis showed that the ABCs are a subset of B cells, 
distinct from naïve, CD5+ and memory B cell subsets, with a unique transcriptome profile. 
ABCs had a high expression of chemokine receptors, such as CXCR3, as well as adhesion 
molecules, such as integrins and CD97, supporting a role for the migration of these cells 
into inflammatory sites. In addition, ABCs also had high expression of apoptotic markers, 
such as caspases and Fas. Finally, the functional characterisation of ABCs showed that 
these cells are capable of secreting IgM and IgG after stimulation. However, due to low 
cell numbers and high cell death, very low quantities of secreted cytokines were detected; 
making it very difficult to determine if these cells could contribute to inflammation. Due to 
the high expression of FcRL3 by ABCs I generated a stably transfected B cell line, which 
overexpressed FcRL3, in order to determine the role of FcRL3 on B cell function. However, 
due to time limitations these functional experiments were limited and I was unable to 
stimulate the FcRL3+ B cell line via FcRL3. I was able to perform a limited number of 
preliminary experiments simply stimulating the B cell line with a strong B cell stimulation 
cocktail and the only difference between the control and the FcRL3+ cells was in 
susceptibility to apoptosis, with FcRL3+ Ramos B cells being more prone to apoptosis. 
Further work is needed to clarify how cross-linking of the overexpressed FcRL3 receptor 
affects B cell function.  
Overall, I confirmed that the ABC subset is an activated memory-like B cell subset which 
could potentially migrate into inflammatory sites and promote disease pathogenesis. 
However, exactly how these cells contribute to RA pathogenesis is still unknown and 
further functional work will help elucidate their role in autoimmunity. Nevertheless, in the 
next year I will investigate the possible role of CD97 expression on ABCs and its 
interaction with its ligand, CD55, expressed on synovial fibroblasts. This will aid in our 
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ABCB1  C6  CD164  CD96  CXCL11  
ABL1  C7  CD19  CD97  CXCL12  
ADA  C8A  CD1A  CD99  CXCL13  
AHR  C8B  CD1D  CDH5  CXCL2  
AICDA  C8G  CD2  CDKN1A  CYBB  
AIRE  C9  CD209  CEACAM1  DEFB1  
APP  CAMP  CD22  CEACAM6  DEFB103A  
ARG1  CARD9  CD24  CEACAM8  DEFB103B  
ARG2  CASP1  CD244  CEBPB  DEFB4A  
ARHGDIB  CASP10  CD247  CFB  DPP4  
ATG10  CASP2  CD27  CFD  DUSP4  
ATG12  CASP3  CD274  CFH  EBI3  
ATG16L1  CASP8  CD276  CFI  EDNRB  
ATG5  CCBP2  CD28  CFP  EGR1  
ATG7  CCL11  CD34  CHUK  EGR2  
ATM  CCL13  CD36  CIITA  ENTPD1  
B2M  CCL15  CD3D  CISH  EOMES  
B3GAT1  CCL16  CD3E  CLEC4A  ETS1  
BATF  CCL18  CD3EAP  CLEC4E  FADD  
BATF3  CCL19  CD4  CLEC5A  FAS  
BAX  CCL2  CD40  CLEC6A  FCAR  
BCAP31  CCL20  CD40LG  CLEC7A  FCER1A  
BCL10  CCL22  CD44  CLU  FCER1G  
BCL2  CCL23  CD46  CMKLR1  FCGR1A/B  
BCL2L11  CCL24  CD48  CR1  FCGR2A  
BCL3  CCL26  CD5  CR2  FCGR2A/C  
BCL6  CCL3  CD53  CRADD  FCGR2B  
BID  CCL4  CD55  CSF1  FCGR3A/B  
BLNK  CCL5  CD58  CSF1R  FCGRT  
BST1  CCL7  CD59  CSF2  FKBP5  
BST2  CCL8  CD6  CSF2RB  FN1  
BTK  CCND3  CD7  CSF3R  FOXP3  





C14orf166  CCR10  CD74  
CTLA4-TM 
(membrane-
bound form)  
GATA3  
C1QA  CCR2  CD79A  
sCTLA4 
(soluble form)  
GBP1  
C1QB  CCR5  CD79B  CTNNB1  GBP5  
C1QBP  CCR6  CD80  CTSC  GFI1  
C1R  CCR7  CD81  CTSG  GNLY  
C1S  CCR8  CD82  CTSS  GP1BB  
C2  CCRL1  CD83  CUL9  GPI  
C3  CCRL2  CD86  CX3CL1  GPR183  
C4A/B  CD14  CD8A  CX3CR1  GZMA  
C4BPA  CD160  CD8B  CXCL1  GZMB  




HAMP IKZF3 IL4 KIR3DL3 MAP4K4 
HAVCR2 IL10 IL4R KIT MAPK1 
HFE IL10RA IL5 KLRAP1 MAPK11 
HLA-A IL11RA IL6 KLRB1 MAPK14 
HLA-B IL12A IL6R KLRC1 MAPKAPK2 
HLA-C IL12B IL6ST KLRC2 MARCO 
HLA-DMA IL12RB1 IL7 KLRC3 MASP1 
HLA-DMB IL13 IL7R KLRC4 MASP2 
HLA-DOB IL13RA1 IL8 KLRD1 MBL2 
HLA-DPA1 IL15 IL9 KLRF1 MBP 
HLA-DPB1 IL16 ILF3 KLRF2 MCL1 
HLA-DQA1 IL17A IRAK1 KLRG1 MIF 
HLA-DQB1 IL17B IRAK2 KLRG2 MME 
HLA-DRA IL17F IRAK3 KLRK1 MR1 
HLA-DRB1 IL18 IRAK4 LAG3 MRC1 
HLA-DRB3 IL18R1 IRF1 LAIR1 MS4A1 
HRAS IL18RAP IRF3 LAMP3 MSR1 
ICAM1 IL19 IRF4 LCK MUC1 
ICAM2 IL1A IRF5 LCP2 MX1 
ICAM3 IL1B IRF7 LEF1 MYD88 
ICAM4 IL1R1 IRF8 LGALS3 NCAM1 
ICAM5 IL1R2 IRGM LIF NCF4 
ICOS IL1RAP ITGA2B LILRA1 NCR1 
ICOSLG IL1RL1 ITGA4 LILRA2 NFATC1 
IDO1 IL1RL2 ITGA5 LILRA3 NFATC2 
IFI16 IL1RN ITGA6 LILRA4 NFATC3 
IFI35 IL2 ITGAE LILRA5 NFIL3 
IFIH1 IL20 ITGAL LILRA6 NFKB1 
IFIT2 IL21 ITGAM LILRB1 NFKB2 
IFITM1 IL21R ITGAX LILRB2 NFKBIA 
IFNA1/13 IL22 ITGB1 LILRB3 NFKBIZ 
IFNA2 IL22RA2 ITGB2 LILRB4 NLRP3 
IFNAR1 IL23A ITLN1 LILRB5 NOD1 
IFNAR2 IL23R ITLN2 LITAF NOD2 
IFNB1 IL26 JAK1 LTA NOS2 
IFNG IL27 JAK2 LTB4R NOTCH1 
IFNGR1 IL28A JAK3 LTB4R2 NOTCH2 

















IKZF1 IL3 KIR3DL1 MAP4K1 PDGFB 




PECAM1  SELL  TLR3   ZEB1 
PIGR  SELPLG  TLR4   
PLA2G2A  SERPING1  TLR5   
PLA2G2E  SH2D1A  TLR7   
PLAU  SIGIRR  TLR8   
PLAUR  SKI  TLR9   
PML  SLAMF1  TMEM173   
POU2F2  SLAMF6  TNF   
PPARG  SLAMF7  TNFAIP3   
PPBP  SLC2A1  TNFAIP6   
PRDM1  SMAD3  TNFRSF10C   
PRF1  SMAD5  TNFRSF11A   
PRKCD  SOCS1  TNFRSF13B   
PSMB10  SOCS3  TNFRSF13C   
PSMB5  SPP1  TNFRSF14   
PSMB7  SRC  TNFRSF17   
PSMB8  STAT1  TNFRSF1B   
PSMB9  STAT2  TNFRSF4   
PSMC2  STAT3  TNFRSF8   
PSMD7  STAT4  TNFRSF9   
PTAFR  STAT5A  TNFSF10   
PTGER4  STAT5B  TNFSF11   
PTGS2  STAT6  TNFSF12   
PTK2  SYK  TNFSF13B   
PTPN2  TAGAP  TNFSF15   
PTPN22  TAL1  TNFSF4   
PTPN6  TAP1  TNFSF8   
PTPRC_all (common 
probe)  
TAP2  TOLLIP  
 
CD45R0  TAPBP  TP53   
CD45RA  TBK1  TRAF1   
CD45RB  TBX21  TRAF2   
PYCARD  TCF4  TRAF3   
RAF1  TCF7  TRAF4   
RAG1  TFRC  TRAF5   
RAG2  TGFB1  TRAF6   
RARRES3  TGFBI  TYK2   
RELA  TGFBR1  UBE2L3   
RELB  TGFBR2  VCAM1   
RORC  THY1  VTN   
RUNX1  TICAM1  XBP1   
S100A8  TIGIT  XCL1   
S100A9  TIRAP  XCR1   
S1PR1  TLR1  ZAP70   
SELE  TLR2  ZBTB16   
Appendix A. 1. Full list of genes included on NanoString nCounter Human 





























































Appendix A. 2. Sequences of customised probes, designed by Dr Faye Cooles, and used 
in NanoString panel plus nCounter to identify retroelement activity. 
340 
 
Appendix A.3. Demographic characteristics in each phenotypic panel in eRA patients. 




Number 8 11 11 15 - 
Age (years; median 
and range) 
64.5 
(33 - 84) 
69 
(33 - 84) 
69 
(33 - 84) 
73 
(51 - 82) 
0.74# 
Percentage of 












(median and range) 
4.97 
(1.33 - 7.01) 
5.24 
(1.33 – 7.01) 
5.24 






CCP+ or RhF+ 










Appendix A. 3. Comparison of the demographic characteristics for each phenotypic 
panel in eRA patients. Early RA patients’ demographic characteristics were recorded and 
the characteristics for each cohort of patients used for the different flow cytometry panels 


















Number 8 14 8 6 - 
Age (years; median and 
range) 
64.5 
(33 - 84) 
52 
(20 - 93) 
62.5 
(50 - 84) 
61.5 
(53 - 64) 
0.03# 
Percentage of females 











(median and range) 
4.97 
(1.33 - 7.01) 
3.4 
(1.54 – 7.06) 
2.58 
(0.68 – 3.74) 
- 0.058# 
Seropositive – anti-
CCP+ or RhF+ 








Table A. 1. Demographic characteristics for all the cohorts used for the activation 
panel. Demographical data for the disease cohorts: early RA patients, n=8; early DC 
patients, n=14; established RA patients, n=8; and the healthy control cohort (n=6) used for 


















Number 11 15 8 8 - 
Age (years; median and 
range) 
69 
(33 - 84) 
52 
(20 - 93) 
62.5 
(50 - 84) 
61 
(51 - 64) 
0.024# 
Percentage of females 











(median and range) 
5.24 
(1.33 – 7.01) 
3.3 
(1.54 – 7.06) 
2.58 
(0.68 – 3.74) 
- 0.015# 
Seropositive – anti-
CCP+ or RhF+ 








Table A. 2. Demographic characteristics for all the cohorts used for the FcRLs panel. 
Demographical data for the disease cohorts: early RA patients, n=11; early DC patients, 
n=15; established RA patients, n=8; and the healthy control cohort (n=8) used for the 















Number 15 12 4 8 - 
Age (years; median and 
range) 
73 
(51 - 82) 
48.5 
(32 - 74) 
67.5 
(48 - 72) 
59.5 
(50 - 73) 
0.0006# 
Percentage of females 











(median and range) 
5.14 
(2.4 – 6.21) 
3.42 
(1.05 – 5.17) 
- - 0.006ǂ 
Seropositive – anti-
CCP+ or RhF+ 








Table A. 3. Demographic characteristics for all the cohorts used for the 
immunoglobulins panel. Demographical data for the disease cohorts: early RA patients, 
n=15; early DC patients, n=12; established RA patients, n=4; and the healthy control cohort 
(n=8) used for the immunoglobulins panel. # Kruskal-Wallis test with Dunn’s multiple 
















Number 11 15 10 8 - 
Age (years; median and 
range) 
69 
(33 - 84) 
52 
(20 - 93) 
65.5 
(50 - 84) 
61 
(51 - 64) 
0.013# 
Percentage of females 











(median and range) 
5.24 
(1.33 – 7.01) 
3.3 
(1.54 - 7.06) 
2.58 
(0.68 – 3.74) 
- 0.016# 
Seropositive – anti-
CCP+ or RhF+ 








Table A. 4. Demographic characteristics for all the cohorts used for the intracellular 
panel. Demographical data for the disease cohorts: early RA patients, n=11; early DC 
patients, n=15; established RA patients, n=10; and the healthy control cohort (n=8) used 















Number 9 7 11 8 - 
Age (years; median and 
range) 
62 
(28 - 82) 
39 
(20 - 57) 
64 
(48 - 84) 
61.5 
(50 - 64) 
0.009# 
Percentage of females 











(median and range) 
5.11 
(3.2 – 6.37) 
3.3 
(2.03 – 7.06) 
2.58 
(0.68 – 3.74) 
- 0.006# 
Seropositive – anti-
CCP+ or RhF+ 








Table A. 5. Demographic characteristics for all the cohorts used for the FcRL1 panel. 
Demographical data for the disease cohorts: early RA patients, n=9; early DC patients, n=7; 
established RA patients, n=11; and the healthy control cohort (n=8) used for the FcRL1 
















Number 10 10 5 6 - 
Age (years; median and 
range) 
57 
(31 - 89) 
40.5 
(22 - 76) 
68 
(48 - 73) 
57 
(50 - 62) 
0.22# 
Percentage of females 











(median and range) 
3.8 
(1.9 – 5) 
4.2 
(1.05 – 5.89) 
- - 0.54ǂ 
Seropositive – anti-
CCP+ or RhF+ 








Table A. 6. Demographic characteristics for all the cohorts used for the FcRL2 panel. 
Demographical data for the disease cohorts: early RA patients, n=10; early DC patients, 
n=10; established RA patients, n=5; and the healthy control cohort (n=6) used for the 
FcRL2 panel. # Kruskal-Wallis test with Dunn’s multiple comparisons. + Chi-square test. 




Appendix A.5. BLAST analysis of the FcRL3 transcript contained in the pcDNA3 
plasmid using the EMBOSS Needle Tool (EMBL-EBI, Hinxton, UK).  
Forward sequencing alignment: 
EMBOSS_001        85 GGTACCGAGCTCGGATCCACTAGTAACGGCCGCCAGTGTGCTGGAATTCT    134 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
EMBOSS_001       951 GGTACCGAGCTCGGATCCACTAGTAACGGCCGCCAGTGTGCTGGAATTCT   1000 
 
EMBOSS_001       135 GCAGATATCAAAGCCACCATGCTTCTGTGGCTGCTGCTGCTGATCCTGAC    184 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
EMBOSS_001      1001 GCAGATATCAAAGCCACCATGCTTCTGTGGCTGCTGCTGCTGATCCTGAC   1050 
 
EMBOSS_001       185 TCCTGGAAGAGAACAATCAGGGGTGGCCCCAAAAGCTGTACTTCTCCTCA    234 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
EMBOSS_001      1051 TCCTGGAAGAGAACAATCAGGGGTGGCCCCAAAAGCTGTACTTCTCCTCA   1100 
 
EMBOSS_001       235 ATCCTCCATGGTCCACAGCCTTCAAAGGAGAAAAAGTGGCTCTCATATGC    284 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
EMBOSS_001      1101 ATCCTCCATGGTCCACAGCCTTCAAAGGAGAAAAAGTGGCTCTCATATGC   1150 
 
EMBOSS_001       285 AGCAGCATATCACATTCCCTAGCCCAGGGAGACACATATTGGTATCACGA    334 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
EMBOSS_001      1151 AGCAGCATATCACATTCCCTAGCCCAGGGAGACACATATTGGTATCACGA   1200 
 
EMBOSS_001       335 TGAGAAGTTGTTGAAAATAAAACATGACAAGATCCAAATTACAGAGCCTG    384 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
EMBOSS_001      1201 TGAGAAGTTGTTGAAAATAAAACATGACAAGATCCAAATTACAGAGCCTG   1250 
 
EMBOSS_001       385 GAAATTACCAATGTAAGACCCGAGGATCCTCCCTCAGTGATGCCGTGCAT    434 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
EMBOSS_001      1251 GAAATTACCAATGTAAGACCCGAGGATCCTCCCTCAGTGATGCCGTGCAT   1300 
 
EMBOSS_001       435 GTGGAATTTTCACCTGACTGGCTGATCCTGCAGGCTTTACATCCTGTCTT    484 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
EMBOSS_001      1301 GTGGAATTTTCACCTGACTGGCTGATCCTGCAGGCTTTACATCCTGTCTT   1350 
 
EMBOSS_001       485 TGAAGGAGACAATGTCATTCTGAGATGTCAGGGGAAAGACAACAAAAACA    534 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
EMBOSS_001      1351 TGAAGGAGACAATGTCATTCTGAGATGTCAGGGGAAAGACAACAAAAACA   1400 
 
EMBOSS_001       535 CTCATCAAAAGGTTTACTACAAGGATGGAAAACAGCTTCCTAATAGTTAT    584 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
EMBOSS_001      1401 CTCATCAAAAGGTTTACTACAAGGATGGAAAACAGCTTCCTAATAGTTAT   1450 
 
EMBOSS_001       585 AATTTAGAGAAGATCACAGTGAATTCAGTCTCCAGGGATAATAGCAAATA    634 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
EMBOSS_001      1451 AATTTAGAGAAGATCACAGTGAATTCAGTCTCCAGGGATAATAGCAAATA   1500 
 
EMBOSS_001       635 TCATTGTACTGCTTATAGGAAGTTTTACATACTTGACATTGAAGTAACTT    684 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
EMBOSS_001      1501 TCATTGTACTGCTTATAGGAAGTTTTACATACTTGACATTGAAGTAACTT   1550 
 
EMBOSS_001       685 CAAAACCCCTAAATATCCAAGTTCAAGAGCTGTTTCTACATCCTGTGCTG    734 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
EMBOSS_001      1551 CAAAACCCCTAAATATCCAAGTTCAAGAGCTGTTTCTACATCCTGTGCTG   1600 
 
EMBOSS_001       735 AGAGCCAGCTCTTCCACGCCCATAGAGGGGAGTCCCATGACCCTGACCTG    784 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
EMBOSS_001      1601 AGAGCCAGCTCTTCCACGCCCATAGAGGGGAGTCCCATGACCCTGACCTG   1650 
 
EMBOSS_001       785 TGAGACCCAGCTCTCTCCACAGAGGCCAGATGTCCAGCTGCAATTCTCCC    834 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 






EMBOSS_001       835 TCTTCAGAGATAGCCAGACCCTCGGATTGGGCTGGAGCAGGTCCCCCAGA    884 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
EMBOSS_001      1701 TCTTCAGAGATAGCCAGACCCTCGGATTGGGCTGGAGCAGGTCCCCCAGA   1750 
 
EMBOSS_001       885 CTCCAGATCCCTGCCATGTGGACTGAAGACTCAGGGTCTTACTGGTGTGA    934 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
EMBOSS_001      1751 CTCCAGATCCCTGCCATGTGGACTGAAGACTCAGGGTCTTACTGGTGTGA   1800 
 
EMBOSS_001       935 GGTGGAGACAGTGACTCACAGCATCAAAAAAAGGAGCCTGAGATCTCAGA    984 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
EMBOSS_001      1801 GGTGGAGACAGTGACTCACAGCATCAAAAAAAGGAGCCTGAGATCTCAGA   1850 
 
EMBOSS_001       985 TACGTGTACAGAGAGTCCCTGTGTCTAATGTGAATCTAGAGATCCGGCCC   1034 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
EMBOSS_001      1851 TACGTGTACAGAGAGTCCCTGTGTCTAATGTGAATCTAGAGATCCGGCCC   1900 
 
EMBOSS_001      1035 ACCGGAGGGCAGCTGATTGAAGGAGAAAATATGGTCCTTATTTGCTCAGT   1084 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
EMBOSS_001      1901 ACCGGAGGGCAGCTGATTGAAGGAGAAAATATGGTCCTTATTTGCTCAGT   1950 
 
EMBOSS_001      1085 AGCCCAGGGTTCAGGGACTGTCACATTCTCCTGGCACAAAGAAGGAAGAG   1134 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
EMBOSS_001      1951 AGCCCAGGGTTCAGGGACTGTCACATTCTCCTGGCACAAAGAAGGAAGAG   2000 
 
EMBOSS_001      1135 TAAGAAGCCTGGGTAGAAAGACCCAGCGTTCCCTGTTGGCAGAGCTGCAT   1184 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
EMBOSS_001      2001 TAAGAAGCCTGGGTAGAAAGACCCAGCGTTCCCTGTTGGCAGAGCTGCAT   2050 
 
EMBOSS_001      1185 GTTCTCACCGTGAAGGAGAGTGATGCAGGGAGATACTACTGTGCAGCTGA   1234 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
EMBOSS_001      2051 GTTCTCACCGTGAAGGAGAGTGATGCAGGGAGATACTACTGTGCAGCTGA   2100 
 
EMBOSS_001      1235 TAACGTTCACAGCCCCATCCTCAGCACGTGGATTCGAGTCACCGTGAGAA   1284 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
EMBOSS_001      2101 TAACGTTCACAGCCCCATCCTCAGCACGTGGATTCGAGTCACCGTGAGAA   2150 
 
EMBOSS_001      1285 TTCCGGTATCTCACCCTGTCCTCACCTTCAGGGCTCCCAGGGCCCACACT   1334 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
EMBOSS_001      2151 TTCCGGTATCTCACCCTGTCCTCACCTTCAGGGCTCCCAGGGCCCACACT   2200 
 
EMBOSS_001      1335 GTGGTGGGGGACCTGCTGGAGCTTCACTGTGAGTCCCTGAGAGGCTCTCC   1384 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
EMBOSS_001      2201 GTGGTGGGGGACCTGCTGGAGCTTCACTGTGAGTCCCTGAGAGGCTCTCC   2250 
 
EMBOSS_001      1385 CCCGATCCTGTACCGATTTTATCATGAGGATGTCACCCTGGGGAACAGCT   1434 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
EMBOSS_001      2251 CCCGATCCTGTACCGATTTTATCATGAGGATGTCACCCTGGGGAACAGCT   2300 
 
EMBOSS_001      1435 CAGCCCCCTCTGGAGGAGGAGCCTCCTTCAACCTCTCTCTGACTGCAGAA   1484 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
EMBOSS_001      2301 CAGCCCCCTCTGGAGGAGGAGCCTCCTTCAACCTCTCTCTGACTGCAGAA   2350 
 
EMBOSS_001      1485 CATTCTGGAAACTACTCCTGTGATGCAGACAATGGCCTGGGGGCCCAGCA   1534 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
EMBOSS_001      2351 CATTCTGGAAACTACTCCTGTGATGCAGACAATGGCCTGGGGGCCCAGCA   2400 
 
EMBOSS_001      1535 CAGTCATGGAGTGAGTCTCAGGGTCACAGTTCCGGTGTCTCGCCCCGTCC   1584 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
EMBOSS_001      2401 CAGTCATGGAGTGAGTCTCAGGGTCACAGTTCCGGTGTCTCGCCCCGTCC   2450 
 
EMBOSS_001      1585 TCACCCTCAGGGCTCCCGGGGCCCAGGCTGTGGTGGGGGACCTGCTGGAG   1634 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
EMBOSS_001      2451 TCACCCTCAGGGCTCCCGGGGCCCAGGCTGTGGTGGGGGACCTGCTGGAG   2500 
 
EMBOSS_001      1635 CTTCACTGTGAGTCCCTGAGAGGCTCCTTCCCGATCCTGTACTGGTTTTA   1684 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 




EMBOSS_001      1685 TCACGAGGATGACACCTTGGGGAACATCTCGGCCCACTCTGGAGGAGGGG   1734 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
EMBOSS_001      2551 TCACGAGGATGACACCTTGGGGAACATCTCGGCCCACTCTGGAGGAGGGG   2600 
 
EMBOSS_001      1735 CATCCTTCAACCTCTCTCTGACTACAGAACATTCTGGAAACTACTCATGT   1784 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
EMBOSS_001      2601 CATCCTTCAACCTCTCTCTGACTACAGAACATTCTGGAAACTACTCATGT   2650 
 
EMBOSS_001      1785 GAGGCTGACAATGGCCTGGGGGCCCAGCACAGTAAAGTGGTGACACTCAA   1834 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
EMBOSS_001      2651 GAGGCTGACAATGGCCTGGGGGCCCAGCACAGTAAAGTGGTGACACTCAA   2700 
 
EMBOSS_001      1835 TGTTACAGGAACTTCCAGGAACAGAACAGGCCTTACCGCTGCGGGAATCA   1884 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
EMBOSS_001      2701 TGTTACAGGAACTTCCAGGAACAGAACAGGCCTTACCGCTGCGGGAATCA   2750 
 
EMBOSS_001      1885 CGGGGCTGGTGCTCAGCATCCTCGTCCTTGCTGCTGCTGCTGCTCTGCTG   1934 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
EMBOSS_001      2751 CGGGGCTGGTGCTCAGCATCCTCGTCCTTGCTGCTGCTGCTGCTCTGCTG   2800 
 
EMBOSS_001      1935 CATTACGCCAGGGCCCGAAGGAAACCAGGAGGACTTTCTGCCACTGGAAC   1984 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
EMBOSS_001      2801 CATTACGCCAGGGCCCGAAGGAAACCAGGAGGACTTTCTGCCACTGGAAC   2850 
 
EMBOSS_001      1985 ATCTAGTCACAGTCCTAGTGAGTGTCAGGAGCCTTCCTCGTCCAGGCCTT   2034 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
EMBOSS_001      2851 ATCTAGTCACAGTCCTAGTGAGTGTCAGGAGCCTTCCTCGTCCAGGCCTT   2900 
 
EMBOSS_001      2035 CCAGGATAGACCCTCAAGAGCCCACTCACTCTAAACCACTAGCCCCAATG   2084 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
EMBOSS_001      2901 CCAGGATAGACCCTCAAGAGCCCACTCACTCTAAACCACTAGCCCCAATG   2950 
 
EMBOSS_001      2085 GAGCTGGAGCCAATGTACAGCAATGTAAATCCTGGAGATAGCAACCCGAT   2134 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
EMBOSS_001      2951 GAGCTGGAGCCAATGTACAGCAATGTAAATCCTGGAGATAGCAACCCGAT   3000 
 
Reverse sequencing alignment: 
EMBOSS_001       981 CGCCAGTGTGCTGGAATTCTGCAGATATCAAAGCCACCATGCTTCTGTGG   1030 
                     ||     ||||                         |||||||||||||| 
EMBOSS_001       285 CG-----GTGC-------------------------CCATGCTTCTGTGG    304 
 
EMBOSS_001      1031 CTGCTGCTGCTGATCCTGACTCCTGGAAGAGAACAATCAGGGGTGGCCCC   1080 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
EMBOSS_001       305 CTGCTGCTGCTGATCCTGACTCCTGGAAGAGAACAATCAGGGGTGGCCCC    354 
 
EMBOSS_001      1081 AAAAGCTGTACTTCTCCTCAATCCTCCATGGTCCACAGCCTTCAAAGGAG   1130 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
EMBOSS_001       355 AAAAGCTGTACTTCTCCTCAATCCTCCATGGTCCACAGCCTTCAAAGGAG    404 
 
EMBOSS_001      1131 AAAAAGTGGCTCTCATATGCAGCAGCATATCACATTCCCTAGCCCAGGGA   1180 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
EMBOSS_001       405 AAAAAGTGGCTCTCATATGCAGCAGCATATCACATTCCCTAGCCCAGGGA    454 
 
EMBOSS_001      1181 GACACATATTGGTATCACGATGAGAAGTTGTTGAAAATAAAACATGACAA   1230 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
EMBOSS_001       455 GACACATATTGGTATCACGATGAGAAGTTGTTGAAAATAAAACATGACAA    504 
 
EMBOSS_001      1231 GATCCAAATTACAGAGCCTGGAAATTACCAATGTAAGACCCGAGGATCCT   1280 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
EMBOSS_001       505 GATCCAAATTACAGAGCCTGGAAATTACCAATGTAAGACCCGAGGATCCT    554 
 
EMBOSS_001      1281 CCCTCAGTGATGCCGTGCATGTGGAATTTTCACCTGACTGGCTGATCCTG   1330 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 




EMBOSS_001      1331 CAGGCTTTACATCCTGTCTTTGAAGGAGACAATGTCATTCTGAGATGTCA   1380 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
EMBOSS_001       605 CAGGCTTTACATCCTGTCTTTGAAGGAGACAATGTCATTCTGAGATGTCA    654 
 
EMBOSS_001      1381 GGGGAAAGACAACAAAAACACTCATCAAAAGGTTTACTACAAGGATGGAA   1430 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
EMBOSS_001       655 GGGGAAAGACAACAAAAACACTCATCAAAAGGTTTACTACAAGGATGGAA    704 
 
EMBOSS_001      1431 AACAGCTTCCTAATAGTTATAATTTAGAGAAGATCACAGTGAATTCAGTC   1480 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
EMBOSS_001       705 AACAGCTTCCTAATAGTTATAATTTAGAGAAGATCACAGTGAATTCAGTC    754 
 
EMBOSS_001      1481 TCCAGGGATAATAGCAAATATCATTGTACTGCTTATAGGAAGTTTTACAT   1530 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
EMBOSS_001       755 TCCAGGGATAATAGCAAATATCATTGTACTGCTTATAGGAAGTTTTACAT    804 
 
EMBOSS_001      1531 ACTTGACATTGAAGTAACTTCAAAACCCCTAAATATCCAAGTTCAAGAGC   1580 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
EMBOSS_001       805 ACTTGACATTGAAGTAACTTCAAAACCCCTAAATATCCAAGTTCAAGAGC    854 
 
EMBOSS_001      1581 TGTTTCTACATCCTGTGCTGAGAGCCAGCTCTTCCACGCCCATAGAGGGG   1630 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
EMBOSS_001       855 TGTTTCTACATCCTGTGCTGAGAGCCAGCTCTTCCACGCCCATAGAGGGG    904 
 
EMBOSS_001      1631 AGTCCCATGACCCTGACCTGTGAGACCCAGCTCTCTCCACAGAGGCCAGA   1680 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
EMBOSS_001       905 AGTCCCATGACCCTGACCTGTGAGACCCAGCTCTCTCCACAGAGGCCAGA    954 
 
EMBOSS_001      1681 TGTCCAGCTGCAATTCTCCCTCTTCAGAGATAGCCAGACCCTCGGATTGG   1730 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
EMBOSS_001       955 TGTCCAGCTGCAATTCTCCCTCTTCAGAGATAGCCAGACCCTCGGATTGG   1004 
 
EMBOSS_001      1731 GCTGGAGCAGGTCCCCCAGACTCCAGATCCCTGCCATGTGGACTGAAGAC   1780 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
EMBOSS_001      1005 GCTGGAGCAGGTCCCCCAGACTCCAGATCCCTGCCATGTGGACTGAAGAC   1054 
 
EMBOSS_001      1781 TCAGGGTCTTACTGGTGTGAGGTGGAGACAGTGACTCACAGCATCAAAAA   1830 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
EMBOSS_001      1055 TCAGGGTCTTACTGGTGTGAGGTGGAGACAGTGACTCACAGCATCAAAAA   1104 
 
EMBOSS_001      1831 AAGGAGCCTGAGATCTCAGATACGTGTACAGAGAGTCCCTGTGTCTAATG   1880 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
EMBOSS_001      1105 AAGGAGCCTGAGATCTCAGATACGTGTACAGAGAGTCCCTGTGTCTAATG   1154 
 
EMBOSS_001      1881 TGAATCTAGAGATCCGGCCCACCGGAGGGCAGCTGATTGAAGGAGAAAAT   1930 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
EMBOSS_001      1155 TGAATCTAGAGATCCGGCCCACCGGAGGGCAGCTGATTGAAGGAGAAAAT   1204 
 
EMBOSS_001      1931 ATGGTCCTTATTTGCTCAGTAGCCCAGGGTTCAGGGACTGTCACATTCTC   1980 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
EMBOSS_001      1205 ATGGTCCTTATTTGCTCAGTAGCCCAGGGTTCAGGGACTGTCACATTCTC   1254 
 
EMBOSS_001      1981 CTGGCACAAAGAAGGAAGAGTAAGAAGCCTGGGTAGAAAGACCCAGCGTT   2030 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
EMBOSS_001      1255 CTGGCACAAAGAAGGAAGAGTAAGAAGCCTGGGTAGAAAGACCCAGCGTT   1304 
 
EMBOSS_001      2031 CCCTGTTGGCAGAGCTGCATGTTCTCACCGTGAAGGAGAGTGATGCAGGG   2080 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
EMBOSS_001      1305 CCCTGTTGGCAGAGCTGCATGTTCTCACCGTGAAGGAGAGTGATGCAGGG   1354 
 
EMBOSS_001      2081 AGATACTACTGTGCAGCTGATAACGTTCACAGCCCCATCCTCAGCACGTG   2130 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
EMBOSS_001      1355 AGATACTACTGTGCAGCTGATAACGTTCACAGCCCCATCCTCAGCACGTG   1404 
 
EMBOSS_001      2131 GATTCGAGTCACCGTGAGAATTCCGGTATCTCACCCTGTCCTCACCTTCA   2180 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 




EMBOSS_001      2181 GGGCTCCCAGGGCCCACACTGTGGTGGGGGACCTGCTGGAGCTTCACTGT   2230 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
EMBOSS_001      1455 GGGCTCCCAGGGCCCACACTGTGGTGGGGGACCTGCTGGAGCTTCACTGT   1504 
 
EMBOSS_001      2231 GAGTCCCTGAGAGGCTCTCCCCCGATCCTGTACCGATTTTATCATGAGGA   2280 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
EMBOSS_001      1505 GAGTCCCTGAGAGGCTCTCCCCCGATCCTGTACCGATTTTATCATGAGGA   1554 
 
EMBOSS_001      2281 TGTCACCCTGGGGAACAGCTCAGCCCCCTCTGGAGGAGGAGCCTCCTTCA   2330 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
EMBOSS_001      1555 TGTCACCCTGGGGAACAGCTCAGCCCCCTCTGGAGGAGGAGCCTCCTTCA   1604 
 
EMBOSS_001      2331 ACCTCTCTCTGACTGCAGAACATTCTGGAAACTACTCCTGTGATGCAGAC   2380 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
EMBOSS_001      1605 ACCTCTCTCTGACTGCAGAACATTCTGGAAACTACTCCTGTGATGCAGAC   1654 
 
EMBOSS_001      2381 AATGGCCTGGGGGCCCAGCACAGTCATGGAGTGAGTCTCAGGGTCACAGT   2430 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
EMBOSS_001      1655 AATGGCCTGGGGGCCCAGCACAGTCATGGAGTGAGTCTCAGGGTCACAGT   1704 
 
EMBOSS_001      2431 TCCGGTGTCTCGCCCCGTCCTCACCCTCAGGGCTCCCGGGGCCCAGGCTG   2480 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
EMBOSS_001      1705 TCCGGTGTCTCGCCCCGTCCTCACCCTCAGGGCTCCCGGGGCCCAGGCTG   1754 
 
EMBOSS_001      2481 TGGTGGGGGACCTGCTGGAGCTTCACTGTGAGTCCCTGAGAGGCTCCTTC   2530 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
EMBOSS_001      1755 TGGTGGGGGACCTGCTGGAGCTTCACTGTGAGTCCCTGAGAGGCTCCTTC   1804 
 
EMBOSS_001      2531 CCGATCCTGTACTGGTTTTATCACGAGGATGACACCTTGGGGAACATCTC   2580 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
EMBOSS_001      1805 CCGATCCTGTACTGGTTTTATCACGAGGATGACACCTTGGGGAACATCTC   1854 
 
EMBOSS_001      2581 GGCCCACTCTGGAGGAGGGGCATCCTTCAACCTCTCTCTGACTACAGAAC   2630 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
EMBOSS_001      1855 GGCCCACTCTGGAGGAGGGGCATCCTTCAACCTCTCTCTGACTACAGAAC   1904 
 
EMBOSS_001      2631 ATTCTGGAAACTACTCATGTGAGGCTGACAATGGCCTGGGGGCCCAGCAC   2680 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
EMBOSS_001      1905 ATTCTGGAAACTACTCATGTGAGGCTGACAATGGCCTGGGGGCCCAGCAC   1954 
 
EMBOSS_001      2681 AGTAAAGTGGTGACACTCAATGTTACAGGAACTTCCAGGAACAGAACAGG   2730 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
EMBOSS_001      1955 AGTAAAGTGGTGACACTCAATGTTACAGGAACTTCCAGGAACAGAACAGG   2004 
 
EMBOSS_001      2731 CCTTACCGCTGCGGGAATCACGGGGCTGGTGCTCAGCATCCTCGTCCTTG   2780 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
EMBOSS_001      2005 CCTTACCGCTGCGGGAATCACGGGGCTGGTGCTCAGCATCCTCGTCCTTG   2054 
 
EMBOSS_001      2781 CTGCTGCTGCTGCTCTGCTGCATTACGCCAGGGCCCGAAGGAAACCAGGA   2830 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
EMBOSS_001      2055 CTGCTGCTGCTGCTCTGCTGCATTACGCCAGGGCCCGAAGGAAACCAGGA   2104 
 
EMBOSS_001      2831 GGACTTTCTGCCACTGGAACATCTAGTCACAGTCCTAGTGAGTGTCAGGA   2880 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
EMBOSS_001      2105 GGACTTTCTGCCACTGGAACATCTAGTCACAGTCCTAGTGAGTGTCAGGA   2154 
 
EMBOSS_001      2881 GCCTTCCTCGTCCAGGCCTTCCAGGATAGACCCTCAAGAGCCCACTCACT   2930 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
EMBOSS_001      2155 GCCTTCCTCGTCCAGGCCTTCCAGGATAGACCCTCAAGAGCCCACTCACT   2204 
 
EMBOSS_001      2931 CTAAACCACTAGCCCCAATGGAGCTGGAGCCAATGTACAGCAATGTAAAT   2980 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
EMBOSS_001      2205 CTAAACCACTAGCCCCAATGGAGCTGGAGCCAATGTACAGCAATGTAAAT   2254 
 
EMBOSS_001      2981 CCTGGAGATAGCAACCCGATTTATTCCCAGATCTGGAGCATCCAGCATAC   3030 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
EMBOSS_001      2255 CCTGGAGATAGCAACCCGATTTATTCCCAGATCTGGAGCATCCAGCATAC   2304 
350 
 
Appendix A.6. BLAST analysis of the FcRL3 transcript contained in the pIG plasmid 
using the EMBOSS Needle Tool (EMBL-EBI, Hinxton, UK).  
Forward sequencing alignment: 
EMBOSS_001         1 -------ATGCTTCTGTGGCTGCTGCTGCTGATCCTGACTCCTGGAAGAG     43 
                            ||||||||||||||||||||||||||||||||||||||||||| 
EMBOSS_001         1 TCTCGAGATGCTTCTGTGGCTGCTGCTGCTGATCCTGACTCCTGGAAGAG     50 
 
EMBOSS_001        44 AACAATCAGGGGTGGCCCCAAAAGCTGTACTTCTCCTCAATCCTCCATGG     93 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
EMBOSS_001        51 AACAATCAGGGGTGGCCCCAAAAGCTGTACTTCTCCTCAATCCTCCATGG    100 
 
EMBOSS_001        94 TCCACAGCCTTCAAAGGAGAAAAAGTGGCTCTCATATGCAGCAGCATATC    143 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
EMBOSS_001       101 TCCACAGCCTTCAAAGGAGAAAAAGTGGCTCTCATATGCAGCAGCATATC    150 
 
EMBOSS_001       144 ACATTCCCTAGCCCAGGGAGACACATATTGGTATCACGATGAGAAGTTGT    193 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
EMBOSS_001       151 ACATTCCCTAGCCCAGGGAGACACATATTGGTATCACGATGAGAAGTTGT    200 
 
EMBOSS_001       194 TGAAAATAAAACATGACAAGATCCAAATTACAGAGCCTGGAAATTACCAA    243 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
EMBOSS_001       201 TGAAAATAAAACATGACAAGATCCAAATTACAGAGCCTGGAAATTACCAA    250 
 
EMBOSS_001       244 TGTAAGACCCGAGGATCCTCCCTCAGTGATGCCGTGCATGTGGAATTTTC    293 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
EMBOSS_001       251 TGTAAGACCCGAGGATCCTCCCTCAGTGATGCCGTGCATGTGGAATTTTC    300 
 
EMBOSS_001       294 ACCTGACTGGCTGATCCTGCAGGCTTTACATCCTGTCTTTGAAGGAGACA    343 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
EMBOSS_001       301 ACCTGACTGGCTGATCCTGCAGGCTTTACATCCTGTCTTTGAAGGAGACA    350 
 
EMBOSS_001       344 ATGTCATTCTGAGATGTCAGGGGAAAGACAACAAAAACACTCATCAAAAG    393 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
EMBOSS_001       351 ATGTCATTCTGAGATGTCAGGGGAAAGACAACAAAAACACTCATCAAAAG    400 
 
EMBOSS_001       394 GTTTACTACAAGGATGGAAAACAGCTTCCTAATAGTTATAATTTAGAGAA    443 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
EMBOSS_001       401 GTTTACTACAAGGATGGAAAACAGCTTCCTAATAGTTATAATTTAGAGAA    450 
 
EMBOSS_001       444 GATCACAGTGAATTCAGTCTCCAGGGATAATAGCAAATATCATTGTACTG    493 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
EMBOSS_001       451 GATCACAGTGAATTCAGTCTCCAGGGATAATAGCAAATATCATTGTACTG    500 
 
EMBOSS_001       494 CTTATAGGAAGTTTTACATACTTGACATTGAAGTAACTTCAAAACCCCTA    543 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
EMBOSS_001       501 CTTATAGGAAGTTTTACATACTTGACATTGAAGTAACTTCAAAACCCCTA    550 
 
EMBOSS_001       544 AATATCCAAGTTCAAGAGCTGTTTCTACATCCTGTGCTGAGAGCCAGCTC    593 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
EMBOSS_001       551 AATATCCAAGTTCAAGAGCTGTTTCTACATCCTGTGCTGAGAGCCAGCTC    600 
 
EMBOSS_001       594 TTCCACGCCCATAGAGGGGAGTCCCATGACCCTGACCTGTGAGACCCAGC    643 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
EMBOSS_001       601 TTCCACGCCCATAGAGGGGAGTCCCATGACCCTGACCTGTGAGACCCAGC    650 
 
EMBOSS_001       644 TCTCTCCACAGAGGCCAGATGTCCAGCTGCAATTCTCCCTCTTCAGAGAT    693 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
EMBOSS_001       651 TCTCTCCACAGAGGCCAGATGTCCAGCTGCAATTCTCCCTCTTCAGAGAT    700 
 
EMBOSS_001       694 AGCCAGACCCTCGGATTGGGCTGGAGCAGGTCCCCCAGACTCCAGATCCC    743 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 





EMBOSS_001       744 TGCCATGTGGACTGAAGACTCAGGGTCTTACTGGTGTGAGGTGGAGACAG    793 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
EMBOSS_001       751 TGCCATGTGGACTGAAGACTCAGGGTCTTACTGGTGTGAGGTGGAGACAG    800 
 
EMBOSS_001       794 TGACTCACAGCATCAAAAAAAGGAGCCTGAGATCTCAGATACGTGTACAG    843 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
EMBOSS_001       801 TGACTCACAGCATCAAAAAAAGGAGCCTGAGATCTCAGATACGTGTACAG    850 
 
EMBOSS_001       844 AGAGTCCCTGTGTCTAATGTGAATCTAGAGATCCGGCCCACCGGAGGGCA    893 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
EMBOSS_001       851 AGAGTCCCTGTGTCTAATGTGAATCTAGAGATCCGGCCCACCGGAGGGCA    900 
 
EMBOSS_001       894 GCTGATTGAAGGAGAAAATATGGTCCTTATTTGCTCAGTAGCCCAGGGTT    943 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
EMBOSS_001       901 GCTGATTGAAGGAGAAAATATGGTCCTTATTTGCTCAGTAGCCCAGGGTT    950 
 
EMBOSS_001       944 CAGGGACTGTCACATTCTCCTGGCACAAAGAAGGAAGAGTAAGAAGCCTG    993 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
EMBOSS_001       951 CAGGGACTGTCACATTCTCCTGGCACAAAGAAGGAAGAGTAAGAAGCCTG   1000 
 
EMBOSS_001       994 GGTAGAAAGACCCAGCGTTCCCTGTTGGCAGAGCTGCATGTTCTCACCGT   1043 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
EMBOSS_001      1001 GGTAGAAAGACCCAGCGTTCCCTGTTGGCAGAGCTGCATGTTCTCACCGT   1050 
 
EMBOSS_001      1044 GAAGGAGAGTGATGCAGGGAGATACTACTGTGCAGCTGATAACGTTCACA   1093 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
EMBOSS_001      1051 GAAGGAGAGTGATGCAGGGAGATACTACTGTGCAGCTGATAACGTTCACA   1100 
 
EMBOSS_001      1094 GCCCCATCCTCAGCACGTGGATTCGAGTCACCGTGAGAATTCCGGTATCT   1143 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
EMBOSS_001      1101 GCCCCATCCTCAGCACGTGGATTCGAGTCACCGTGAGAATTCCGGTATCT   1150 
 
EMBOSS_001      1144 CACCCTGTCCTCACCTTCAGGGCTCCCAGGGCCCACACTGTGGTGGGGGA   1193 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
EMBOSS_001      1151 CACCCTGTCCTCACCTTCAGGGCTCCCAGGGCCCACACTGTGGTGGGGGA   1200 
 
EMBOSS_001      1194 CCTGCTGGAGCTTCACTGTGAGTCCCTGAGAGGCTCTCCCCCGATCCTGT   1243 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
EMBOSS_001      1201 CCTGCTGGAGCTTCACTGTGAGTCCCTGAGAGGCTCTCCCCCGATCCTGT   1250 
 
EMBOSS_001      1244 ACCGATTTTATCATGAGGATGTCACCCTGGGGAACAGCTCAGCCCCCTCT   1293 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
EMBOSS_001      1251 ACCGATTTTATCATGAGGATGTCACCCTGGGGAACAGCTCAGCCCCCTCT   1300 
 
EMBOSS_001      1294 GGAGGAGGAGCCTCCTTCAACCTCTCTCTGACTGCAGAACATTCTGGAAA   1343 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
EMBOSS_001      1301 GGAGGAGGAGCCTCCTTCAACCTCTCTCTGACTGCAGAACATTCTGGAAA   1350 
 
EMBOSS_001      1344 CTACTCCTGTGATGCAGACAATGGCCTGGGGGCCCAGCACAGTCATGGAG   1393 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
EMBOSS_001      1351 CTACTCCTGTGATGCAGACAATGGCCTGGGGGCCCAGCACAGTCATGGAG   1400 
 
EMBOSS_001      1394 TGAGTCTCAGGGTCACAGTTCCGGTGTCTCGCCCCGTCCTCACCCTCAGG   1443 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
EMBOSS_001      1401 TGAGTCTCAGGGTCACAGTTCCGGTGTCTCGCCCCGTCCTCACCCTCAGG   1450 
 
EMBOSS_001      1444 GCTCCCGGGGCCCAGGCTGTGGTGGGGGACCTGCTGGAGCTTCACTGTGA   1493 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
EMBOSS_001      1451 GCTCCCGGGGCCCAGGCTGTGGTGGGGGACCTGCTGGAGCTTCACTGTGA   1500 
 
EMBOSS_001      1494 GTCCCTGAGAGGCTCCTTCCCGATCCTGTACTGGTTTTATCACGAGGATG   1543 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
EMBOSS_001      1501 GTCCCTGAGAGGCTCCTTCCCGATCCTGTACTGGTTTTATCACGAGGATG   1550 
 
EMBOSS_001      1544 ACACCTTGGGGAACATCTCGGCCCACTCTGGAGGAGGGGCATCCTTCAAC   1593 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 




EMBOSS_001      1594 CTCTCTCTGACTACAGAACATTCTGGAAACTACTCATGTGAGGCTGACAA   1643 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
EMBOSS_001      1601 CTCTCTCTGACTACAGAACATTCTGGAAACTACTCATGTGAGGCTGACAA   1650 
 
EMBOSS_001      1644 TGGCCTGGGGGCCCAGCACAGTAAAGTGGTGACACTCAATGTTACAGGAA   1693 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
EMBOSS_001      1651 TGGCCTGGGGGCCCAGCACAGTAAAGTGGTGACACTCAATGTTACAGGAA   1700 
 
EMBOSS_001      1694 CTTCCAGGAACAGAACAGGCCTTACCGCTGCGGGAATCACGGGGCTGGTG   1743 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
EMBOSS_001      1701 CTTCCAGGAACAGAACAGGCCTTACCGCTGCGGGAATCACGGGGCTGGTG   1750 
 
EMBOSS_001      1744 CTCAGCATCCTCGTCCTTGCTGCTGCTGCTGCTCTGCTGCATTACGCCAG   1793 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
EMBOSS_001      1751 CTCAGCATCCTCGTCCTTGCTGCTGCTGCTGCTCTGCTGCATTACGCCAG   1800 
 
EMBOSS_001      1794 GGCCCGAAGGAAACCAGGAGGACTTTCTGCCACTGGAACATCTAGTCACA   1843 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
EMBOSS_001      1801 GGCCCGAAGGAAACCAGGAGGACTTTCTGCCACTGGAACATCTAGTCACA   1850 
 
EMBOSS_001      1844 GTCCTAGTGAGTGTCAGGAGCCTTCCTCGTCCAGGCCTTCCAGGATAGAC   1893 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
EMBOSS_001      1851 GTCCTAGTGAGTGTCAGGAGCCTTCCTCGTCCAGGCCTTCCAGGATAGAC   1900 
 
EMBOSS_001      1894 CCTCAAGAGCCCACTCACTCTAAACCACTAG-------------------   1924 
                     |||||||||||||||||||||||||||||||                    
EMBOSS_001      1901 CCTCAAGAGCCCACTCACTCTAAACCACTAGCCCCAATGGAGCTGGAGCC   1950 
 
 
Reverse sequencing alignment: 
EMBOSS_001         1 -------------ATGCTTCTGTGGCTGCTGCTGCTGATCCTGACTCCTG     37 
                                  ||||||||||||||||||||||||||||||||||||| 
EMBOSS_001       651 TAGATCTCTCGAGATGCTTCTGTGGCTGCTGCTGCTGATCCTGACTCCTG    700 
 
EMBOSS_001        38 GAAGAGAACAATCAGGGGTGGCCCCAAAAGCTGTACTTCTCCTCAATCCT     87 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
EMBOSS_001       701 GAAGAGAACAATCAGGGGTGGCCCCAAAAGCTGTACTTCTCCTCAATCCT    750 
 
EMBOSS_001        88 CCATGGTCCACAGCCTTCAAAGGAGAAAAAGTGGCTCTCATATGCAGCAG    137 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
EMBOSS_001       751 CCATGGTCCACAGCCTTCAAAGGAGAAAAAGTGGCTCTCATATGCAGCAG    800 
 
EMBOSS_001       138 CATATCACATTCCCTAGCCCAGGGAGACACATATTGGTATCACGATGAGA    187 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
EMBOSS_001       801 CATATCACATTCCCTAGCCCAGGGAGACACATATTGGTATCACGATGAGA    850 
 
EMBOSS_001       188 AGTTGTTGAAAATAAAACATGACAAGATCCAAATTACAGAGCCTGGAAAT    237 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
EMBOSS_001       851 AGTTGTTGAAAATAAAACATGACAAGATCCAAATTACAGAGCCTGGAAAT    900 
 
EMBOSS_001       238 TACCAATGTAAGACCCGAGGATCCTCCCTCAGTGATGCCGTGCATGTGGA    287 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
EMBOSS_001       901 TACCAATGTAAGACCCGAGGATCCTCCCTCAGTGATGCCGTGCATGTGGA    950 
 
EMBOSS_001       288 ATTTTCACCTGACTGGCTGATCCTGCAGGCTTTACATCCTGTCTTTGAAG    337 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
EMBOSS_001       951 ATTTTCACCTGACTGGCTGATCCTGCAGGCTTTACATCCTGTCTTTGAAG   1000 
 
EMBOSS_001       338 GAGACAATGTCATTCTGAGATGTCAGGGGAAAGACAACAAAAACACTCAT    387 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
EMBOSS_001      1001 GAGACAATGTCATTCTGAGATGTCAGGGGAAAGACAACAAAAACACTCAT   1050 
 
EMBOSS_001       388 CAAAAGGTTTACTACAAGGATGGAAAACAGCTTCCTAATAGTTATAATTT    437 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
EMBOSS_001      1051 CAAAAGGTTTACTACAAGGATGGAAAACAGCTTCCTAATAGTTATAATTT   1100 
353 
 
EMBOSS_001       438 AGAGAAGATCACAGTGAATTCAGTCTCCAGGGATAATAGCAAATATCATT    487 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
EMBOSS_001      1101 AGAGAAGATCACAGTGAATTCAGTCTCCAGGGATAATAGCAAATATCATT   1150 
 
EMBOSS_001       488 GTACTGCTTATAGGAAGTTTTACATACTTGACATTGAAGTAACTTCAAAA    537 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
EMBOSS_001      1151 GTACTGCTTATAGGAAGTTTTACATACTTGACATTGAAGTAACTTCAAAA   1200 
 
EMBOSS_001       538 CCCCTAAATATCCAAGTTCAAGAGCTGTTTCTACATCCTGTGCTGAGAGC    587 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
EMBOSS_001      1201 CCCCTAAATATCCAAGTTCAAGAGCTGTTTCTACATCCTGTGCTGAGAGC   1250 
 
EMBOSS_001       588 CAGCTCTTCCACGCCCATAGAGGGGAGTCCCATGACCCTGACCTGTGAGA    637 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
EMBOSS_001      1251 CAGCTCTTCCACGCCCATAGAGGGGAGTCCCATGACCCTGACCTGTGAGA   1300 
 
EMBOSS_001       638 CCCAGCTCTCTCCACAGAGGCCAGATGTCCAGCTGCAATTCTCCCTCTTC    687 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
EMBOSS_001      1301 CCCAGCTCTCTCCACAGAGGCCAGATGTCCAGCTGCAATTCTCCCTCTTC   1350 
 
EMBOSS_001       688 AGAGATAGCCAGACCCTCGGATTGGGCTGGAGCAGGTCCCCCAGACTCCA    737 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
EMBOSS_001      1351 AGAGATAGCCAGACCCTCGGATTGGGCTGGAGCAGGTCCCCCAGACTCCA   1400 
 
EMBOSS_001       738 GATCCCTGCCATGTGGACTGAAGACTCAGGGTCTTACTGGTGTGAGGTGG    787 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
EMBOSS_001      1401 GATCCCTGCCATGTGGACTGAAGACTCAGGGTCTTACTGGTGTGAGGTGG   1450 
 
EMBOSS_001       788 AGACAGTGACTCACAGCATCAAAAAAAGGAGCCTGAGATCTCAGATACGT    837 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
EMBOSS_001      1451 AGACAGTGACTCACAGCATCAAAAAAAGGAGCCTGAGATCTCAGATACGT   1500 
 
EMBOSS_001       838 GTACAGAGAGTCCCTGTGTCTAATGTGAATCTAGAGATCCGGCCCACCGG    887 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
EMBOSS_001      1501 GTACAGAGAGTCCCTGTGTCTAATGTGAATCTAGAGATCCGGCCCACCGG   1550 
 
EMBOSS_001       888 AGGGCAGCTGATTGAAGGAGAAAATATGGTCCTTATTTGCTCAGTAGCCC    937 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
EMBOSS_001      1551 AGGGCAGCTGATTGAAGGAGAAAATATGGTCCTTATTTGCTCAGTAGCCC   1600 
 
EMBOSS_001       938 AGGGTTCAGGGACTGTCACATTCTCCTGGCACAAAGAAGGAAGAGTAAGA    987 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
EMBOSS_001      1601 AGGGTTCAGGGACTGTCACATTCTCCTGGCACAAAGAAGGAAGAGTAAGA   1650 
 
EMBOSS_001       988 AGCCTGGGTAGAAAGACCCAGCGTTCCCTGTTGGCAGAGCTGCATGTTCT   1037 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
EMBOSS_001      1651 AGCCTGGGTAGAAAGACCCAGCGTTCCCTGTTGGCAGAGCTGCATGTTCT   1700 
 
EMBOSS_001      1038 CACCGTGAAGGAGAGTGATGCAGGGAGATACTACTGTGCAGCTGATAACG   1087 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
EMBOSS_001      1701 CACCGTGAAGGAGAGTGATGCAGGGAGATACTACTGTGCAGCTGATAACG   1750 
 
EMBOSS_001      1088 TTCACAGCCCCATCCTCAGCACGTGGATTCGAGTCACCGTGAGAATTCCG   1137 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
EMBOSS_001      1751 TTCACAGCCCCATCCTCAGCACGTGGATTCGAGTCACCGTGAGAATTCCG   1800 
 
EMBOSS_001      1138 GTATCTCACCCTGTCCTCACCTTCAGGGCTCCCAGGGCCCACACTGTGGT   1187 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
EMBOSS_001      1801 GTATCTCACCCTGTCCTCACCTTCAGGGCTCCCAGGGCCCACACTGTGGT   1850 
 
EMBOSS_001      1188 GGGGGACCTGCTGGAGCTTCACTGTGAGTCCCTGAGAGGCTCTCCCCCGA   1237 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
EMBOSS_001      1851 GGGGGACCTGCTGGAGCTTCACTGTGAGTCCCTGAGAGGCTCTCCCCCGA   1900 
 
EMBOSS_001      1238 TCCTGTACCGATTTTATCATGAGGATGTCACCCTGGGGAACAGCTCAGCC   1287 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 




EMBOSS_001      1288 CCCTCTGGAGGAGGAGCCTCCTTCAACCTCTCTCTGACTGCAGAACATTC   1337 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
EMBOSS_001      1951 CCCTCTGGAGGAGGAGCCTCCTTCAACCTCTCTCTGACTGCAGAACATTC   2000 
 
EMBOSS_001      1338 TGGAAACTACTCCTGTGATGCAGACAATGGCCTGGGGGCCCAGCACAGTC   1387 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
EMBOSS_001      2001 TGGAAACTACTCCTGTGATGCAGACAATGGCCTGGGGGCCCAGCACAGTC   2050 
 
EMBOSS_001      1388 ATGGAGTGAGTCTCAGGGTCACAGTTCCGGTGTCTCGCCCCGTCCTCACC   1437 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
EMBOSS_001      2051 ATGGAGTGAGTCTCAGGGTCACAGTTCCGGTGTCTCGCCCCGTCCTCACC   2100 
 
EMBOSS_001      1438 CTCAGGGCTCCCGGGGCCCAGGCTGTGGTGGGGGACCTGCTGGAGCTTCA   1487 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
EMBOSS_001      2101 CTCAGGGCTCCCGGGGCCCAGGCTGTGGTGGGGGACCTGCTGGAGCTTCA   2150 
 
EMBOSS_001      1488 CTGTGAGTCCCTGAGAGGCTCCTTCCCGATCCTGTACTGGTTTTATCACG   1537 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
EMBOSS_001      2151 CTGTGAGTCCCTGAGAGGCTCCTTCCCGATCCTGTACTGGTTTTATCACG   2200 
 
EMBOSS_001      1538 AGGATGACACCTTGGGGAACATCTCGGCCCACTCTGGAGGAGGGGCATCC   1587 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
EMBOSS_001      2201 AGGATGACACCTTGGGGAACATCTCGGCCCACTCTGGAGGAGGGGCATCC   2250 
 
EMBOSS_001      1588 TTCAACCTCTCTCTGACTACAGAACATTCTGGAAACTACTCATGTGAGGC   1637 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
EMBOSS_001      2251 TTCAACCTCTCTCTGACTACAGAACATTCTGGAAACTACTCATGTGAGGC   2300 
 
EMBOSS_001      1638 TGACAATGGCCTGGGGGCCCAGCACAGTAAAGTGGTGACACTCAATGTTA   1687 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
EMBOSS_001      2301 TGACAATGGCCTGGGGGCCCAGCACAGTAAAGTGGTGACACTCAATGTTA   2350 
 
EMBOSS_001      1688 CAGGAACTTCCAGGAACAGAACAGGCCTTACCGCTGCGGGAATCACGGGG   1737 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
EMBOSS_001      2351 CAGGAACTTCCAGGAACAGAACAGGCCTTACCGCTGCGGGAATCACGGGG   2400 
 
EMBOSS_001      1738 CTGGTGCTCAGCATCCTCGTCCTTGCTGCTGCTGCTGCTCTGCTGCATTA   1787 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
EMBOSS_001      2401 CTGGTGCTCAGCATCCTCGTCCTTGCTGCTGCTGCTGCTCTGCTGCATTA   2450 
 
EMBOSS_001      1788 CGCCAGGGCCCGAAGGAAACCAGGAGGACTTTCTGCCACTGGAACATCTA   1837 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
EMBOSS_001      2451 CGCCAGGGCCCGAAGGAAACCAGGAGGACTTTCTGCCACTGGAACATCTA   2500 
 
EMBOSS_001      1838 GTCACAGTCCTAGTGAGTGTCAGGAGCCTTCCTCGTCCAGGCCTTCCAGG   1887 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
EMBOSS_001      2501 GTCACAGTCCTAGTGAGTGTCAGGAGCCTTCCTCGTCCAGGCCTTCCAGG   2550 
 
EMBOSS_001      1888 ATAGACCCTCAAGAGCCCACTCACTCTAAACCACTAG-------------   1924 
                     |||||||||||||||||||||||||||||||||||||              
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